{"14e32f59e2a61ddb8c3af14d64fb4ecfb9d62670": [["IntroductionThe clearance from the lung of an inhaled nebulised radioaerosol has been in use now for many years as a measure of lung function.", [["lung", "ANATOMY", 35, 39], ["lung", "ANATOMY", 128, 132], ["radioaerosol", "CHEMICAL", 64, 76], ["lung", "ORGAN", 35, 39], ["lung", "ORGAN", 128, 132], ["an inhaled nebulised radioaerosol", "TREATMENT", 43, 76], ["lung", "ANATOMY", 35, 39], ["lung", "ANATOMY", 128, 132], ["function", "OBSERVATION", 133, 141]]], ["The test has not only generated considerable physiological interest but has also been proposed as a sensitive and valuable means of detecting and quantifying a wide spectrum of subtle to clinically obvious degrees of lung injury.", [["lung", "ANATOMY", 217, 221], ["lung injury", "DISEASE", 217, 228], ["lung", "ORGAN", 217, 221], ["lung injury", "PROBLEM", 217, 228], ["lung", "ANATOMY", 217, 221], ["injury", "OBSERVATION", 222, 228]]], ["The test, however, has perhaps not been adopted by nuclear medicine units as much as its early promise seemed to justify.", [["The test", "TEST", 0, 8]]], ["This review, after discussing the physiology of the test and its potential clinical applications, identifies some possible reasons for this.IntroductionCorrespondence to: A.M. Peters, Department of Radiology, Hammersmith Hospital, Du Cane Road, London W12 0HS, UKTheoretical basis of solute transferThe pulmonary blood-gas barierTheoretical basis of solute transferThe barrier separating pulmonary capillary blood from alveolar air in a lung unit consists of vascular endothelium, alveolar epithelium and the intervening pulmonary interstitium.", [["pulmonary blood", "ANATOMY", 303, 318], ["pulmonary capillary blood", "ANATOMY", 388, 413], ["alveolar air", "ANATOMY", 419, 431], ["lung unit", "ANATOMY", 437, 446], ["vascular endothelium", "ANATOMY", 459, 479], ["alveolar epithelium", "ANATOMY", 481, 500], ["pulmonary interstitium", "ANATOMY", 521, 543], ["pulmonary", "ORGAN", 303, 312], ["blood", "ORGANISM_SUBSTANCE", 313, 318], ["solute", "SIMPLE_CHEMICAL", 350, 356], ["barrier", "TISSUE", 369, 376], ["pulmonary capillary blood", "ORGANISM_SUBSTANCE", 388, 413], ["alveolar air", "MULTI-TISSUE_STRUCTURE", 419, 431], ["lung", "ORGAN", 437, 441], ["vascular endothelium", "TISSUE", 459, 479], ["alveolar epithelium", "TISSUE", 481, 500], ["pulmonary interstitium", "MULTI-TISSUE_STRUCTURE", 521, 543], ["the test", "TEST", 48, 56], ["The pulmonary blood", "TEST", 299, 318], ["The barrier separating pulmonary capillary blood", "PROBLEM", 365, 413], ["alveolar air", "PROBLEM", 419, 431], ["alveolar epithelium and the intervening pulmonary interstitium", "PROBLEM", 481, 543], ["pulmonary", "ANATOMY", 303, 312], ["gas barier", "OBSERVATION", 319, 329], ["barrier", "OBSERVATION_MODIFIER", 369, 376], ["pulmonary", "ANATOMY", 388, 397], ["capillary blood", "OBSERVATION", 398, 413], ["alveolar air", "OBSERVATION", 419, 431], ["lung", "ANATOMY", 437, 441], ["unit", "ANATOMY_MODIFIER", 442, 446], ["vascular endothelium", "ANATOMY", 459, 479], ["alveolar", "ANATOMY_MODIFIER", 481, 489], ["epithelium", "ANATOMY_MODIFIER", 490, 500], ["pulmonary", "ANATOMY", 521, 530], ["interstitium", "ANATOMY_MODIFIER", 531, 543]]], ["It also includes a film of fluid lining the airspace within which inhaled solutes are dissolved.", [["airspace", "ANATOMY", 44, 52], ["airspace", "MULTI-TISSUE_STRUCTURE", 44, 52], ["a film of", "TEST", 17, 26], ["fluid lining the airspace", "PROBLEM", 27, 52], ["fluid", "OBSERVATION", 27, 32], ["airspace", "ANATOMY_MODIFIER", 44, 52], ["inhaled solutes", "OBSERVATION", 66, 81], ["dissolved", "OBSERVATION_MODIFIER", 86, 95]]], ["Because they can penetrate cells directly, small lipophilic molecules, such as hexamethylpropylene amine oxime, rapidly penetrate the barrier [1] and the capacity for transfer from alveolus to blood is dependent on how rapidly they can be carried away from the barrier by pulmonary venous blood; i.e. their transfer rate is blood flow or perfusion-dependent.", [["cells", "ANATOMY", 27, 32], ["alveolus", "ANATOMY", 181, 189], ["blood", "ANATOMY", 193, 198], ["pulmonary venous blood", "ANATOMY", 272, 294], ["blood", "ANATOMY", 324, 329], ["hexamethylpropylene amine oxime", "CHEMICAL", 79, 110], ["hexamethylpropylene amine oxime", "CHEMICAL", 79, 110], ["cells", "CELL", 27, 32], ["hexamethylpropylene amine oxime", "SIMPLE_CHEMICAL", 79, 110], ["alveolus", "ORGAN", 181, 189], ["blood", "ORGANISM_SUBSTANCE", 193, 198], ["barrier", "TISSUE", 261, 268], ["pulmonary venous", "MULTI-TISSUE_STRUCTURE", 272, 288], ["blood", "ORGANISM_SUBSTANCE", 289, 294], ["blood", "ORGANISM_SUBSTANCE", 324, 329], ["small lipophilic molecules", "PROBLEM", 43, 69], ["hexamethylpropylene amine oxime", "TREATMENT", 79, 110], ["pulmonary venous blood", "TEST", 272, 294], ["blood flow", "TEST", 324, 334], ["small", "OBSERVATION_MODIFIER", 43, 48], ["lipophilic molecules", "OBSERVATION", 49, 69], ["pulmonary venous", "ANATOMY", 272, 288]]], ["Transfer of hydrophilic solutes across the blood-gas barrier, on the other hand, is much slower as it depends on passive diffusion through the intercellular junctions of the epithelium and endothelium [2] [3] [4] ; the cross-sectional area of these spaces is miniscule compared with the total surface area of the barrier.", [["blood", "ANATOMY", 43, 48], ["intercellular junctions", "ANATOMY", 143, 166], ["epithelium", "ANATOMY", 174, 184], ["endothelium", "ANATOMY", 189, 200], ["surface area", "ANATOMY", 293, 305], ["blood", "ORGANISM_SUBSTANCE", 43, 48], ["intercellular junctions", "CELLULAR_COMPONENT", 143, 166], ["epithelium", "TISSUE", 174, 184], ["endothelium", "TISSUE", 189, 200], ["barrier", "TISSUE", 313, 320], ["hydrophilic solutes", "PROBLEM", 12, 31], ["the blood", "TEST", 39, 48], ["hydrophilic solutes", "OBSERVATION_MODIFIER", 12, 31], ["blood", "ANATOMY", 43, 48], ["intercellular", "ANATOMY_MODIFIER", 143, 156], ["junctions", "ANATOMY_MODIFIER", 157, 166], ["epithelium", "ANATOMY_MODIFIER", 174, 184], ["endothelium", "ANATOMY", 189, 200], ["spaces", "OBSERVATION", 249, 255]]], ["Blood flow exerts a negligible influence on the transfer rate of a hydrophilic solute, which is said, therefore, to be perfusion-independent, or alternatively diffusion-dependent.", [["Blood", "ANATOMY", 0, 5], ["Blood", "ORGANISM_SUBSTANCE", 0, 5], ["Blood flow", "TEST", 0, 10], ["a negligible influence", "PROBLEM", 18, 40], ["negligible", "OBSERVATION_MODIFIER", 20, 30]]], ["Nevertheless, as blood flow decreases to low levels, diffusion-dependent transfer gradually becomes perfusion-dependent.Restricted and unrestricted diffusionThe diffusion rate of a hydrophilic solute in aqueous solution (free diffusion) is approximately inversely proportional to the cube root of molecular size.", [["blood", "ANATOMY", 17, 22], ["blood", "ORGANISM_SUBSTANCE", 17, 22], ["blood flow", "TEST", 17, 27], ["low levels", "PROBLEM", 41, 51], ["The diffusion rate", "TEST", 157, 175], ["hydrophilic", "OBSERVATION_MODIFIER", 181, 192], ["cube root", "OBSERVATION", 284, 293], ["molecular", "OBSERVATION_MODIFIER", 297, 306], ["size", "OBSERVATION_MODIFIER", 307, 311]]], ["If a solute is small compared with the diameter of a pore in an epithelial or endothelial membrane through which it diffuses, then the transfer rate across the membrane is similar to the rate of free diffusion and can be described as unrestricted.", [["pore", "ANATOMY", 53, 57], ["epithelial", "ANATOMY", 64, 74], ["endothelial membrane", "ANATOMY", 78, 98], ["membrane", "ANATOMY", 160, 168], ["epithelial", "TISSUE", 64, 74], ["endothelial membrane", "CELLULAR_COMPONENT", 78, 98], ["membrane", "CELLULAR_COMPONENT", 160, 168], ["solute", "OBSERVATION_MODIFIER", 5, 11], ["small", "OBSERVATION_MODIFIER", 15, 20], ["pore", "OBSERVATION_MODIFIER", 53, 57], ["epithelial", "ANATOMY_MODIFIER", 64, 74], ["endothelial membrane", "ANATOMY", 78, 98], ["diffuses", "OBSERVATION_MODIFIER", 116, 124], ["free diffusion", "OBSERVATION", 195, 209]]], ["If, on the other hand, the size of the molecule begins to approach that of the diameter of the pore, then diffusion is slowed to a rate less than the rate of free diffusion in solution, and diffusion across the membrane can be described as restricted.", [["pore", "ANATOMY", 95, 99], ["membrane", "ANATOMY", 211, 219], ["membrane", "CELLULAR_COMPONENT", 211, 219], ["a rate", "TEST", 129, 135], ["size", "OBSERVATION_MODIFIER", 27, 31], ["molecule", "OBSERVATION", 39, 47], ["diameter", "OBSERVATION_MODIFIER", 79, 87], ["pore", "OBSERVATION_MODIFIER", 95, 99], ["slowed", "OBSERVATION_MODIFIER", 119, 125]]], ["\"Molecular sieving\" is an apt term to describe this aspect of barrier function.Pulmonary alveolar epithelial permeability as an index of lung damageEpithelial permeability is about l0 times lower than endothelial permeability.", [["barrier", "ANATOMY", 62, 69], ["Pulmonary alveolar epithelial", "ANATOMY", 79, 108], ["lung", "ANATOMY", 137, 141], ["Epithelial", "ANATOMY", 148, 158], ["endothelial", "ANATOMY", 201, 212], ["lung damage", "DISEASE", 137, 148], ["barrier", "TISSUE", 62, 69], ["Pulmonary alveolar epithelial", "TISSUE", 79, 108], ["lung", "ORGAN", 137, 141], ["Epithelial", "TISSUE", 148, 158], ["endothelial", "TISSUE", 201, 212], ["Pulmonary alveolar epithelial permeability", "PROBLEM", 79, 121], ["lung damage", "PROBLEM", 137, 148], ["Epithelial permeability", "PROBLEM", 148, 171], ["alveolar", "ANATOMY_MODIFIER", 89, 97], ["epithelial", "ANATOMY_MODIFIER", 98, 108], ["permeability", "OBSERVATION", 109, 121], ["lung", "ANATOMY", 137, 141], ["damage", "OBSERVATION", 142, 148], ["permeability", "OBSERVATION", 159, 171], ["about l0 times lower", "OBSERVATION_MODIFIER", 175, 195], ["endothelial", "ANATOMY", 201, 212], ["permeability", "OBSERVATION", 213, 225]]], ["It is therefore the rate-limiting variable in the diffusion of solutes across the barrier [5] and can be quantified by measuring the rate of transfer of a hydrophilic solute from alveolus to blood.", [["alveolus", "ANATOMY", 179, 187], ["blood", "ANATOMY", 191, 196], ["alveolus", "ORGAN", 179, 187], ["blood", "ORGANISM_SUBSTANCE", 191, 196], ["the rate", "TEST", 16, 24], ["variable", "OBSERVATION_MODIFIER", 34, 42]]], ["As the alveolar permeability to a hydrophilic solute is readily influenced by lung damage [6, 7] , the rate of clearance of an inhaled nebulised solute has become established as a means of detecting and quantifying the severity of diffuse interstitial pulmonary disease [2, 3, [6] [7] [8] .", [["alveolar", "ANATOMY", 7, 15], ["lung", "ANATOMY", 78, 82], ["diffuse interstitial pulmonary", "ANATOMY", 231, 261], ["lung damage", "DISEASE", 78, 89], ["interstitial pulmonary disease", "DISEASE", 239, 269], ["alveolar", "MULTI-TISSUE_STRUCTURE", 7, 15], ["lung", "ORGAN", 78, 82], ["pulmonary", "ORGAN", 252, 261], ["[6] [7] [8]", "SIMPLE_CHEMICAL", 277, 288], ["lung damage", "PROBLEM", 78, 89], ["an inhaled nebulised solute", "TREATMENT", 124, 151], ["diffuse interstitial pulmonary disease", "PROBLEM", 231, 269], ["alveolar", "ANATOMY_MODIFIER", 7, 15], ["lung", "ANATOMY", 78, 82], ["damage", "OBSERVATION", 83, 89], ["diffuse", "OBSERVATION_MODIFIER", 231, 238], ["interstitial", "ANATOMY_MODIFIER", 239, 251], ["pulmonary", "ANATOMY", 252, 261], ["disease", "OBSERVATION", 262, 269]]], ["Because of its availability and convenience, technetium-99m diethylene triamine penta-acetic acid (99mTc-DTPA) has become established as the solute for this approach.", [["technetium-99m diethylene triamine penta-acetic acid", "CHEMICAL", 45, 97], ["99mTc-DTPA", "CHEMICAL", 99, 109], ["technetium", "CHEMICAL", 45, 55], ["diethylene triamine penta-acetic acid", "CHEMICAL", 60, 97], ["99mTc-DTPA", "CHEMICAL", 99, 109], ["technetium-99m diethylene triamine penta-acetic acid", "SIMPLE_CHEMICAL", 45, 97], ["99mTc-DTPA", "SIMPLE_CHEMICAL", 99, 109], ["technetium", "TEST", 45, 55], ["diethylene triamine penta-acetic acid (99mTc-DTPA", "TREATMENT", 60, 109], ["this approach", "TREATMENT", 152, 165]]], ["Following inhalation, 99mTc-DTPA is cleared from the distal airway into pulmonary capillary blood and ultimately excreted in the urine.", [["distal airway", "ANATOMY", 53, 66], ["pulmonary capillary blood", "ANATOMY", 72, 97], ["urine", "ANATOMY", 129, 134], ["99mTc-DTPA", "CHEMICAL", 22, 32], ["99mTc", "CHEMICAL", 22, 27], ["DTPA", "CHEMICAL", 28, 32], ["99mTc-DTPA", "SIMPLE_CHEMICAL", 22, 32], ["airway", "MULTI-TISSUE_STRUCTURE", 60, 66], ["pulmonary capillary blood", "ORGANISM_SUBSTANCE", 72, 97], ["urine", "ORGANISM_SUBSTANCE", 129, 134], ["inhalation", "TREATMENT", 10, 20], ["99mTc-DTPA", "TREATMENT", 22, 32], ["pulmonary capillary blood", "TEST", 72, 97], ["distal", "ANATOMY_MODIFIER", 53, 59], ["airway", "ANATOMY", 60, 66], ["pulmonary capillary", "ANATOMY", 72, 91]]], ["The rate of disappearance can be monitored by continuous scintigraphic detection using a gamma camera or scintillation probe and expressed as a t m or rate constant of clearance.Aerosol generation and deliveryThe penetration into distal lung by an aerosol is dependent on nebulised particle size.", [["distal lung", "ANATOMY", 230, 241], ["lung", "ORGAN", 237, 241], ["continuous scintigraphic detection", "TEST", 46, 80], ["a gamma camera", "TREATMENT", 87, 101], ["scintillation probe", "TREATMENT", 105, 124], ["Aerosol generation", "TREATMENT", 178, 196], ["delivery", "TREATMENT", 201, 209], ["The penetration into distal lung", "PROBLEM", 209, 241], ["penetration", "OBSERVATION", 213, 224], ["distal", "ANATOMY_MODIFIER", 230, 236], ["lung", "ANATOMY", 237, 241], ["aerosol", "OBSERVATION", 248, 255], ["dependent", "OBSERVATION_MODIFIER", 259, 268], ["particle", "OBSERVATION_MODIFIER", 282, 290], ["size", "OBSERVATION_MODIFIER", 291, 295]]], ["Although the movement of gas in the airways beyond the 16th generation of bronchi is by molecular diffusion in air rather than convection [9] , there is evidence that aerosol particles penetrate to the distal airways and alveoli.", [["airways", "ANATOMY", 36, 43], ["bronchi", "ANATOMY", 74, 81], ["distal airways", "ANATOMY", 202, 216], ["alveoli", "ANATOMY", 221, 228], ["airways", "MULTI-TISSUE_STRUCTURE", 36, 43], ["bronchi", "MULTI-TISSUE_STRUCTURE", 74, 81], ["airways", "MULTI-TISSUE_STRUCTURE", 209, 216], ["alveoli", "MULTI-TISSUE_STRUCTURE", 221, 228], ["gas in the airways", "PROBLEM", 25, 43], ["molecular diffusion in air", "PROBLEM", 88, 114], ["aerosol particles", "TREATMENT", 167, 184], ["movement", "OBSERVATION_MODIFIER", 13, 21], ["gas", "OBSERVATION", 25, 28], ["airways", "ANATOMY", 36, 43], ["bronchi", "ANATOMY", 74, 81], ["molecular", "OBSERVATION_MODIFIER", 88, 97], ["diffusion", "OBSERVATION_MODIFIER", 98, 107], ["aerosol particles", "OBSERVATION", 167, 184], ["distal", "ANATOMY_MODIFIER", 202, 208], ["airways", "ANATOMY", 209, 216], ["alveoli", "ANATOMY_MODIFIER", 221, 228]]], ["Thus, whilst the half-time of 99mTc-DTPA pulmonary clearance in normal dogs is about 20 min, it is increased by ligation of the pulmonary artery but not of the bronchial arteries [10] .", [["pulmonary", "ANATOMY", 41, 50], ["pulmonary artery", "ANATOMY", 128, 144], ["bronchial arteries", "ANATOMY", 160, 178], ["99mTc-DTPA", "CHEMICAL", 30, 40], ["99mTc", "CHEMICAL", 30, 35], ["DTPA", "CHEMICAL", 36, 40], ["99mTc-DTPA", "SIMPLE_CHEMICAL", 30, 40], ["pulmonary", "ORGAN", 41, 50], ["dogs", "ORGANISM", 71, 75], ["pulmonary artery", "MULTI-TISSUE_STRUCTURE", 128, 144], ["bronchial arteries", "MULTI-TISSUE_STRUCTURE", 160, 178], ["pulmonary", "ANATOMY", 41, 50], ["normal dogs", "OBSERVATION", 64, 75], ["increased", "OBSERVATION_MODIFIER", 99, 108], ["ligation", "OBSERVATION", 112, 120], ["pulmonary artery", "ANATOMY", 128, 144], ["bronchial arteries", "ANATOMY", 160, 178]]], ["Occlusion of both pulmonary and bronchial flows greatly increases the half-time because collateral bronchial flow is responsible for the clearance after pulmonary arterial occlusion.Quantitative basis of epithelial transferIn the lung, the transfer rate, J, of solute per unit of lung tissue can be defined in terms of the permeability-surface area (PS) product of the blood-gas barrier and the solute concentration, C, in alveolar fluid:Quantitative basis of epithelial transferDividing both sides of the above equation by M, the amount of solute present, gives: J C --~-=PS.", [["pulmonary", "ANATOMY", 18, 27], ["bronchial", "ANATOMY", 32, 41], ["collateral bronchial", "ANATOMY", 88, 108], ["pulmonary arterial", "ANATOMY", 153, 171], ["epithelial", "ANATOMY", 204, 214], ["lung", "ANATOMY", 230, 234], ["lung tissue", "ANATOMY", 280, 291], ["blood", "ANATOMY", 369, 374], ["alveolar fluid", "ANATOMY", 423, 437], ["epithelial", "ANATOMY", 460, 470], ["pulmonary arterial occlusion", "DISEASE", 153, 181], ["pulmonary", "ORGAN", 18, 27], ["bronchial", "MULTI-TISSUE_STRUCTURE", 32, 41], ["collateral bronchial", "MULTI-TISSUE_STRUCTURE", 88, 108], ["pulmonary arterial", "MULTI-TISSUE_STRUCTURE", 153, 171], ["epithelial", "TISSUE", 204, 214], ["lung", "ORGAN", 230, 234], ["lung tissue", "TISSUE", 280, 291], ["blood", "ORGANISM_SUBSTANCE", 369, 374], ["solute", "SIMPLE_CHEMICAL", 395, 401], ["C", "SIMPLE_CHEMICAL", 417, 418], ["epithelial", "TISSUE", 460, 470], ["Occlusion of both pulmonary and bronchial flows", "PROBLEM", 0, 47], ["collateral bronchial flow", "PROBLEM", 88, 113], ["pulmonary arterial occlusion", "PROBLEM", 153, 181], ["epithelial transfer", "TREATMENT", 204, 223], ["solute per unit of lung tissue", "TREATMENT", 261, 291], ["the blood-gas barrier", "TREATMENT", 365, 386], ["the solute concentration", "TREATMENT", 391, 415], ["epithelial transfer", "TREATMENT", 460, 479], ["both", "ANATOMY_MODIFIER", 13, 17], ["pulmonary", "ANATOMY", 18, 27], ["bronchial", "ANATOMY", 32, 41], ["flows", "ANATOMY_MODIFIER", 42, 47], ["collateral", "OBSERVATION_MODIFIER", 88, 98], ["bronchial flow", "OBSERVATION", 99, 113], ["pulmonary arterial", "ANATOMY", 153, 171], ["occlusion", "OBSERVATION", 172, 181], ["epithelial", "ANATOMY_MODIFIER", 204, 214], ["lung", "ANATOMY", 230, 234], ["lung", "ANATOMY", 280, 284], ["tissue", "OBSERVATION", 285, 291], ["alveolar", "ANATOMY", 423, 431], ["fluid", "OBSERVATION", 432, 437], ["epithelial", "ANATOMY_MODIFIER", 460, 470], ["amount", "OBSERVATION_MODIFIER", 531, 537]]], ["M\" J/M is the fractional clearance rate, k, of solute and C/M is equal to UV, where Vis alveolar fluid volume, so:Quantitative basis of epithelial transferIt can be seen from this that the rate constant of clearance is directly dependent on the permeability coeffi-cient and surface area for exchange, and inversely dependent on the volume of alveolar fluid in which the solute is dispersed.", [["alveolar fluid", "ANATOMY", 88, 102], ["epithelial", "ANATOMY", 136, 146], ["surface area", "ANATOMY", 275, 287], ["alveolar fluid", "ANATOMY", 343, 357], ["solute", "SIMPLE_CHEMICAL", 47, 53], ["epithelial", "TISSUE", 136, 146], ["alveolar fluid", "MULTI-TISSUE_STRUCTURE", 343, 357], ["the fractional clearance rate", "TEST", 10, 39], ["solute and C/M", "PROBLEM", 47, 61], ["Vis alveolar fluid volume", "TEST", 84, 109], ["epithelial transfer", "TREATMENT", 136, 155], ["epithelial", "ANATOMY", 136, 146], ["dependent", "OBSERVATION_MODIFIER", 228, 237], ["surface", "OBSERVATION_MODIFIER", 275, 282], ["inversely", "OBSERVATION_MODIFIER", 306, 315], ["dependent", "OBSERVATION_MODIFIER", 316, 325], ["alveolar", "ANATOMY", 343, 351], ["fluid", "OBSERVATION", 352, 357]]], ["The permeability coefficient itself can be expressed thus:Factors determining clearance rateThe clearance rate of a solute from distal airway is dependent on several factors related to the properties of both the solute and the lung.", [["distal airway", "ANATOMY", 128, 141], ["lung", "ANATOMY", 227, 231], ["airway", "MULTI-TISSUE_STRUCTURE", 135, 141], ["lung", "ORGAN", 227, 231], ["clearance rate", "TEST", 78, 92], ["clearance", "OBSERVATION_MODIFIER", 96, 105], ["distal", "ANATOMY_MODIFIER", 128, 134], ["airway", "ANATOMY", 135, 141], ["dependent", "OBSERVATION_MODIFIER", 145, 154], ["both", "ANATOMY_MODIFIER", 203, 207], ["solute", "ANATOMY_MODIFIER", 212, 218], ["lung", "ANATOMY", 227, 231]]], ["As already mentioned, lipophilic solutes are cleared very rapidly as a result of their ability to cross the epithelium by direct cellular penetration.", [["epithelium", "ANATOMY", 108, 118], ["cellular", "ANATOMY", 129, 137], ["lipophilic solutes", "SIMPLE_CHEMICAL", 22, 40], ["epithelium", "TISSUE", 108, 118], ["cellular", "CELL", 129, 137], ["lipophilic solutes", "PROBLEM", 22, 40], ["lipophilic solutes", "OBSERVATION", 22, 40], ["cellular penetration", "OBSERVATION", 129, 149]]], ["Since their removal rate is perfusion-dependent, they have no value for the determination of epithelial integrity in the setting of radiolabelled solute clearance studies.", [["epithelial", "ANATOMY", 93, 103], ["epithelial", "TISSUE", 93, 103], ["solute", "SIMPLE_CHEMICAL", 146, 152], ["epithelial integrity", "PROBLEM", 93, 113], ["radiolabelled solute clearance studies", "TEST", 132, 170], ["epithelial integrity", "OBSERVATION", 93, 113]]], ["Hydrophilic solutes, in contrast, exchange across the alveolar epithelium rauch more slowly at rates which depend on molecular charge and size.", [["alveolar epithelium", "ANATOMY", 54, 73], ["alveolar epithelium", "TISSUE", 54, 73], ["solutes", "OBSERVATION", 12, 19], ["alveolar", "ANATOMY_MODIFIER", 54, 62], ["epithelium", "ANATOMY_MODIFIER", 63, 73], ["slowly", "OBSERVATION_MODIFIER", 85, 91], ["molecular charge", "OBSERVATION", 117, 133], ["size", "OBSERVATION_MODIFIER", 138, 142]]], ["At normal levels of pulmonary blood flow, their transfer rates are diffusion-dependent and unaffected by changes in blood flow.", [["pulmonary blood", "ANATOMY", 20, 35], ["blood", "ANATOMY", 116, 121], ["pulmonary", "MULTI-TISSUE_STRUCTURE", 20, 29], ["blood", "ORGANISM_SUBSTANCE", 30, 35], ["blood", "ORGANISM_SUBSTANCE", 116, 121], ["pulmonary blood flow", "TEST", 20, 40], ["diffusion-dependent", "PROBLEM", 67, 86], ["blood flow", "TEST", 116, 126], ["pulmonary", "ANATOMY", 20, 29], ["blood flow", "OBSERVATION", 30, 40], ["blood flow", "OBSERVATION", 116, 126]]], ["The pores in the alveolar epithelium through which hydrophilic solutes diffuse are electrically charged and this explains why the transfer rate of a solute is dependent to some extent on its charge as well as its size.", [["pores", "ANATOMY", 4, 9], ["alveolar epithelium", "ANATOMY", 17, 36], ["alveolar epithelium", "TISSUE", 17, 36], ["pores", "OBSERVATION_MODIFIER", 4, 9], ["alveolar", "ANATOMY_MODIFIER", 17, 25], ["epithelium", "ANATOMY_MODIFIER", 26, 36], ["hydrophilic", "OBSERVATION_MODIFIER", 51, 62], ["solutes", "OBSERVATION_MODIFIER", 63, 70], ["diffuse", "OBSERVATION_MODIFIER", 71, 78], ["electrically", "OBSERVATION_MODIFIER", 83, 95], ["charged", "OBSERVATION", 96, 103], ["some extent", "OBSERVATION_MODIFIER", 172, 183], ["size", "OBSERVATION_MODIFIER", 213, 217]]], ["This was demonstrated by Barrowcliffe et al. [11] , who showed that neutral dextran has a shorter clearance half-time than similarly sized anionic or cationic dextran.", [["dextran", "CHEMICAL", 76, 83], ["dextran", "CHEMICAL", 159, 166], ["dextran", "SIMPLE_CHEMICAL", 76, 83], ["cationic dextran", "SIMPLE_CHEMICAL", 150, 166], ["neutral dextran", "TREATMENT", 68, 83], ["cationic dextran", "TREATMENT", 150, 166], ["cationic dextran", "OBSERVATION", 150, 166]]], ["The difference disappeared, however, following injury to the blood gas barrier induced by i.v. oleic acid, suggesting that the pore size and/or number increased and, additionally, lost charge.", [["blood", "ANATOMY", 61, 66], ["pore", "ANATOMY", 127, 131], ["oleic acid", "CHEMICAL", 95, 105], ["oleic acid", "CHEMICAL", 95, 105], ["blood", "ORGANISM_SUBSTANCE", 61, 66], ["i.v. oleic acid", "SIMPLE_CHEMICAL", 90, 105], ["pore", "CELLULAR_COMPONENT", 127, 131], ["injury", "PROBLEM", 47, 53], ["the blood gas barrier", "TEST", 57, 78], ["i.v. oleic acid", "TEST", 90, 105], ["the pore size", "TEST", 123, 136], ["difference", "OBSERVATION_MODIFIER", 4, 14], ["disappeared", "OBSERVATION_MODIFIER", 15, 26], ["pore", "OBSERVATION_MODIFIER", 127, 131], ["size", "OBSERVATION_MODIFIER", 132, 136], ["increased", "OBSERVATION_MODIFIER", 151, 160]]], ["The pulmonary factors of potential importance in determining the rate of solute transfer, apart from disease itself, include regional surface area available for exchange, regional lung volume, intra-alveolar pressure, the composition and volume of the fluid in the alveoli, surfactant, and back-diffusion of solute from blood to lung interstitium.Factors determining clearance rateSurface area, lung volume and intra-alveolar pressure are closely related in their effects on solute clearance rate.", [["pulmonary", "ANATOMY", 4, 13], ["surface area", "ANATOMY", 134, 146], ["lung", "ANATOMY", 180, 184], ["intra-alveolar", "ANATOMY", 193, 207], ["fluid", "ANATOMY", 252, 257], ["alveoli", "ANATOMY", 265, 272], ["blood", "ANATOMY", 320, 325], ["lung interstitium", "ANATOMY", 329, 346], ["rateSurface area", "ANATOMY", 377, 393], ["lung", "ANATOMY", 395, 399], ["intra-alveolar", "ANATOMY", 411, 425], ["pulmonary", "ORGAN", 4, 13], ["lung", "ORGAN", 180, 184], ["intra-alveolar", "IMMATERIAL_ANATOMICAL_ENTITY", 193, 207], ["alveoli", "MULTI-TISSUE_STRUCTURE", 265, 272], ["blood", "ORGANISM_SUBSTANCE", 320, 325], ["lung interstitium", "MULTI-TISSUE_STRUCTURE", 329, 346], ["lung", "ORGAN", 395, 399], ["intra-alveolar", "IMMATERIAL_ANATOMICAL_ENTITY", 411, 425], ["solute", "SIMPLE_CHEMICAL", 475, 481], ["pulmonary factors", "PROTEIN", 4, 21], ["disease itself", "PROBLEM", 101, 115], ["regional surface area", "TREATMENT", 125, 146], ["regional lung volume", "TEST", 171, 191], ["intra-alveolar pressure", "TEST", 193, 216], ["surfactant", "TREATMENT", 274, 284], ["lung volume", "TEST", 395, 406], ["intra-alveolar pressure", "TEST", 411, 434], ["solute clearance rate", "TEST", 475, 496], ["pulmonary", "ANATOMY", 4, 13], ["disease", "OBSERVATION", 101, 108], ["lung", "ANATOMY", 180, 184], ["volume", "OBSERVATION", 185, 191], ["intra-alveolar pressure", "OBSERVATION", 193, 216], ["volume", "OBSERVATION_MODIFIER", 238, 244], ["fluid", "OBSERVATION", 252, 257], ["alveoli", "ANATOMY", 265, 272], ["surfactant", "OBSERVATION_MODIFIER", 274, 284], ["back", "ANATOMY", 290, 294], ["lung", "ANATOMY", 329, 333], ["interstitium", "ANATOMY_MODIFIER", 334, 346], ["lung", "ANATOMY", 395, 399], ["volume", "OBSERVATION", 400, 406], ["intra-alveolar pressure", "OBSERVATION", 411, 434]]], ["Marks et al. [12] addressed surface area and lung volume by measuring half-time of 99mTc-DTPA clearance at resting and elevated lung volumes.", [["surface area", "ANATOMY", 28, 40], ["lung", "ANATOMY", 45, 49], ["lung", "ANATOMY", 128, 132], ["99mTc-DTPA", "CHEMICAL", 83, 93], ["99mTc", "CHEMICAL", 83, 88], ["DTPA", "CHEMICAL", 89, 93], ["lung", "ORGAN", 45, 49], ["99mTc-DTPA", "SIMPLE_CHEMICAL", 83, 93], ["lung", "ORGAN", 128, 132], ["lung volume", "TEST", 45, 56], ["99mTc", "TEST", 83, 88], ["DTPA clearance", "TEST", 89, 103], ["elevated lung volumes", "PROBLEM", 119, 140], ["lung", "ANATOMY", 45, 49], ["volume", "ANATOMY_MODIFIER", 50, 56], ["elevated", "OBSERVATION", 119, 127], ["lung", "ANATOMY", 128, 132], ["volumes", "ANATOMY_MODIFIER", 133, 140]]], ["They were unable to distinguish between lung volume itself and the increase in surface area that accompanies an increase in lung volume, whether it was during or after inhalation of the solute.", [["lung", "ANATOMY", 40, 44], ["surface area", "ANATOMY", 79, 91], ["lung", "ANATOMY", 124, 128], ["lung", "ORGAN", 40, 44], ["lung", "ORGAN", 124, 128], ["the increase in surface area", "PROBLEM", 63, 91], ["an increase in lung volume", "PROBLEM", 109, 135], ["lung", "ANATOMY", 40, 44], ["volume", "OBSERVATION", 45, 51], ["increase", "OBSERVATION_MODIFIER", 67, 75], ["surface", "OBSERVATION_MODIFIER", 79, 86], ["area", "OBSERVATION_MODIFIER", 87, 91], ["increase", "OBSERVATION_MODIFIER", 112, 120], ["lung", "ANATOMY", 124, 128], ["volume", "OBSERVATION", 129, 135]]], ["Expansion of the lung might be expected to stretch epithelial cells and pull them apart, thereby enlarging the diameter of the pores.", [["lung", "ANATOMY", 17, 21], ["epithelial cells", "ANATOMY", 51, 67], ["pores", "ANATOMY", 127, 132], ["lung", "ORGAN", 17, 21], ["epithelial cells", "CELL", 51, 67], ["stretch epithelial cells", "CELL_TYPE", 43, 67], ["Expansion of the lung", "PROBLEM", 0, 21], ["stretch epithelial cells", "PROBLEM", 43, 67], ["lung", "ANATOMY", 17, 21], ["might be expected to", "UNCERTAINTY", 22, 42], ["stretch epithelial cells", "OBSERVATION", 43, 67], ["enlarging", "OBSERVATION_MODIFIER", 97, 106], ["diameter", "OBSERVATION_MODIFIER", 111, 119], ["pores", "OBSERVATION_MODIFIER", 127, 132]]], ["Because of the arrangement of the alveolar septa in pleats, however, expansion in lung volume may not necessarily be associated with stretching of the alveolar walls [12, 13] .Factors determining clearance rateSurfactant seems to play a role in determining epithelial permeability to hydrophilic solutes but the mechanism is unclear [14] .", [["alveolar septa", "ANATOMY", 34, 48], ["pleats", "ANATOMY", 52, 58], ["lung", "ANATOMY", 82, 86], ["alveolar walls", "ANATOMY", 151, 165], ["epithelial", "ANATOMY", 257, 267], ["rateSurfactant", "CHEMICAL", 206, 220], ["alveolar septa", "MULTI-TISSUE_STRUCTURE", 34, 48], ["lung", "ORGAN", 82, 86], ["alveolar walls", "MULTI-TISSUE_STRUCTURE", 151, 165], ["rateSurfactant", "SIMPLE_CHEMICAL", 206, 220], ["epithelial", "TISSUE", 257, 267], ["the alveolar septa in pleats", "PROBLEM", 30, 58], ["expansion in lung volume", "PROBLEM", 69, 93], ["epithelial permeability to hydrophilic solutes", "PROBLEM", 257, 303], ["alveolar septa", "OBSERVATION", 34, 48], ["expansion", "OBSERVATION_MODIFIER", 69, 78], ["lung", "ANATOMY", 82, 86], ["volume", "OBSERVATION", 87, 93], ["may not necessarily be associated with", "UNCERTAINTY", 94, 132], ["stretching", "OBSERVATION", 133, 143], ["alveolar", "ANATOMY_MODIFIER", 151, 159], ["walls", "ANATOMY_MODIFIER", 160, 165]]], ["Alveolar fluid volume and diffusion distances within the alveolus are difficult to study.Factors determining clearance rateAlthough it is evident from Eq.", [["Alveolar fluid", "ANATOMY", 0, 14], ["alveolus", "ANATOMY", 57, 65], ["Alveolar fluid", "MULTI-TISSUE_STRUCTURE", 0, 14], ["alveolus", "MULTI-TISSUE_STRUCTURE", 57, 65], ["Alveolar fluid volume", "TEST", 0, 21], ["diffusion distances within the alveolus", "PROBLEM", 26, 65], ["fluid volume", "OBSERVATION", 9, 21], ["diffusion distances", "OBSERVATION", 26, 45], ["alveolus", "ANATOMY", 57, 65]]], ["2 that an increase in fluid volume would, by itself, be expected to decrease solute transfer rate as a result of a lower intra-alveolar fluid solute concentration, cardiogenic pulmonary oedema is not associated with reduced solute clearance [15] .", [["fluid", "ANATOMY", 22, 27], ["intra-alveolar fluid", "ANATOMY", 121, 141], ["pulmonary", "ANATOMY", 176, 185], ["cardiogenic pulmonary oedema", "DISEASE", 164, 192], ["fluid", "ORGANISM_SUBSTANCE", 22, 27], ["pulmonary", "ORGAN", 176, 185], ["an increase in fluid volume", "TREATMENT", 7, 34], ["solute transfer rate", "TREATMENT", 77, 97], ["a lower intra-alveolar fluid solute concentration", "TREATMENT", 113, 162], ["cardiogenic pulmonary oedema", "PROBLEM", 164, 192], ["reduced solute clearance", "PROBLEM", 216, 240], ["increase", "OBSERVATION_MODIFIER", 10, 18], ["fluid volume", "OBSERVATION", 22, 34], ["lower", "OBSERVATION_MODIFIER", 115, 120], ["intra-alveolar fluid", "OBSERVATION", 121, 141], ["solute concentration", "OBSERVATION", 142, 162], ["cardiogenic", "OBSERVATION_MODIFIER", 164, 175], ["pulmonary", "ANATOMY", 176, 185], ["oedema", "OBSERVATION", 186, 192]]], ["Pulmonay oedema due to lung injury, on the other hand, results in a greatly increased transfer rate by virtue of an increase in permeability.The bi-exponential clearanceAn interesting feature of the severely injured lung is that the clearance curve may b\u00ebcome bi-exponential [16] .", [["lung", "ANATOMY", 23, 27], ["lung", "ANATOMY", 216, 220], ["oedema", "DISEASE", 9, 15], ["lung injury", "DISEASE", 23, 34], ["lung", "ORGAN", 23, 27], ["lung", "ORGAN", 216, 220], ["Pulmonay oedema", "PROBLEM", 0, 15], ["lung injury", "PROBLEM", 23, 34], ["the severely injured lung", "PROBLEM", 195, 220], ["the clearance curve", "TEST", 229, 248], ["oedema", "OBSERVATION", 9, 15], ["lung", "ANATOMY", 23, 27], ["injury", "OBSERVATION", 28, 34], ["increase", "OBSERVATION_MODIFIER", 116, 124], ["permeability", "OBSERVATION_MODIFIER", 128, 140], ["severely", "OBSERVATION_MODIFIER", 199, 207], ["injured", "OBSERVATION", 208, 215], ["lung", "ANATOMY", 216, 220]]], ["It has been suggested that this is the result of two populations of lung units with different degrees of damage and correspondingly different clearance rates.", [["lung", "ANATOMY", 68, 72], ["lung", "ORGAN", 68, 72], ["lung units", "TREATMENT", 68, 78], ["damage", "PROBLEM", 105, 111], ["lung", "ANATOMY", 68, 72], ["different degrees", "OBSERVATION_MODIFIER", 84, 101], ["damage", "OBSERVATION", 105, 111], ["correspondingly", "OBSERVATION_MODIFIER", 116, 131], ["different", "OBSERVATION_MODIFIER", 132, 141], ["clearance", "OBSERVATION_MODIFIER", 142, 151]]], ["The evidence for this is that lung damage produced by i.v. oleic acid is not homogeneous.", [["lung", "ANATOMY", 30, 34], ["lung damage", "DISEASE", 30, 41], ["oleic acid", "CHEMICAL", 59, 69], ["oleic acid", "CHEMICAL", 59, 69], ["lung", "ORGAN", 30, 34], ["i.v. oleic acid", "SIMPLE_CHEMICAL", 54, 69], ["lung damage", "PROBLEM", 30, 41], ["i.v. oleic acid", "TEST", 54, 69], ["evidence for", "UNCERTAINTY", 4, 16], ["lung", "ANATOMY", 30, 34], ["damage", "OBSERVATION", 35, 41], ["oleic acid", "OBSERVATION", 59, 69], ["not", "UNCERTAINTY", 73, 76], ["homogeneous", "OBSERVATION_MODIFIER", 77, 88]]], ["However, a biexponential curve is often seen when the clearance rate is markedly increased from any cause, raising the possibility of other explanations for the bi-exponential shape.", [["a biexponential curve", "TEST", 9, 30], ["the clearance rate", "TEST", 50, 68], ["the bi-exponential shape", "PROBLEM", 157, 181], ["markedly", "OBSERVATION_MODIFIER", 72, 80], ["increased", "OBSERVATION_MODIFIER", 81, 90], ["raising the possibility of", "UNCERTAINTY", 107, 133]]], ["These include firstly, deposition of aerosol more proximally in the airway, with slower clearance, and secondly, back-diffusion of tracer from blood to interstitium.", [["airway", "ANATOMY", 68, 74], ["blood", "ANATOMY", 143, 148], ["interstitium", "ANATOMY", 152, 164], ["airway", "MULTI-TISSUE_STRUCTURE", 68, 74], ["blood", "ORGANISM_SUBSTANCE", 143, 148], ["interstitium", "MULTI-TISSUE_STRUCTURE", 152, 164], ["deposition of aerosol", "TREATMENT", 23, 44], ["deposition", "OBSERVATION_MODIFIER", 23, 33], ["aerosol", "OBSERVATION", 37, 44], ["proximally", "ANATOMY_MODIFIER", 50, 60], ["airway", "ANATOMY", 68, 74], ["slower", "OBSERVATION_MODIFIER", 81, 87], ["clearance", "OBSERVATION_MODIFIER", 88, 97], ["interstitium", "ANATOMY", 152, 164]]], ["It is easy to see how the latter could contribute towards a slower exponential, especially if alveolar flnid volume was increased as a direct consequence of an increase in permeability.Effects of cigarette smokingCigarette smokers with normal lung function have an increased clearance rate [3, 17, 18] which effectively disqualifies them from the test.", [["alveolar flnid", "ANATOMY", 94, 108], ["lung", "ANATOMY", 243, 247], ["Cigarette", "CHEMICAL", 213, 222], ["alveolar flnid", "MULTI-TISSUE_STRUCTURE", 94, 108], ["cigarette", "ORGANISM", 196, 205], ["Cigarette", "ORGANISM", 213, 222], ["lung", "ORGAN", 243, 247], ["alveolar flnid volume", "PROBLEM", 94, 115], ["an increase in permeability", "PROBLEM", 157, 184], ["an increased clearance rate", "PROBLEM", 262, 289], ["the test", "TEST", 343, 351], ["slower", "OBSERVATION_MODIFIER", 60, 66], ["exponential", "OBSERVATION_MODIFIER", 67, 78], ["increase", "OBSERVATION_MODIFIER", 160, 168], ["permeability", "OBSERVATION_MODIFIER", 172, 184], ["lung", "ANATOMY", 243, 247], ["increased", "OBSERVATION_MODIFIER", 265, 274]]], ["An approach which might be applicable to smokers is the simultaneous use of two tracers [19, 20] .", [["An approach", "TREATMENT", 0, 11]]], ["By inhaling two solutes of different size and measuring k for both, V/S in Eq.", [["measuring k", "TEST", 46, 57], ["V/S", "TEST", 68, 71], ["size", "OBSERVATION_MODIFIER", 37, 41]]], ["2 cancels out because it is identical for the two solutes and kl/k2=P1/P2.", [["P1", "DNA", 68, 70], ["P2", "DNA", 71, 73]]], ["(4) If PffP2 is greater than the ratio of free diffusion coefficients of the two solutes then restricted diffusion to at least the larger of the two taust be present [21] [22] [23] .", [["PffP2", "GENE_OR_GENE_PRODUCT", 7, 12], ["PffP2", "PROTEIN", 7, 12], ["PffP2", "TEST", 7, 12], ["restricted diffusion", "PROBLEM", 94, 114], ["larger", "OBSERVATION_MODIFIER", 131, 137]]], ["If smoking failed to influence restriction to diffusion, kl/k 2 would be unaffected and consequently transparent to the possible effects of disease.Effects of cigarette smokingRestriction to diffusion is closely related to the radius of the solute in relation to the radius of the pore; if pore radius were to increase, tben restriction to diffusion of a given solute may be lost.", [["pore", "ANATOMY", 281, 285], ["pore", "ANATOMY", 290, 294], ["smoking", "CHEMICAL", 3, 10], ["kl/k 2", "GENE_OR_GENE_PRODUCT", 57, 63], ["cigarette", "ORGANISM_SUBDIVISION", 159, 168], ["diffusion, kl/k 2", "TEST", 46, 63], ["disease", "PROBLEM", 140, 147], ["pore radius", "PROBLEM", 290, 301], ["disease", "OBSERVATION", 140, 147], ["cigarette smokingRestriction", "OBSERVATION", 159, 187], ["radius", "ANATOMY_MODIFIER", 227, 233], ["radius", "ANATOMY_MODIFIER", 267, 273], ["pore", "OBSERVATION_MODIFIER", 281, 285]]], ["If the increased clearance rate of a solute in smokers is not the result of an incre\u00e4se in pore radius then restriction to diffusion of a critical sized solute may be retained.", [["pore", "ANATOMY", 91, 95], ["an incre\u00e4se in pore radius", "TREATMENT", 76, 102], ["a critical sized solute", "TREATMENT", 136, 159], ["increased", "OBSERVATION_MODIFIER", 7, 16], ["clearance", "OBSERVATION_MODIFIER", 17, 26], ["pore radius", "OBSERVATION", 91, 102], ["may be", "UNCERTAINTY", 160, 166], ["retained", "OBSERVATION", 167, 175]]], ["Based on pore theory, the rate constant of clearance of solute across the epithelium can be described by:Effects of cigarette smokingwhere D is the free diffusion coefficient, A is the total cross-sectional area of pores and Ax is path length.", [["epithelium", "ANATOMY", 74, 84], ["epithelium", "TISSUE", 74, 84], ["the free diffusion coefficient", "PROBLEM", 144, 174]]], ["F is a constant which is a function of the ratio of the molecular radius (a) of the solute to pore radius (r); it ranges from 0 for a completely non-permeable solute to 1 for a freely diffusing solute (i.e. no restriction) and incorporates the effect of electrical charge [21, 22] .", [["pore", "ANATOMY", 94, 98], ["a freely diffusing solute", "PROBLEM", 175, 200], ["constant", "OBSERVATION_MODIFIER", 7, 15], ["molecular radius", "ANATOMY", 56, 72]]], ["Smoking could increase clearance by increasing A (i.e. increasing pore number), increasing r, changing the electrical charge of the pores, or decreasing alveolar fluid volume.", [["pore", "ANATOMY", 66, 70], ["alveolar fluid", "ANATOMY", 153, 167], ["Smoking", "DISEASE", 0, 7], ["alveolar fluid", "TISSUE", 153, 167], ["increasing r", "PROBLEM", 80, 92], ["decreasing alveolar fluid volume", "PROBLEM", 142, 174], ["decreasing", "OBSERVATION_MODIFIER", 142, 152], ["alveolar", "OBSERVATION", 153, 161], ["fluid volume", "OBSERVATION", 162, 174]]], ["A failure of smoking to induce any change in the ratio of clearances would argue against the predominant effect being on F, and therefore on pore radius.Measurement of radioaerosol clearance99rnTc-DTPA aerosol can be nebulised and delivered using conventional systems designed for routine ventilation imaging as apart of a V/Q scan.", [["pore", "ANATOMY", 141, 145], ["smoking", "CHEMICAL", 13, 20], ["radioaerosol clearance99rnTc-DTPA", "CHEMICAL", 168, 201], ["DTPA", "CHEMICAL", 197, 201], ["radioaerosol", "SIMPLE_CHEMICAL", 168, 180], ["clearance99rnTc-DTPA", "SIMPLE_CHEMICAL", 181, 201], ["A failure", "PROBLEM", 0, 9], ["any change", "PROBLEM", 31, 41], ["radioaerosol clearance99rnTc-DTPA aerosol", "TREATMENT", 168, 209], ["routine ventilation imaging", "TEST", 281, 308], ["a V/Q scan", "TEST", 321, 331], ["failure", "OBSERVATION", 2, 9]]], ["Immediately following the inhalation of aerosol, the count rate over the lung is continuously monitored with a scintillation probe or a gamma camera.", [["lung", "ANATOMY", 73, 77], ["lung", "ORGAN", 73, 77], ["the inhalation of aerosol", "TREATMENT", 22, 47], ["the count rate", "TEST", 49, 63], ["a scintillation probe", "TREATMENT", 109, 130], ["a gamma camera", "TREATMENT", 134, 148], ["lung", "ANATOMY", 73, 77]]], ["Scintillation probes are more suited to the ICU, but a gamma camera is preferable if logistically possible.", [["Scintillation probes", "TREATMENT", 0, 20], ["a gamma camera", "TREATMENT", 53, 67]]], ["The curve recorded during the first 7-10 min in a normal subject is generally a straight line on a semilogarithmic plot but it then \"flattens off', partly because of recirculating intravascular tracer.", [["intravascular", "ANATOMY", 180, 193], ["intravascular", "IMMATERIAL_ANATOMICAL_ENTITY", 180, 193], ["The curve", "TEST", 0, 9], ["a semilogarithmic plot", "TREATMENT", 97, 119], ["recirculating intravascular tracer", "PROBLEM", 166, 200], ["normal", "OBSERVATION", 50, 56], ["straight line", "OBSERVATION_MODIFIER", 80, 93], ["intravascular tracer", "OBSERVATION", 180, 200]]], ["When using a probe, the estimation of this blood background activity has conventionally been based on the count rate recorded from the thigh with a separate scintillation probe.", [["blood", "ANATOMY", 43, 48], ["thigh", "ANATOMY", 135, 140], ["blood", "ORGANISM_SUBSTANCE", 43, 48], ["thigh", "ORGANISM_SUBDIVISION", 135, 140], ["a probe", "TREATMENT", 11, 18], ["this blood background activity", "PROBLEM", 38, 68], ["the count rate", "TEST", 102, 116], ["a separate scintillation probe", "TREATMENT", 146, 176], ["thigh", "ANATOMY", 135, 140]]], ["The relationship between the thigh count rate and the pulmonary background signal is determined by giving an i.v. injection of a small dose of 99mTc-DTPA after the aerosol clearance rate has been measured.", [["thigh", "ANATOMY", 29, 34], ["pulmonary", "ANATOMY", 54, 63], ["99mTc-DTPA", "CHEMICAL", 143, 153], ["99mTc-DTPA", "CHEMICAL", 143, 153], ["thigh", "ORGANISM_SUBDIVISION", 29, 34], ["pulmonary", "ORGAN", 54, 63], ["99mTc-DTPA", "SIMPLE_CHEMICAL", 143, 153], ["the thigh count rate", "TEST", 25, 45], ["an i.v. injection", "TREATMENT", 106, 123], ["a small dose of 99mTc-DTPA", "TREATMENT", 127, 153], ["the aerosol clearance rate", "TEST", 160, 186], ["thigh", "ANATOMY", 29, 34], ["pulmonary", "ANATOMY", 54, 63]]], ["This approach assumes that the distribution of solute between intravascular and extravascular spaces is the same in the two regions.", [["intravascular", "ANATOMY", 62, 75], ["extravascular spaces", "ANATOMY", 80, 100], ["intravascular", "IMMATERIAL_ANATOMICAL_ENTITY", 62, 75], ["extravascular", "IMMATERIAL_ANATOMICAL_ENTITY", 80, 93], ["solute between intravascular and extravascular spaces", "PROBLEM", 47, 100], ["distribution", "OBSERVATION_MODIFIER", 31, 43], ["solute", "OBSERVATION_MODIFIER", 47, 53], ["intravascular", "ANATOMY_MODIFIER", 62, 75], ["extravascular spaces", "OBSERVATION", 80, 100], ["two", "ANATOMY_MODIFIER", 120, 123], ["regions", "ANATOMY_MODIFIER", 124, 131]]], ["99mTc-DTPA, the pulmonay signal is predominantly an intravascular orte, while the thigh signal is an extravascular orte, this assumption is erroneous for the thigh.", [["intravascular orte", "ANATOMY", 52, 70], ["thigh", "ANATOMY", 82, 87], ["extravascular orte", "ANATOMY", 101, 119], ["thigh", "ANATOMY", 158, 163], ["99mTc-DTPA", "CHEMICAL", 0, 10], ["99mTc", "CHEMICAL", 0, 5], ["DTPA", "CHEMICAL", 6, 10], ["99mTc-DTPA", "SIMPLE_CHEMICAL", 0, 10], ["intravascular orte", "CANCER", 52, 70], ["thigh", "ORGANISM_SUBDIVISION", 82, 87], ["thigh", "ORGANISM_SUBDIVISION", 158, 163], ["the pulmonay signal", "TEST", 12, 31], ["predominantly", "OBSERVATION_MODIFIER", 35, 48], ["intravascular orte", "OBSERVATION", 52, 70], ["thigh", "ANATOMY", 82, 87], ["extravascular orte", "OBSERVATION", 101, 119], ["erroneous", "OBSERVATION", 140, 149], ["thigh", "ANATOMY", 158, 163]]], ["Use of a gamma camera to monitor pulmonary activity widens the scope of background correction since regions of interest can be placed over extrapulmonary tissues other than a limb.", [["pulmonary", "ANATOMY", 33, 42], ["extrapulmonary tissues", "ANATOMY", 139, 161], ["limb", "ANATOMY", 175, 179], ["pulmonary", "ORGAN", 33, 42], ["extrapulmonary tissues", "TISSUE", 139, 161], ["limb", "ORGANISM_SUBDIVISION", 175, 179], ["a gamma camera", "TREATMENT", 7, 21], ["background correction", "TREATMENT", 72, 93], ["pulmonary", "ANATOMY", 33, 42], ["extrapulmonary tissues", "ANATOMY", 139, 161], ["limb", "ANATOMY", 175, 179]]], ["A useful background tissue is the liver since its extracellular space consists of intravascular and extravascular spaces of similar relative volumes as in the lung [24] .", [["tissue", "ANATOMY", 20, 26], ["liver", "ANATOMY", 34, 39], ["extracellular space", "ANATOMY", 50, 69], ["intravascular", "ANATOMY", 82, 95], ["extravascular", "ANATOMY", 100, 113], ["lung", "ANATOMY", 159, 163], ["tissue", "TISSUE", 20, 26], ["liver", "ORGAN", 34, 39], ["extracellular space", "IMMATERIAL_ANATOMICAL_ENTITY", 50, 69], ["intravascular", "IMMATERIAL_ANATOMICAL_ENTITY", 82, 95], ["extravascular", "IMMATERIAL_ANATOMICAL_ENTITY", 100, 113], ["lung", "ORGAN", 159, 163], ["tissue", "OBSERVATION", 20, 26], ["liver", "ANATOMY", 34, 39], ["extracellular", "ANATOMY_MODIFIER", 50, 63], ["space", "ANATOMY_MODIFIER", 64, 69], ["intravascular", "ANATOMY_MODIFIER", 82, 95], ["extravascular spaces", "OBSERVATION", 100, 120], ["similar", "OBSERVATION_MODIFIER", 124, 131], ["relative", "OBSERVATION_MODIFIER", 132, 140], ["volumes", "OBSERVATION_MODIFIER", 141, 148], ["lung", "ANATOMY", 159, 163]]], ["It is, furthermore, included in the field of view of the camera and projects a reasonably large area over which to place a region of interest.", [["reasonably", "OBSERVATION_MODIFIER", 79, 89], ["large", "OBSERVATION_MODIFIER", 90, 95], ["area", "OBSERVATION_MODIFIER", 96, 100]]], ["Conventionally, the i.v. dose of 99mTc-DTPA for calibration of background is given after the inhalation dose, but it is preferable to give it before because, as a smaller signal, it is more accurate to subtract it from the succeeding larger inhalation signal than the other way round.", [["99mTc-DTPA", "CHEMICAL", 33, 43], ["99mTc-DTPA", "CHEMICAL", 33, 43], ["99mTc-DTPA", "SIMPLE_CHEMICAL", 33, 43], ["DTPA", "TREATMENT", 39, 43], ["the inhalation dose", "TREATMENT", 89, 108], ["a smaller signal", "PROBLEM", 161, 177], ["larger", "OBSERVATION_MODIFIER", 234, 240], ["inhalation", "OBSERVATION", 241, 251], ["round", "OBSERVATION_MODIFIER", 278, 283]]], ["Indeed, it is not necessary to subtract the i.v. signal from the subsequent inhalation signal because since the liver curve has a shape identical to the intravascular background curve in the lung [24] it can be used for background subtraction at any stage of the lung curve, before or after inhalation.", [["liver", "ANATOMY", 112, 117], ["intravascular", "ANATOMY", 153, 166], ["lung", "ANATOMY", 191, 195], ["lung", "ANATOMY", 263, 267], ["liver", "ORGAN", 112, 117], ["lung", "ORGAN", 191, 195], ["lung", "ORGAN", 263, 267], ["the i.v. signal", "TEST", 40, 55], ["the subsequent inhalation signal", "TEST", 61, 93], ["the liver curve", "TEST", 108, 123], ["background subtraction", "TEST", 220, 242], ["the lung curve", "TEST", 259, 273], ["liver", "ANATOMY", 112, 117], ["shape", "OBSERVATION_MODIFIER", 130, 135], ["intravascular", "OBSERVATION_MODIFIER", 153, 166], ["background", "OBSERVATION_MODIFIER", 167, 177], ["curve", "OBSERVATION_MODIFIER", 178, 183], ["lung", "ANATOMY", 191, 195], ["lung", "ANATOMY", 263, 267]]], ["Indeed, it can be imagined that the i.v. dose has essentially the same effect as an early rapid transfer of 99mTc-DTPA from alveolus to blood.", [["alveolus", "ANATOMY", 124, 132], ["blood", "ANATOMY", 136, 141], ["99mTc-DTPA", "CHEMICAL", 108, 118], ["99mTc-DTPA", "CHEMICAL", 108, 118], ["99mTc-DTPA", "SIMPLE_CHEMICAL", 108, 118], ["alveolus", "ORGAN", 124, 132], ["blood", "ORGANISM_SUBSTANCE", 136, 141], ["the i.v. dose", "TREATMENT", 32, 45]]], ["Irrational approaches to background correction may be the main reason why several authorities have concluded that background subtraction causes more error than it corrects.", [["Irrational approaches", "TREATMENT", 0, 21], ["background subtraction", "PROBLEM", 114, 136]]], ["In any event background correction is probably unnecessary for routine measurements, provided the rate constant is based on no more than the first 10 min of data recorded after inhalation.", [["routine measurements", "TEST", 63, 83]]], ["In normal individuals, the clearance rate of 99mTc-DTPA is about 0.01 min -1, or 1% per min.", [["99mTc-DTPA", "CHEMICAL", 45, 55], ["99mTc-DTPA", "CHEMICAL", 45, 55], ["99mTc-DTPA", "SIMPLE_CHEMICAL", 45, 55], ["the clearance rate", "TEST", 23, 41], ["normal individuals", "OBSERVATION", 3, 21]]], ["It is, however, about 4% per min in normal cigarette smokers.Clinical applications of alveolar permeability measurementAlthough measurements of pulmonary epithelial permeability are simple to perform and allow insight into several pathological processes in the lung, they have made little clinical impact.", [["alveolar", "ANATOMY", 86, 94], ["pulmonary epithelial", "ANATOMY", 144, 164], ["lung", "ANATOMY", 261, 265], ["cigarette", "ORGANISM", 43, 52], ["alveolar", "MULTI-TISSUE_STRUCTURE", 86, 94], ["pulmonary epithelial", "TISSUE", 144, 164], ["lung", "ORGAN", 261, 265], ["alveolar permeability measurement", "TEST", 86, 119], ["several pathological processes in the lung", "PROBLEM", 223, 265], ["cigarette smokers", "OBSERVATION", 43, 60], ["alveolar permeability", "OBSERVATION", 86, 107], ["pulmonary", "ANATOMY", 144, 153], ["epithelial permeability", "OBSERVATION", 154, 177], ["several", "OBSERVATION_MODIFIER", 223, 230], ["pathological", "OBSERVATION", 231, 243], ["lung", "ANATOMY", 261, 265], ["little", "OBSERVATION_MODIFIER", 282, 288]]], ["Before considering this question, it is necessary to briefly review the disease processes where the technique may make a useful clinical contribution.", [["the disease processes", "PROBLEM", 68, 89], ["the technique", "TREATMENT", 96, 109]]], ["Although varied, these are largely confined to diseases which would be expected to cause an abnormality of the lung parenchyma.", [["lung parenchyma", "ANATOMY", 111, 126], ["lung parenchyma", "MULTI-TISSUE_STRUCTURE", 111, 126], ["diseases", "PROBLEM", 47, 55], ["an abnormality of the lung parenchyma", "PROBLEM", 89, 126], ["varied", "OBSERVATION_MODIFIER", 9, 15], ["diseases", "OBSERVATION", 47, 55], ["abnormality", "OBSERVATION", 92, 103], ["lung", "ANATOMY", 111, 115], ["parenchyma", "ANATOMY_MODIFIER", 116, 126]]], ["A knowledge of the physiological processes that result in changes of permeability, defined by either the half-time of clearance or a modified rate, is essential and outlined above.Clinical applications of alveolar permeability measurementDiseases causing pulmonary epithelial abnormalities are numerous.", [["alveolar", "ANATOMY", 205, 213], ["pulmonary epithelial", "ANATOMY", 255, 275], ["pulmonary epithelial abnormalities", "DISEASE", 255, 289], ["alveolar", "MULTI-TISSUE_STRUCTURE", 205, 213], ["pulmonary epithelial", "MULTI-TISSUE_STRUCTURE", 255, 275], ["the physiological processes", "PROBLEM", 15, 42], ["alveolar permeability measurement", "TEST", 205, 238], ["Diseases", "PROBLEM", 238, 246], ["pulmonary epithelial abnormalities", "PROBLEM", 255, 289], ["alveolar permeability", "OBSERVATION", 205, 226], ["pulmonary", "ANATOMY", 255, 264], ["epithelial", "ANATOMY_MODIFIER", 265, 275], ["abnormalities", "OBSERVATION", 276, 289], ["numerous", "OBSERVATION_MODIFIER", 294, 302]]], ["Pulmonary inflammatory diseases may be due to a variety of allergens or infective agents or may be iatrogenic.", [["Pulmonary", "ANATOMY", 0, 9], ["Pulmonary inflammatory diseases", "DISEASE", 0, 31], ["Pulmonary", "ORGAN", 0, 9], ["Pulmonary inflammatory diseases", "PROBLEM", 0, 31], ["allergens", "PROBLEM", 59, 68], ["infective agents", "TREATMENT", 72, 88], ["iatrogenic", "PROBLEM", 99, 109], ["inflammatory", "OBSERVATION", 10, 22], ["may be due to", "UNCERTAINTY", 32, 45], ["allergens", "OBSERVATION", 59, 68], ["infective", "OBSERVATION", 72, 81], ["may be", "UNCERTAINTY", 92, 98], ["iatrogenic", "OBSERVATION_MODIFIER", 99, 109]]], ["Pointers to the disease process may be obtained from the clinical history, for example the patient's occupation, hobbies and medication, or from a history of immunosuppression related to the immunodeficiency virus (HIV) or drug therapy.", [["immunosuppression related to the immunodeficiency virus (HIV)", "DISEASE", 158, 219], ["patient", "ORGANISM", 91, 98], ["immunodeficiency virus", "ORGANISM", 191, 213], ["HIV", "ORGANISM", 215, 218], ["patient", "SPECIES", 91, 98], ["HIV", "SPECIES", 215, 218], ["the disease process", "PROBLEM", 12, 31], ["medication", "TREATMENT", 125, 135], ["immunosuppression", "TREATMENT", 158, 175], ["the immunodeficiency virus", "PROBLEM", 187, 213], ["drug therapy", "TREATMENT", 223, 235], ["disease", "OBSERVATION", 16, 23]]], ["Progressive deterioration in lung function may initially occur in the presence of a normal chest radiograph or more commonly with one showing infiltrates.AlveolitisExtrinsic allergic alveolitis and cryptogenic fibrosing alveolitis may lead to oedema, and thickening and disruption of the alveolar walls and basement membrane.", [["lung", "ANATOMY", 29, 33], ["chest", "ANATOMY", 91, 96], ["alveolar walls", "ANATOMY", 288, 302], ["basement membrane", "ANATOMY", 307, 324], ["Alveolitis", "DISEASE", 154, 164], ["allergic alveolitis", "DISEASE", 174, 193], ["alveolitis", "DISEASE", 220, 230], ["oedema", "DISEASE", 243, 249], ["lung", "ORGAN", 29, 33], ["alveolar walls", "MULTI-TISSUE_STRUCTURE", 288, 302], ["basement membrane", "CELLULAR_COMPONENT", 307, 324], ["Progressive deterioration in lung function", "PROBLEM", 0, 42], ["a normal chest radiograph", "TEST", 82, 107], ["infiltrates", "PROBLEM", 142, 153], ["Alveolitis", "PROBLEM", 154, 164], ["Extrinsic allergic alveolitis", "PROBLEM", 164, 193], ["cryptogenic fibrosing alveolitis", "PROBLEM", 198, 230], ["oedema", "PROBLEM", 243, 249], ["thickening", "PROBLEM", 255, 265], ["disruption of the alveolar walls and basement membrane", "PROBLEM", 270, 324], ["deterioration", "OBSERVATION", 12, 25], ["lung", "ANATOMY", 29, 33], ["function", "OBSERVATION", 34, 42], ["chest", "ANATOMY", 91, 96], ["infiltrates", "OBSERVATION", 142, 153], ["allergic alveolitis", "OBSERVATION", 174, 193], ["cryptogenic", "OBSERVATION_MODIFIER", 198, 209], ["fibrosing", "OBSERVATION_MODIFIER", 210, 219], ["alveolitis", "OBSERVATION", 220, 230], ["may lead to", "UNCERTAINTY", 231, 242], ["oedema", "OBSERVATION", 243, 249], ["thickening", "OBSERVATION", 255, 265], ["alveolar", "ANATOMY_MODIFIER", 288, 296], ["walls", "ANATOMY_MODIFIER", 297, 302], ["basement", "ANATOMY_MODIFIER", 307, 315], ["membrane", "ANATOMY_MODIFIER", 316, 324]]], ["In pigeon fancier's lung, 99mTc-DTPA transfer is abnormal [25] , and shows an increased clearance rate which is proportional to circulating antibody titre.", [["lung", "ANATOMY", 20, 24], ["99mTc-DTPA", "CHEMICAL", 26, 36], ["99mTc", "CHEMICAL", 26, 31], ["DTPA", "CHEMICAL", 32, 36], ["pigeon", "ORGANISM", 3, 9], ["lung", "ORGAN", 20, 24], ["99mTc-DTPA", "SIMPLE_CHEMICAL", 26, 36], ["pigeon", "SPECIES", 3, 9], ["pigeon fancier", "SPECIES", 3, 17], ["abnormal", "PROBLEM", 49, 57], ["an increased clearance rate", "PROBLEM", 75, 102], ["circulating antibody titre", "TEST", 128, 154], ["lung", "ANATOMY", 20, 24], ["increased", "OBSERVATION_MODIFIER", 78, 87], ["clearance", "OBSERVATION", 88, 97], ["antibody titre", "OBSERVATION", 140, 154]]], ["Patients without circulating antibody but with a history of antigen exposure have clearance times faster than normal controls hut not as fast as those with detectable antibody.", [["Patients", "ORGANISM", 0, 8], ["circulating antibody", "PROTEIN", 17, 37], ["Patients", "SPECIES", 0, 8], ["circulating antibody", "PROBLEM", 17, 37], ["antigen exposure", "PROBLEM", 60, 76], ["without", "UNCERTAINTY", 9, 16], ["circulating antibody", "OBSERVATION", 17, 37]]], ["Pulmonary function tests are often normal in the presence of accelerated clearance rates.", [["Pulmonary", "ANATOMY", 0, 9], ["Pulmonary", "ORGAN", 0, 9], ["Pulmonary function tests", "TEST", 0, 24], ["accelerated clearance rates", "PROBLEM", 61, 88]]], ["Similarly, cryptogenic fibrosing alveolitis or alveolitis associated with connective tissue diseases [26] is associated with an increase in the transfer rate of 99mTc-DTPA.", [["connective tissue", "ANATOMY", 74, 91], ["alveolitis", "DISEASE", 33, 43], ["alveolitis", "DISEASE", 47, 57], ["connective tissue diseases", "DISEASE", 74, 100], ["99mTc-DTPA", "CHEMICAL", 161, 171], ["99mTc-DTPA", "CHEMICAL", 161, 171], ["connective tissue", "TISSUE", 74, 91], ["99mTc-DTPA", "SIMPLE_CHEMICAL", 161, 171], ["cryptogenic fibrosing alveolitis", "PROBLEM", 11, 43], ["alveolitis", "PROBLEM", 47, 57], ["connective tissue diseases", "PROBLEM", 74, 100], ["cryptogenic", "OBSERVATION_MODIFIER", 11, 22], ["fibrosing", "OBSERVATION_MODIFIER", 23, 32], ["alveolitis", "OBSERVATION", 33, 43], ["alveolitis", "OBSERVATION", 47, 57], ["connective tissue diseases", "OBSERVATION", 74, 100], ["increase", "OBSERVATION_MODIFIER", 128, 136]]], ["In cryptogenic fibrosing alveolitis, serial measurements of 99mTc-DTPA clearance have been used to monitor therapeutic response [27, 28] .", [["alveolitis", "DISEASE", 25, 35], ["99mTc-DTPA", "CHEMICAL", 60, 70], ["99mTc", "CHEMICAL", 60, 65], ["DTPA", "CHEMICAL", 66, 70], ["99mTc-DTPA", "SIMPLE_CHEMICAL", 60, 70], ["cryptogenic fibrosing alveolitis", "PROBLEM", 3, 35], ["serial measurements", "TEST", 37, 56], ["DTPA clearance", "TEST", 66, 80], ["cryptogenic", "OBSERVATION_MODIFIER", 3, 14], ["fibrosing", "OBSERVATION_MODIFIER", 15, 24], ["alveolitis", "OBSERVATION", 25, 35]]], ["Labrune et al. [27] demonstrated that the clearance rate decreased following a positive clinical response to corticosteroids but not down to normal levels.", [["corticosteroids", "CHEMICAL", 109, 124], ["corticosteroids", "CHEMICAL", 109, 124], ["corticosteroids", "SIMPLE_CHEMICAL", 109, 124], ["the clearance rate", "TEST", 38, 56], ["corticosteroids", "TREATMENT", 109, 124]]], ["This persistent increase in the clearance rate may be the result of irreversible stretching of lung units by fibrosis.", [["lung", "ANATOMY", 95, 99], ["fibrosis", "DISEASE", 109, 117], ["lung", "ORGAN", 95, 99], ["the clearance rate", "TEST", 28, 46], ["irreversible stretching of lung units", "PROBLEM", 68, 105], ["fibrosis", "PROBLEM", 109, 117], ["persistent", "OBSERVATION_MODIFIER", 5, 15], ["increase", "OBSERVATION_MODIFIER", 16, 24], ["may be the result of", "UNCERTAINTY", 47, 67], ["irreversible", "OBSERVATION_MODIFIER", 68, 80], ["stretching", "OBSERVATION", 81, 91], ["lung", "ANATOMY", 95, 99], ["units", "OBSERVATION_MODIFIER", 100, 105], ["fibrosis", "OBSERVATION", 109, 117]]], ["Uh et al. [29] found that in patients with diffuse infiltrative lung disease, clearance rates were significantly fastet in all lobes compared with normal controls hut that, compared with late disease, early stage disease was associated with slower clearance in the upper and middle lobes.", [["diffuse infiltrative lung", "ANATOMY", 43, 68], ["lobes", "ANATOMY", 127, 132], ["upper", "ANATOMY", 265, 270], ["middle lobes", "ANATOMY", 275, 287], ["lung disease", "DISEASE", 64, 76], ["patients", "ORGANISM", 29, 37], ["lung", "ORGAN", 64, 68], ["upper", "ORGANISM_SUBDIVISION", 265, 270], ["lobes", "ORGAN", 282, 287], ["patients", "SPECIES", 29, 37], ["diffuse infiltrative lung disease", "PROBLEM", 43, 76], ["clearance rates", "TEST", 78, 93], ["significantly fastet in all lobes", "PROBLEM", 99, 132], ["late disease", "PROBLEM", 187, 199], ["early stage disease", "PROBLEM", 201, 220], ["slower clearance in the upper and middle lobes", "PROBLEM", 241, 287], ["diffuse", "OBSERVATION_MODIFIER", 43, 50], ["infiltrative", "OBSERVATION_MODIFIER", 51, 63], ["lung", "ANATOMY", 64, 68], ["disease", "OBSERVATION", 69, 76], ["all lobes", "ANATOMY", 123, 132], ["early", "OBSERVATION_MODIFIER", 201, 206], ["stage", "OBSERVATION_MODIFIER", 207, 212], ["disease", "OBSERVATION", 213, 220], ["slower", "OBSERVATION_MODIFIER", 241, 247], ["clearance", "OBSERVATION", 248, 257], ["upper", "ANATOMY_MODIFIER", 265, 270], ["middle lobes", "ANATOMY", 275, 287]]], ["There was, however, overlap between the ranges in normals and those with disease such that it was difficult to use the test to identify patients with disease but with normal carbon monoxide transfer values.", [["carbon monoxide", "CHEMICAL", 174, 189], ["carbon monoxide", "CHEMICAL", 174, 189], ["patients", "ORGANISM", 136, 144], ["carbon monoxide", "SIMPLE_CHEMICAL", 174, 189], ["patients", "SPECIES", 136, 144], ["disease", "PROBLEM", 73, 80], ["the test", "TEST", 115, 123], ["disease", "PROBLEM", 150, 157], ["ranges", "OBSERVATION_MODIFIER", 40, 46], ["carbon monoxide", "OBSERVATION", 174, 189]]], ["Thus, although the cle\u00e4rance rate is unlikely to be a diagnostic test, it may be used to monitor therapy and relapse.Connective tissue disorders aff\u00e8cting the lungMost connective tissue diseases can potentially affect the lung.", [["Connective tissue", "ANATOMY", 117, 134], ["lung", "ANATOMY", 159, 163], ["connective tissue", "ANATOMY", 168, 185], ["lung", "ANATOMY", 222, 226], ["Connective tissue disorders", "DISEASE", 117, 144], ["connective tissue diseases", "DISEASE", 168, 194], ["Connective tissue", "TISSUE", 117, 134], ["lung", "ORGAN", 159, 163], ["connective tissue", "TISSUE", 168, 185], ["lung", "ORGAN", 222, 226], ["a diagnostic test", "TEST", 52, 69], ["therapy", "TREATMENT", 97, 104], ["relapse", "PROBLEM", 109, 116], ["Connective tissue disorders", "PROBLEM", 117, 144], ["connective tissue diseases", "PROBLEM", 168, 194], ["tissue", "ANATOMY", 128, 134], ["disorders", "OBSERVATION", 135, 144], ["lung", "ANATOMY", 159, 163], ["Most", "OBSERVATION_MODIFIER", 163, 167], ["connective tissue", "OBSERVATION", 168, 185], ["lung", "ANATOMY", 222, 226]]], ["The inflammatory process usually affects the bases more than the apices.", [["apices", "ANATOMY", 65, 71], ["apices", "TISSUE", 65, 71], ["The inflammatory process", "PROBLEM", 0, 24], ["inflammatory", "OBSERVATION", 4, 16], ["bases", "ANATOMY_MODIFIER", 45, 50], ["apices", "ANATOMY_MODIFIER", 65, 71]]], ["Chopra et al. [2] studied a group of patients with systemic sclerosis and found that the DTPA clearance was rauch faster in the affected lower zones.", [["lower zones", "ANATOMY", 137, 148], ["systemic sclerosis", "DISEASE", 51, 69], ["DTPA", "CHEMICAL", 89, 93], ["DTPA", "CHEMICAL", 89, 93], ["patients", "ORGANISM", 37, 45], ["DTPA", "SIMPLE_CHEMICAL", 89, 93], ["patients", "SPECIES", 37, 45], ["systemic sclerosis", "PROBLEM", 51, 69], ["the DTPA clearance", "TEST", 85, 103], ["systemic", "ANATOMY", 51, 59], ["sclerosis", "OBSERVATION", 60, 69], ["affected", "ANATOMY_MODIFIER", 128, 136], ["lower", "ANATOMY_MODIFIER", 137, 142], ["zones", "ANATOMY_MODIFIER", 143, 148]]], ["Similarly increased clearance rates would be anticipated in association with the acute changes of rheumatoid arthritis and polyarthritis nodosa.SarcoidosisSarcoidosis is a multi-system inflammatory granulomatosis disease which preominantly presents with pulmonary involvement but can affect almost any organ.", [["pulmonary", "ANATOMY", 254, 263], ["organ", "ANATOMY", 302, 307], ["rheumatoid arthritis", "DISEASE", 98, 118], ["polyarthritis", "DISEASE", 123, 136], ["nodosa", "DISEASE", 137, 143], ["SarcoidosisSarcoidosis", "DISEASE", 144, 166], ["granulomatosis disease", "DISEASE", 198, 220], ["pulmonary", "ORGAN", 254, 263], ["organ", "ORGAN", 302, 307], ["increased clearance rates", "PROBLEM", 10, 35], ["the acute changes", "PROBLEM", 77, 94], ["rheumatoid arthritis", "PROBLEM", 98, 118], ["polyarthritis nodosa", "PROBLEM", 123, 143], ["SarcoidosisSarcoidosis", "PROBLEM", 144, 166], ["a multi-system inflammatory granulomatosis disease", "PROBLEM", 170, 220], ["pulmonary involvement", "PROBLEM", 254, 275], ["increased", "OBSERVATION_MODIFIER", 10, 19], ["clearance", "OBSERVATION", 20, 29], ["acute", "OBSERVATION_MODIFIER", 81, 86], ["rheumatoid arthritis", "OBSERVATION", 98, 118], ["polyarthritis", "OBSERVATION", 123, 136], ["multi-system", "OBSERVATION_MODIFIER", 172, 184], ["inflammatory", "OBSERVATION_MODIFIER", 185, 197], ["granulomatosis", "OBSERVATION", 198, 212], ["pulmonary", "ANATOMY", 254, 263], ["involvement", "OBSERVATION", 264, 275]]], ["Presenting features in relation to the lung are pulmonary infiltrates and/or hilar or mediastinal lymphadenopathy.", [["lung", "ANATOMY", 39, 43], ["pulmonary", "ANATOMY", 48, 57], ["hilar", "ANATOMY", 77, 82], ["mediastinal lymphadenopathy", "ANATOMY", 86, 113], ["lymphadenopathy", "DISEASE", 98, 113], ["lung", "ORGAN", 39, 43], ["pulmonary", "ORGAN", 48, 57], ["hilar", "CANCER", 77, 82], ["pulmonary infiltrates", "PROBLEM", 48, 69], ["hilar or mediastinal lymphadenopathy", "PROBLEM", 77, 113], ["lung", "ANATOMY", 39, 43], ["pulmonary", "ANATOMY", 48, 57], ["infiltrates", "OBSERVATION", 58, 69], ["hilar", "ANATOMY", 77, 82], ["mediastinal", "ANATOMY", 86, 97], ["lymphadenopathy", "OBSERVATION", 98, 113]]], ["The chest radiograph however, is, highly insensitive and up to 60% of patients with parenchymal granulomata may have a normal chest radiograph.", [["chest", "ANATOMY", 4, 9], ["parenchymal granulomata", "ANATOMY", 84, 107], ["chest", "ANATOMY", 126, 131], ["granulomata", "DISEASE", 96, 107], ["chest", "ORGAN", 4, 9], ["patients", "ORGANISM", 70, 78], ["parenchymal granulomata", "CANCER", 84, 107], ["patients", "SPECIES", 70, 78], ["The chest radiograph", "TEST", 0, 20], ["parenchymal granulomata", "PROBLEM", 84, 107], ["chest", "ANATOMY", 4, 9], ["parenchymal", "ANATOMY_MODIFIER", 84, 95], ["granulomata", "OBSERVATION", 96, 107], ["chest", "ANATOMY", 126, 131]]], ["An increase in pulmonary alveolar permeability has been observed in all grades of pulmonary sarcoidosis [30] [31] [32] .", [["pulmonary alveolar", "ANATOMY", 15, 33], ["pulmonary", "ANATOMY", 82, 91], ["pulmonary sarcoidosis", "DISEASE", 82, 103], ["pulmonary alveolar", "MULTI-TISSUE_STRUCTURE", 15, 33], ["pulmonary", "ORGAN", 82, 91], ["An increase in pulmonary alveolar permeability", "PROBLEM", 0, 46], ["pulmonary sarcoidosis", "PROBLEM", 82, 103], ["increase", "OBSERVATION_MODIFIER", 3, 11], ["pulmonary", "ANATOMY", 15, 24], ["alveolar", "ANATOMY_MODIFIER", 25, 33], ["permeability", "OBSERVATION", 34, 46], ["all grades", "OBSERVATION_MODIFIER", 68, 78], ["pulmonary", "ANATOMY", 82, 91], ["sarcoidosis", "OBSERVATION", 92, 103]]], ["The DTPA transfer rate increases with deterioration in pulmonary function and decreases in response to treatment with corticosteroids [30] .", [["pulmonary", "ANATOMY", 55, 64], ["DTPA", "CHEMICAL", 4, 8], ["DTPA", "CHEMICAL", 4, 8], ["corticosteroids", "CHEMICAL", 118, 133], ["DTPA", "SIMPLE_CHEMICAL", 4, 8], ["pulmonary", "ORGAN", 55, 64], ["The DTPA transfer rate", "TREATMENT", 0, 22], ["deterioration in pulmonary function", "PROBLEM", 38, 73], ["treatment", "TREATMENT", 103, 112], ["corticosteroids", "TREATMENT", 118, 133], ["pulmonary", "ANATOMY", 55, 64], ["decreases", "OBSERVATION_MODIFIER", 78, 87]]], ["Clearance rates appear to be related to the degree of inflammation but have no definite relationship to serum angiotensin converting enzyme levels or the lymphocyte content of bronchoalveolar lavage fluid.Drug-and radiation-induced pneumonitisSeveral drugs, including bleomycin and amiodarone, can cause a pneumonitis.", [["serum", "ANATOMY", 104, 109], ["lymphocyte", "ANATOMY", 154, 164], ["bronchoalveolar lavage fluid", "ANATOMY", 176, 204], ["inflammation", "DISEASE", 54, 66], ["angiotensin", "CHEMICAL", 110, 121], ["pneumonitis", "DISEASE", 232, 243], ["bleomycin", "CHEMICAL", 268, 277], ["amiodarone", "CHEMICAL", 282, 292], ["pneumonitis", "DISEASE", 306, 317], ["bleomycin", "CHEMICAL", 268, 277], ["amiodarone", "CHEMICAL", 282, 292], ["serum", "ORGANISM_SUBSTANCE", 104, 109], ["angiotensin converting enzyme", "GENE_OR_GENE_PRODUCT", 110, 139], ["lymphocyte", "CELL", 154, 164], ["bronchoalveolar lavage fluid", "ORGANISM_SUBSTANCE", 176, 204], ["bleomycin", "SIMPLE_CHEMICAL", 268, 277], ["amiodarone", "SIMPLE_CHEMICAL", 282, 292], ["serum angiotensin converting enzyme", "PROTEIN", 104, 139], ["Clearance rates", "PROBLEM", 0, 15], ["inflammation", "PROBLEM", 54, 66], ["serum angiotensin", "TEST", 104, 121], ["enzyme levels", "TEST", 133, 146], ["the lymphocyte content", "TEST", 150, 172], ["bronchoalveolar lavage fluid", "TEST", 176, 204], ["Drug", "TREATMENT", 205, 209], ["radiation", "TREATMENT", 214, 223], ["pneumonitis", "PROBLEM", 232, 243], ["Several drugs", "TREATMENT", 243, 256], ["bleomycin", "TREATMENT", 268, 277], ["amiodarone", "TREATMENT", 282, 292], ["a pneumonitis", "PROBLEM", 304, 317], ["inflammation", "OBSERVATION", 54, 66], ["no definite", "UNCERTAINTY", 76, 87], ["lymphocyte content", "OBSERVATION", 154, 172], ["bronchoalveolar lavage fluid", "OBSERVATION", 176, 204], ["pneumonitis", "OBSERVATION", 232, 243], ["pneumonitis", "OBSERVATION", 306, 317]]], ["A clinical difficulty with such drug toxicity is in the distinction of alveolitis from interstitial pulmonary oedema due to heart failure, since the drug may be used in pafients with cardiac disease or alternafively cardiac disease may be associ\u00e4ted with therapy.", [["interstitial pulmonary", "ANATOMY", 87, 109], ["heart", "ANATOMY", 124, 129], ["cardiac", "ANATOMY", 183, 190], ["cardiac", "ANATOMY", 216, 223], ["toxicity", "DISEASE", 37, 45], ["alveolitis", "DISEASE", 71, 81], ["interstitial pulmonary oedema", "DISEASE", 87, 116], ["heart failure", "DISEASE", 124, 137], ["cardiac disease", "DISEASE", 183, 198], ["cardiac disease", "DISEASE", 216, 231], ["pulmonary", "ORGAN", 100, 109], ["heart", "ORGAN", 124, 129], ["cardiac", "ORGAN", 183, 190], ["cardiac", "ORGAN", 216, 223], ["A clinical difficulty with such drug toxicity", "PROBLEM", 0, 45], ["alveolitis", "PROBLEM", 71, 81], ["interstitial pulmonary oedema", "PROBLEM", 87, 116], ["heart failure", "PROBLEM", 124, 137], ["cardiac disease", "PROBLEM", 183, 198], ["alternafively cardiac disease", "PROBLEM", 202, 231], ["therapy", "TREATMENT", 255, 262], ["alveolitis", "OBSERVATION", 71, 81], ["interstitial", "ANATOMY_MODIFIER", 87, 99], ["pulmonary", "ANATOMY", 100, 109], ["oedema", "OBSERVATION", 110, 116], ["heart", "ANATOMY", 124, 129], ["failure", "OBSERVATION", 130, 137], ["cardiac", "ANATOMY", 183, 190], ["disease", "OBSERVATION", 191, 198], ["cardiac", "ANATOMY", 216, 223], ["disease", "OBSERVATION", 224, 231]]], ["Cardiac failure does not significantly alter alveolar capillary permeability and so the clearance rate of DTPA in these conditions is normal [15] and should be able to separate c\u00e4rdiogenic ffom an alveolific cause of breathlessness.", [["Cardiac", "ANATOMY", 0, 7], ["alveolar capillary", "ANATOMY", 45, 63], ["Cardiac failure", "DISEASE", 0, 15], ["DTPA", "CHEMICAL", 106, 110], ["breathlessness", "DISEASE", 217, 231], ["DTPA", "CHEMICAL", 106, 110], ["Cardiac", "ORGAN", 0, 7], ["alveolar capillary", "TISSUE", 45, 63], ["DTPA", "SIMPLE_CHEMICAL", 106, 110], ["Cardiac failure", "PROBLEM", 0, 15], ["significantly alter alveolar capillary permeability", "PROBLEM", 25, 76], ["the clearance rate", "TEST", 84, 102], ["DTPA", "TREATMENT", 106, 110], ["breathlessness", "PROBLEM", 217, 231], ["failure", "OBSERVATION", 8, 15], ["alveolar", "ANATOMY_MODIFIER", 45, 53], ["capillary permeability", "OBSERVATION", 54, 76], ["normal", "OBSERVATION", 134, 140]]], ["Terra-Filho et al. [33] demonstrated th\u00e4t clearance rates were faster than in normal smokers and in patients receiving amiodarone but with no respiratory problems.", [["respiratory", "ANATOMY", 142, 153], ["amiodarone", "CHEMICAL", 119, 129], ["respiratory problems", "DISEASE", 142, 162], ["amiodarone", "CHEMICAL", 119, 129], ["patients", "ORGANISM", 100, 108], ["amiodarone", "SIMPLE_CHEMICAL", 119, 129], ["patients", "SPECIES", 100, 108], ["th\u00e4t clearance rates", "PROBLEM", 37, 57], ["amiodarone", "TREATMENT", 119, 129], ["respiratory problems", "PROBLEM", 142, 162], ["no", "UNCERTAINTY", 139, 141], ["respiratory", "ANATOMY", 142, 153], ["problems", "OBSERVATION", 154, 162]]], ["DTPA clearance was more sensitive than spirometry in the detection of this condition.", [["DTPA", "CHEMICAL", 0, 4], ["DTPA", "CHEMICAL", 0, 4], ["DTPA", "SIMPLE_CHEMICAL", 0, 4], ["DTPA clearance", "TEST", 0, 14], ["this condition", "PROBLEM", 70, 84]]], ["The test would not have been able, however, to identify pneumonitis in smokers.", [["pneumonitis", "DISEASE", 56, 67], ["pneumonitis", "PROBLEM", 56, 67], ["pneumonitis", "OBSERVATION", 56, 67]]], ["Further abnormalifies have been reported in the inflammatory response associated with \"crack\" use, in which increased clearance rates have been reported [34] .Adult respiratory distress syndromePulmonary alveolar DTPA transfer is accelerated in adult respiratory distress syndrome (ARDS) [4, 5, 15, 35, 36] , in which the severity of endothelial damage has also been quantified with indium-113m transferrin accumulation within the lung interstitial space.", [["respiratory", "ANATOMY", 165, 176], ["alveolar", "ANATOMY", 204, 212], ["respiratory", "ANATOMY", 251, 262], ["endothelial", "ANATOMY", 334, 345], ["lung interstitial space", "ANATOMY", 431, 454], ["respiratory distress", "DISEASE", 165, 185], ["DTPA", "CHEMICAL", 213, 217], ["respiratory distress syndrome", "DISEASE", 251, 280], ["ARDS", "DISEASE", 282, 286], ["endothelial damage", "DISEASE", 334, 352], ["DTPA", "CHEMICAL", 213, 217], ["indium", "CHEMICAL", 383, 389], ["alveolar", "MULTI-TISSUE_STRUCTURE", 204, 212], ["endothelial", "TISSUE", 334, 345], ["transferrin", "GENE_OR_GENE_PRODUCT", 395, 406], ["lung interstitial", "MULTI-TISSUE_STRUCTURE", 431, 448], ["transferrin", "PROTEIN", 395, 406], ["Further abnormalifies", "PROBLEM", 0, 21], ["Adult respiratory distress", "PROBLEM", 159, 185], ["alveolar DTPA", "PROBLEM", 204, 217], ["adult respiratory distress syndrome", "PROBLEM", 245, 280], ["ARDS", "PROBLEM", 282, 286], ["endothelial damage", "PROBLEM", 334, 352], ["indium-113m transferrin accumulation within the lung interstitial space", "PROBLEM", 383, 454], ["inflammatory", "OBSERVATION_MODIFIER", 48, 60], ["respiratory distress", "OBSERVATION", 165, 185], ["alveolar DTPA", "OBSERVATION", 204, 217], ["respiratory distress", "OBSERVATION", 251, 271], ["ARDS", "OBSERVATION", 282, 286], ["endothelial", "ANATOMY", 334, 345], ["damage", "OBSERVATION", 346, 352], ["transferrin accumulation", "OBSERVATION", 395, 419], ["lung", "ANATOMY", 431, 435], ["interstitial", "ANATOMY_MODIFIER", 436, 448]]], ["Braude et al. [5, 36] found a correlation between alveolar permeability to DTPA and endothelial permeability to transferrin in patients with ARDS, illustrating that the diffusion of molecules from the vasculature to the interstitium can give results comparable with diffusion from airspace to vasculature.Detection of inflammation/infection in the lungs of immunosuppressed patientsThe lung is offen damaged by infection or inflammation in the immunocompromised host, with a resulting high mortality.", [["alveolar", "ANATOMY", 50, 58], ["endothelial", "ANATOMY", 84, 95], ["vasculature", "ANATOMY", 201, 212], ["interstitium", "ANATOMY", 220, 232], ["airspace", "ANATOMY", 281, 289], ["vasculature", "ANATOMY", 293, 304], ["lungs", "ANATOMY", 348, 353], ["lung", "ANATOMY", 386, 390], ["DTPA", "CHEMICAL", 75, 79], ["ARDS", "DISEASE", 141, 145], ["inflammation", "DISEASE", 318, 330], ["infection", "DISEASE", 331, 340], ["infection", "DISEASE", 411, 420], ["inflammation", "DISEASE", 424, 436], ["DTPA", "CHEMICAL", 75, 79], ["alveolar", "TISSUE", 50, 58], ["DTPA", "SIMPLE_CHEMICAL", 75, 79], ["endothelial", "TISSUE", 84, 95], ["transferrin", "GENE_OR_GENE_PRODUCT", 112, 123], ["patients", "ORGANISM", 127, 135], ["vasculature", "MULTI-TISSUE_STRUCTURE", 201, 212], ["interstitium", "MULTI-TISSUE_STRUCTURE", 220, 232], ["airspace", "MULTI-TISSUE_STRUCTURE", 281, 289], ["vasculature", "MULTI-TISSUE_STRUCTURE", 293, 304], ["lungs", "ORGAN", 348, 353], ["patients", "ORGANISM", 374, 382], ["lung", "ORGAN", 386, 390], ["transferrin", "PROTEIN", 112, 123], ["patients", "SPECIES", 127, 135], ["patients", "SPECIES", 374, 382], ["DTPA", "TEST", 75, 79], ["endothelial permeability", "TEST", 84, 108], ["ARDS", "PROBLEM", 141, 145], ["inflammation", "PROBLEM", 318, 330], ["infection in the lungs of immunosuppressed patients", "PROBLEM", 331, 382], ["infection", "PROBLEM", 411, 420], ["inflammation", "PROBLEM", 424, 436], ["a resulting high mortality", "PROBLEM", 473, 499], ["alveolar", "ANATOMY_MODIFIER", 50, 58], ["endothelial", "ANATOMY", 84, 95], ["ARDS", "OBSERVATION", 141, 145], ["vasculature", "ANATOMY", 201, 212], ["interstitium", "ANATOMY", 220, 232], ["airspace", "OBSERVATION", 281, 289], ["vasculature", "ANATOMY", 293, 304], ["inflammation", "OBSERVATION", 318, 330], ["infection", "OBSERVATION", 331, 340], ["lungs", "ANATOMY", 348, 353], ["immunosuppressed", "OBSERVATION", 357, 373], ["lung", "ANATOMY", 386, 390], ["infection", "OBSERVATION", 411, 420], ["inflammation", "OBSERVATION", 424, 436], ["immunocompromised host", "OBSERVATION", 444, 466], ["high", "OBSERVATION_MODIFIER", 485, 489], ["mortality", "OBSERVATION", 490, 499]]], ["There are many potential causes of fever in this group, which tends to prompt empirical therapy.", [["fever", "DISEASE", 35, 40], ["fever", "PROBLEM", 35, 40], ["empirical therapy", "TREATMENT", 78, 95], ["fever", "OBSERVATION", 35, 40]]], ["Patients are offen debilitated from their underlying disease and so invasive investigations are hazardous.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["their underlying disease", "PROBLEM", 36, 60], ["invasive investigations", "TEST", 68, 91], ["disease", "OBSERVATION", 53, 60]]], ["The frequency of certain infections varies between HIV+ve patients and those with other causes of immunosuppression; for example, transplanted patients have a higher incidence of cytomegalovirus (CMV) infection [37] , whilst HIV+ve patients have a higher incidence of Pneumocystis carinii pneumonia (PCP) and bacterial infections such as Streptococcus pneumoniae, Pseudomonas aeruginosa and mycobacteria.", [["infections", "DISEASE", 25, 35], ["cytomegalovirus (CMV) infection", "DISEASE", 179, 210], ["Pneumocystis carinii pneumonia", "DISEASE", 268, 298], ["PCP", "DISEASE", 300, 303], ["bacterial infections", "DISEASE", 309, 329], ["Streptococcus pneumoniae, Pseudomonas aeruginosa and mycobacteria", "DISEASE", 338, 403], ["HIV", "ORGANISM", 51, 54], ["patients", "ORGANISM", 58, 66], ["patients", "ORGANISM", 143, 151], ["cytomegalovirus", "ORGANISM", 179, 194], ["CMV", "ORGANISM", 196, 199], ["HIV", "ORGANISM", 225, 228], ["patients", "ORGANISM", 232, 240], ["Pneumocystis carinii", "ORGANISM", 268, 288], ["Streptococcus pneumoniae", "ORGANISM", 338, 362], ["Pseudomonas aeruginosa", "ORGANISM", 364, 386], ["HIV", "SPECIES", 51, 54], ["patients", "SPECIES", 58, 66], ["patients", "SPECIES", 143, 151], ["HIV", "SPECIES", 225, 228], ["patients", "SPECIES", 232, 240], ["Pneumocystis carinii", "SPECIES", 268, 288], ["Streptococcus pneumoniae", "SPECIES", 338, 362], ["Pseudomonas aeruginosa", "SPECIES", 364, 386], ["HIV", "SPECIES", 51, 54], ["CMV", "SPECIES", 196, 199], ["HIV", "SPECIES", 225, 228], ["Pneumocystis carinii", "SPECIES", 268, 288], ["Streptococcus pneumoniae", "SPECIES", 338, 362], ["Pseudomonas aeruginosa", "SPECIES", 364, 386], ["certain infections", "PROBLEM", 17, 35], ["immunosuppression", "TREATMENT", 98, 115], ["cytomegalovirus (CMV) infection", "PROBLEM", 179, 210], ["Pneumocystis carinii pneumonia", "PROBLEM", 268, 298], ["bacterial infections", "PROBLEM", 309, 329], ["Streptococcus pneumoniae", "PROBLEM", 338, 362], ["Pseudomonas aeruginosa", "PROBLEM", 364, 386], ["mycobacteria", "PROBLEM", 391, 403], ["certain", "OBSERVATION_MODIFIER", 17, 24], ["infections", "OBSERVATION", 25, 35], ["cytomegalovirus", "OBSERVATION", 179, 194], ["higher incidence", "OBSERVATION_MODIFIER", 248, 264], ["Pneumocystis carinii pneumonia", "OBSERVATION", 268, 298], ["bacterial", "OBSERVATION_MODIFIER", 309, 318], ["infections", "OBSERVATION", 319, 329], ["Streptococcus pneumoniae", "OBSERVATION", 338, 362], ["mycobacteria", "OBSERVATION", 391, 403]]], ["Fungal infections may occur in either group.Detection of inflammation/infection in the lungs of immunosuppressed patientsIn the patient who is neutropenic as a result of chemotherapy, the investigating clinician needs an instant test to demonstrate the type and distribution of abnormality in order to direct further investigation.", [["lungs", "ANATOMY", 87, 92], ["Fungal infections", "DISEASE", 0, 17], ["inflammation", "DISEASE", 57, 69], ["infection", "DISEASE", 70, 79], ["neutropenic", "DISEASE", 143, 154], ["lungs", "ORGAN", 87, 92], ["patients", "ORGANISM", 113, 121], ["patient", "ORGANISM", 128, 135], ["patients", "SPECIES", 113, 121], ["patient", "SPECIES", 128, 135], ["Fungal infections", "PROBLEM", 0, 17], ["inflammation", "PROBLEM", 57, 69], ["infection in the lungs of immunosuppressed patients", "PROBLEM", 70, 121], ["neutropenic", "PROBLEM", 143, 154], ["chemotherapy", "TREATMENT", 170, 182], ["an instant test", "TEST", 218, 233], ["abnormality", "PROBLEM", 278, 289], ["direct further investigation", "TEST", 302, 330], ["infections", "OBSERVATION", 7, 17], ["inflammation", "OBSERVATION", 57, 69], ["infection", "OBSERVATION", 70, 79], ["lungs", "ANATOMY", 87, 92], ["immunosuppressed", "OBSERVATION", 96, 112], ["neutropenic", "OBSERVATION", 143, 154], ["abnormality", "OBSERVATION", 278, 289]]], ["DTPA clearance can demonstrate the location of the main ven-tilatory abnormality before changes in the chest radiograph if there is a focal problem such as lobar pneumonia, segmental infection or pneumonitis.", [["chest", "ANATOMY", 103, 108], ["lobar", "ANATOMY", 156, 161], ["DTPA", "CHEMICAL", 0, 4], ["pneumonia", "DISEASE", 162, 171], ["infection", "DISEASE", 183, 192], ["pneumonitis", "DISEASE", 196, 207], ["DTPA", "CHEMICAL", 0, 4], ["DTPA", "SIMPLE_CHEMICAL", 0, 4], ["DTPA clearance", "TEST", 0, 14], ["the main ven-tilatory abnormality", "PROBLEM", 47, 80], ["the chest radiograph", "TEST", 99, 119], ["a focal problem", "PROBLEM", 132, 147], ["lobar pneumonia", "PROBLEM", 156, 171], ["segmental infection", "PROBLEM", 173, 192], ["pneumonitis", "PROBLEM", 196, 207], ["main", "OBSERVATION_MODIFIER", 51, 55], ["ven-tilatory", "OBSERVATION_MODIFIER", 56, 68], ["abnormality", "OBSERVATION", 69, 80], ["chest", "ANATOMY", 103, 108], ["focal", "OBSERVATION_MODIFIER", 134, 139], ["lobar", "OBSERVATION_MODIFIER", 156, 161], ["pneumonia", "OBSERVATION", 162, 171], ["segmental", "OBSERVATION_MODIFIER", 173, 182], ["infection", "OBSERVATION", 183, 192], ["pneumonitis", "OBSERVATION", 196, 207]]], ["Thus in renal transplant recipients, PCP is associated with a rapid transfer rate of DTPA [38] .", [["renal transplant", "ANATOMY", 8, 24], ["PCP", "DISEASE", 37, 40], ["DTPA", "CHEMICAL", 85, 89], ["PCP", "CHEMICAL", 37, 40], ["DTPA", "CHEMICAL", 85, 89], ["renal", "ORGAN", 8, 13], ["DTPA", "SIMPLE_CHEMICAL", 85, 89], ["renal", "ANATOMY", 8, 13], ["transplant", "OBSERVATION", 14, 24]]], ["These changes, however, would also occur with CMV infection, which is common in transplant recipients, whereas fluid overload or a bacteriopneumonia would not cause significant abnormalities.", [["fluid", "ANATOMY", 111, 116], ["CMV infection", "DISEASE", 46, 59], ["fluid overload", "DISEASE", 111, 125], ["bacteriopneumonia", "DISEASE", 131, 148], ["CMV", "ORGANISM", 46, 49], ["recipients", "ORGANISM", 91, 101], ["fluid", "ORGANISM_SUBSTANCE", 111, 116], ["CMV", "SPECIES", 46, 49], ["CMV infection", "PROBLEM", 46, 59], ["transplant recipients", "TREATMENT", 80, 101], ["fluid overload", "PROBLEM", 111, 125], ["a bacteriopneumonia", "PROBLEM", 129, 148], ["significant abnormalities", "PROBLEM", 165, 190], ["infection", "OBSERVATION", 50, 59], ["fluid overload", "OBSERVATION", 111, 125], ["abnormalities", "OBSERVATION", 177, 190]]], ["The clinician can be directed towards a definitive invasive test, such as transbronchial biopsy, or an urgent induced-sputum examination.Detection of inflammation/infection in the lungs of immunosuppressed patientsPulmonary DTPA transfer rate can give rapid clear guidance as to whether there is pulmonary pathology in patients with HIV infection who have cough, breathlessness and fever, and offen the likely nature of that pathology.", [["transbronchial", "ANATOMY", 74, 88], ["sputum", "ANATOMY", 118, 124], ["lungs", "ANATOMY", 180, 185], ["Pulmonary", "ANATOMY", 214, 223], ["pulmonary", "ANATOMY", 296, 305], ["inflammation", "DISEASE", 150, 162], ["infection", "DISEASE", 163, 172], ["DTPA", "CHEMICAL", 224, 228], ["HIV infection", "DISEASE", 333, 346], ["cough", "DISEASE", 356, 361], ["breathlessness", "DISEASE", 363, 377], ["fever", "DISEASE", 382, 387], ["DTPA", "CHEMICAL", 224, 228], ["lungs", "ORGAN", 180, 185], ["patients", "ORGANISM", 206, 214], ["Pulmonary", "ORGAN", 214, 223], ["DTPA", "SIMPLE_CHEMICAL", 224, 228], ["pulmonary", "ORGAN", 296, 305], ["patients", "ORGANISM", 319, 327], ["patients", "SPECIES", 206, 214], ["patients", "SPECIES", 319, 327], ["HIV", "SPECIES", 333, 336], ["HIV", "SPECIES", 333, 336], ["a definitive invasive test", "TEST", 38, 64], ["transbronchial biopsy", "TEST", 74, 95], ["an urgent induced-sputum examination", "TEST", 100, 136], ["inflammation", "PROBLEM", 150, 162], ["infection in the lungs of immunosuppressed patients", "PROBLEM", 163, 214], ["Pulmonary DTPA transfer rate", "TREATMENT", 214, 242], ["pulmonary pathology", "PROBLEM", 296, 315], ["HIV infection", "PROBLEM", 333, 346], ["cough", "PROBLEM", 356, 361], ["breathlessness", "PROBLEM", 363, 377], ["fever", "PROBLEM", 382, 387], ["that pathology", "PROBLEM", 420, 434], ["transbronchial", "ANATOMY", 74, 88], ["inflammation", "OBSERVATION", 150, 162], ["infection", "OBSERVATION", 163, 172], ["lungs", "ANATOMY", 180, 185], ["immunosuppressed", "OBSERVATION", 189, 205], ["pulmonary", "ANATOMY", 296, 305], ["pathology", "OBSERVATION", 306, 315], ["pathology", "OBSERVATION", 425, 434]]], ["The technique has been used in PCP and other lung infections by a number of groups [39] [40] [41] [42] [43] [44] [45] , all of whom have documented a rapid clearance rate.", [["lung", "ANATOMY", 45, 49], ["PCP", "DISEASE", 31, 34], ["lung infections", "DISEASE", 45, 60], ["PCP", "CHEMICAL", 31, 34], ["lung", "ORGAN", 45, 49], ["[39] [40] [41] [42] [43] [44", "SIMPLE_CHEMICAL", 83, 111], ["The technique", "TREATMENT", 0, 13], ["other lung infections", "PROBLEM", 39, 60], ["a rapid clearance rate", "PROBLEM", 148, 170], ["lung", "ANATOMY", 45, 49], ["infections", "OBSERVATION", 50, 60]]], ["Studies have shown that in alveolitis, the clearance curve is biphasic with a rapid first component (half-time less than 4 min; 12.5% per min).", [["alveolitis", "DISEASE", 27, 37], ["Studies", "TEST", 0, 7], ["alveolitis", "PROBLEM", 27, 37], ["the clearance curve", "TEST", 39, 58], ["a rapid first component", "PROBLEM", 76, 99], ["alveolitis", "OBSERVATION", 27, 37], ["biphasic", "OBSERVATION_MODIFIER", 62, 70], ["rapid", "OBSERVATION_MODIFIER", 78, 83]]], ["The most likely cause of an alveolitis with this biphasic pattern in HIV-ve patients is still PCP but other causes include CMV infection, lymphocytic interstitial pneumonitis and non-specific interstitial pneumonitis.", [["lymphocytic interstitial", "ANATOMY", 138, 162], ["interstitial", "ANATOMY", 192, 204], ["alveolitis", "DISEASE", 28, 38], ["HIV-ve", "DISEASE", 69, 75], ["PCP", "DISEASE", 94, 97], ["CMV infection", "DISEASE", 123, 136], ["interstitial pneumonitis", "DISEASE", 150, 174], ["interstitial pneumonitis", "DISEASE", 192, 216], ["PCP", "CHEMICAL", 94, 97], ["HIV-ve", "ORGANISM", 69, 75], ["patients", "ORGANISM", 76, 84], ["CMV", "ORGANISM", 123, 126], ["HIV", "SPECIES", 69, 72], ["patients", "SPECIES", 76, 84], ["HIV", "SPECIES", 69, 72], ["CMV", "SPECIES", 123, 126], ["an alveolitis", "PROBLEM", 25, 38], ["this biphasic pattern", "PROBLEM", 44, 65], ["HIV", "PROBLEM", 69, 72], ["PCP", "PROBLEM", 94, 97], ["CMV infection", "PROBLEM", 123, 136], ["lymphocytic interstitial pneumonitis", "PROBLEM", 138, 174], ["non-specific interstitial pneumonitis", "PROBLEM", 179, 216], ["most likely", "UNCERTAINTY", 4, 15], ["alveolitis", "OBSERVATION", 28, 38], ["biphasic", "OBSERVATION_MODIFIER", 49, 57], ["pattern", "OBSERVATION_MODIFIER", 58, 65], ["CMV infection", "OBSERVATION", 123, 136], ["lymphocytic", "OBSERVATION_MODIFIER", 138, 149], ["interstitial", "ANATOMY_MODIFIER", 150, 162], ["pneumonitis", "OBSERVATION", 163, 174], ["non-specific", "OBSERVATION_MODIFIER", 179, 191], ["interstitial", "ANATOMY_MODIFIER", 192, 204], ["pneumonitis", "OBSERVATION", 205, 216]]], ["The test has a high sensitivity and specificity for PCP in this patient population but false-negative results may occur [42] .", [["PCP", "DISEASE", 52, 55], ["patient", "ORGANISM", 64, 71], ["patient", "SPECIES", 64, 71], ["The test", "TEST", 0, 8], ["PCP", "PROBLEM", 52, 55], ["false", "TEST", 87, 92]]], ["Occasionally a biphasic curve is found in heavy smokers with HIV infection in the absence of an alveolitis and it is therefore suggested that baseline scans are obtained in all smokers (authors' experience).", [["HIV infection", "DISEASE", 61, 74], ["alveolitis", "DISEASE", 96, 106], ["HIV", "ORGANISM", 61, 64], ["HIV", "SPECIES", 61, 64], ["HIV", "SPECIES", 61, 64], ["a biphasic curve", "PROBLEM", 13, 29], ["HIV infection", "PROBLEM", 61, 74], ["an alveolitis", "PROBLEM", 93, 106], ["baseline scans", "TEST", 142, 156], ["heavy", "OBSERVATION_MODIFIER", 42, 47], ["smokers", "OBSERVATION", 48, 55], ["infection", "OBSERVATION", 65, 74], ["alveolitis", "OBSERVATION", 96, 106]]], ["Transfer times are generally not biexponential in other bacterial infections with the exception of Legionella pneumophila [41] .", [["infections", "DISEASE", 66, 76], ["Legionella pneumophila", "DISEASE", 99, 121], ["Legionella pneumophila", "ORGANISM", 99, 121], ["Legionella pneumophila", "SPECIES", 99, 121], ["Legionella pneumophila", "SPECIES", 99, 121], ["other bacterial infections", "PROBLEM", 50, 76], ["Legionella pneumophila", "PROBLEM", 99, 121]]], ["Rosso et al. [40] have demonstrated that the DTPA technique has a higher sensitivity than gallium-67 scanning (92% compared with the 72%) for infectious pulmonary complications.", [["pulmonary", "ANATOMY", 153, 162], ["DTPA", "CHEMICAL", 45, 49], ["gallium-67", "CHEMICAL", 90, 100], ["infectious pulmonary complications", "DISEASE", 142, 176], ["DTPA", "CHEMICAL", 45, 49], ["gallium-67", "CHEMICAL", 90, 100], ["DTPA", "SIMPLE_CHEMICAL", 45, 49], ["gallium-67", "SIMPLE_CHEMICAL", 90, 100], ["pulmonary", "ORGAN", 153, 162], ["the DTPA technique", "TEST", 41, 59], ["gallium", "TEST", 90, 97], ["infectious pulmonary complications", "PROBLEM", 142, 176], ["infectious", "OBSERVATION_MODIFIER", 142, 152], ["pulmonary", "ANATOMY", 153, 162], ["complications", "OBSERVATION", 163, 176]]], ["This difference is more marked for patients with normal chest radiographs and normal blood gases.", [["chest", "ANATOMY", 56, 61], ["blood", "ANATOMY", 85, 90], ["patients", "ORGANISM", 35, 43], ["chest", "ORGANISM_SUBDIVISION", 56, 61], ["blood", "ORGANISM_SUBSTANCE", 85, 90], ["patients", "SPECIES", 35, 43], ["normal chest radiographs", "TEST", 49, 73], ["more marked", "OBSERVATION_MODIFIER", 19, 30], ["chest", "ANATOMY", 56, 61]]], ["The combination of a normal chest radiograph and a normal DTPA clearance virtually excludes pulmonary infection/inflammation significant enough to require therapy.", [["chest", "ANATOMY", 28, 33], ["pulmonary", "ANATOMY", 92, 101], ["DTPA", "CHEMICAL", 58, 62], ["pulmonary infection", "DISEASE", 92, 111], ["inflammation", "DISEASE", 112, 124], ["DTPA", "CHEMICAL", 58, 62], ["DTPA", "SIMPLE_CHEMICAL", 58, 62], ["pulmonary", "ORGAN", 92, 101], ["a normal chest radiograph", "TEST", 19, 44], ["a normal DTPA clearance", "TEST", 49, 72], ["pulmonary infection", "PROBLEM", 92, 111], ["inflammation", "PROBLEM", 112, 124], ["therapy", "TREATMENT", 155, 162], ["chest", "ANATOMY", 28, 33], ["pulmonary", "ANATOMY", 92, 101], ["infection", "OBSERVATION", 102, 111], ["inflammation", "OBSERVATION", 112, 124]]], ["A recent review of DTPA transfer in HIV+ve patients has outlined an algorithm for its use in HIV infection [45] ; this will continue to be of use only while PCP is the most common cause of alveolitis in HIV+ve patients.Detection of inflammation/infection in the lungs of immunosuppressed patientsHeart/lung transplants DTPA clearance has been used to identify rejection in patients with lung transplants [46] [47] [48] .", [["lungs", "ANATOMY", 262, 267], ["Heart", "ANATOMY", 296, 301], ["lung", "ANATOMY", 302, 306], ["lung", "ANATOMY", 387, 391], ["DTPA", "CHEMICAL", 19, 23], ["HIV infection", "DISEASE", 93, 106], ["PCP", "DISEASE", 157, 160], ["alveolitis", "DISEASE", 189, 199], ["inflammation", "DISEASE", 232, 244], ["infection", "DISEASE", 245, 254], ["DTPA", "CHEMICAL", 319, 323], ["DTPA", "CHEMICAL", 19, 23], ["PCP", "CHEMICAL", 157, 160], ["DTPA", "CHEMICAL", 319, 323], ["DTPA", "SIMPLE_CHEMICAL", 19, 23], ["HIV", "ORGANISM", 36, 39], ["patients", "ORGANISM", 43, 51], ["HIV", "ORGANISM", 93, 96], ["patients", "ORGANISM", 210, 218], ["lungs", "ORGAN", 262, 267], ["patients", "ORGANISM", 288, 296], ["Heart", "ORGAN", 296, 301], ["lung", "ORGAN", 302, 306], ["DTPA", "SIMPLE_CHEMICAL", 319, 323], ["patients", "ORGANISM", 373, 381], ["lung", "ORGAN", 387, 391], ["HIV", "SPECIES", 36, 39], ["patients", "SPECIES", 43, 51], ["HIV", "SPECIES", 203, 206], ["patients", "SPECIES", 210, 218], ["patients", "SPECIES", 288, 296], ["patients", "SPECIES", 373, 381], ["HIV", "SPECIES", 36, 39], ["HIV", "SPECIES", 93, 96], ["HIV", "SPECIES", 203, 206], ["DTPA transfer", "TREATMENT", 19, 32], ["an algorithm", "TEST", 65, 77], ["HIV infection", "PROBLEM", 93, 106], ["alveolitis", "PROBLEM", 189, 199], ["inflammation", "PROBLEM", 232, 244], ["infection in the lungs of immunosuppressed patients", "PROBLEM", 245, 296], ["Heart/lung transplants DTPA clearance", "TREATMENT", 296, 333], ["rejection", "PROBLEM", 360, 369], ["lung transplants", "TREATMENT", 387, 403], ["alveolitis", "OBSERVATION", 189, 199], ["inflammation", "OBSERVATION", 232, 244], ["infection", "OBSERVATION", 245, 254], ["lungs", "ANATOMY", 262, 267], ["immunosuppressed", "OBSERVATION", 271, 287], ["lung", "ANATOMY", 302, 306], ["transplants", "OBSERVATION", 307, 318], ["rejection", "OBSERVATION", 360, 369], ["lung", "ANATOMY", 387, 391], ["transplants", "OBSERVATION", 392, 403]]], ["The clearance was faster in patients with lung transplants (2.62%++0.12%/min) but increased further during rejection (3.65%__0.41%), giving a sensitivity and specificity of 69% and 82% respectively.", [["lung", "ANATOMY", 42, 46], ["patients", "ORGANISM", 28, 36], ["lung", "ORGAN", 42, 46], ["patients", "SPECIES", 28, 36], ["lung transplants", "TREATMENT", 42, 58], ["rejection", "PROBLEM", 107, 116], ["a sensitivity", "TEST", 140, 153], ["specificity", "TEST", 158, 169], ["lung", "ANATOMY", 42, 46], ["transplants", "OBSERVATION", 47, 58], ["increased", "OBSERVATION_MODIFIER", 82, 91]]], ["These data suggest that the technique may be a simple method for monitoring this patient group, indicating biopsy if the clearance is increasing.", [["patient", "ORGANISM", 81, 88], ["patient", "SPECIES", 81, 88], ["biopsy", "TEST", 107, 113], ["the clearance", "TEST", 117, 130], ["increasing", "OBSERVATION_MODIFIER", 134, 144]]], ["Other pathologies such as CMV and PCP would be expected to result in similar changes in clearance.Why is the DTPA clearance technique not in wider clinical use?As with many other nuclear medicine investigations, the technique, although non-specific, is rapid, easy to perform and extremely sensitive in the detection of lung pathology in certain circumstances.", [["lung", "ANATOMY", 320, 324], ["PCP", "DISEASE", 34, 37], ["DTPA", "CHEMICAL", 109, 113], ["PCP", "CHEMICAL", 34, 37], ["DTPA", "CHEMICAL", 109, 113], ["CMV", "ORGANISM", 26, 29], ["DTPA", "SIMPLE_CHEMICAL", 109, 113], ["lung", "ORGAN", 320, 324], ["CMV", "SPECIES", 26, 29], ["Other pathologies", "PROBLEM", 0, 17], ["CMV", "PROBLEM", 26, 29], ["the DTPA clearance technique", "TREATMENT", 105, 133], ["the technique", "TEST", 212, 225], ["lung pathology", "PROBLEM", 320, 334], ["non-specific", "OBSERVATION_MODIFIER", 236, 248], ["lung", "ANATOMY", 320, 324], ["pathology", "OBSERVATION", 325, 334]]], ["It has been applied only to HIV+ve patients in any sizeable numbers and more recently to patients with fibrosing alveolitis.", [["alveolitis", "DISEASE", 113, 123], ["HIV", "ORGANISM", 28, 31], ["patients", "ORGANISM", 35, 43], ["patients", "ORGANISM", 89, 97], ["patients", "SPECIES", 35, 43], ["patients", "SPECIES", 89, 97], ["HIV", "SPECIES", 28, 31], ["fibrosing alveolitis", "PROBLEM", 103, 123], ["fibrosing", "OBSERVATION_MODIFIER", 103, 112], ["alveolitis", "OBSERVATION", 113, 123]]], ["The strength of the test is its ease of use and sensitivity in the detection of a pulmonary abnormality.", [["pulmonary", "ANATOMY", 82, 91], ["pulmonary abnormality", "DISEASE", 82, 103], ["pulmonary", "ORGAN", 82, 91], ["the test", "TEST", 16, 24], ["sensitivity", "TEST", 48, 59], ["a pulmonary abnormality", "PROBLEM", 80, 103], ["pulmonary", "ANATOMY", 82, 91], ["abnormality", "OBSERVATION", 92, 103]]], ["Its major weakness is that smokers also have an abnormally fast clearance half time, although, as mentioned above, this might be circumvented by dual isotope studies.", [["smokers", "ORGANISM", 27, 34], ["Its major weakness", "PROBLEM", 0, 18], ["an abnormally fast clearance", "PROBLEM", 45, 73], ["dual isotope studies", "TEST", 145, 165], ["major", "OBSERVATION_MODIFIER", 4, 9], ["weakness", "OBSERVATION", 10, 18], ["abnormally", "OBSERVATION_MODIFIER", 48, 58], ["fast", "OBSERVATION_MODIFIER", 59, 63]]], ["The test is reproducible and so capable of following individual patients before and after therapy.Why is the DTPA clearance technique not in wider clinical use?Patients in whom the test should be at an advantage are those who are HIV+ve with a cough and/or fever.", [["DTPA", "CHEMICAL", 109, 113], ["cough", "DISEASE", 244, 249], ["fever", "DISEASE", 257, 262], ["DTPA", "CHEMICAL", 109, 113], ["patients", "ORGANISM", 64, 72], ["DTPA", "SIMPLE_CHEMICAL", 109, 113], ["Patients", "ORGANISM", 160, 168], ["HIV", "ORGANISM", 230, 233], ["patients", "SPECIES", 64, 72], ["Patients", "SPECIES", 160, 168], ["HIV", "SPECIES", 230, 233], ["The test", "TEST", 0, 8], ["therapy", "TREATMENT", 90, 97], ["the DTPA clearance technique", "TREATMENT", 105, 133], ["HIV", "PROBLEM", 230, 233], ["a cough", "PROBLEM", 242, 249], ["fever", "PROBLEM", 257, 262], ["reproducible", "OBSERVATION_MODIFIER", 12, 24], ["cough", "OBSERVATION", 244, 249]]], ["The technique should be available on a same-day basis, thereby leading to a real improvement in patient management.", [["patient", "ORGANISM", 96, 103], ["patient", "SPECIES", 96, 103], ["patient management", "TREATMENT", 96, 114]]], ["The utility is particularly high in patients with a normal chest radiograph in whom urgent further investigations may be directed.", [["patients", "ORGANISM", 36, 44], ["chest", "ORGANISM_SUBDIVISION", 59, 64], ["patients", "SPECIES", 36, 44], ["a normal chest radiograph", "TEST", 50, 75], ["further investigations", "TEST", 91, 113], ["high", "OBSERVATION_MODIFIER", 28, 32], ["chest", "ANATOMY", 59, 64]]], ["As an alternative, gallium-67 imaging takes several days to organize and complete and is more expensive than a clearance study.", [["gallium", "CHEMICAL", 19, 26], ["gallium-67", "CHEMICAL", 19, 29], ["gallium-67", "SIMPLE_CHEMICAL", 19, 29], ["gallium-67 imaging", "TEST", 19, 37], ["a clearance study", "TEST", 109, 126]]], ["Nevertheless, it may give additional useful information on the presence or otherwise of disease elsewhere in the body, particularly lymph node disease.", [["body", "ANATOMY", 113, 117], ["lymph node", "ANATOMY", 132, 142], ["lymph node disease", "DISEASE", 132, 150], ["body", "ORGANISM_SUBDIVISION", 113, 117], ["lymph node", "MULTI-TISSUE_STRUCTURE", 132, 142], ["disease", "PROBLEM", 88, 95], ["lymph node disease", "PROBLEM", 132, 150], ["disease", "OBSERVATION", 88, 95], ["body", "ANATOMY", 113, 117], ["lymph node disease", "OBSERVATION", 132, 150]]], ["If available on the same day or within 24 h, a clearance measurement may be useful for patient reassurance if normal or to suggest urgent investigation or empirical therapy if abnormal.Why is the DTPA clearance technique not in wider clinical use?There area number of explanations for the unpopularity of the technique:Why is the DTPA clearance technique not in wider clinical use?1.", [["DTPA", "CHEMICAL", 196, 200], ["DTPA", "CHEMICAL", 330, 334], ["DTPA", "CHEMICAL", 196, 200], ["DTPA", "CHEMICAL", 330, 334], ["patient", "ORGANISM", 87, 94], ["DTPA", "SIMPLE_CHEMICAL", 196, 200], ["DTPA", "SIMPLE_CHEMICAL", 330, 334], ["patient", "SPECIES", 87, 94], ["a clearance measurement", "TEST", 45, 68], ["urgent investigation", "TEST", 131, 151], ["empirical therapy", "TREATMENT", 155, 172], ["abnormal", "PROBLEM", 176, 184], ["the DTPA clearance technique", "TREATMENT", 192, 220], ["the DTPA clearance technique", "TREATMENT", 326, 354]]], ["Other centres have tried the test and found it to be unhelpful.", [["the test", "TEST", 25, 33]]], ["There is no evidence in the literature to support this contention.", [["no evidence in", "UNCERTAINTY", 9, 23]]], ["The technique is cheaper than gallium imaging, with less revenue to the department and individuals performing the test.", [["gallium", "CHEMICAL", 30, 37], ["gallium", "SIMPLE_CHEMICAL", 30, 37], ["gallium imaging", "TEST", 30, 45], ["the test", "TEST", 110, 118]]], ["Tbis is unlikely in the current financial climate.", [["Tbis", "GENE_OR_GENE_PRODUCT", 0, 4], ["Tbis", "PROBLEM", 0, 4], ["unlikely", "UNCERTAINTY", 8, 16]]], ["The clinician prefers to have definite histological proof and therefore opt for an induced sputum examination or bronchoscopy.", [["sputum", "ANATOMY", 91, 97], ["an induced sputum examination", "TEST", 80, 109], ["bronchoscopy", "TEST", 113, 125]]], ["The failure rate of induced sputum examination is high, especially in the presence of a normal or near-normal chest radiograph.", [["sputum", "ANATOMY", 28, 34], ["chest", "ANATOMY", 110, 115], ["chest", "ORGAN", 110, 115], ["induced sputum examination", "TEST", 20, 46], ["failure", "OBSERVATION", 4, 11], ["sputum", "OBSERVATION", 28, 34], ["high", "OBSERVATION_MODIFIER", 50, 54], ["normal", "OBSERVATION", 88, 94], ["chest", "ANATOMY", 110, 115]]], ["Bronchoscopy is expensive, invasive and carries a definite risk.", [["Bronchoscopy", "TREATMENT", 0, 12]]], ["It is too expensive to carry out in all patients with a cough and fever, in whom there is a suspicion of PCR The DTPA technique should allow patient selection but the additional cost may not be favoured by the clinician who is capable of performing the bronehoscopy on his/her own patients.", [["cough", "DISEASE", 56, 61], ["fever", "DISEASE", 66, 71], ["DTPA", "CHEMICAL", 113, 117], ["DTPA", "CHEMICAL", 113, 117], ["patients", "ORGANISM", 40, 48], ["DTPA", "SIMPLE_CHEMICAL", 113, 117], ["patient", "ORGANISM", 141, 148], ["patients", "ORGANISM", 281, 289], ["patients", "SPECIES", 40, 48], ["patient", "SPECIES", 141, 148], ["patients", "SPECIES", 281, 289], ["a cough", "PROBLEM", 54, 61], ["fever", "PROBLEM", 66, 71], ["PCR", "PROBLEM", 105, 108], ["The DTPA technique", "TREATMENT", 109, 127], ["cough", "OBSERVATION", 56, 61]]], ["This may be true.", [["may be", "UNCERTAINTY", 5, 11], ["true", "OBSERVATION_MODIFIER", 12, 16]]], ["Patients with HIV are concentrated in major cities in Europe, the United States and Australia and thus limited numbers of hospitals see large numbers of such patients.", [["Patients", "ORGANISM", 0, 8], ["patients", "ORGANISM", 158, 166], ["Patients", "SPECIES", 0, 8], ["HIV", "SPECIES", 14, 17], ["patients", "SPECIES", 158, 166], ["HIV", "SPECIES", 14, 17], ["HIV", "PROBLEM", 14, 17], ["HIV", "OBSERVATION", 14, 17], ["concentrated", "OBSERVATION_MODIFIER", 22, 34]]], ["Policies will be forged by previous experience and so changing from a technique such as gallium scanning, with which clinicians have become accustomed during the emergence of AIDS in the United States, will be difficult, in spite of the demonstration by Rosso et al. [40] of a higher sensitivity for the detection of lung pathology.", [["lung", "ANATOMY", 317, 321], ["gallium", "CHEMICAL", 88, 95], ["AIDS", "DISEASE", 175, 179], ["gallium", "CHEMICAL", 88, 95], ["lung", "ORGAN", 317, 321], ["a technique", "TREATMENT", 68, 79], ["gallium scanning", "TEST", 88, 104], ["lung pathology", "PROBLEM", 317, 331], ["lung", "ANATOMY", 317, 321], ["pathology", "OBSERVATION", 322, 331]]], ["The technique is limited to the identification of problems in the lung parenchyma, particularly alveolitis.", [["lung parenchyma", "ANATOMY", 66, 81], ["alveolitis", "DISEASE", 96, 106], ["lung parenchyma", "MULTI-TISSUE_STRUCTURE", 66, 81], ["problems in the lung parenchyma", "PROBLEM", 50, 81], ["alveolitis", "PROBLEM", 96, 106], ["problems", "OBSERVATION", 50, 58], ["lung", "ANATOMY", 66, 70], ["parenchyma", "ANATOMY_MODIFIER", 71, 81], ["alveolitis", "OBSERVATION", 96, 106]]], ["Certainly, gallium has the advantage that it may demonstrate other pathology in the lung and in lymph nodes.", [["lung", "ANATOMY", 84, 88], ["lymph nodes", "ANATOMY", 96, 107], ["gallium", "CHEMICAL", 11, 18], ["gallium", "CHEMICAL", 11, 18], ["gallium", "SIMPLE_CHEMICAL", 11, 18], ["lung", "ORGAN", 84, 88], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 96, 107], ["other pathology in the lung and in lymph nodes", "PROBLEM", 61, 107], ["pathology", "OBSERVATION", 67, 76], ["lung", "ANATOMY", 84, 88], ["lymph nodes", "OBSERVATION", 96, 107]]], ["Since the technique has to be made available every day at short notice, it is not compatible with the routine practice of nuclear medicine departments.", [["not compatible with", "UNCERTAINTY", 78, 97]]], ["Busy departments, where the test is likely to be offered, usually make provision for urgent investigations.", [["urgent investigations", "TEST", 85, 106]]], ["Clinicians, nurses and technicians are still inherently concerned about the potential infection hazard of HIV+ve patients and will be resistant to a scanning service in this patient group.", [["infection", "DISEASE", 86, 95], ["HIV", "ORGANISM", 106, 109], ["patients", "ORGANISM", 113, 121], ["patient", "ORGANISM", 174, 181], ["patients", "SPECIES", 113, 121], ["patient", "SPECIES", 174, 181], ["HIV", "SPECIES", 106, 109], ["a scanning service", "TREATMENT", 147, 165]]], ["Further reassurance may be necessary.Why is the DTPA clearance technique not in wider clinical use?The DTPA clearance technique should provide a rapid screening evaluation of the HIV+ve patient with predominantly chest symptoms.", [["chest", "ANATOMY", 213, 218], ["DTPA", "CHEMICAL", 48, 52], ["DTPA", "CHEMICAL", 103, 107], ["chest symptoms", "DISEASE", 213, 227], ["DTPA", "CHEMICAL", 48, 52], ["DTPA", "CHEMICAL", 103, 107], ["DTPA", "SIMPLE_CHEMICAL", 48, 52], ["DTPA", "SIMPLE_CHEMICAL", 103, 107], ["HIV", "ORGANISM", 179, 182], ["patient", "ORGANISM", 186, 193], ["chest", "ORGANISM_SUBDIVISION", 213, 218], ["patient", "SPECIES", 186, 193], ["HIV", "SPECIES", 179, 182], ["Further reassurance", "TREATMENT", 0, 19], ["the DTPA clearance technique", "TREATMENT", 44, 72], ["The DTPA clearance technique", "TREATMENT", 99, 127], ["a rapid screening evaluation", "TEST", 143, 171], ["the HIV", "TEST", 175, 182], ["predominantly chest symptoms", "PROBLEM", 199, 227], ["chest", "ANATOMY", 213, 218]]], ["Gallium scanning should be reserved for patients with pyrexia of unknown origin.", [["Gallium", "CHEMICAL", 0, 7], ["pyrexia", "DISEASE", 54, 61], ["Gallium", "CHEMICAL", 0, 7], ["Gallium", "SIMPLE_CHEMICAL", 0, 7], ["patients", "ORGANISM", 40, 48], ["patients", "SPECIES", 40, 48], ["Gallium scanning", "TEST", 0, 16], ["pyrexia", "PROBLEM", 54, 61]]], ["Neither test will be utilized by the clinician who believes bronchoscopy should be used as the first investigation after the chest radiograph in all patients with chest symptoms.", [["chest", "ANATOMY", 125, 130], ["chest", "ANATOMY", 163, 168], ["chest symptoms", "DISEASE", 163, 177], ["patients", "ORGANISM", 149, 157], ["chest", "ORGANISM_SUBDIVISION", 163, 168], ["patients", "SPECIES", 149, 157], ["bronchoscopy", "TREATMENT", 60, 72], ["the first investigation", "TEST", 91, 114], ["the chest radiograph", "TEST", 121, 141], ["chest symptoms", "PROBLEM", 163, 177], ["chest", "ANATOMY", 125, 130], ["chest", "ANATOMY", 163, 168]]]], "PMC7532346": [], "PMC7228273": [["INTRODUCTIONNowadays, biological expression systems are used for the production of heterologous proteins in industrial and medical fields.", [["heterologous proteins", "PROTEIN", 83, 104], ["heterologous proteins in industrial and medical fields", "PROBLEM", 83, 137]]], ["These proteins can consist of recombinant vaccines, drugs, and agricultural products (Gomes, Byregowda, Veeregowda, & Balamurugan, 2016).", [["recombinant vaccines", "TREATMENT", 30, 50], ["drugs", "TREATMENT", 52, 57], ["agricultural products", "TREATMENT", 63, 84]]], ["One of the obstacles in this area is the production of a large number of recombinant proteins in both the medical field and research.", [["recombinant proteins", "PROTEIN", 73, 93], ["obstacles", "OBSERVATION", 11, 20], ["production", "OBSERVATION_MODIFIER", 41, 51], ["large", "OBSERVATION_MODIFIER", 57, 62], ["number", "OBSERVATION_MODIFIER", 63, 69], ["recombinant", "OBSERVATION_MODIFIER", 73, 84], ["proteins", "OBSERVATION", 85, 93]]], ["Therefore, researchers apply both prokaryotic and eukaryotic cells to overcome the difficulties associated with the production of recombinants proteins (Balamurugan, Sen, Saravanan, & Singh, 2006).", [["cells", "ANATOMY", 61, 66], ["eukaryotic cells", "CELL", 50, 66], ["prokaryotic and eukaryotic cells", "CELL_TYPE", 34, 66], ["recombinants proteins", "PROTEIN", 130, 151], ["eukaryotic cells", "TREATMENT", 50, 66], ["the difficulties", "PROBLEM", 79, 95], ["eukaryotic cells", "OBSERVATION", 50, 66]]], ["Already used expression systems include: bacteria, yeasts, molds, mammals, plants, and insects.", [["expression systems", "PROBLEM", 13, 31], ["bacteria", "PROBLEM", 41, 49], ["yeasts", "PROBLEM", 51, 57], ["molds", "PROBLEM", 59, 64], ["bacteria", "OBSERVATION", 41, 49]]], ["Prokaryotic cells such as Gram\u2010negative bacteria are among the first cells used in engineering genetic technology.", [["cells", "ANATOMY", 12, 17], ["cells", "ANATOMY", 69, 74], ["cells", "CELL", 12, 17], ["cells", "CELL", 69, 74], ["Prokaryotic cells", "CELL_TYPE", 0, 17], ["Prokaryotic cells", "PROBLEM", 0, 17], ["Gram\u2010negative bacteria", "PROBLEM", 26, 48]]], ["One of the most important cells is Escherichia coli, that has been widely used for cloning recombinant DNA and subsequently, for the production of heterologous proteins (Baneyx, 1999).", [["cells", "ANATOMY", 26, 31], ["cells", "CELL", 26, 31], ["Escherichia coli", "ORGANISM", 35, 51], ["DNA", "CELLULAR_COMPONENT", 103, 106], ["cloning recombinant DNA", "DNA", 83, 106], ["heterologous proteins", "PROTEIN", 147, 168], ["Escherichia coli", "SPECIES", 35, 51], ["Escherichia coli", "SPECIES", 35, 51], ["Escherichia coli", "PROBLEM", 35, 51], ["cloning recombinant DNA", "TREATMENT", 83, 106], ["heterologous proteins", "PROBLEM", 147, 168], ["most important", "OBSERVATION_MODIFIER", 11, 25], ["cells", "OBSERVATION", 26, 31], ["Escherichia coli", "OBSERVATION", 35, 51]]], ["Bacterial expression system has several advantages including rapid multiplication, simple and inexpensive nutritional requirements, high\u2010level expression, and fast and easy transformation process.", [["Bacterial expression system", "PROBLEM", 0, 27], ["rapid multiplication", "PROBLEM", 61, 81], ["simple and inexpensive nutritional requirements", "PROBLEM", 83, 130], ["high\u2010level expression", "PROBLEM", 132, 153], ["fast and easy transformation process", "PROBLEM", 159, 195], ["rapid", "OBSERVATION_MODIFIER", 61, 66], ["multiplication", "OBSERVATION", 67, 81], ["easy transformation", "OBSERVATION", 168, 187]]], ["However, this cell factory has some limitations such as intracellular aggregation and misfolding of heterologous proteins, production of lipopolysaccharide, lack of posttranslational modification, and protein degradation due to proteases (Rosano & Ceccarelli, 2014).", [["cell", "ANATOMY", 14, 18], ["intracellular", "ANATOMY", 56, 69], ["lipopolysaccharide", "CHEMICAL", 137, 155], ["cell", "CELL", 14, 18], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 56, 69], ["lipopolysaccharide", "SIMPLE_CHEMICAL", 137, 155], ["heterologous proteins", "PROTEIN", 100, 121], ["proteases", "PROTEIN", 228, 237], ["intracellular aggregation", "PROBLEM", 56, 81], ["heterologous proteins", "PROBLEM", 100, 121], ["lipopolysaccharide", "PROBLEM", 137, 155], ["posttranslational modification", "PROBLEM", 165, 195], ["protein degradation", "PROBLEM", 201, 220], ["proteases", "TEST", 228, 237], ["intracellular aggregation", "OBSERVATION", 56, 81], ["posttranslational modification", "OBSERVATION", 165, 195]]], ["Another part of expression systems is the eukaryotic cells which include mammalian and yeast cells.", [["cells", "ANATOMY", 53, 58], ["cells", "ANATOMY", 93, 98], ["cells", "CELL", 53, 58], ["yeast cells", "CELL", 87, 98], ["eukaryotic cells", "CELL_TYPE", 42, 58], ["mammalian and yeast cells", "CELL_TYPE", 73, 98], ["yeast", "SPECIES", 87, 92], ["yeast", "SPECIES", 87, 92], ["the eukaryotic cells", "PROBLEM", 38, 58], ["mammalian and yeast cells", "PROBLEM", 73, 98], ["eukaryotic cells", "OBSERVATION", 42, 58], ["yeast cells", "OBSERVATION", 87, 98]]], ["The most common mammalian cell lines are Chinese hamster ovary (CHO) cells.", [["cell lines", "ANATOMY", 26, 36], ["hamster ovary (CHO) cells", "ANATOMY", 49, 74], ["mammalian cell lines", "CELL", 16, 36], ["Chinese hamster ovary (CHO) cells", "CELL", 41, 74], ["mammalian cell lines", "CELL_LINE", 16, 36], ["Chinese hamster ovary (CHO) cells", "CELL_LINE", 41, 74], ["Chinese hamster", "SPECIES", 41, 56], ["most common", "OBSERVATION_MODIFIER", 4, 15], ["mammalian cell lines", "OBSERVATION", 16, 36], ["ovary", "ANATOMY", 57, 62]]], ["Currently, CHO cells are used to produce biopharmaceutical compounds, monoclonal antibodies, and Fc\u2010fusion proteins.", [["CHO cells", "ANATOMY", 11, 20], ["CHO cells", "CELL", 11, 20], ["Fc\u2010fusion proteins", "GENE_OR_GENE_PRODUCT", 97, 115], ["CHO cells", "CELL_LINE", 11, 20], ["monoclonal antibodies", "PROTEIN", 70, 91], ["Fc\u2010fusion proteins", "PROTEIN", 97, 115], ["CHO cells", "PROBLEM", 11, 20], ["biopharmaceutical compounds", "PROBLEM", 41, 68], ["monoclonal antibodies", "TEST", 70, 91], ["Fc\u2010fusion proteins", "PROBLEM", 97, 115], ["biopharmaceutical compounds", "OBSERVATION", 41, 68]]], ["Apart from this, baby hamster kidney, human embryonic kidney 293 and NS0, SP2/0 (mouse\u2010derived myeloma) cell lines have also received legal permissions (Pican\u00e7o\u2010Castro, Cristina Correa de Freitas, Bomfim, & Maria de Sousa Russo, 2014).", [["kidney", "ANATOMY", 30, 36], ["embryonic kidney 293", "ANATOMY", 44, 64], ["NS0", "ANATOMY", 69, 72], ["\u2010derived myeloma) cell lines", "ANATOMY", 86, 114], ["hamster", "ORGANISM", 22, 29], ["kidney", "ORGAN", 30, 36], ["human", "ORGANISM", 38, 43], ["embryonic kidney 293", "CELL", 44, 64], ["NS0", "CELL", 69, 72], ["SP2/0", "ORGANISM", 74, 79], ["mouse", "ORGANISM", 81, 86], ["\u2010derived myeloma) cell lines", "CELL", 86, 114], ["human embryonic kidney 293", "CELL_LINE", 38, 64], ["NS0, SP2/0 (mouse\u2010derived myeloma) cell lines", "CELL_LINE", 69, 114], ["hamster", "SPECIES", 22, 29], ["human", "SPECIES", 38, 43], ["mouse", "SPECIES", 81, 86], ["hamster", "SPECIES", 22, 29], ["human", "SPECIES", 38, 43], ["mouse", "SPECIES", 81, 86], ["human embryonic kidney", "TEST", 38, 60], ["NS0", "TEST", 69, 72], ["SP2", "TEST", 74, 77], ["mouse\u2010derived myeloma) cell lines", "PROBLEM", 81, 114], ["kidney", "ANATOMY", 30, 36], ["kidney", "ANATOMY", 54, 60], ["myeloma", "OBSERVATION", 95, 102], ["cell lines", "OBSERVATION", 104, 114]]], ["Significant advantages of this system include proper protein folding, posttranslational modifications, and glycosylation of recombinant proteins in the correct sites which is important for protein stability (Khan, 2013).", [["recombinant proteins", "PROTEIN", 124, 144], ["this system", "TREATMENT", 26, 37], ["proper protein folding", "TREATMENT", 46, 68], ["posttranslational modifications", "TREATMENT", 70, 101], ["glycosylation of recombinant proteins", "TREATMENT", 107, 144], ["protein folding", "OBSERVATION", 53, 68]]], ["Besides, mammalian expression systems grow slowly and the relevant nutrient requirement is costly.", [["mammalian expression systems", "PROBLEM", 9, 37], ["the relevant nutrient requirement", "PROBLEM", 54, 87], ["nutrient requirement", "OBSERVATION", 67, 87]]], ["On the other hand, potential contamination of culture medium with some viruses has limited its use in large\u2010scale production (Yin, Li, Ren, & Herrler, 2007).", [["potential contamination of culture medium", "PROBLEM", 19, 60], ["some viruses", "PROBLEM", 66, 78], ["contamination", "OBSERVATION", 29, 42], ["viruses", "OBSERVATION", 71, 78]]], ["Yeasts are other eukaryotic cells that are widely used for the expression of several proteins in vaccine and pharmaceutical production.", [["Yeasts", "ANATOMY", 0, 6], ["cells", "ANATOMY", 28, 33], ["Yeasts", "CELL", 0, 6], ["cells", "CELL", 28, 33], ["eukaryotic cells", "CELL_TYPE", 17, 33], ["other eukaryotic cells", "PROBLEM", 11, 33], ["several proteins in vaccine", "PROBLEM", 77, 104], ["pharmaceutical production", "PROBLEM", 109, 134], ["eukaryotic cells", "OBSERVATION", 17, 33], ["several", "OBSERVATION_MODIFIER", 77, 84], ["proteins", "OBSERVATION", 85, 93], ["pharmaceutical production", "OBSERVATION", 109, 134]]], ["The mechanism of protein expression in these microorganisms is close to the ones in mammalian cells.", [["cells", "ANATOMY", 94, 99], ["mammalian cells", "CELL", 84, 99], ["mammalian cells", "CELL_TYPE", 84, 99], ["protein expression", "PROBLEM", 17, 35], ["these microorganisms", "PROBLEM", 39, 59], ["protein expression", "OBSERVATION", 17, 35], ["mammalian cells", "OBSERVATION", 84, 99]]], ["Compared with bacteria, yeast cells have significant advantages including growth speed, posttranslational modification, secretory expression, and easy genetic manipulation.", [["yeast cells", "ANATOMY", 24, 35], ["yeast cells", "CELL", 24, 35], ["yeast cells", "CELL_TYPE", 24, 35], ["yeast", "SPECIES", 24, 29], ["yeast", "SPECIES", 24, 29], ["bacteria", "PROBLEM", 14, 22], ["yeast cells", "PROBLEM", 24, 35], ["growth speed", "PROBLEM", 74, 86], ["posttranslational modification", "TREATMENT", 88, 118], ["yeast cells", "OBSERVATION", 24, 35], ["significant", "OBSERVATION_MODIFIER", 41, 52]]], ["Furthermore, linearized foreign DNA can be inserted in a chromosome in high efficiency via cross recombination phenomena to generate stable cell lines (Daly & Hearn, 2005).", [["chromosome", "ANATOMY", 57, 67], ["cell lines", "ANATOMY", 140, 150], ["DNA", "CELLULAR_COMPONENT", 32, 35], ["chromosome", "CELLULAR_COMPONENT", 57, 67], ["cell lines", "CELL", 140, 150], ["linearized foreign DNA", "DNA", 13, 35], ["stable cell lines", "CELL_LINE", 133, 150], ["linearized foreign DNA", "TREATMENT", 13, 35], ["cross recombination phenomena", "PROBLEM", 91, 120], ["foreign DNA", "OBSERVATION", 24, 35], ["high efficiency", "OBSERVATION_MODIFIER", 71, 86], ["recombination phenomena", "OBSERVATION", 97, 120], ["stable", "OBSERVATION_MODIFIER", 133, 139], ["cell lines", "OBSERVATION", 140, 150]]], ["Among yeast cells, Saccharomyces cerevisiae is used in the manufacture of hepatitis B and human papillomavirus vaccines, both of which produce a protective immune response against wild\u2010type viruses (Bill, 2015).", [["yeast cells", "ANATOMY", 6, 17], ["hepatitis B", "DISEASE", 74, 85], ["yeast cells", "CELL", 6, 17], ["Saccharomyces cerevisiae", "ORGANISM", 19, 43], ["hepatitis B", "ORGANISM", 74, 85], ["human", "ORGANISM", 90, 95], ["papillomavirus", "ORGANISM", 96, 110], ["wild\u2010type viruses", "ORGANISM", 180, 197], ["yeast cells", "CELL_TYPE", 6, 17], ["yeast", "SPECIES", 6, 11], ["Saccharomyces cerevisiae", "SPECIES", 19, 43], ["human", "SPECIES", 90, 95], ["papillomavirus", "SPECIES", 96, 110], ["yeast", "SPECIES", 6, 11], ["Saccharomyces cerevisiae", "SPECIES", 19, 43], ["hepatitis B", "SPECIES", 74, 85], ["human papillomavirus", "SPECIES", 90, 110], ["Among yeast cells", "PROBLEM", 0, 17], ["Saccharomyces cerevisiae", "TREATMENT", 19, 43], ["hepatitis B", "TREATMENT", 74, 85], ["human papillomavirus vaccines", "TREATMENT", 90, 119], ["yeast cells", "OBSERVATION", 6, 17], ["Saccharomyces cerevisiae", "OBSERVATION", 19, 43]]], ["The expression proteins in S. cerevisiae are often N and O\u2010hyperglycosylated, which may affect protein immunogenicity (Rasala & Mayfield, 2015).", [["S. cerevisiae", "ORGANISM", 27, 40], ["expression proteins", "PROTEIN", 4, 23], ["S. cerevisiae", "SPECIES", 27, 40], ["S. cerevisiae", "SPECIES", 27, 40]]], ["In recent years, to solve the problem of protein expression, methylotrophic yeasts such as Hansenulla polymorpha and Pichia pastoris (P. pastoris; syn.", [["Hansenulla polymorpha", "ORGANISM", 91, 112], ["Pichia pastoris", "ORGANISM", 117, 132], ["P. pastoris", "ORGANISM", 134, 145], ["Hansenulla polymorpha", "SPECIES", 91, 112], ["Pichia pastoris", "SPECIES", 117, 132], ["P. pastoris", "SPECIES", 134, 145], ["Hansenulla polymorpha", "SPECIES", 91, 112], ["Pichia pastoris", "SPECIES", 117, 132], ["P. pastoris", "SPECIES", 134, 145], ["protein expression", "PROBLEM", 41, 59], ["methylotrophic yeasts", "PROBLEM", 61, 82], ["Hansenulla polymorpha and Pichia pastoris", "PROBLEM", 91, 132], ["methylotrophic yeasts", "OBSERVATION", 61, 82], ["Pichia pastoris", "OBSERVATION", 117, 132]]], ["Komagataella phaffii) have been developed.", [["Komagataella phaffii", "ORGANISM", 0, 20], ["Komagataella phaffii", "SPECIES", 0, 20], ["Komagataella phaffii", "SPECIES", 0, 20], ["Komagataella phaffii", "TREATMENT", 0, 20]]], ["Among these, P. pastoris has become the most popular for its cost and expression host system.", [["P. pastoris", "ORGANISM", 13, 24], ["P. pastoris", "SPECIES", 13, 24], ["P. pastoris", "SPECIES", 13, 24], ["P. pastoris", "PROBLEM", 13, 24]]], ["This microorganism can produce high yields of recombinant proteins with the high similarity of glycosylation to the mammalian cells (Balamurugan, Reddy, & Suryanarayana, 2007).", [["cells", "ANATOMY", 126, 131], ["cells", "CELL", 126, 131], ["recombinant proteins", "PROTEIN", 46, 66], ["mammalian cells", "CELL_TYPE", 116, 131], ["This microorganism", "PROBLEM", 0, 18], ["recombinant proteins", "PROBLEM", 46, 66], ["glycosylation", "TREATMENT", 95, 108], ["mammalian cells", "OBSERVATION", 116, 131]]], ["Overall, the benefits of protein production by P. pastoris system include appropriate folding (in the endoplasmic reticulum [ER]) and secretion (by Kex2 as signal peptidase) of recombinant proteins to the external environment of the cell (S. Yang et al., 2013).", [["endoplasmic reticulum", "ANATOMY", 102, 123], ["ER", "ANATOMY", 125, 127], ["cell", "ANATOMY", 233, 237], ["P. pastoris", "ORGANISM", 47, 58], ["endoplasmic reticulum", "CELLULAR_COMPONENT", 102, 123], ["ER", "GENE_OR_GENE_PRODUCT", 125, 127], ["Kex2", "GENE_OR_GENE_PRODUCT", 148, 152], ["cell", "CELL", 233, 237], ["ER", "PROTEIN", 125, 127], ["Kex2", "PROTEIN", 148, 152], ["signal peptidase", "PROTEIN", 156, 172], ["recombinant proteins", "PROTEIN", 177, 197], ["P. pastoris", "SPECIES", 47, 58], ["P. pastoris", "SPECIES", 47, 58], ["protein production", "TREATMENT", 25, 43], ["P. pastoris system", "PROBLEM", 47, 65], ["recombinant proteins", "PROBLEM", 177, 197], ["endoplasmic reticulum", "ANATOMY", 102, 123], ["cell", "ANATOMY", 233, 237]]], ["Given the fact that some proteins produced by their original host are secreted out of the cell; P. pastoris is suitable for the production of recombinant proteins since it is equipped with a secretion system (Ahmad, Hirz, Pichler & Schwab, 2014).", [["cell", "ANATOMY", 90, 94], ["cell", "CELL", 90, 94], ["P. pastoris", "ORGANISM", 96, 107], ["recombinant proteins", "PROTEIN", 142, 162], ["P. pastoris", "SPECIES", 96, 107], ["P. pastoris", "SPECIES", 96, 107], ["some proteins", "PROBLEM", 20, 33], ["P. pastoris", "PROBLEM", 96, 107], ["recombinant proteins", "PROBLEM", 142, 162]]], ["The basic characteristics of different host systems for the expression of recombinant proteins are summarized in Table 1.BACKGROUND OF P. pastoris AS A EUKARYOTIC EXPRESSION SYSTEMHistorically, P. pastoris yeast was first isolated from the exudates of a chestnut tree in France and was named Zygosaccharomyces pastoris by Guilliermond (Zahrl, Pe\u00f1a, Mattanovich, & Gasser, 2017).", [["exudates", "ANATOMY", 240, 248], ["P. pastoris", "ORGANISM", 135, 146], ["P. pastoris", "ORGANISM", 194, 205], ["yeast", "ORGANISM", 206, 211], ["chestnut", "ORGANISM", 254, 262], ["tree", "ORGANISM_SUBDIVISION", 263, 267], ["Zygosaccharomyces pastoris", "ORGANISM", 292, 318], ["recombinant proteins", "PROTEIN", 74, 94], ["P. pastoris", "SPECIES", 135, 146], ["P. pastoris", "SPECIES", 194, 205], ["yeast", "SPECIES", 206, 211], ["Zygosaccharomyces pastoris", "SPECIES", 292, 318], ["P. pastoris", "SPECIES", 135, 146], ["P. pastoris yeast", "SPECIES", 194, 211], ["Zygosaccharomyces pastoris", "SPECIES", 292, 318], ["recombinant proteins", "PROBLEM", 74, 94], ["P. pastoris", "PROBLEM", 135, 146], ["P. pastoris yeast", "PROBLEM", 194, 211], ["different host", "OBSERVATION_MODIFIER", 29, 43], ["P. pastoris", "OBSERVATION", 135, 146], ["exudates", "OBSERVATION", 240, 248], ["chestnut tree", "OBSERVATION", 254, 267]]], ["It has been proven that P. pastoris, as an engineered methylotrophic microorganism, can use methanol as sole carbon and energy source (Cereghino, Cereghino, Ilgen & Cregg, 2002).", [["methanol", "CHEMICAL", 92, 100], ["methanol", "CHEMICAL", 92, 100], ["carbon", "CHEMICAL", 109, 115], ["P. pastoris", "ORGANISM", 24, 35], ["methanol", "SIMPLE_CHEMICAL", 92, 100], ["carbon", "SIMPLE_CHEMICAL", 109, 115], ["P. pastoris", "SPECIES", 24, 35], ["P. pastoris", "SPECIES", 24, 35], ["P. pastoris", "PROBLEM", 24, 35], ["an engineered methylotrophic microorganism", "PROBLEM", 40, 82], ["methanol", "TREATMENT", 92, 100]]], ["Unlike, Y\u201011430 strain (wild\u2010type), which is not used for protein expression, GS115 is one of the most popular strains used as an important expression system particularly in industry and medicine fields (Julien, 2006).", [["Y\u201011430", "CHEMICAL", 8, 15], ["GS115", "CHEMICAL", 78, 83], ["Y\u201011430", "GENE_OR_GENE_PRODUCT", 8, 15], ["GS115", "GENE_OR_GENE_PRODUCT", 78, 83], ["Y\u201011430 strain", "SPECIES", 8, 22], ["protein expression", "PROBLEM", 58, 76]]], ["P. pastoris GS115 strain has two encoding genes (AOX1 and AOX2) of alcohol oxidase (AOX) enzyme.", [["alcohol", "CHEMICAL", 67, 74], ["alcohol", "CHEMICAL", 67, 74], ["P. pastoris GS115 strain", "ORGANISM", 0, 24], ["AOX1", "GENE_OR_GENE_PRODUCT", 49, 53], ["AOX2", "GENE_OR_GENE_PRODUCT", 58, 62], ["alcohol oxidase", "GENE_OR_GENE_PRODUCT", 67, 82], ["AOX", "GENE_OR_GENE_PRODUCT", 84, 87], ["encoding genes", "DNA", 33, 47], ["AOX1", "DNA", 49, 53], ["AOX2", "DNA", 58, 62], ["alcohol oxidase (AOX) enzyme", "PROTEIN", 67, 95], ["P. pastoris", "SPECIES", 0, 11], ["P. pastoris", "SPECIES", 0, 11], ["enzyme", "TEST", 89, 95]]], ["In the presence of methanol, the transcription of these genes is induced and finally produces a high amount of AOX enzyme (Vanz et al., 2012).", [["methanol", "CHEMICAL", 19, 27], ["methanol", "CHEMICAL", 19, 27], ["methanol", "SIMPLE_CHEMICAL", 19, 27], ["AOX enzyme", "GENE_OR_GENE_PRODUCT", 111, 121], ["AOX enzyme", "PROTEIN", 111, 121], ["methanol", "TREATMENT", 19, 27]]], ["Although both genes are used for the production of an AOX enzyme, AOX1 produces more enzyme.", [["AOX", "GENE_OR_GENE_PRODUCT", 54, 57], ["AOX1", "GENE_OR_GENE_PRODUCT", 66, 70], ["AOX enzyme", "PROTEIN", 54, 64], ["AOX1", "PROTEIN", 66, 70], ["enzyme", "PROTEIN", 85, 91], ["an AOX enzyme", "TEST", 51, 64]]], ["Therefore, by knocking out the AOX1 gene, the growth on methanol is slowed down drastically.", [["methanol", "CHEMICAL", 56, 64], ["methanol", "CHEMICAL", 56, 64], ["AOX1", "GENE_OR_GENE_PRODUCT", 31, 35], ["methanol", "SIMPLE_CHEMICAL", 56, 64], ["AOX1 gene", "DNA", 31, 40], ["methanol", "TREATMENT", 56, 64], ["growth", "OBSERVATION_MODIFIER", 46, 52]]], ["This phenotype is called methanol utilization slow (MutS).", [["methanol", "CHEMICAL", 25, 33], ["methanol", "SIMPLE_CHEMICAL", 25, 33]]], ["A knockout of the AOX2 gene will not decelerate growth on methanol and the growth rates are comparable to methanol utilizing plus (Mut+) phenotype (wild\u2010type).", [["methanol", "CHEMICAL", 58, 66], ["methanol", "CHEMICAL", 58, 66], ["methanol", "CHEMICAL", 106, 114], ["AOX2", "GENE_OR_GENE_PRODUCT", 18, 22], ["methanol", "SIMPLE_CHEMICAL", 58, 66], ["methanol", "SIMPLE_CHEMICAL", 106, 114], ["AOX2 gene", "DNA", 18, 27], ["methanol", "TREATMENT", 58, 66], ["the growth rates", "TEST", 71, 87], ["methanol utilizing plus (Mut+) phenotype (wild\u2010type)", "TREATMENT", 106, 158]]], ["However, by knocking out both genes, the strains are unable to grow on methanol (methanol utilizing minus [Mut\u2212]; C\u00e1mara et al., 2017).", [["methanol", "CHEMICAL", 71, 79], ["methanol", "CHEMICAL", 71, 79], ["methanol", "CHEMICAL", 81, 89], ["methanol", "SIMPLE_CHEMICAL", 71, 79], ["methanol", "SIMPLE_CHEMICAL", 81, 89], ["the strains", "PROBLEM", 37, 48], ["methanol (methanol", "TREATMENT", 71, 89]]], ["In the KM71 strain, as a derivative of GS115, aox1 gene has been deleted; therefore, this strain is known as MutS strain (Charoenrat et al., 2013).", [["GS115", "CHEMICAL", 39, 44], ["KM71", "GENE_OR_GENE_PRODUCT", 7, 11], ["GS115", "GENE_OR_GENE_PRODUCT", 39, 44], ["aox1", "GENE_OR_GENE_PRODUCT", 46, 50], ["MutS", "GENE_OR_GENE_PRODUCT", 109, 113], ["GS115", "DNA", 39, 44], ["aox1 gene", "DNA", 46, 55], ["a derivative of GS115", "TREATMENT", 23, 44], ["MutS strain", "PROBLEM", 109, 120]]], ["Older strains such as KM7121, MC100\u20103, and MC101\u20101, cannot use methanol as a food source (Mut\u2212), because no AOX genes were detected in these strains and therefore they were unable to grow in the presence of methanol (Cregg, Madden, Barringer, Thill, & Stillman, 1989).Advantages and drawbacks of the P. pastoris expression system ::: THE CHARACTERISTIC FEATURES OF P. pastoris EXPRESSION SYSTEMPichia expression system has advantages for the expression of different recombinant proteins.", [["methanol", "CHEMICAL", 63, 71], ["methanol", "CHEMICAL", 207, 215], ["methanol", "CHEMICAL", 63, 71], ["methanol", "CHEMICAL", 207, 215], ["MC100\u20103", "CELL", 30, 37], ["MC101\u20101", "GENE_OR_GENE_PRODUCT", 43, 50], ["methanol", "SIMPLE_CHEMICAL", 63, 71], ["AOX", "GENE_OR_GENE_PRODUCT", 108, 111], ["methanol", "SIMPLE_CHEMICAL", 207, 215], ["Cregg", "SIMPLE_CHEMICAL", 217, 222], ["P. pastoris", "ORGANISM", 300, 311], ["P. pastoris", "ORGANISM", 365, 376], ["AOX genes", "DNA", 108, 117], ["SYSTEMPichia", "PROTEIN", 388, 400], ["recombinant proteins", "PROTEIN", 466, 486], ["P. pastoris", "SPECIES", 300, 311], ["P. pastoris", "SPECIES", 365, 376], ["P. pastoris", "SPECIES", 300, 311], ["P. pastoris", "SPECIES", 365, 376], ["Older strains", "PROBLEM", 0, 13], ["KM7121", "TEST", 22, 28], ["MC100", "TEST", 30, 35], ["methanol", "TREATMENT", 63, 71], ["AOX genes", "PROBLEM", 108, 117], ["P. pastoris EXPRESSION SYSTEMPichia expression system", "TREATMENT", 365, 418], ["different recombinant proteins", "TREATMENT", 456, 486]]], ["As noted, P. pastoris is a methylotrophic yeast which is known as a recombinant expression host system.", [["P. pastoris", "ORGANISM", 10, 21], ["P. pastoris", "SPECIES", 10, 21], ["yeast", "SPECIES", 42, 47], ["P. pastoris", "SPECIES", 10, 21], ["yeast", "SPECIES", 42, 47], ["P. pastoris", "PROBLEM", 10, 21], ["a methylotrophic yeast", "PROBLEM", 25, 47], ["methylotrophic yeast", "OBSERVATION", 27, 47]]], ["One of the advantages of the Pichia system is its high similarity with advanced eukaryotic expression systems such as CHO cell lines.", [["CHO cell lines", "ANATOMY", 118, 132], ["CHO cell lines", "CELL", 118, 132], ["CHO cell lines", "CELL_LINE", 118, 132], ["the Pichia system", "TREATMENT", 25, 42], ["advanced eukaryotic expression systems", "TREATMENT", 71, 109], ["CHO cell lines", "TREATMENT", 118, 132], ["CHO cell lines", "OBSERVATION", 118, 132]]], ["This yeast system is inexpensive, it also has relatively rapid expression times, cotranslational and posttranslational processing.", [["yeast", "SPECIES", 5, 10], ["yeast", "SPECIES", 5, 10], ["cotranslational and posttranslational processing", "PROBLEM", 81, 129]]], ["By the use of industrial bioreactors, proteins of interest can be produced on a large scale from small culture volumes.", [["industrial bioreactors", "TREATMENT", 14, 36], ["a large scale", "TREATMENT", 78, 91], ["small culture volumes", "TEST", 97, 118], ["small", "OBSERVATION_MODIFIER", 97, 102]]], ["Recently, studies have shown that the Pichia expression system is unique in the production of membrane proteins including calcium and potassium channels, nitrate and phosphate transporter, and histamine H1 receptor (Byrne, 2015).", [["membrane", "ANATOMY", 94, 102], ["calcium", "CHEMICAL", 122, 129], ["potassium", "CHEMICAL", 134, 143], ["nitrate", "CHEMICAL", 154, 161], ["phosphate", "CHEMICAL", 166, 175], ["histamine", "CHEMICAL", 193, 202], ["calcium", "CHEMICAL", 122, 129], ["potassium", "CHEMICAL", 134, 143], ["nitrate", "CHEMICAL", 154, 161], ["phosphate", "CHEMICAL", 166, 175], ["histamine", "CHEMICAL", 193, 202], ["Pichia", "GENE_OR_GENE_PRODUCT", 38, 44], ["membrane", "CELLULAR_COMPONENT", 94, 102], ["calcium", "SIMPLE_CHEMICAL", 122, 129], ["potassium", "SIMPLE_CHEMICAL", 134, 143], ["nitrate", "SIMPLE_CHEMICAL", 154, 161], ["phosphate", "SIMPLE_CHEMICAL", 166, 175], ["histamine H1 receptor", "GENE_OR_GENE_PRODUCT", 193, 214], ["membrane proteins", "PROTEIN", 94, 111], ["calcium and potassium channels", "PROTEIN", 122, 152], ["nitrate and phosphate transporter", "PROTEIN", 154, 187], ["histamine H1 receptor", "PROTEIN", 193, 214], ["the Pichia expression system", "PROBLEM", 34, 62], ["membrane proteins", "TREATMENT", 94, 111], ["calcium and potassium channels", "TREATMENT", 122, 152], ["nitrate", "TREATMENT", 154, 161], ["phosphate transporter", "TREATMENT", 166, 187], ["histamine H1 receptor", "TREATMENT", 193, 214]]], ["Furthermore, P. pastoris is a suitable microorganism in the secretory production of recombinant proteins directly into the supernatant of the culture medium.", [["supernatant", "ANATOMY", 123, 134], ["P. pastoris", "ORGANISM", 13, 24], ["recombinant proteins", "PROTEIN", 84, 104], ["P. pastoris", "SPECIES", 13, 24], ["P. pastoris", "SPECIES", 13, 24], ["P. pastoris", "PROBLEM", 13, 24], ["a suitable microorganism", "PROBLEM", 28, 52], ["recombinant proteins", "TREATMENT", 84, 104], ["the culture medium", "TEST", 138, 156]]], ["In the P. pastoris expression system due to its limited production of endogenous secretory proteins, the purification of recombinant protein is easy (Tachioka et al., 2016).Advantages and drawbacks of the P. pastoris expression system ::: THE CHARACTERISTIC FEATURES OF P. pastoris EXPRESSION SYSTEMAnother advantage of P. pastoris as a protein production host is its ability to perform posttranslational modifications such as O\u2010 and N\u2010linked glycosylation and disulfide bond formation.", [["O\u2010", "CHEMICAL", 427, 429], ["O\u2010", "CHEMICAL", 427, 429], ["N\u2010linked", "CHEMICAL", 434, 442], ["disulfide", "CHEMICAL", 461, 470], ["P. pastoris", "ORGANISM", 7, 18], ["secretory proteins", "GENE_OR_GENE_PRODUCT", 81, 99], ["P. pastoris", "ORGANISM", 205, 216], ["P. pastoris", "ORGANISM", 270, 281], ["P. pastoris", "ORGANISM", 320, 331], ["O\u2010", "SIMPLE_CHEMICAL", 427, 429], ["N\u2010linked", "SIMPLE_CHEMICAL", 434, 442], ["disulfide bond", "SIMPLE_CHEMICAL", 461, 475], ["endogenous secretory proteins", "PROTEIN", 70, 99], ["recombinant protein", "PROTEIN", 121, 140], ["P. pastoris", "SPECIES", 7, 18], ["P. pastoris", "SPECIES", 205, 216], ["P. pastoris", "SPECIES", 270, 281], ["P. pastoris", "SPECIES", 320, 331], ["P. pastoris", "SPECIES", 7, 18], ["P. pastoris", "SPECIES", 205, 216], ["P. pastoris", "SPECIES", 270, 281], ["P. pastoris", "SPECIES", 320, 331], ["endogenous secretory proteins", "PROBLEM", 70, 99], ["P. pastoris", "PROBLEM", 320, 331], ["a protein production host", "TREATMENT", 335, 360], ["posttranslational modifications", "TREATMENT", 387, 418], ["O\u2010 and N\u2010linked glycosylation", "TREATMENT", 427, 456], ["disulfide bond formation", "TREATMENT", 461, 485]]], ["Many therapeutic proteins are glycoproteins and require the attachment of carbohydrate structures to the protein backbone (glycosylation) to allow for correct folding, solubility, stability, and proper biological activity (Cereghino et al., 2002).", [["carbohydrate", "CHEMICAL", 74, 86], ["glycoproteins", "PROTEIN", 30, 43], ["glycoproteins", "TREATMENT", 30, 43], ["the attachment of carbohydrate structures", "TREATMENT", 56, 97], ["the protein backbone (glycosylation", "TREATMENT", 101, 136], ["therapeutic", "OBSERVATION_MODIFIER", 5, 16], ["proteins", "OBSERVATION", 17, 25], ["stability", "OBSERVATION_MODIFIER", 180, 189]]], ["There are two main types of glycosylation in yeast cells (N\u2010linked and O\u2010linked glycosylation) that takes place in the ER or Golgi apparatus.", [["yeast cells", "ANATOMY", 45, 56], ["ER", "ANATOMY", 119, 121], ["Golgi apparatus", "ANATOMY", 125, 140], ["yeast cells", "CELL", 45, 56], ["N\u2010linked", "SIMPLE_CHEMICAL", 58, 66], ["ER", "GENE_OR_GENE_PRODUCT", 119, 121], ["Golgi apparatus", "CELLULAR_COMPONENT", 125, 140], ["yeast cells", "CELL_TYPE", 45, 56], ["ER", "PROTEIN", 119, 121], ["yeast", "SPECIES", 45, 50], ["yeast", "SPECIES", 45, 50], ["glycosylation in yeast cells", "TREATMENT", 28, 56], ["N\u2010linked and O\u2010linked glycosylation", "TREATMENT", 58, 93], ["two", "OBSERVATION_MODIFIER", 10, 13], ["main", "OBSERVATION_MODIFIER", 14, 18], ["glycosylation", "OBSERVATION", 28, 41], ["yeast cells", "OBSERVATION", 45, 56]]], ["In yeast, the structure of N\u2010linked glycans is typical of the hypermannose type, whereas, in humans, complex and hybrid structures are of the predominant type.", [["N\u2010linked glycans", "GENE_OR_GENE_PRODUCT", 27, 43], ["humans", "ORGANISM", 93, 99], ["N\u2010linked glycans", "PROTEIN", 27, 43], ["yeast", "SPECIES", 3, 8], ["humans", "SPECIES", 93, 99], ["yeast", "SPECIES", 3, 8], ["humans", "SPECIES", 93, 99], ["N\u2010linked glycans", "PROBLEM", 27, 43], ["the hypermannose type", "PROBLEM", 58, 79], ["N\u2010linked glycans", "OBSERVATION", 27, 43], ["hypermannose type", "OBSERVATION", 62, 79], ["complex", "OBSERVATION_MODIFIER", 101, 108], ["hybrid structures", "OBSERVATION", 113, 130], ["predominant", "OBSERVATION_MODIFIER", 142, 153], ["type", "OBSERVATION_MODIFIER", 154, 158]]], ["For providing N\u2010linked glycosylation, oligosaccharides are attached to the amide nitrogen of asparagine (Asn) residue through an N\u2010glycosyl linkage within the consensus sequence Asn\u2010X\u2010Ser/Thr (where X is any amino acid except proline).", [["amide nitrogen", "CHEMICAL", 75, 89], ["asparagine", "CHEMICAL", 93, 103], ["Asn", "CHEMICAL", 105, 108], ["N\u2010glycosyl", "CHEMICAL", 129, 139], ["amino acid", "CHEMICAL", 208, 218], ["proline", "CHEMICAL", 226, 233], ["amide", "CHEMICAL", 75, 80], ["nitrogen", "CHEMICAL", 81, 89], ["asparagine", "CHEMICAL", 93, 103], ["Asn", "CHEMICAL", 105, 108], ["N\u2010glycosyl", "CHEMICAL", 129, 139], ["Ser", "CHEMICAL", 184, 187], ["Thr", "CHEMICAL", 188, 191], ["amino acid", "CHEMICAL", 208, 218], ["proline", "CHEMICAL", 226, 233], ["asparagine", "AMINO_ACID", 93, 103], ["Asn)", "AMINO_ACID", 105, 109], ["residue", "AMINO_ACID", 110, 117], ["N\u2010glycosyl", "SIMPLE_CHEMICAL", 129, 139], ["Ser/Thr", "AMINO_ACID", 184, 191], ["amino acid", "AMINO_ACID", 208, 218], ["proline", "AMINO_ACID", 226, 233], ["consensus sequence", "PROTEIN", 159, 177], ["N\u2010linked glycosylation", "TREATMENT", 14, 36], ["oligosaccharides", "TREATMENT", 38, 54], ["the amide nitrogen of asparagine (Asn) residue", "TREATMENT", 71, 117], ["an N\u2010glycosyl linkage", "TREATMENT", 126, 147], ["Ser/Thr", "TREATMENT", 184, 191], ["any amino acid except proline", "TREATMENT", 204, 233]]], ["For yielding the O\u2010linked type of glycosylation, oligosaccharides are attached to serine or threonine residues through a glycosidic linkage.", [["threonine", "CHEMICAL", 92, 101], ["serine", "CHEMICAL", 82, 88], ["threonine", "CHEMICAL", 92, 101], ["serine", "AMINO_ACID", 82, 88], ["threonine", "AMINO_ACID", 92, 101], ["glycosylation", "TREATMENT", 34, 47], ["oligosaccharides", "TREATMENT", 49, 65], ["threonine residues", "TREATMENT", 92, 110], ["a glycosidic linkage", "TREATMENT", 119, 139], ["glycosidic linkage", "OBSERVATION", 121, 139]]], ["The O\u2010linked saccharides are typically much smaller than N\u2010linked saccharides (<5 residues).", [["N\u2010linked", "CHEMICAL", 57, 65], ["O\u2010linked saccharides", "SIMPLE_CHEMICAL", 4, 24], ["N\u2010linked saccharides", "SIMPLE_CHEMICAL", 57, 77], ["The O\u2010linked saccharides", "TEST", 0, 24], ["saccharides", "OBSERVATION_MODIFIER", 13, 24], ["typically", "OBSERVATION_MODIFIER", 29, 38], ["much", "OBSERVATION_MODIFIER", 39, 43], ["smaller", "OBSERVATION_MODIFIER", 44, 51]]], ["N\u2010glycosylation in S. cerevisiae is characterized by hypermannosylation with \u03b1\u20101,2\u2010, \u03b1\u20101,6\u2010, and \u03b1\u20101,3\u2010mannosyltransferases (Figure 1b).", [["S. cerevisiae", "ORGANISM", 19, 32], ["\u03b1\u20101", "GENE_OR_GENE_PRODUCT", 77, 80], ["2\u2010", "GENE_OR_GENE_PRODUCT", 81, 83], ["\u03b1\u20101,6\u2010", "GENE_OR_GENE_PRODUCT", 85, 91], ["\u03b1\u20101", "GENE_OR_GENE_PRODUCT", 97, 100], ["\u03b1\u20101", "PROTEIN", 77, 80], ["2\u2010", "PROTEIN", 81, 83], ["\u2010", "PROTEIN", 90, 91], ["\u03b1\u20101", "PROTEIN", 97, 100], ["\u2010mannosyltransferases", "PROTEIN", 102, 123], ["S. cerevisiae", "SPECIES", 19, 32], ["S. cerevisiae", "SPECIES", 19, 32], ["N\u2010glycosylation", "TREATMENT", 0, 15], ["hypermannosylation", "TEST", 53, 71], ["\u03b1\u20101", "TEST", 77, 80], ["\u03b1\u20101", "TEST", 97, 100], ["\u2010mannosyltransferases", "TEST", 102, 123]]], ["In comparison to S. cerevisiae, P. pastoris may have an advantage in the glycosylation of secreted proteins because it may not hyperglycosylated.", [["S. cerevisiae", "ORGANISM", 17, 30], ["P. pastoris", "ORGANISM", 32, 43], ["secreted proteins", "PROTEIN", 90, 107], ["S. cerevisiae", "SPECIES", 17, 30], ["P. pastoris", "SPECIES", 32, 43], ["S. cerevisiae", "SPECIES", 17, 30], ["P. pastoris", "SPECIES", 32, 43], ["P. pastoris", "PROBLEM", 32, 43], ["secreted proteins", "PROBLEM", 90, 107]]], ["In P. pastoris N\u2010glycans (Man8\u201014GlcNAc2) are frequently shorter than the long oligosaccharide chains (Man > 50GlcNAc2) found in the S. cerevisiae.", [["P. pastoris N\u2010glycans", "ORGANISM", 3, 24], ["Man8\u201014GlcNAc2", "GENE_OR_GENE_PRODUCT", 26, 40], ["Man > 50GlcNAc2", "GENE_OR_GENE_PRODUCT", 103, 118], ["S. cerevisiae", "ORGANISM", 133, 146], ["long oligosaccharide chains", "PROTEIN", 74, 101], ["50GlcNAc2", "PROTEIN", 109, 118], ["P. pastoris", "SPECIES", 3, 14], ["S. cerevisiae", "SPECIES", 133, 146], ["P. pastoris", "SPECIES", 3, 14], ["S. cerevisiae", "SPECIES", 133, 146], ["P. pastoris N\u2010glycans", "TREATMENT", 3, 24], ["the long oligosaccharide chains", "TREATMENT", 70, 101]]], ["Besides, S. cerevisiae core oligosaccharides have terminal \u03b1\u20101,3 glycan linkages whereas P. pastoris does not.", [["S. cerevisiae", "ORGANISM", 9, 22], ["P. pastoris", "ORGANISM", 89, 100], ["S. cerevisiae", "SPECIES", 9, 22], ["P. pastoris", "SPECIES", 89, 100], ["S. cerevisiae", "SPECIES", 9, 22], ["P. pastoris", "SPECIES", 89, 100], ["P. pastoris", "PROBLEM", 89, 100]]], ["Unlike S. cerevisiae, P. pastoris does not hyperglycosylated therapeutic proteins and does not contain potentially immunogenic terminal \u03b1\u20101,3\u2010linked mannoses (Figure 1c).", [["S. cerevisiae", "ORGANISM", 7, 20], ["P. pastoris", "ORGANISM", 22, 33], ["hyperglycosylated therapeutic proteins", "PROTEIN", 43, 81], ["S. cerevisiae", "SPECIES", 7, 20], ["P. pastoris", "SPECIES", 22, 33], ["S. cerevisiae", "SPECIES", 7, 20], ["P. pastoris", "SPECIES", 22, 33], ["P. pastoris", "TEST", 22, 33]]], ["It is believed that the \u03b1\u20101,3 glycan linkages in glycosylated proteins produced from S. cerevisiae are primarily responsible for the hyper\u2010antigenic nature of these proteins making them particularly unsuitable for therapeutic use.", [["\u03b1\u20101,3", "GENE_OR_GENE_PRODUCT", 24, 29], ["S. cerevisiae", "ORGANISM", 85, 98], ["glycosylated proteins", "PROTEIN", 49, 70], ["S. cerevisiae", "SPECIES", 85, 98], ["S. cerevisiae", "SPECIES", 85, 98], ["glycosylated proteins", "PROBLEM", 49, 70], ["S. cerevisiae", "PROBLEM", 85, 98], ["these proteins", "PROBLEM", 159, 173]]], ["Moreover, very little O\u2010linked glycosylation has been observed in P. pastoris (Bretthauer & Castellino, 1999).", [["P. pastoris", "ORGANISM", 66, 77], ["P. pastoris", "SPECIES", 66, 77], ["P. pastoris", "SPECIES", 66, 77], ["very little O\u2010linked glycosylation", "PROBLEM", 10, 44]]], ["Due to its attractive characteristics for heterologous protein production (low incidence of hyperglycosylation), P. pastoris is an interesting organism for the production of therapeutic glycoproteins.", [["P. pastoris", "ORGANISM", 113, 124], ["therapeutic glycoproteins", "PROTEIN", 174, 199], ["P. pastoris", "SPECIES", 113, 124], ["P. pastoris", "SPECIES", 113, 124], ["heterologous protein production", "PROBLEM", 42, 73], ["hyperglycosylation", "PROBLEM", 92, 110], ["P. pastoris", "PROBLEM", 113, 124], ["an interesting organism", "PROBLEM", 128, 151], ["therapeutic glycoproteins", "TREATMENT", 174, 199]]], ["The N\u2010glycosylation plays an important role in achieving complete biological activities of therapeutic proteins such as interferon, erythropoietin, and monoclonal antibodies.", [["N\u2010glycosylation", "CHEMICAL", 4, 19], ["interferon", "GENE_OR_GENE_PRODUCT", 120, 130], ["erythropoietin", "GENE_OR_GENE_PRODUCT", 132, 146], ["therapeutic proteins", "PROTEIN", 91, 111], ["interferon", "PROTEIN", 120, 130], ["erythropoietin", "PROTEIN", 132, 146], ["monoclonal antibodies", "PROTEIN", 152, 173], ["therapeutic proteins", "TREATMENT", 91, 111], ["interferon", "TREATMENT", 120, 130], ["erythropoietin", "TREATMENT", 132, 146], ["monoclonal antibodies", "TREATMENT", 152, 173]]], ["The N\u2010glycosylation pathway in mammalian cells consists of the addition of one or more N\u2010acetylglucosamine (GlcNAc) residues followed by the sequential addition of galactose (Gal) and sialic acid which creates a complex type of N\u2010glycans (Figure 1a).", [["mammalian cells", "ANATOMY", 31, 46], ["N\u2010acetylglucosamine", "CHEMICAL", 87, 106], ["galactose", "CHEMICAL", 164, 173], ["sialic acid", "CHEMICAL", 184, 195], ["N\u2010acetylglucosamine", "CHEMICAL", 87, 106], ["GlcNAc", "CHEMICAL", 108, 114], ["galactose", "CHEMICAL", 164, 173], ["Gal", "CHEMICAL", 175, 178], ["sialic acid", "CHEMICAL", 184, 195], ["mammalian cells", "CELL", 31, 46], ["N\u2010acetylglucosamine", "SIMPLE_CHEMICAL", 87, 106], ["galactose", "SIMPLE_CHEMICAL", 164, 173], ["Gal", "GENE_OR_GENE_PRODUCT", 175, 178], ["sialic acid", "SIMPLE_CHEMICAL", 184, 195], ["N\u2010glycans", "GENE_OR_GENE_PRODUCT", 228, 237], ["mammalian cells", "CELL_TYPE", 31, 46], ["N\u2010glycans", "PROTEIN", 228, 237], ["The N\u2010glycosylation pathway", "TREATMENT", 0, 27], ["mammalian cells", "TREATMENT", 31, 46], ["more N\u2010acetylglucosamine (GlcNAc) residues", "TREATMENT", 82, 124], ["galactose (Gal)", "TREATMENT", 164, 179], ["sialic acid", "TREATMENT", 184, 195], ["mammalian cells", "OBSERVATION", 31, 46]]], ["While, hypermannosylation of recombinant protein in the P. pastoris expression system can lead to immunologic reaction and decreased serum half\u2010life (Laukens, De Wachter, & Callewaert, 2015).", [["serum", "ANATOMY", 133, 138], ["P. pastoris", "ORGANISM", 56, 67], ["serum", "ORGANISM_SUBSTANCE", 133, 138], ["recombinant protein", "PROTEIN", 29, 48], ["P. pastoris", "SPECIES", 56, 67], ["P. pastoris", "SPECIES", 56, 67], ["recombinant protein", "PROBLEM", 29, 48], ["the P. pastoris expression system", "PROBLEM", 52, 85], ["immunologic reaction", "PROBLEM", 98, 118], ["decreased serum half\u2010life", "PROBLEM", 123, 148], ["recombinant protein", "OBSERVATION", 29, 48]]], ["Recently, new strategies have been designed to engineer the P. pastoris N\u2010glycosylation pathway.", [["P. pastoris", "ORGANISM", 60, 71], ["P. pastoris", "SPECIES", 60, 71], ["P. pastoris", "SPECIES", 60, 71]]], ["With Pichia GlycoSwitch, the yeast's own hyperglycosyl N\u2010glycans are switched to the more human biantennary complex\u2010type N\u2010glycans.", [["hyperglycosyl N\u2010glycans", "CHEMICAL", 41, 64], ["N\u2010glycans", "GENE_OR_GENE_PRODUCT", 55, 64], ["human", "ORGANISM", 90, 95], ["N\u2010glycans", "GENE_OR_GENE_PRODUCT", 121, 130], ["Pichia GlycoSwitch", "PROTEIN", 5, 23], ["hyperglycosyl N\u2010glycans", "PROTEIN", 41, 64], ["human biantennary complex\u2010type N\u2010glycans", "PROTEIN", 90, 130], ["yeast", "SPECIES", 29, 34], ["human", "SPECIES", 90, 95], ["yeast", "SPECIES", 29, 34], ["human", "SPECIES", 90, 95], ["Pichia GlycoSwitch", "TREATMENT", 5, 23], ["the yeast", "PROBLEM", 25, 34], ["hyperglycosyl N\u2010glycans", "TREATMENT", 41, 64], ["the more human biantennary complex\u2010type N\u2010glycans", "TREATMENT", 81, 130]]], ["In glycoengineering strategy by disruption of an endogenous glycosyltransferase gene (OCH1) and introducing heterologous enzyme activities, Pichia has been engineered to produce human\u2010like glycoproteins (Jacobs, Geysens, Vervecken, Contreras, & Callewaert, 2009).", [["OCH1", "GENE_OR_GENE_PRODUCT", 86, 90], ["Pichia", "GENE_OR_GENE_PRODUCT", 140, 146], ["endogenous glycosyltransferase gene", "DNA", 49, 84], ["OCH1", "DNA", 86, 90], ["Pichia", "PROTEIN", 140, 146], ["human\u2010like glycoproteins", "PROTEIN", 178, 202], ["an endogenous glycosyltransferase gene (OCH1)", "TREATMENT", 46, 91], ["introducing heterologous enzyme activities", "PROBLEM", 96, 138]]], ["Indeed, the first step of humanizing Pichia glycosylation or GlycoSwitch\u00ae strategy is the knockout of the gene coding for \u03b1\u20101,6\u2010mannosyltransferase (OCH1) which is responsible for the initiation of hypermannosylation.", [["Pichia glycosylation", "GENE_OR_GENE_PRODUCT", 37, 57], ["GlycoSwitch\u00ae", "GENE_OR_GENE_PRODUCT", 61, 73], ["\u03b1\u20101,6\u2010mannosyltransferase", "GENE_OR_GENE_PRODUCT", 122, 147], ["OCH1", "GENE_OR_GENE_PRODUCT", 149, 153], ["\u03b1\u20101,6\u2010mannosyltransferase", "PROTEIN", 122, 147], ["OCH1", "PROTEIN", 149, 153], ["humanizing Pichia glycosylation", "TREATMENT", 26, 57], ["GlycoSwitch", "TREATMENT", 61, 72], ["hypermannosylation", "TREATMENT", 198, 216]]], ["The next step in this process is the co\u2010overexpression of several glycosyltransferases or glycosidase to produce human\u2010like glycoproteins.", [["glycosidase", "GENE_OR_GENE_PRODUCT", 90, 101], ["glycosyltransferases", "PROTEIN", 66, 86], ["glycosidase", "PROTEIN", 90, 101], ["human\u2010like glycoproteins", "PROTEIN", 113, 137], ["several glycosyltransferases", "TREATMENT", 58, 86], ["glycosidase", "TREATMENT", 90, 101], ["human\u2010like glycoproteins", "PROBLEM", 113, 137]]], ["Commonly employed Pichia GlycoSwitch\u00ae strains (BioGrammatics, Carlsbad, CA) are SuperMan5, SuperMan5HIS\u2212, SuperMan5pep4\u2013, SuperMan5(aox1\u2013, Muts), SuperMan5(pep4\u2013, prb1\u2013) and SuperMan5(pep4\u2013, sub2\u2013).", [["CA", "GENE_OR_GENE_PRODUCT", 72, 74], ["SuperMan5", "GENE_OR_GENE_PRODUCT", 80, 89], ["SuperMan5HIS", "GENE_OR_GENE_PRODUCT", 91, 103], ["SuperMan5pep4\u2013", "GENE_OR_GENE_PRODUCT", 106, 120], ["SuperMan5", "GENE_OR_GENE_PRODUCT", 122, 131], ["aox1\u2013", "GENE_OR_GENE_PRODUCT", 132, 137], ["Muts", "GENE_OR_GENE_PRODUCT", 139, 143], ["SuperMan5", "GENE_OR_GENE_PRODUCT", 146, 155], ["pep4\u2013", "GENE_OR_GENE_PRODUCT", 156, 161], ["prb1\u2013", "GENE_OR_GENE_PRODUCT", 163, 168], ["SuperMan5", "GENE_OR_GENE_PRODUCT", 174, 183], ["pep4\u2013", "GENE_OR_GENE_PRODUCT", 184, 189], ["SuperMan5", "PROTEIN", 80, 89], ["SuperMan5HIS", "PROTEIN", 91, 103], ["SuperMan5pep4\u2013", "PROTEIN", 106, 120], ["SuperMan5", "PROTEIN", 122, 131], ["aox1\u2013", "PROTEIN", 132, 137], ["Muts", "PROTEIN", 139, 143], ["SuperMan5", "PROTEIN", 146, 155], ["pep4\u2013", "PROTEIN", 156, 161], ["prb1\u2013", "PROTEIN", 163, 168], ["SuperMan5", "PROTEIN", 174, 183], ["pep4\u2013", "PROTEIN", 184, 189], ["sub2\u2013", "PROTEIN", 191, 196], ["Pichia GlycoSwitch\u00ae strains", "TREATMENT", 18, 45], ["Carlsbad, CA)", "TREATMENT", 62, 75], ["SuperMan5pep4\u2013", "TREATMENT", 106, 120], ["SuperMan5(aox1\u2013, Muts", "TREATMENT", 122, 143], ["SuperMan5(pep4\u2013, prb1\u2013)", "TREATMENT", 146, 169], ["SuperMan5(pep4\u2013", "TREATMENT", 174, 189]]], ["These strains, OCH1 inactivated strains that express an ER\u2010targeted \u03b1\u20101,2\u2010mannosidase, express target protein with a mannose\u20105 structure at N\u2010linked site (Ahmad et al., 2014; Figure 1d).", [["mannose\u20105", "CHEMICAL", 117, 126], ["\u03b1\u20101", "GENE_OR_GENE_PRODUCT", 68, 71], ["2\u2010mannosidase", "GENE_OR_GENE_PRODUCT", 72, 85], ["mannose\u20105", "SIMPLE_CHEMICAL", 117, 126], ["ER\u2010targeted \u03b1\u20101,2\u2010mannosidase", "PROTEIN", 56, 85], ["mannose\u20105 structure", "PROTEIN", 117, 136], ["N\u2010linked site", "DNA", 140, 153], ["These strains", "PROBLEM", 0, 13], ["OCH1 inactivated strains", "PROBLEM", 15, 39], ["a mannose\u20105 structure", "TREATMENT", 115, 136]]], ["The SuperMan5 strain is commonly used to express of vaccine antigens.", [["SuperMan5", "CHEMICAL", 4, 13], ["SuperMan5", "GENE_OR_GENE_PRODUCT", 4, 13], ["vaccine antigens", "PROTEIN", 52, 68], ["The SuperMan5 strain", "TREATMENT", 0, 20], ["vaccine antigens", "TREATMENT", 52, 68]]], ["Moreover, by introducing heterologous enzyme activities and adding of N\u2010acetyl glucose amine (GN) or Gal, the SuperMan5 strain has been engineered to produce human\u2010like glycoproteins (M5GN and M5GNGal strains).", [["N\u2010acetyl glucose amine", "CHEMICAL", 70, 92], ["N\u2010acetyl glucose amine", "CHEMICAL", 70, 92], ["Gal", "CHEMICAL", 101, 104], ["N\u2010acetyl glucose amine", "SIMPLE_CHEMICAL", 70, 92], ["GN", "SIMPLE_CHEMICAL", 94, 96], ["Gal", "GENE_OR_GENE_PRODUCT", 101, 104], ["SuperMan5", "GENE_OR_GENE_PRODUCT", 110, 119], ["M5GN", "GENE_OR_GENE_PRODUCT", 184, 188], ["M5GNGal", "GENE_OR_GENE_PRODUCT", 193, 200], ["human\u2010like glycoproteins", "PROTEIN", 158, 182], ["M5GN", "PROTEIN", 184, 188], ["M5GNGal", "PROTEIN", 193, 200], ["introducing heterologous enzyme activities", "TEST", 13, 55], ["N\u2010acetyl glucose amine", "TREATMENT", 70, 92], ["Gal", "TREATMENT", 101, 104], ["the SuperMan5 strain", "PROBLEM", 106, 126], ["human\u2010like glycoproteins", "TREATMENT", 158, 182], ["M5GN and M5GNGal strains", "TREATMENT", 184, 208]]], ["M5GN and M5GNGal strains (BioGrammatics) are commonly used to express vaccine antigens, cytokines, and antibodies.Advantages and drawbacks of the P. pastoris expression system ::: THE CHARACTERISTIC FEATURES OF P. pastoris EXPRESSION SYSTEMHowever, like other expression systems, this eukaryotic system has some disadvantages.", [["M5GN", "GENE_OR_GENE_PRODUCT", 0, 4], ["M5GNGal", "GENE_OR_GENE_PRODUCT", 9, 16], ["P. pastoris", "ORGANISM", 146, 157], ["P. pastoris", "ORGANISM", 211, 222], ["vaccine antigens", "PROTEIN", 70, 86], ["cytokines", "PROTEIN", 88, 97], ["antibodies", "PROTEIN", 103, 113], ["P. pastoris", "SPECIES", 146, 157], ["P. pastoris", "SPECIES", 146, 157], ["P. pastoris", "SPECIES", 211, 222], ["M5GN", "TREATMENT", 0, 4], ["M5GNGal strains (BioGrammatics", "TREATMENT", 9, 39], ["cytokines", "TEST", 88, 97], ["P. pastoris EXPRESSION SYSTEMHowever", "PROBLEM", 211, 247], ["pastoris EXPRESSION", "OBSERVATION", 214, 233]]], ["In the transformation stage, unlike the bacterial system, competent cells require large (\u00b5g\u2010level) amounts of the plasmid.", [["cells", "ANATOMY", 68, 73], ["plasmid", "ANATOMY", 114, 121], ["cells", "CELL", 68, 73], ["competent cells", "CELL_TYPE", 58, 73], ["plasmid", "DNA", 114, 121], ["the bacterial system", "PROBLEM", 36, 56], ["large (\u00b5g\u2010level) amounts", "TREATMENT", 82, 106], ["the plasmid", "TREATMENT", 110, 121], ["transformation stage", "OBSERVATION", 7, 27], ["bacterial system", "OBSERVATION", 40, 56], ["large", "OBSERVATION_MODIFIER", 82, 87]]], ["The number of E. coli transformants (108\u20131011) is higher than P. pastoris transformants (103\u2013104) per \u00b5g of DNA (S. Wu & Letchworth, 2004).", [["transformants", "ANATOMY", 22, 35], ["transformants", "ANATOMY", 74, 87], ["E. coli", "ORGANISM", 14, 21], ["transformants", "CELL", 22, 35], ["P. pastoris", "ORGANISM", 62, 73], ["transformants", "CELL", 74, 87], ["DNA", "CELLULAR_COMPONENT", 108, 111], ["E. coli", "SPECIES", 14, 21], ["P. pastoris", "SPECIES", 62, 73], ["E. coli", "SPECIES", 14, 21], ["P. pastoris", "SPECIES", 62, 73], ["E. coli transformants", "PROBLEM", 14, 35], ["E. coli transformants", "OBSERVATION", 14, 35]]], ["The production of recombinant protein in this system is regulated through two promoters: Promoter of glyceraldehyde\u20103\u2010phosphate dehydrogenase (PGAP) and promoter of AOX (PAOX1).", [["glyceraldehyde\u20103\u2010phosphate", "CHEMICAL", 101, 127], ["glyceraldehyde\u20103\u2010phosphate", "CHEMICAL", 101, 127], ["glyceraldehyde\u20103\u2010phosphate dehydrogenase", "GENE_OR_GENE_PRODUCT", 101, 141], ["PGAP", "GENE_OR_GENE_PRODUCT", 143, 147], ["AOX", "GENE_OR_GENE_PRODUCT", 165, 168], ["PAOX1", "GENE_OR_GENE_PRODUCT", 170, 175], ["recombinant protein", "PROTEIN", 18, 37], ["promoters", "DNA", 78, 87], ["glyceraldehyde\u20103\u2010phosphate dehydrogenase", "PROTEIN", 101, 141], ["PGAP", "PROTEIN", 143, 147], ["AOX", "PROTEIN", 165, 168], ["PAOX1", "PROTEIN", 170, 175], ["recombinant protein in this system", "PROBLEM", 18, 52], ["glyceraldehyde\u20103\u2010phosphate dehydrogenase (PGAP)", "TREATMENT", 101, 148], ["recombinant protein", "OBSERVATION", 18, 37]]], ["Despite several advantages, both promoters have no tenability (Rajamanickam, Metzger, Schmid, & Spadiut, 2017).", [["promoters", "DNA", 33, 42], ["no", "UNCERTAINTY", 48, 50]]], ["Protein production in yeast systems is dependent on the consumption of methanol.", [["methanol", "CHEMICAL", 71, 79], ["methanol", "CHEMICAL", 71, 79], ["methanol", "SIMPLE_CHEMICAL", 71, 79], ["yeast", "SPECIES", 22, 27], ["yeast", "SPECIES", 22, 27], ["Protein production in yeast systems", "PROBLEM", 0, 35], ["methanol", "TREATMENT", 71, 79], ["yeast systems", "OBSERVATION", 22, 35], ["dependent", "OBSERVATION_MODIFIER", 39, 48]]], ["Based on EasySelect\u2122 Pichia Expression Kit (Catalog no. K1750\u201001, Invitrogen, Carlsbad, CA), at least 0.5% concentration of methanol is required for the expression of recombinant proteins.", [["methanol", "CHEMICAL", 124, 132], ["methanol", "CHEMICAL", 124, 132], ["methanol", "SIMPLE_CHEMICAL", 124, 132], ["recombinant proteins", "PROTEIN", 167, 187], ["Invitrogen", "TEST", 66, 76], ["methanol", "TREATMENT", 124, 132], ["recombinant proteins", "PROBLEM", 167, 187]]], ["The production could reach to the maximum level of 2\u20132.5% (wt/vol) of methanol (Z. Wang et al., 2010).", [["methanol", "CHEMICAL", 70, 78], ["methanol", "SIMPLE_CHEMICAL", 70, 78]]], ["Normally, the concentration of methanol up to 5% is tolerable for the organisms, but high levels of methanol concentrations (above 5%) are very toxic for cell viability and can stop the production process (Santoso, Herawati, & Rubiana, 2012).", [["cell", "ANATOMY", 154, 158], ["methanol", "CHEMICAL", 31, 39], ["methanol", "CHEMICAL", 100, 108], ["methanol", "CHEMICAL", 31, 39], ["methanol", "CHEMICAL", 100, 108], ["methanol", "SIMPLE_CHEMICAL", 31, 39], ["methanol", "SIMPLE_CHEMICAL", 100, 108], ["cell", "CELL", 154, 158], ["methanol", "TREATMENT", 31, 39], ["the organisms", "PROBLEM", 66, 79], ["methanol concentrations", "TREATMENT", 100, 123], ["very toxic", "PROBLEM", 139, 149], ["cell viability", "PROBLEM", 154, 168], ["cell viability", "OBSERVATION", 154, 168]]], ["Another limitation in the Pichia system is the presence of a few selectable markers for P. pastoris transformation.", [["P. pastoris transformation", "DISEASE", 88, 114], ["P. pastoris", "ORGANISM", 88, 99], ["P. pastoris", "SPECIES", 88, 99], ["P. pastoris", "SPECIES", 88, 99], ["the Pichia system", "TEST", 22, 39], ["P. pastoris transformation", "PROBLEM", 88, 114], ["pastoris transformation", "OBSERVATION", 91, 114]]], ["Selectable marker genes include his4, arg4, and Shble (needed to resist against Zeocin antibiotic) (Cereghino & Cregg, 1999).", [["Zeocin", "CHEMICAL", 80, 86], ["his4", "GENE_OR_GENE_PRODUCT", 32, 36], ["arg4", "GENE_OR_GENE_PRODUCT", 38, 42], ["Shble", "GENE_OR_GENE_PRODUCT", 48, 53], ["Selectable marker genes", "DNA", 0, 23], ["his4", "DNA", 32, 36], ["arg4", "DNA", 38, 42], ["Shble", "DNA", 48, 53], ["Zeocin antibiotic", "TREATMENT", 80, 97]]], ["A common occurrence in this system is the contamination of expressive broth culture with saprophytic bacteria and fungi.", [["A common occurrence in this system", "PROBLEM", 0, 34], ["expressive broth culture", "TEST", 59, 83], ["saprophytic bacteria", "PROBLEM", 89, 109], ["fungi", "PROBLEM", 114, 119], ["saprophytic bacteria", "OBSERVATION", 89, 109]]], ["The secreted proteases of these microorganisms potentially hydrolyze the secreted proteins to the supernatant (Stewart, 2015).", [["supernatant", "ANATOMY", 98, 109], ["secreted proteases", "PROTEIN", 4, 22], ["secreted proteins", "PROTEIN", 73, 90], ["these microorganisms", "PROBLEM", 26, 46]]], ["Indeed, one of the problems in the P. pastoris expression system is the destruction of proteins produced by proteases.", [["P. pastoris", "ORGANISM", 35, 46], ["proteases", "PROTEIN", 108, 117], ["P. pastoris", "SPECIES", 35, 46], ["P. pastoris", "SPECIES", 35, 46], ["the problems", "PROBLEM", 15, 27], ["the P. pastoris expression system", "TREATMENT", 31, 64], ["the destruction of proteins", "PROBLEM", 68, 95], ["destruction", "OBSERVATION", 72, 83]]], ["New P. pastoris strains such as SMD1163 (his4 pep4 prb1), SMD1165 (his4 pep4), SMD1168 (his4 pep4), BG21, and Pichia pink have no protease; therefore, the degradation of a secreted protein is prevented.", [["P. pastoris strains", "ORGANISM", 4, 23], ["SMD1163", "GENE_OR_GENE_PRODUCT", 32, 39], ["his4 pep4 prb1", "GENE_OR_GENE_PRODUCT", 41, 55], ["SMD1165", "GENE_OR_GENE_PRODUCT", 58, 65], ["his4 pep4", "GENE_OR_GENE_PRODUCT", 67, 76], ["SMD1168", "GENE_OR_GENE_PRODUCT", 79, 86], ["his4 pep4", "GENE_OR_GENE_PRODUCT", 88, 97], ["BG21", "GENE_OR_GENE_PRODUCT", 100, 104], ["Pichia pink", "GENE_OR_GENE_PRODUCT", 110, 121], ["SMD1163", "PROTEIN", 32, 39], ["his4 pep4 prb1", "PROTEIN", 41, 55], ["SMD1165", "PROTEIN", 58, 65], ["his4 pep4", "PROTEIN", 67, 76], ["SMD1168", "PROTEIN", 79, 86], ["his4 pep4", "PROTEIN", 88, 97], ["BG21", "PROTEIN", 100, 104], ["Pichia pink", "PROTEIN", 110, 121], ["protease", "PROTEIN", 130, 138], ["secreted protein", "PROTEIN", 172, 188], ["P. pastoris", "SPECIES", 4, 15], ["P. pastoris", "SPECIES", 4, 15], ["Pichia pink", "SPECIES", 110, 121], ["New P. pastoris strains", "PROBLEM", 0, 23], ["his4 pep4 prb1", "TEST", 41, 55], ["his4 pep4", "TEST", 67, 76], ["SMD1168", "TEST", 79, 86], ["his4 pep4", "TEST", 88, 97], ["BG21", "TEST", 100, 104], ["Pichia pink", "PROBLEM", 110, 121], ["protease", "PROBLEM", 130, 138], ["a secreted protein", "TREATMENT", 170, 188], ["pastoris strains", "OBSERVATION", 7, 23], ["no", "UNCERTAINTY", 127, 129], ["protease", "OBSERVATION", 130, 138]]], ["In these strains, to achieve high product yields and the quality of recombinant proteins, the genes encoding of proteinase A (pep4) and proteinase B (prb1) have been disrupted (Safder, Khan, Islam, & Kazim, 2018).General topics for cloning and expression in P. pastoris::: THE CHARACTERISTIC FEATURES OF P. pastoris EXPRESSION SYSTEMThe expression of any recombinant gene in P. pastoris has three phase: (a) Cloning of a new gene into a suitable expression vector, (b) insertion of the cloned vector into P. pastoris host genome; and (c) trial of the potential different strains for the expression of the recombinant integrated gene (Macauley\u2010Patrick, Fazenda, McNeil, & Harvey, 2005).", [["proteinase A", "GENE_OR_GENE_PRODUCT", 112, 124], ["pep4", "GENE_OR_GENE_PRODUCT", 126, 130], ["proteinase B", "GENE_OR_GENE_PRODUCT", 136, 148], ["prb1", "GENE_OR_GENE_PRODUCT", 150, 154], ["P. pastoris", "ORGANISM", 258, 269], ["P. pastoris", "ORGANISM", 304, 315], ["P. pastoris", "ORGANISM", 375, 386], ["P. pastoris", "ORGANISM", 505, 516], ["recombinant proteins", "PROTEIN", 68, 88], ["proteinase A", "PROTEIN", 112, 124], ["pep4", "PROTEIN", 126, 130], ["proteinase B", "PROTEIN", 136, 148], ["prb1", "PROTEIN", 150, 154], ["recombinant gene", "DNA", 355, 371], ["P. pastoris host genome", "DNA", 505, 528], ["recombinant integrated gene", "DNA", 605, 632], ["Macauley", "DNA", 634, 642], ["P. pastoris", "SPECIES", 258, 269], ["P. pastoris", "SPECIES", 304, 315], ["P. pastoris", "SPECIES", 375, 386], ["P. pastoris", "SPECIES", 505, 516], ["P. pastoris", "SPECIES", 258, 269], ["P. pastoris", "SPECIES", 304, 315], ["P. pastoris", "SPECIES", 375, 386], ["P. pastoris", "SPECIES", 505, 516], ["proteinase A (pep4)", "TREATMENT", 112, 131], ["proteinase B (prb1", "TREATMENT", 136, 154], ["the cloned vector", "TREATMENT", 482, 499], ["the potential different strains", "TREATMENT", 547, 578]]], ["Based on EasySelect\u2122 Pichia Expression Kit (Invitrogen), to increase the efficacy of external DNA integration into the Pichia genome, first, the cloned vector should be linear with restriction enzymes such as Sac I, PmeI, and BstX I. Then, linear DNA should be inserted into the competent cells by electroporation.", [["cells", "ANATOMY", 289, 294], ["DNA", "CELLULAR_COMPONENT", 94, 97], ["Sac I", "GENE_OR_GENE_PRODUCT", 209, 214], ["PmeI", "GENE_OR_GENE_PRODUCT", 216, 220], ["DNA", "CELLULAR_COMPONENT", 247, 250], ["cells", "CELL", 289, 294], ["Pichia genome", "DNA", 119, 132], ["restriction enzymes", "PROTEIN", 181, 200], ["Sac I", "PROTEIN", 209, 214], ["PmeI", "PROTEIN", 216, 220], ["BstX", "PROTEIN", 226, 230], ["linear DNA", "DNA", 240, 250], ["competent cells", "CELL_TYPE", 279, 294], ["EasySelect", "TREATMENT", 9, 19], ["external DNA integration", "TREATMENT", 85, 109], ["the Pichia genome", "TREATMENT", 115, 132], ["the cloned vector", "TREATMENT", 141, 158], ["restriction enzymes", "TREATMENT", 181, 200], ["Sac I", "TREATMENT", 209, 214], ["PmeI", "TREATMENT", 216, 220], ["BstX I.", "TREATMENT", 226, 233], ["linear DNA", "TREATMENT", 240, 250], ["Pichia genome", "OBSERVATION", 119, 132], ["competent cells", "OBSERVATION", 279, 294]]], ["The entered gene is integrated into the cell genome via the crossover recombination phenomenon (Figure 2), and consequently, recombinant cells are formed.", [["cell genome", "ANATOMY", 40, 51], ["cells", "ANATOMY", 137, 142], ["cell", "CELL", 40, 44], ["cells", "CELL", 137, 142], ["cell genome", "DNA", 40, 51], ["recombinant cells", "CELL_LINE", 125, 142], ["the crossover recombination phenomenon", "TREATMENT", 56, 94], ["cell genome", "OBSERVATION", 40, 51]]], ["In most cases, a single crossover occurs in the genome, but multiple insertions occur in 1\u201310% of the cases (Kit).General topics for cloning and expression in P. pastoris::: THE CHARACTERISTIC FEATURES OF P. pastoris EXPRESSION SYSTEMThe expression vectors in the P. pastoris expression system are one of the major components of this system.", [["Kit", "GENE_OR_GENE_PRODUCT", 109, 112], ["P. pastoris", "ORGANISM", 159, 170], ["P. pastoris", "ORGANISM", 205, 216], ["P. pastoris", "ORGANISM", 264, 275], ["P. pastoris", "SPECIES", 159, 170], ["P. pastoris", "SPECIES", 205, 216], ["P. pastoris", "SPECIES", 264, 275], ["P. pastoris", "SPECIES", 159, 170], ["P. pastoris", "SPECIES", 205, 216], ["P. pastoris", "SPECIES", 264, 275], ["P. pastoris EXPRESSION SYSTEMThe expression vectors", "TREATMENT", 205, 256], ["the P. pastoris expression system", "TREATMENT", 260, 293], ["multiple", "OBSERVATION_MODIFIER", 60, 68], ["insertions", "OBSERVATION", 69, 79]]], ["These vectors are composed of three sequences: Promoter sequence (most often AOX1) in 5\u2032 region; transcriptional termination sequence in 3\u2032 region which is essential in the processing and polyadenylation of messenger RNAs; and one sequence that contains single or multiple cloning sites, necessary for the insertion of the gene of interest.", [["AOX1", "GENE_OR_GENE_PRODUCT", 77, 81], ["Promoter sequence", "DNA", 47, 64], ["AOX1", "DNA", 77, 81], ["5\u2032 region", "DNA", 86, 95], ["transcriptional termination sequence", "DNA", 97, 133], ["messenger RNAs", "RNA", 207, 221], ["cloning sites", "DNA", 273, 286], ["Promoter sequence", "TEST", 47, 64], ["transcriptional termination sequence", "TEST", 97, 133], ["polyadenylation of messenger RNAs", "PROBLEM", 188, 221], ["multiple cloning sites", "TREATMENT", 264, 286], ["the insertion", "TREATMENT", 302, 315], ["messenger RNAs", "OBSERVATION", 207, 221], ["multiple", "OBSERVATION_MODIFIER", 264, 272]]], ["The episomal vectors can replicate either autonomously in the cytoplasm or as part of a chromosome.", [["cytoplasm", "ANATOMY", 62, 71], ["chromosome", "ANATOMY", 88, 98], ["cytoplasm", "ORGANISM_SUBSTANCE", 62, 71], ["chromosome", "CELLULAR_COMPONENT", 88, 98], ["chromosome", "DNA", 88, 98], ["The episomal vectors", "TREATMENT", 0, 20], ["episomal vectors", "OBSERVATION", 4, 20]]], ["But the vectors used in P. pastoris have no stable episomal status; therefore, they should first be linearized with enzymes and then be integrated into the P. pastoris chromosome (Li et al., 2007).", [["chromosome", "ANATOMY", 168, 178], ["P. pastoris", "ORGANISM", 24, 35], ["P. pastoris", "ORGANISM", 156, 167], ["chromosome", "CELLULAR_COMPONENT", 168, 178], ["enzymes", "PROTEIN", 116, 123], ["P. pastoris", "SPECIES", 24, 35], ["P. pastoris", "SPECIES", 156, 167], ["P. pastoris", "SPECIES", 24, 35], ["P. pastoris", "SPECIES", 156, 167], ["the vectors", "TREATMENT", 4, 15], ["enzymes", "TEST", 116, 123]]], ["Like E. coli, expression vectors in P. pastoris are shuttle vectors that is they can propagate in two different host species.", [["E. coli", "ORGANISM", 5, 12], ["P. pastoris", "ORGANISM", 36, 47], ["expression vectors", "DNA", 14, 32], ["E. coli", "SPECIES", 5, 12], ["P. pastoris", "SPECIES", 36, 47], ["E. coli", "SPECIES", 5, 12], ["P. pastoris", "SPECIES", 36, 47], ["E. coli", "PROBLEM", 5, 12], ["expression vectors", "TREATMENT", 14, 32], ["shuttle vectors", "TREATMENT", 52, 67], ["E. coli", "OBSERVATION", 5, 12], ["host species", "OBSERVATION", 112, 124]]], ["The vectors also contain one drug resistance genes such as Kan, Shble, Bsd, Amp, or FLD1, which are resistant to geneticin, zeocin, blasticidin, ampicillin, and formaldehyde, respectively (Ilgen, Lin\u2010Cereghino, & Cregg, 2005).", [["geneticin", "CHEMICAL", 113, 122], ["zeocin", "CHEMICAL", 124, 130], ["blasticidin", "CHEMICAL", 132, 143], ["ampicillin", "CHEMICAL", 145, 155], ["formaldehyde", "CHEMICAL", 161, 173], ["geneticin", "CHEMICAL", 113, 122], ["zeocin", "CHEMICAL", 124, 130], ["blasticidin", "CHEMICAL", 132, 143], ["ampicillin", "CHEMICAL", 145, 155], ["formaldehyde", "CHEMICAL", 161, 173], ["Kan", "GENE_OR_GENE_PRODUCT", 59, 62], ["Shble", "GENE_OR_GENE_PRODUCT", 64, 69], ["Bsd", "GENE_OR_GENE_PRODUCT", 71, 74], ["Amp", "GENE_OR_GENE_PRODUCT", 76, 79], ["FLD1", "GENE_OR_GENE_PRODUCT", 84, 88], ["geneticin", "SIMPLE_CHEMICAL", 113, 122], ["zeocin", "SIMPLE_CHEMICAL", 124, 130], ["blasticidin", "SIMPLE_CHEMICAL", 132, 143], ["ampicillin", "SIMPLE_CHEMICAL", 145, 155], ["formaldehyde", "SIMPLE_CHEMICAL", 161, 173], ["drug resistance genes", "DNA", 29, 50], ["Kan", "DNA", 59, 62], ["Shble", "DNA", 64, 69], ["Bsd", "DNA", 71, 74], ["Amp", "DNA", 76, 79], ["FLD1", "DNA", 84, 88], ["The vectors", "TREATMENT", 0, 11], ["one drug resistance genes", "PROBLEM", 25, 50], ["Amp", "TEST", 76, 79], ["FLD1", "TREATMENT", 84, 88], ["geneticin", "TREATMENT", 113, 122], ["zeocin", "TREATMENT", 124, 130], ["blasticidin", "TREATMENT", 132, 143], ["ampicillin", "TREATMENT", 145, 155], ["formaldehyde", "TREATMENT", 161, 173], ["drug resistance", "OBSERVATION", 29, 44]]], ["Common plasmids used in the P. pastoris expression system to produce extracellular and intracellular proteins are listed in Tables 2 and 3, respectively.Subunit vaccines expressed in Pichia pastoris::: THE CHARACTERISTIC FEATURES OF P. pastoris EXPRESSION SYSTEMRecombinant protein therapeutics is a growing market within the human medical biotechnology industry.", [["plasmids", "ANATOMY", 7, 15], ["extracellular", "ANATOMY", 69, 82], ["intracellular", "ANATOMY", 87, 100], ["P. pastoris", "ORGANISM", 28, 39], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 69, 82], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 87, 100], ["Pichia pastoris", "ORGANISM", 183, 198], ["P. pastoris", "ORGANISM", 233, 244], ["human", "ORGANISM", 326, 331], ["plasmids", "DNA", 7, 15], ["extracellular and intracellular proteins", "PROTEIN", 69, 109], ["P. pastoris", "SPECIES", 28, 39], ["Pichia pastoris", "SPECIES", 183, 198], ["P. pastoris", "SPECIES", 233, 244], ["human", "SPECIES", 326, 331], ["P. pastoris", "SPECIES", 28, 39], ["Pichia pastoris", "SPECIES", 183, 198], ["P. pastoris", "SPECIES", 233, 244], ["human", "SPECIES", 326, 331], ["Common plasmids", "TREATMENT", 0, 15], ["the P. pastoris expression system", "TREATMENT", 24, 57], ["extracellular and intracellular proteins", "PROBLEM", 69, 109], ["Subunit vaccines", "TREATMENT", 153, 169], ["plasmids", "OBSERVATION", 7, 15], ["extracellular", "OBSERVATION_MODIFIER", 69, 82], ["intracellular proteins", "OBSERVATION", 87, 109]]], ["The majority of all approved biopharmaceuticals are protein\u2010based and include blood factors, anticoagulants, hormones, hematopoietic growth factors, interferons, interleukins, vaccines, and monoclonal antibodies.", [["blood", "ANATOMY", 78, 83], ["blood", "ORGANISM_SUBSTANCE", 78, 83], ["anticoagulants", "SIMPLE_CHEMICAL", 93, 107], ["hematopoietic growth factors", "GENE_OR_GENE_PRODUCT", 119, 147], ["interferons", "GENE_OR_GENE_PRODUCT", 149, 160], ["interleukins", "GENE_OR_GENE_PRODUCT", 162, 174], ["blood factors", "PROTEIN", 78, 91], ["hematopoietic growth factors", "PROTEIN", 119, 147], ["interferons", "PROTEIN", 149, 160], ["interleukins", "PROTEIN", 162, 174], ["monoclonal antibodies", "PROTEIN", 190, 211], ["blood factors", "PROBLEM", 78, 91], ["anticoagulants", "TREATMENT", 93, 107], ["hormones", "TREATMENT", 109, 117], ["hematopoietic growth factors", "PROBLEM", 119, 147], ["interferons", "TREATMENT", 149, 160], ["interleukins", "TREATMENT", 162, 174], ["vaccines", "TREATMENT", 176, 184], ["monoclonal antibodies", "PROBLEM", 190, 211], ["majority", "OBSERVATION_MODIFIER", 4, 12], ["hematopoietic", "ANATOMY", 119, 132]]], ["Vaccine production is one of the major protective strategies against infectious diseases.", [["infectious diseases", "DISEASE", 69, 88], ["Vaccine production", "TREATMENT", 0, 18], ["infectious diseases", "PROBLEM", 69, 88]]], ["In general, vaccines used for all pathogens are divided into three groups: live attenuated, inactivated/killed, and subunit vaccines (Schiller & Lowy, 2014).", [["vaccines", "TREATMENT", 12, 20], ["all pathogens", "PROBLEM", 30, 43]]], ["After the injection of live attenuated vaccines, microorganisms start to replicate in the injection area and could induce strong immune responses.", [["live attenuated vaccines", "TREATMENT", 23, 47], ["microorganisms", "PROBLEM", 49, 63]]], ["However, reversion of attenuated pathogen to its wild\u2010type strain especially in immunocompromised individuals has restricted the application of these vaccines (Minor, 2015).", [["wild\u2010type strain", "ORGANISM", 49, 65], ["attenuated pathogen", "PROBLEM", 22, 41], ["its wild\u2010type strain", "PROBLEM", 45, 65], ["immunocompromised individuals", "PROBLEM", 80, 109], ["these vaccines", "TREATMENT", 144, 158], ["attenuated", "OBSERVATION_MODIFIER", 22, 32], ["pathogen", "OBSERVATION", 33, 41]]], ["Although, inactivated/killed vaccines are safe, they are relatively less effective in the induction of strong immune responses.", [["inactivated/killed vaccines", "TREATMENT", 10, 37]]], ["Therefore, these vaccines should be injected in multiple doses along with suitable adjuvants (S. Lee & Nguyen, 2015).", [["these vaccines", "TREATMENT", 11, 25], ["suitable adjuvants", "TREATMENT", 74, 92]]], ["Subunit vaccines consist of one or more immunodominant antigens of pathogens that can be produced in eukaryotic and prokaryotic systems.", [["immunodominant antigens", "PROTEIN", 40, 63], ["Subunit vaccines", "TREATMENT", 0, 16], ["pathogens", "PROBLEM", 67, 76]]], ["Unlike live attenuated and killed/inactivated vaccines, subunit vaccines are completely safe and cost\u2010effective.", [["killed/inactivated vaccines", "TREATMENT", 27, 54], ["subunit vaccines", "TREATMENT", 56, 72]]], ["Recently, subunit vaccines have been replaced with other forms of vaccines.", [["subunit vaccines", "TREATMENT", 10, 26], ["vaccines", "TREATMENT", 66, 74]]], ["Also, for the production of recombinant subunit vaccines, P. pastoris is more famous than other expression systems (Wang, Jiang, & Wang, 2016).", [["P. pastoris", "ORGANISM", 58, 69], ["P. pastoris", "SPECIES", 58, 69], ["P. pastoris", "SPECIES", 58, 69], ["recombinant subunit vaccines", "TREATMENT", 28, 56], ["P. pastoris", "PROBLEM", 58, 69]]], ["Subunit vaccines often suffer from poor immunogenicity and require certain helper molecules known as adjuvants to induce or enhance an appropriate immune response to the antigen.", [["Subunit vaccines", "TREATMENT", 0, 16], ["poor immunogenicity", "PROBLEM", 35, 54], ["certain helper molecules", "TREATMENT", 67, 91], ["adjuvants", "TREATMENT", 101, 110]]], ["Antigens mannosylated by P. pastoris have shown to have enhanced antigen presentation and T\u2010cell activation properties compared with their nonglycosylated counterparts.", [["T\u2010cell", "ANATOMY", 90, 96], ["P. pastoris", "ORGANISM", 25, 36], ["P. pastoris", "SPECIES", 25, 36], ["P. pastoris", "SPECIES", 25, 36], ["P. pastoris", "TEST", 25, 36], ["enhanced antigen presentation", "PROBLEM", 56, 85], ["T\u2010cell activation properties", "PROBLEM", 90, 118]]], ["Therefore, glycoproteins derived from P. pastoris have the potential to function as adjuvants.", [["P. pastoris", "ORGANISM", 38, 49], ["glycoproteins", "PROTEIN", 11, 24], ["P. pastoris", "SPECIES", 38, 49], ["P. pastoris", "SPECIES", 38, 49], ["glycoproteins", "TREATMENT", 11, 24], ["P. pastoris", "TREATMENT", 38, 49]]], ["The increased immunogenicity of mannosylated glycoproteins is thought to be linked to certain mannose\u2010binding receptors carried by professional antigen\u2010presenting cells, like dendritic cells and macrophages (Luong, Lam, Chen, & Levitz, 2007).", [["antigen\u2010presenting cells", "ANATOMY", 144, 168], ["dendritic cells", "ANATOMY", 175, 190], ["macrophages", "ANATOMY", 195, 206], ["antigen\u2010presenting cells", "CELL", 144, 168], ["dendritic cells", "CELL", 175, 190], ["macrophages", "CELL", 195, 206], ["mannosylated glycoproteins", "PROTEIN", 32, 58], ["mannose\u2010binding receptors", "PROTEIN", 94, 119], ["professional antigen\u2010presenting cells", "CELL_TYPE", 131, 168], ["dendritic cells", "CELL_TYPE", 175, 190], ["macrophages", "CELL_TYPE", 195, 206], ["The increased immunogenicity of mannosylated glycoproteins", "PROBLEM", 0, 58], ["dendritic cells", "PROBLEM", 175, 190], ["macrophages", "PROBLEM", 195, 206], ["increased", "OBSERVATION_MODIFIER", 4, 13], ["immunogenicity", "OBSERVATION_MODIFIER", 14, 28], ["mannosylated glycoproteins", "OBSERVATION", 32, 58], ["dendritic cells", "OBSERVATION", 175, 190], ["macrophages", "OBSERVATION_MODIFIER", 195, 206], ["Lam", "ANATOMY", 215, 218]]], ["Some of the new recombinant subunit vaccines that have been expressed in P. pastoris system are listed in Table 4.The impact of Mut forms and methanol on protein concentration ::: STRATEGIES TO IMPROVE PROTEIN EXPRESSION IN P. pastoris", [["methanol", "CHEMICAL", 142, 150], ["methanol", "CHEMICAL", 142, 150], ["P. pastoris", "ORGANISM", 73, 84], ["Mut", "GENE_OR_GENE_PRODUCT", 128, 131], ["methanol", "SIMPLE_CHEMICAL", 142, 150], ["P. pastoris", "ORGANISM", 224, 235], ["P. pastoris", "SPECIES", 73, 84], ["P. pastoris", "SPECIES", 224, 235], ["P. pastoris", "SPECIES", 73, 84], ["P. pastoris", "SPECIES", 224, 235], ["the new recombinant subunit vaccines", "TREATMENT", 8, 44], ["new", "OBSERVATION_MODIFIER", 12, 15]]]], "ef0abccb225bdad3236abc06e3e15983c1a42424": [["healthcare waste management problem.", [["healthcare waste management", "TREATMENT", 0, 27]]], ["Samanlioglu (2013) presented a multi-objective model for the location-routing problem which has been used for managing industrial hazardous wastes in the Marmara region of Turkey.", [["hazardous wastes", "OBSERVATION", 130, 146]]], ["The proposed model aimed to minimize total costs, transportation risk, and total risk for the population existing around the disposal and treatment sites.", [["total costs", "TREATMENT", 37, 48], ["the population", "PROBLEM", 90, 104], ["the disposal", "TREATMENT", 121, 133], ["treatment sites", "TREATMENT", 138, 153]]], ["Hachicha et al. (2014) modeled the off-site transportation of infectious healthcare wastes as a Capacitated Vehicle Routing Problem (CVRP).", [["infectious healthcare wastes", "TREATMENT", 62, 90], ["infectious", "OBSERVATION", 62, 72]]], ["Nolz et al. (2014) focused on an inventory routing problem and they applied it for the collection of infectious medical materials.", [["an inventory routing problem", "PROBLEM", 30, 58], ["infectious medical materials", "TREATMENT", 101, 129], ["infectious", "OBSERVATION", 101, 111]]], ["Zhao et al. (2016) developed improved approaches for the network design problem that has been applied in a hazardous waste management system.", [["a hazardous waste management system", "TREATMENT", 105, 140]]], ["They have used three multi-objective optimization methods including: (1) Weighted-Sum Method (WSM), (2) Augmented Weighted Tchebycheff Method (AWTM), and (3) Augmented \u03b5-constraint Method (AECM) to solve the proposed problem.", [["Augmented Weighted Tchebycheff Method (AWTM)", "TREATMENT", 104, 148], ["Augmented \u03b5-constraint Method (AECM)", "TREATMENT", 158, 194]]], ["Naji-Azimi et al. (2016) focused on the Multi-Trip Vehicle Routing Problem (MT-VRP) for transportation of biomedical samples.", [["biomedical samples", "TEST", 106, 124]]], ["An optimization model has been proposed by Mantzaras and Voudrias (2017) for collection, transportation, treatment, and disposal of healthcare wastes.", [["collection", "PROBLEM", 77, 87], ["treatment", "TREATMENT", 105, 114], ["healthcare wastes", "TREATMENT", 132, 149]]], ["Hajar et al. (2018) studied the on-site medical waste collection problem and modeled it as a vehicle routing problem with time windows.", [["medical waste collection problem", "TREATMENT", 40, 72]]], ["Rabbani et al. (2018a) proposed a multi-objective model for collection of hazardous wastes.", [["a multi-objective model", "TREATMENT", 32, 55], ["hazardous wastes", "PROBLEM", 74, 90], ["hazardous wastes", "OBSERVATION", 74, 90]]], ["They developed an augmented -constraint method to solve the problem.", [["an augmented -constraint method", "TREATMENT", 15, 46], ["augmented", "OBSERVATION", 18, 27]]], ["In another study, Rabbani et al. (2018b) developed a new model for the industrial hazardous waste locating-routing problem, where there are compatibility restrictions between some types of wastes.", [["hazardous waste", "OBSERVATION", 82, 97], ["wastes", "OBSERVATION", 189, 195]]], ["To find solutions to their model, they used two meta-heuristics, namely the Non-dominated Sorting Genetic Algorithm II (NSGA-II) and Multi-Objective Particle Swarm Optimization (MOPSO) algorithm.", [["Multi-Objective Particle Swarm Optimization (MOPSO) algorithm", "TREATMENT", 133, 194]]]], "603a2a2681ceb33e70dca8c77adbc83327f7e5be": [["aside traditional international diplomatic conventions.", [["diplomatic conventions", "OBSERVATION", 32, 54]]], ["Thus far, 54 countries have placed restrictions on the export of ICU ventilators 7 .", [["ICU ventilators", "TREATMENT", 65, 80]]]], "PMC7190947": [["INTRODUCTIONThe coronavirus is a category of enveloped, single-stranded, positive-sense RNA viruses.", [["coronavirus", "DISEASE", 16, 27], ["coronavirus", "ORGANISM", 16, 27], ["coronavirus", "PROBLEM", 16, 27], ["sense RNA viruses", "PROBLEM", 82, 99], ["RNA viruses", "OBSERVATION", 88, 99]]], ["In the 21st century, the severe acute respiratory syndrome coronavirus (SARS-CoV) and the middle east respiratory syndrome coronavirus (MERS-CoV) both caused worldwide epidemics with high morbidity and mortality[1-3].", [["acute respiratory syndrome coronavirus", "DISEASE", 32, 70], ["SARS-CoV)", "DISEASE", 72, 81], ["respiratory syndrome coronavirus", "DISEASE", 102, 134], ["severe acute respiratory syndrome coronavirus", "ORGANISM", 25, 70], ["SARS-CoV", "ORGANISM", 72, 80], ["middle east respiratory syndrome coronavirus", "ORGANISM", 90, 134], ["MERS-CoV", "ORGANISM", 136, 144], ["severe acute respiratory syndrome coronavirus", "SPECIES", 25, 70], ["SARS-CoV", "SPECIES", 72, 80], ["middle east respiratory syndrome coronavirus", "SPECIES", 90, 134], ["MERS-CoV", "SPECIES", 136, 144], ["the severe acute respiratory syndrome coronavirus", "PROBLEM", 21, 70], ["the middle east respiratory syndrome coronavirus", "PROBLEM", 86, 134], ["high morbidity", "PROBLEM", 183, 197], ["severe", "OBSERVATION_MODIFIER", 25, 31], ["acute", "OBSERVATION_MODIFIER", 32, 37], ["respiratory syndrome coronavirus", "OBSERVATION", 38, 70], ["middle", "ANATOMY_MODIFIER", 90, 96], ["respiratory syndrome", "OBSERVATION", 102, 122]]], ["Recently, the SARS-CoV-2 that emerged in Wuhan, China in December 2019 has spread globally with alarming infections and deaths[4-10].", [["infections", "DISEASE", 105, 115], ["deaths", "DISEASE", 120, 126], ["SARS-CoV-2", "ORGANISM", 14, 24], ["SARS-CoV", "SPECIES", 14, 22], ["alarming infections", "PROBLEM", 96, 115]]], ["The disease caused by SARS-CoV-2 is named as coronavirus disease 2019 (COVID-19)[11], which is also a highly contagious disease[9,12,13].", [["SARS", "DISEASE", 22, 26], ["coronavirus disease", "DISEASE", 45, 64], ["SARS-CoV-2", "ORGANISM", 22, 32], ["SARS-CoV-2", "SPECIES", 22, 32], ["The disease", "PROBLEM", 0, 11], ["SARS", "PROBLEM", 22, 26], ["CoV", "TEST", 27, 30], ["coronavirus disease", "PROBLEM", 45, 64], ["COVID", "TEST", 71, 76], ["a highly contagious disease", "PROBLEM", 100, 127], ["disease", "OBSERVATION", 4, 11], ["highly", "OBSERVATION_MODIFIER", 102, 108], ["contagious", "OBSERVATION", 109, 119]]], ["As of April 11, 2020, there have been 83 400 confirmed infections, 3 349 fatalities in China, and 1 623 873 confirmed cases with 99 617 deaths in 209 other countries[14,15].", [["infections", "DISEASE", 55, 65], ["fatalities", "DISEASE", 73, 83], ["deaths", "DISEASE", 136, 142], ["infections", "PROBLEM", 55, 65], ["infections", "OBSERVATION", 55, 65]]], ["The SARS-CoV-2 is presumed to be transmitted by respiratory droplets, viral aerosols, close contacts, and self-inoculation to nose, mouth, or eyes after touching a contaminated surface[16].", [["respiratory droplets", "ANATOMY", 48, 68], ["nose", "ANATOMY", 126, 130], ["mouth", "ANATOMY", 132, 137], ["eyes", "ANATOMY", 142, 146], ["surface", "ANATOMY", 177, 184], ["SARS", "DISEASE", 4, 8], ["SARS-CoV-2", "ORGANISM", 4, 14], ["nose", "ORGANISM_SUBDIVISION", 126, 130], ["mouth", "ORGANISM_SUBDIVISION", 132, 137], ["eyes", "ORGAN", 142, 146], ["SARS-CoV", "SPECIES", 4, 12], ["The SARS", "TEST", 0, 8], ["respiratory droplets", "PROBLEM", 48, 68], ["viral aerosols", "PROBLEM", 70, 84], ["presumed to be", "UNCERTAINTY", 18, 32], ["respiratory droplets", "OBSERVATION", 48, 68], ["viral aerosols", "OBSERVATION", 70, 84], ["mouth", "ANATOMY", 132, 137], ["eyes", "ANATOMY", 142, 146]]], ["However, there are still many controversies about the airborne transmission and infectivity of SARS-CoV on inanimate surfaces.", [["SARS", "DISEASE", 95, 99], ["SARS-CoV", "ORGANISM", 95, 103], ["SARS-CoV", "SPECIES", 95, 103], ["SARS", "PROBLEM", 95, 99], ["infectivity", "OBSERVATION_MODIFIER", 80, 91]]], ["We therefore reviewed the persistence and infectivity of viruses on inanimate surfaces to provide clear information for containing the epidemic of SARS-CoV-2.SEARCH STRATEGYThe references were systematically searched and reviewed on the homepage of the National Library of Medicine and the web of science without language limitations.", [["SARS", "DISEASE", 147, 151], ["SARS-CoV-2", "ORGANISM", 147, 157], ["SARS-CoV", "SPECIES", 147, 155], ["viruses", "PROBLEM", 57, 64], ["CoV", "TEST", 152, 155]]], ["The search terms were applied as follows: SARS-CoV-2, SARS-CoV, coronavirus, corona virus, 2019 nCoV, COVID-19, survival, viability, transmission, persistence, surface, and persistence hand.", [["surface", "ANATOMY", 160, 167], ["hand", "ANATOMY", 185, 189], ["SARS", "DISEASE", 54, 58], ["SARS-CoV-2", "ORGANISM", 42, 52], ["SARS-CoV", "ORGANISM", 54, 62], ["coronavirus", "ORGANISM", 64, 75], ["corona virus", "ORGANISM", 77, 89], ["hand", "ORGANISM_SUBDIVISION", 185, 189], ["coronavirus", "SPECIES", 64, 75], ["SARS-CoV", "SPECIES", 54, 62], ["SARS", "TEST", 42, 46], ["CoV", "TEST", 47, 50], ["SARS", "PROBLEM", 54, 58], ["coronavirus", "PROBLEM", 64, 75], ["corona virus", "PROBLEM", 77, 89], ["COVID", "TEST", 102, 107], ["corona virus", "ANATOMY", 77, 89], ["surface", "OBSERVATION_MODIFIER", 160, 167]]], ["Published articles were included and reviewed, and the related results were extracted given that they provided original data on coronavirus persistence.", [["coronavirus", "DISEASE", 128, 139], ["coronavirus", "ORGANISM", 128, 139], ["coronavirus persistence", "PROBLEM", 128, 151]]], ["Data of commercial products based on types of biocidal agents were excluded.", [["commercial products", "TREATMENT", 8, 27], ["biocidal agents", "TREATMENT", 46, 61], ["biocidal agents", "OBSERVATION", 46, 61]]], ["Two reviewers screened all identified records against the protocol, undertook the risk of bias assessments, and extracted data using a piloted form.Are there any viruses persisting in the air? ::: RESULTS AND DISCUSSIONSIn normal conditions without epidemic, the air should be free of any viruses.", [["the protocol", "TEST", 54, 66], ["bias assessments", "TEST", 90, 106], ["any viruses", "PROBLEM", 158, 169], ["epidemic", "PROBLEM", 249, 257], ["any viruses", "PROBLEM", 285, 296], ["viruses", "OBSERVATION", 162, 169], ["air", "OBSERVATION", 188, 191], ["viruses", "OBSERVATION", 289, 296]]], ["Upon SARS-CoV-2 outbreak, when COVID-19 patients cough, sneeze, or even talk, they could shed SARS-CoV-2 into the air, and air transmission may exist within 1 m in close proximity of COVID-19 patients.", [["cough", "DISEASE", 49, 54], ["sneeze", "DISEASE", 56, 62], ["SARS", "DISEASE", 94, 98], ["patients", "ORGANISM", 40, 48], ["patients", "ORGANISM", 192, 200], ["patients", "SPECIES", 40, 48], ["patients", "SPECIES", 192, 200], ["SARS", "TEST", 5, 9], ["CoV", "TEST", 10, 13], ["COVID", "TEST", 31, 36], ["cough", "PROBLEM", 49, 54], ["air", "ANATOMY", 114, 117]]], ["Thus, the public worry about the possibility of SARS-CoV-2 flowing in the air.Are there any viruses persisting in the air? ::: RESULTS AND DISCUSSIONSOng et al[17] in Singapore collected air and surface samples from COVID-19 patients bedrooms before and after routine cleaning.", [["surface samples", "ANATOMY", 195, 210], ["SARS", "DISEASE", 48, 52], ["patients", "ORGANISM", 225, 233], ["patients", "SPECIES", 225, 233], ["SARS", "PROBLEM", 48, 52], ["CoV", "TEST", 53, 56], ["any viruses", "PROBLEM", 88, 99], ["surface samples", "TEST", 195, 210], ["COVID", "TEST", 216, 221], ["routine cleaning", "TREATMENT", 260, 276], ["air", "ANATOMY", 74, 77], ["viruses", "OBSERVATION", 92, 99], ["air", "OBSERVATION", 118, 121]]], ["Before routine cleaning, reverse transcription-polymerase chain reaction (RT-PCR) results were positive with 13 (87%) of 15 room sites (including air outlet fans) and 3 (60%) of 5 toilet sites (toilet bowl, sink, and door handle), suggesting that the ward environment was extensively contaminated and that viral shedding in stool could be a potential route of transmission.", [["stool", "ANATOMY", 324, 329], ["stool", "ORGANISM_SUBSTANCE", 324, 329], ["routine cleaning", "TREATMENT", 7, 23], ["reverse transcription", "TEST", 25, 46], ["polymerase chain reaction", "PROBLEM", 47, 72], ["RT-PCR", "TEST", 74, 80], ["air outlet fans", "TEST", 146, 161], ["the ward environment", "PROBLEM", 247, 267], ["viral shedding in stool", "PROBLEM", 306, 329], ["air outlet", "OBSERVATION", 146, 156]]], ["Anteroom and corridor samples were negative.", [["corridor samples", "ANATOMY", 13, 29], ["corridor samples", "CANCER", 13, 29], ["corridor samples", "TEST", 13, 29], ["negative", "OBSERVATION", 35, 43]]], ["One COVID-19 patient had upper respiratory tract infection with no pneumonia or diarrhea, and his two stool samples were positive for SARS-CoV-2 on RT-PCR.", [["upper respiratory tract", "ANATOMY", 25, 48], ["stool samples", "ANATOMY", 102, 115], ["respiratory tract infection", "DISEASE", 31, 58], ["pneumonia", "DISEASE", 67, 76], ["diarrhea", "DISEASE", 80, 88], ["patient", "ORGANISM", 13, 20], ["upper", "ORGANISM_SUBDIVISION", 25, 30], ["respiratory tract", "ORGANISM_SUBDIVISION", 31, 48], ["patient", "SPECIES", 13, 20], ["SARS-CoV", "SPECIES", 134, 142], ["One COVID", "TEST", 0, 9], ["upper respiratory tract infection", "PROBLEM", 25, 58], ["pneumonia", "PROBLEM", 67, 76], ["diarrhea", "PROBLEM", 80, 88], ["his two stool samples", "TEST", 94, 115], ["SARS", "PROBLEM", 134, 138], ["CoV", "TEST", 139, 142], ["RT", "TEST", 148, 150], ["PCR", "TEST", 151, 154], ["upper", "ANATOMY_MODIFIER", 25, 30], ["respiratory tract", "ANATOMY", 31, 48], ["infection", "OBSERVATION", 49, 58], ["no", "UNCERTAINTY", 64, 66], ["pneumonia", "OBSERVATION", 67, 76], ["diarrhea", "OBSERVATION", 80, 88]]], ["After routine cleaning of the room, samples collected from another two patients were negative.", [["samples", "ANATOMY", 36, 43], ["patients", "ORGANISM", 71, 79], ["patients", "SPECIES", 71, 79], ["samples", "TEST", 36, 43], ["negative", "OBSERVATION", 85, 93]]], ["Only one swab from the surface of a shoe front was positive.", [["swab", "ANATOMY", 9, 13], ["surface", "ANATOMY", 23, 30], ["surface", "CELLULAR_COMPONENT", 23, 30], ["one swab", "TEST", 5, 13], ["swab", "OBSERVATION", 9, 13], ["positive", "OBSERVATION", 51, 59]]], ["All air samples were negative[17] despite the extent of environmental contamination.", [["air samples", "ANATOMY", 4, 15], ["air samples", "CANCER", 4, 15], ["All air samples", "TEST", 0, 15], ["environmental contamination", "PROBLEM", 56, 83], ["environmental contamination", "OBSERVATION", 56, 83]]], ["Swabs taken from the air exhaust outlets tested positive, suggesting that small virus-laden droplets may be displaced by airflows and deposited on equipment such as vents[17].", [["Swabs", "ANATOMY", 0, 5], ["Swabs", "TEST", 0, 5], ["the air exhaust outlets", "TEST", 17, 40], ["small virus-laden droplets", "PROBLEM", 74, 100], ["small", "OBSERVATION_MODIFIER", 74, 79], ["virus", "OBSERVATION", 80, 85]]], ["The risk of transmission from contaminated footwear is likely low, as evidenced by negative results in the anteroom and clean corridor.Are there any viruses persisting in the air? ::: RESULTS AND DISCUSSIONSJang et al[18] studied 28 air samples and 130 surface samples from isolated wards, outpatient fever clinics, guiding service Intensive Care Units, and nurse stations.", [["air samples", "ANATOMY", 233, 244], ["surface samples", "ANATOMY", 253, 268], ["fever", "DISEASE", 301, 306], ["air samples", "CANCER", 233, 244], ["contaminated footwear", "PROBLEM", 30, 51], ["any viruses", "PROBLEM", 145, 156], ["air samples", "TEST", 233, 244], ["viruses", "OBSERVATION", 149, 156], ["air", "OBSERVATION", 175, 178]]], ["RT-PCR results show that only one air sample from Intensive Care Units (1/28, 3.57%) and one surface sample from nurse stations (1/130, 0.77%) were positive for SARS-CoV-2.", [["surface sample", "ANATOMY", 93, 107], ["SARS", "DISEASE", 161, 165], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 161, 171], ["SARS-CoV", "SPECIES", 161, 169], ["RT-PCR", "TEST", 0, 6], ["SARS", "TEST", 161, 165], ["CoV", "TEST", 166, 169]]], ["Tracheal intubation was consistently associated with an increased risk of SARS-CoV transmission among healthcare workers[19].", [["Tracheal", "ANATOMY", 0, 8], ["SARS-CoV transmission", "DISEASE", 74, 95], ["Tracheal", "ORGAN", 0, 8], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 74, 82], ["SARS-CoV", "SPECIES", 74, 82], ["Tracheal intubation", "TREATMENT", 0, 19], ["SARS", "PROBLEM", 74, 78], ["intubation", "OBSERVATION", 9, 19], ["increased", "OBSERVATION_MODIFIER", 56, 65]]], ["In 18 hospitalized patients with PCR-confirmed SARS-CoV-2 infection, viral shedding from the nasopharynx was prolonged for 7 d or longer (15/18, 83%).", [["nasopharynx", "ANATOMY", 93, 104], ["SARS-CoV-2 infection", "DISEASE", 47, 67], ["patients", "ORGANISM", 19, 27], ["SARS-CoV-2", "ORGANISM", 47, 57], ["nasopharynx", "ORGAN", 93, 104], ["patients", "SPECIES", 19, 27], ["CoV-", "SPECIES", 52, 56], ["SARS-CoV-2", "SPECIES", 47, 57], ["PCR", "TEST", 33, 36], ["SARS", "PROBLEM", 47, 51], ["CoV", "PROBLEM", 52, 55], ["2 infection", "PROBLEM", 56, 67], ["viral shedding from the nasopharynx", "PROBLEM", 69, 104], ["infection", "OBSERVATION", 58, 67], ["nasopharynx", "ANATOMY", 93, 104]]], ["Virus was detectable in the stool (4/8, 50%) and blood (1/12, 8%) by RT-PCR[20].Are there any viruses persisting in the air? ::: RESULTS AND DISCUSSIONSSignificant environmental contamination by COVID-19 patients through respiratory droplets and fecal shedding[17,20] suggests that the environment is a potential medium of transmission and supports the need for strict adherence to environmental and hand hygiene.Are there any viruses persisting in the air? ::: RESULTS AND DISCUSSIONSTo investigate the possibility of SARS-CoV transmission in the air[21], air samples were obtained from seven wards and balconies in hospital at a frequency of three times daily for three continuous days.", [["stool", "ANATOMY", 28, 33], ["blood", "ANATOMY", 49, 54], ["respiratory droplets", "ANATOMY", 221, 241], ["fecal", "ANATOMY", 246, 251], ["hand", "ANATOMY", 400, 404], ["samples", "ANATOMY", 561, 568], ["SARS", "DISEASE", 519, 523], ["Virus", "ORGANISM", 0, 5], ["stool", "ORGANISM_SUBSTANCE", 28, 33], ["blood", "ORGANISM_SUBSTANCE", 49, 54], ["patients", "ORGANISM", 204, 212], ["fecal", "ORGANISM_SUBSTANCE", 246, 251], ["hand", "ORGANISM_SUBDIVISION", 400, 404], ["CoV", "ORGANISM", 524, 527], ["air samples", "CANCER", 557, 568], ["patients", "SPECIES", 204, 212], ["SARS-CoV", "SPECIES", 519, 527], ["Virus", "PROBLEM", 0, 5], ["the stool", "TEST", 24, 33], ["blood", "TEST", 49, 54], ["RT-PCR", "TEST", 69, 75], ["any viruses", "PROBLEM", 90, 101], ["COVID", "TEST", 195, 200], ["respiratory droplets", "TREATMENT", 221, 241], ["fecal shedding", "PROBLEM", 246, 260], ["any viruses", "PROBLEM", 423, 434], ["SARS", "PROBLEM", 519, 523], ["air samples", "TEST", 557, 568], ["balconies", "TREATMENT", 604, 613], ["viruses", "OBSERVATION", 94, 101], ["air", "OBSERVATION", 120, 123], ["viruses", "OBSERVATION", 427, 434], ["air", "OBSERVATION", 453, 456]]], ["The N protein gene of SARS-CoV was amplified with RT-PCR, and 29.03% of air samples in the wards and 20.0% of samples in balconies were positive for SARS-CoV; sequential analysis of the positive samples showed that the identity of amplified cDNA fragments to the known SARS-CoV strains was 98%.", [["air samples", "ANATOMY", 72, 83], ["samples", "ANATOMY", 110, 117], ["samples", "ANATOMY", 195, 202], ["SARS", "DISEASE", 149, 153], ["SARS", "DISEASE", 269, 273], ["SARS-CoV", "ORGANISM", 22, 30], ["air samples", "CANCER", 72, 83], ["samples", "CANCER", 110, 117], ["SARS-CoV", "ORGANISM", 149, 157], ["SARS-CoV", "ORGANISM", 269, 277], ["N protein gene", "DNA", 4, 18], ["SARS-CoV", "DNA", 22, 30], ["amplified cDNA fragments", "DNA", 231, 255], ["SARS-CoV", "SPECIES", 22, 30], ["SARS-CoV", "SPECIES", 149, 157], ["SARS-CoV", "SPECIES", 269, 277], ["The N protein gene", "TEST", 0, 18], ["SARS", "PROBLEM", 22, 26], ["RT-PCR", "TEST", 50, 56], ["air samples", "TEST", 72, 83], ["samples in balconies", "TEST", 110, 130], ["SARS", "PROBLEM", 149, 153], ["CoV", "TEST", 154, 157], ["sequential analysis", "TEST", 159, 178], ["the positive samples", "TEST", 182, 202], ["amplified cDNA fragments", "PROBLEM", 231, 255], ["the known SARS", "PROBLEM", 259, 273], ["CoV strains", "TEST", 274, 285]]], ["A strain of live pathogen was isolated and could cause typical cytopathic effects, similar to that of SARS-CoV on Vero-E6 cells, and the effects could be stably passed[21].", [["Vero-E6 cells", "ANATOMY", 114, 127], ["SARS", "DISEASE", 102, 106], ["SARS-CoV", "ORGANISM", 102, 110], ["Vero-E6 cells", "CELL", 114, 127], ["Vero-E6 cells", "CELL_LINE", 114, 127], ["SARS-CoV", "SPECIES", 102, 110], ["Vero-E6", "SPECIES", 114, 121], ["A strain of live pathogen", "PROBLEM", 0, 25], ["typical cytopathic effects", "PROBLEM", 55, 81], ["SARS", "PROBLEM", 102, 106], ["CoV", "PROBLEM", 107, 110], ["Vero-E6 cells", "TREATMENT", 114, 127], ["cytopathic", "OBSERVATION_MODIFIER", 63, 73]]], ["This study indicates that SARS-CoV could exist in the air where SARS patients live, but the infectivity of SARS-CoV in air samples is very weak.Are there any viruses persisting in the air? ::: RESULTS AND DISCUSSIONSViral nucleic acids, as well as viable seasonal and avian influenza viruses, have been detected in aerosols in the air in healthcare settings or in buses.", [["air samples", "ANATOMY", 119, 130], ["SARS", "DISEASE", 26, 30], ["SARS", "DISEASE", 64, 68], ["SARS", "DISEASE", 107, 111], ["nucleic acids", "CHEMICAL", 222, 235], ["influenza viruses", "DISEASE", 274, 291], ["SARS-CoV", "ORGANISM", 26, 34], ["patients", "ORGANISM", 69, 77], ["SARS-CoV", "ORGANISM", 107, 115], ["air samples", "CANCER", 119, 130], ["avian influenza viruses", "ORGANISM", 268, 291], ["patients", "SPECIES", 69, 77], ["avian influenza viruses", "SPECIES", 268, 291], ["SARS-CoV", "SPECIES", 26, 34], ["SARS-CoV", "SPECIES", 107, 115], ["This study", "TEST", 0, 10], ["SARS-CoV", "PROBLEM", 26, 34], ["SARS", "PROBLEM", 107, 111], ["CoV in air samples", "TEST", 112, 130], ["very weak", "PROBLEM", 134, 143], ["any viruses", "PROBLEM", 154, 165], ["DISCUSSIONSViral nucleic acids", "TEST", 205, 235], ["viable seasonal and avian influenza viruses", "PROBLEM", 248, 291], ["SARS", "OBSERVATION", 26, 30], ["air", "ANATOMY", 54, 57], ["weak", "OBSERVATION", 139, 143], ["viruses", "OBSERVATION", 158, 165], ["air", "OBSERVATION", 184, 187], ["air", "ANATOMY", 331, 334]]], ["The viral RNA of respiratory syncytial virus (RSV) was recovered in the air in pediatric or adult ambulatory care clinics, while only a small percentage of them were in particles \u2264 5 \u03bcm[22].", [["respiratory syncytial virus", "DISEASE", 17, 44], ["respiratory syncytial virus", "ORGANISM", 17, 44], ["RSV", "ORGANISM", 46, 49], ["viral RNA", "RNA", 4, 13], ["respiratory syncytial virus", "SPECIES", 17, 44], ["respiratory syncytial virus", "SPECIES", 17, 44], ["RSV", "SPECIES", 46, 49], ["respiratory syncytial virus", "PROBLEM", 17, 44], ["viral RNA", "OBSERVATION", 4, 13], ["respiratory syncytial virus", "OBSERVATION", 17, 44], ["small", "OBSERVATION_MODIFIER", 136, 141]]], ["A recent report in China shows the clustered aerosol transmission of SARS-CoV-2 in buses[23].", [["SARS", "DISEASE", 69, 73], ["SARS-CoV", "SPECIES", 69, 77], ["SARS", "PROBLEM", 69, 73], ["CoV", "TEST", 74, 77]]], ["Infected with SARS-CoV-2 but unaware of that, patient zero travelled in a fully enclosed air conditioned bus from place A to B. During his two-hour journey on the bus, he had infected eight passengers, one of which was asymptomatic.", [["SARS-CoV-2", "ORGANISM", 14, 24], ["patient", "ORGANISM", 46, 53], ["patient", "SPECIES", 46, 53], ["SARS-CoV", "SPECIES", 14, 22], ["SARS", "PROBLEM", 14, 18], ["asymptomatic", "PROBLEM", 219, 231]]], ["At place B, patient zero commuted to another bus right away, and infected two of 12 passengers during this one-hour travel.", [["patient", "ORGANISM", 12, 19], ["patient", "SPECIES", 12, 19]]], ["The bus was not disinfected at the bus station at place B, and 30 min later, shuttled more passengers back to place A. Among them, a passenger sat beside the seat where patient zero was previously seated, and was confirmed to be infected 2 d later, suggesting that the infectivity of SARS-CoV-2 on inanimate surfaces or in aerosol flows in closed buses may last at least 30 min.", [["SARS", "DISEASE", 284, 288], ["patient", "ORGANISM", 169, 176], ["SARS-CoV-2", "ORGANISM", 284, 294], ["patient", "SPECIES", 169, 176], ["SARS-CoV", "SPECIES", 284, 292], ["the infectivity of SARS", "PROBLEM", 265, 288], ["CoV", "TEST", 289, 292], ["inanimate surfaces", "TREATMENT", 298, 316], ["aerosol flows", "TREATMENT", 323, 336], ["infected", "OBSERVATION", 229, 237], ["aerosol flows", "OBSERVATION", 323, 336]]], ["The distance from patient zero to his infected persons is 0.5-4.5 m.", [["patient", "ORGANISM", 18, 25], ["persons", "ORGANISM", 47, 54], ["patient", "SPECIES", 18, 25], ["persons", "SPECIES", 47, 54]]], ["Patient zero and all of the 11 infected passengers in the bus did not wear masks, of which two infected passengers infected two other persons.", [["persons", "ORGANISM", 134, 141], ["Patient", "SPECIES", 0, 7], ["persons", "SPECIES", 134, 141]]], ["Thus, patient zero caused a total of 13 human SARS-CoV-2 infections[23].", [["SARS", "DISEASE", 46, 50], ["infections", "DISEASE", 57, 67], ["patient", "ORGANISM", 6, 13], ["human", "ORGANISM", 40, 45], ["SARS-CoV-2", "ORGANISM", 46, 56], ["patient", "SPECIES", 6, 13], ["human", "SPECIES", 40, 45], ["human", "SPECIES", 40, 45]]], ["Another study found infection of RSV virus from the air obtained over 1 m away from RSV-positive hospitalized infants, which were still present 2 h after the infected infants were discharged[24].", [["infection", "DISEASE", 20, 29], ["RSV", "ORGANISM", 33, 36], ["RSV", "ORGANISM", 84, 87], ["infants", "ORGANISM", 110, 117], ["infants", "ORGANISM", 167, 174], ["RSV virus", "SPECIES", 33, 42], ["infants", "SPECIES", 110, 117], ["infants", "SPECIES", 167, 174], ["RSV virus", "SPECIES", 33, 42], ["RSV", "SPECIES", 84, 87], ["Another study", "TEST", 0, 13], ["infection", "PROBLEM", 20, 29], ["RSV virus", "PROBLEM", 33, 42], ["RSV", "PROBLEM", 84, 87], ["infection", "OBSERVATION", 20, 29], ["RSV virus", "OBSERVATION", 33, 42]]], ["Yip et al[25] studied the air samples emitted by 16 patients infected with influenza virus.", [["air samples", "ANATOMY", 26, 37], ["influenza virus", "DISEASE", 75, 90], ["air samples", "ORGANISM_SUBSTANCE", 26, 37], ["patients", "ORGANISM", 52, 60], ["influenza virus", "ORGANISM", 75, 90], ["patients", "SPECIES", 52, 60], ["influenza virus", "SPECIES", 75, 90], ["the air samples", "TEST", 22, 37], ["influenza virus", "PROBLEM", 75, 90], ["air", "ANATOMY", 26, 29], ["influenza virus", "OBSERVATION", 75, 90]]], ["The air samples adjacent to these patients (0.5-1.0 m and 2.1-2.5 m away) were collected using bio-aerosol samplers, respectively.", [["air samples", "ANATOMY", 4, 15], ["air samples", "CANCER", 4, 15], ["patients", "ORGANISM", 34, 42], ["patients", "SPECIES", 34, 42], ["The air samples", "TEST", 0, 15], ["bio-aerosol samplers", "TREATMENT", 95, 115], ["air", "OBSERVATION", 4, 7]]], ["37.5% of the air samples emitted by these patients were tested positive in viral RNA for all tested particle sizes (< 1, 1-4, and > 5 \u03bcm), which indicates that the viruses exist in the air inclose proximity to the patients.", [["air samples", "ANATOMY", 13, 24], ["air samples", "CANCER", 13, 24], ["patients", "ORGANISM", 42, 50], ["patients", "ORGANISM", 214, 222], ["viral RNA", "RNA", 75, 84], ["patients", "SPECIES", 42, 50], ["patients", "SPECIES", 214, 222], ["the air samples", "TEST", 9, 24], ["the viruses", "PROBLEM", 160, 171], ["viral RNA", "OBSERVATION", 75, 84], ["sizes", "OBSERVATION_MODIFIER", 109, 114], ["viruses", "OBSERVATION", 164, 171], ["air", "OBSERVATION", 185, 188]]], ["There was no correlation between the nasal viral load of the patients and viral RNA recovery from the air, and there was no significant association between RNA detection from the air and demographics or clinical presentation[25].Are there any viruses persisting in the air? ::: RESULTS AND DISCUSSIONSAir samples collected from patient wards and swab samples from frequently touched surfaces in wards and nurse stations were positive by PCR, indicating that the aerosols bearing SARS-CoV-2 could exist in the air temporarily, especially in poorly ventilated areas, such as buses[23] and wards[18].", [["nasal", "ANATOMY", 37, 42], ["samples", "ANATOMY", 305, 312], ["swab samples", "ANATOMY", 346, 358], ["SARS", "DISEASE", 479, 483], ["nasal", "ORGANISM_SUBDIVISION", 37, 42], ["patients", "ORGANISM", 61, 69], ["DISCUSSIONSAir samples", "CANCER", 290, 312], ["patient", "ORGANISM", 328, 335], ["swab samples", "CANCER", 346, 358], ["SARS-CoV-2", "ORGANISM", 479, 489], ["patients", "SPECIES", 61, 69], ["patient", "SPECIES", 328, 335], ["RNA detection", "TEST", 156, 169], ["any viruses", "PROBLEM", 239, 250], ["DISCUSSIONSAir samples", "TEST", 290, 312], ["swab samples", "TEST", 346, 358], ["PCR", "TEST", 437, 440], ["the aerosols bearing SARS", "PROBLEM", 458, 483], ["nasal", "ANATOMY", 37, 42], ["viral load", "OBSERVATION", 43, 53], ["viral RNA recovery", "OBSERVATION", 74, 92], ["air", "OBSERVATION", 102, 105], ["no significant", "UNCERTAINTY", 121, 135], ["viruses", "OBSERVATION", 243, 250], ["air", "OBSERVATION", 269, 272], ["air temporarily", "OBSERVATION", 509, 524], ["poorly", "OBSERVATION_MODIFIER", 540, 546], ["ventilated", "OBSERVATION", 547, 557]]], ["The half-life of coronaviruses in aerosols was reported to be 86 h at 80% humidity in the environment[26].Do respiratory viruses persist in the air in crowded public spaces? ::: RESULTS AND DISCUSSIONSInternational and national traveling in airports or subways have facilitated the rapid spread of respiratory infectious diseases such as COVID-19.", [["respiratory viruses", "DISEASE", 109, 128], ["respiratory infectious diseases", "DISEASE", 298, 329], ["COVID-19", "CHEMICAL", 338, 346], ["coronaviruses", "ORGANISM", 17, 30], ["coronaviruses in aerosols", "TREATMENT", 17, 42], ["respiratory viruses", "PROBLEM", 109, 128], ["respiratory infectious diseases", "PROBLEM", 298, 329], ["COVID", "TEST", 338, 343], ["viruses", "OBSERVATION", 121, 128], ["air", "OBSERVATION_MODIFIER", 144, 147], ["crowded", "OBSERVATION_MODIFIER", 151, 158], ["public spaces", "OBSERVATION", 159, 172], ["respiratory", "ANATOMY", 298, 309], ["infectious", "OBSERVATION", 310, 320]]], ["A relatively prolonged incubation period of SARS-CoV-2 allows travelers with covert coronavirus infection to spread COVID-19 globally.", [["SARS", "DISEASE", 44, 48], ["coronavirus infection", "DISEASE", 84, 105], ["SARS-CoV-2", "ORGANISM", 44, 54], ["travelers", "ORGANISM", 62, 71], ["coronavirus", "ORGANISM", 84, 95], ["COVID-19", "CANCER", 116, 124], ["SARS-CoV", "SPECIES", 44, 52], ["covert coronavirus", "SPECIES", 77, 95], ["SARS", "PROBLEM", 44, 48], ["covert coronavirus infection", "PROBLEM", 77, 105], ["COVID", "TEST", 116, 121]]], ["Air transportation appears important in accelerating and amplifying viral transmission aboard airplanes, at the destination, and possibly at airports[27].Do respiratory viruses persist in the air in crowded public spaces? ::: RESULTS AND DISCUSSIONSIn 2018, a pilot study was performed to detect respiratory viruses in Singapore\u2019s Mass Rapid Transit network[28].", [["respiratory viruses", "DISEASE", 157, 176], ["respiratory viruses", "DISEASE", 296, 315], ["respiratory viruses", "PROBLEM", 157, 176], ["a pilot study", "TEST", 258, 271], ["respiratory viruses", "PROBLEM", 296, 315], ["viruses", "OBSERVATION", 169, 176], ["air", "OBSERVATION_MODIFIER", 192, 195], ["crowded", "OBSERVATION_MODIFIER", 199, 206], ["public spaces", "OBSERVATION", 207, 220]]], ["A total of 89 aerosol samples were collected during peak Mass Rapid Transit ridership hours using noninvasive bioaerosol samplers over 52 wk and tested using real-time RT-PCR: nine (10%) tested positive for adenovirus, four (4.5%) tested positive for RSV type A, and one (1%) tested positive for influenza A virus (IAV).", [["samples", "ANATOMY", 22, 29], ["RSV type A", "DISEASE", 251, 261], ["influenza A virus", "DISEASE", 296, 313], ["adenovirus", "ORGANISM", 207, 217], ["RSV", "ORGANISM", 251, 254], ["influenza A virus", "ORGANISM", 296, 313], ["IAV", "ORGANISM", 315, 318], ["influenza A virus", "SPECIES", 296, 313], ["adenovirus", "SPECIES", 207, 217], ["RSV type A", "SPECIES", 251, 261], ["influenza A virus", "SPECIES", 296, 313], ["IAV", "SPECIES", 315, 318], ["89 aerosol samples", "TEST", 11, 29], ["peak Mass", "PROBLEM", 52, 61], ["noninvasive bioaerosol samplers", "TREATMENT", 98, 129], ["adenovirus", "PROBLEM", 207, 217], ["RSV type A", "PROBLEM", 251, 261], ["influenza", "PROBLEM", 296, 305]]], ["These data show the presence of viruses in crowded public spaces[28].Do respiratory viruses persist in the air in crowded public spaces? ::: RESULTS AND DISCUSSIONSIn Finland from 2015-2016[8], surface and air samples were collected weekly at three different time points during the peak period of seasonal influenza.", [["surface", "ANATOMY", 194, 201], ["air samples", "ANATOMY", 206, 217], ["respiratory viruses", "DISEASE", 72, 91], ["influenza", "DISEASE", 306, 315], ["surface", "CELLULAR_COMPONENT", 194, 201], ["air samples", "CANCER", 206, 217], ["These data", "TEST", 0, 10], ["viruses in crowded public spaces", "PROBLEM", 32, 64], ["respiratory viruses", "PROBLEM", 72, 91], ["air samples", "TEST", 206, 217], ["seasonal influenza", "PROBLEM", 297, 315], ["viruses", "OBSERVATION", 32, 39], ["crowded", "OBSERVATION_MODIFIER", 43, 50], ["public spaces", "OBSERVATION", 51, 64], ["viruses", "OBSERVATION", 84, 91], ["air", "OBSERVATION_MODIFIER", 107, 110], ["crowded", "OBSERVATION_MODIFIER", 114, 121], ["public spaces", "OBSERVATION", 122, 135], ["seasonal influenza", "OBSERVATION", 297, 315]]], ["Swabs from surface samples and air samples were tested by real-time PCR for influenza A and B viruses, RSV, adenovirus, rhinovirus, and coronaviruses (229E, HKU1, NL63, and OC43).", [["Swabs", "ANATOMY", 0, 5], ["surface samples", "ANATOMY", 11, 26], ["air samples", "ANATOMY", 31, 42], ["surface samples", "ORGANISM_SUBSTANCE", 11, 26], ["air samples", "CANCER", 31, 42], ["influenza A and B viruses", "ORGANISM", 76, 101], ["RSV", "ORGANISM", 103, 106], ["adenovirus", "ORGANISM", 108, 118], ["rhinovirus", "ORGANISM", 120, 130], ["coronaviruses", "ORGANISM", 136, 149], ["HKU1", "GENE_OR_GENE_PRODUCT", 157, 161], ["NL63", "GENE_OR_GENE_PRODUCT", 163, 167], ["OC43", "GENE_OR_GENE_PRODUCT", 173, 177], ["RSV", "SPECIES", 103, 106], ["influenza A", "SPECIES", 76, 87], ["B viruses", "SPECIES", 92, 101], ["RSV", "SPECIES", 103, 106], ["adenovirus", "SPECIES", 108, 118], ["Swabs from surface samples", "TEST", 0, 26], ["air samples", "TEST", 31, 42], ["influenza", "PROBLEM", 76, 85], ["B viruses", "PROBLEM", 92, 101], ["RSV", "PROBLEM", 103, 106], ["adenovirus", "PROBLEM", 108, 118], ["rhinovirus", "PROBLEM", 120, 130], ["coronaviruses", "PROBLEM", 136, 149], ["HKU1", "TEST", 157, 161], ["NL63", "TEST", 163, 167]]], ["The nucleic acid of at least one respiratory virus was detected in 10% (9/90) of surface samples from multiple places, such as children\u2019s play grounds, security check areas, buttons of payment terminals, passenger side desks and handrails of stairs.", [["surface samples", "ANATOMY", 81, 96], ["nucleic acid", "CHEMICAL", 4, 16], ["children", "ORGANISM", 127, 135], ["children", "SPECIES", 127, 135], ["The nucleic acid", "TEST", 0, 16], ["one respiratory virus", "PROBLEM", 29, 50], ["nucleic acid", "OBSERVATION", 4, 16], ["respiratory virus", "OBSERVATION", 33, 50]]], ["The ten respiratory viruses identified from surfaces and air samples at various sites were rhinovirus (4/10, 40%), coronavirus (3/10, 30%,), adenovirus (2/10, 20%, one air sample, one surface sample), and influenza A (1/10, 10%).", [["air samples", "ANATOMY", 57, 68], ["sample", "ANATOMY", 172, 178], ["surface sample", "ANATOMY", 184, 198], ["respiratory viruses", "DISEASE", 8, 27], ["coronavirus", "DISEASE", 115, 126], ["influenza A", "DISEASE", 205, 216], ["air samples", "MULTI-TISSUE_STRUCTURE", 57, 68], ["rhinovirus", "ORGANISM", 91, 101], ["coronavirus", "ORGANISM", 115, 126], ["adenovirus", "ORGANISM", 141, 151], ["coronavirus", "SPECIES", 115, 126], ["adenovirus", "SPECIES", 141, 151], ["influenza A", "SPECIES", 205, 216], ["The ten respiratory viruses", "PROBLEM", 0, 27], ["air samples", "TEST", 57, 68], ["rhinovirus", "TEST", 91, 101], ["coronavirus", "TEST", 115, 126], ["adenovirus", "TEST", 141, 151], ["one air sample", "TEST", 164, 178], ["one surface sample", "TEST", 180, 198], ["influenza A", "PROBLEM", 205, 216], ["ten", "OBSERVATION_MODIFIER", 4, 7], ["respiratory viruses", "OBSERVATION", 8, 27], ["surfaces", "OBSERVATION_MODIFIER", 44, 52], ["air samples", "OBSERVATION", 57, 68], ["rhinovirus", "OBSERVATION", 91, 101]]], ["The detection of viral nucleic acids indicates surface contamination on multiple sites in airports associated with high touch rates, such as plastic security screening trays, which are almost inevitable for all embarking passengers to touch[8].Do respiratory viruses persist in the air in crowded public spaces? ::: RESULTS AND DISCUSSIONSLei et al[29] built a model to simulate outbreaks of influenza A H1N1, SARS-CoV, and norovirus in a similar cabin environment.", [["surface", "ANATOMY", 47, 54], ["nucleic acids", "CHEMICAL", 23, 36], ["respiratory viruses", "DISEASE", 247, 266], ["influenza A H1N1", "DISEASE", 392, 408], ["SARS-CoV, and norovirus", "DISEASE", 410, 433], ["influenza A H1N1", "ORGANISM", 392, 408], ["SARS-CoV", "ORGANISM", 410, 418], ["influenza A H1N1", "SPECIES", 392, 408], ["influenza A H1N1", "SPECIES", 392, 408], ["SARS-CoV", "SPECIES", 410, 418], ["viral nucleic acids", "PROBLEM", 17, 36], ["surface contamination", "PROBLEM", 47, 68], ["multiple sites", "PROBLEM", 72, 86], ["high touch rates", "PROBLEM", 115, 131], ["respiratory viruses", "PROBLEM", 247, 266], ["influenza", "PROBLEM", 392, 401], ["SARS", "PROBLEM", 410, 414], ["norovirus", "PROBLEM", 424, 433], ["viral nucleic acids", "OBSERVATION", 17, 36], ["surface", "OBSERVATION_MODIFIER", 47, 54], ["contamination", "OBSERVATION", 55, 68], ["respiratory viruses", "OBSERVATION", 247, 266], ["air", "OBSERVATION_MODIFIER", 282, 285], ["crowded", "OBSERVATION_MODIFIER", 289, 296], ["public spaces", "OBSERVATION", 297, 310]]], ["The simulation results suggest that passengers within two rows of the index case had a significantly higher infection risk than others in the outbreak.", [["infection", "DISEASE", 108, 117], ["a significantly higher infection risk", "PROBLEM", 85, 122], ["higher", "OBSERVATION_MODIFIER", 101, 107], ["infection", "OBSERVATION", 108, 117]]], ["For SARS-CoV, the airborne, close contact, and fomite routes contributed 21%, 29%, and 50% transmission, respectively.", [["SARS", "DISEASE", 4, 8], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 4, 12], ["SARS-CoV", "SPECIES", 4, 12], ["SARS", "PROBLEM", 4, 8]]], ["The close contact route was significant in the in-flight transmission of influenza A H1N1.", [["influenza A H1N1", "DISEASE", 73, 89], ["influenza A H1N1", "ORGANISM", 73, 89], ["influenza A H1N1", "SPECIES", 73, 89], ["influenza A H1N1", "SPECIES", 73, 89], ["influenza A H1N1", "PROBLEM", 73, 89]]], ["For norovirus, the fomite route played the dominant role in most cases[29].Viruses exist in a wide range of aerosol particle sizes ::: RESULTS AND DISCUSSIONSClinically stable asthma patients have similar detection rates of respiratory viruses in samples from the nasopharynx, sputum, and exhaled air[30].", [["samples", "ANATOMY", 247, 254], ["nasopharynx", "ANATOMY", 264, 275], ["sputum", "ANATOMY", 277, 283], ["norovirus", "DISEASE", 4, 13], ["asthma", "DISEASE", 176, 182], ["respiratory viruses", "DISEASE", 224, 243], ["patients", "ORGANISM", 183, 191], ["nasopharynx", "ORGAN", 264, 275], ["patients", "SPECIES", 183, 191], ["norovirus", "PROBLEM", 4, 13], ["Viruses", "PROBLEM", 75, 82], ["asthma", "PROBLEM", 176, 182], ["respiratory viruses in samples from the nasopharynx", "PROBLEM", 224, 275], ["sputum", "TEST", 277, 283], ["exhaled air", "TEST", 289, 300], ["wide", "OBSERVATION_MODIFIER", 94, 98], ["stable", "OBSERVATION_MODIFIER", 169, 175], ["asthma", "OBSERVATION", 176, 182], ["respiratory viruses", "OBSERVATION", 224, 243], ["nasopharynx", "ANATOMY", 264, 275]]], ["When pathogens become airborne, they travel in particles of different sizes and compositions.", [["airborne", "PROBLEM", 22, 30], ["airborne", "OBSERVATION", 22, 30], ["sizes", "OBSERVATION_MODIFIER", 70, 75]]], ["Particle size determines the distance across which pathogens can be transported, as well as the site of deposition and the survivability of the viruses.", [["pathogens", "PROBLEM", 51, 60], ["the viruses", "PROBLEM", 140, 151], ["size", "OBSERVATION_MODIFIER", 9, 13], ["distance", "OBSERVATION_MODIFIER", 29, 37], ["pathogens", "OBSERVATION", 51, 60], ["deposition", "OBSERVATION", 104, 114], ["viruses", "OBSERVATION", 144, 151]]], ["The concentration and size distribution of inhalable particles that transport IAV as well as the viral viability for each particle size range were assessed on experimentally infected pigs, including samples from porcine reproductive and respiratory syndrome virus and porcine epidemic diarrhea virus exhaled by acutely infected pigs.", [["samples", "ANATOMY", 199, 206], ["porcine reproductive and respiratory syndrome", "DISEASE", 212, 257], ["diarrhea", "DISEASE", 285, 293], ["pigs", "ORGANISM", 183, 187], ["porcine reproductive and respiratory syndrome virus", "ORGANISM", 212, 263], ["porcine epidemic diarrhea virus", "ORGANISM", 268, 299], ["pigs", "ORGANISM", 328, 332], ["pigs", "SPECIES", 183, 187], ["porcine", "SPECIES", 212, 219], ["porcine epidemic diarrhea virus", "SPECIES", 268, 299], ["pigs", "SPECIES", 328, 332], ["pigs", "SPECIES", 183, 187], ["porcine epidemic diarrhea virus", "SPECIES", 268, 299], ["pigs", "SPECIES", 328, 332], ["The concentration and size distribution of inhalable particles", "TREATMENT", 0, 62], ["transport IAV", "TREATMENT", 68, 81], ["the viral viability", "PROBLEM", 93, 112], ["experimentally infected pigs", "PROBLEM", 159, 187], ["porcine reproductive", "PROBLEM", 212, 232], ["respiratory syndrome virus", "PROBLEM", 237, 263], ["porcine epidemic diarrhea virus exhaled", "PROBLEM", 268, 307], ["acutely infected pigs", "PROBLEM", 311, 332], ["concentration", "OBSERVATION_MODIFIER", 4, 17], ["size", "OBSERVATION_MODIFIER", 22, 26], ["distribution", "OBSERVATION_MODIFIER", 27, 39], ["inhalable particles", "OBSERVATION", 43, 62], ["viral viability", "OBSERVATION", 97, 112], ["size", "OBSERVATION_MODIFIER", 131, 135], ["infected pigs", "OBSERVATION", 174, 187], ["respiratory syndrome", "OBSERVATION", 237, 257], ["infected pigs", "OBSERVATION", 319, 332]]], ["An Andersen cascade impactor being able to separate particles by size (0.4-10 \u03bcm in diameter) was used to collect aerosols from experimentally infected pigs for 24 d.", [["pigs", "ORGANISM", 152, 156], ["pigs", "SPECIES", 152, 156], ["pigs", "SPECIES", 152, 156], ["An Andersen cascade impactor", "TREATMENT", 0, 28], ["size", "OBSERVATION_MODIFIER", 65, 69]]], ["Infectious status was demonstrated for the three viruses.", [["the three viruses", "PROBLEM", 39, 56]]], ["Quantitative RT-PCR results indicated that airborne porcine epidemic diarrhea virus, IAV, and porcine reproductive and respiratory syndrome virus can be found in a wide range of particle sizes.", [["porcine epidemic diarrhea", "DISEASE", 52, 77], ["porcine reproductive and respiratory syndrome", "DISEASE", 94, 139], ["airborne", "ORGANISM", 43, 51], ["porcine epidemic diarrhea virus", "ORGANISM", 52, 83], ["IAV", "ORGANISM", 85, 88], ["porcine reproductive and respiratory syndrome virus", "ORGANISM", 94, 145], ["porcine epidemic diarrhea virus", "SPECIES", 52, 83], ["porcine", "SPECIES", 94, 101], ["porcine epidemic diarrhea virus", "SPECIES", 52, 83], ["IAV", "SPECIES", 85, 88], ["porcine reproductive and respiratory syndrome virus", "SPECIES", 94, 145], ["Quantitative RT-PCR", "TEST", 0, 19], ["airborne porcine epidemic diarrhea virus", "PROBLEM", 43, 83], ["IAV", "PROBLEM", 85, 88], ["porcine reproductive", "PROBLEM", 94, 114], ["respiratory syndrome virus", "PROBLEM", 119, 145], ["airborne porcine", "OBSERVATION", 43, 59], ["respiratory syndrome", "OBSERVATION", 119, 139], ["particle", "OBSERVATION_MODIFIER", 178, 186], ["sizes", "OBSERVATION_MODIFIER", 187, 192]]], ["The virus viability is particle size-dependent[32].Survival of coronavirus on inanimate surfaces in households or hospitals ::: RESULTS AND DISCUSSIONSA dry or less humid environment is unsuitable for viral survival.", [["coronavirus", "ORGANISM", 63, 74], ["coronavirus", "PROBLEM", 63, 74], ["viral survival", "TREATMENT", 201, 215], ["virus viability", "OBSERVATION", 4, 19], ["particle", "OBSERVATION_MODIFIER", 23, 31], ["size", "OBSERVATION_MODIFIER", 32, 36], ["dependent", "OBSERVATION_MODIFIER", 37, 46], ["coronavirus", "OBSERVATION", 63, 74]]], ["During the SARS-CoV-2 outbreak, the contamination of paper documents, paper money, and mail wrapping paper is a concern for people who handle such documents in their daily work.", [["SARS", "DISEASE", 11, 15], ["people", "ORGANISM", 124, 130], ["people", "SPECIES", 124, 130]]], ["After visiting hospitals and returning home, people worry that their cotton clothes or impervious gowns may carry fomites bearing SARS-CoV-2 into home.Survival of coronavirus on inanimate surfaces in households or hospitals ::: RESULTS AND DISCUSSIONSHuman coronavirus strain 229E (HuCoV-229E) can remain infectious on inanimate surfaces at RT from 2 h to 9 d on different types of materials[33] (Table 1).", [["SARS", "DISEASE", 130, 134], ["HuCoV-229E", "CHEMICAL", 282, 292], ["people", "ORGANISM", 45, 51], ["coronavirus", "ORGANISM", 163, 174], ["DISCUSSIONSHuman coronavirus strain 229E", "ORGANISM", 240, 280], ["HuCoV-229E", "CELL", 282, 292], ["people", "SPECIES", 45, 51], ["coronavirus", "SPECIES", 257, 268], ["DISCUSSIONSHuman coronavirus strain 229E (HuCoV-229E", "SPECIES", 240, 292], ["coronavirus", "PROBLEM", 163, 174], ["DISCUSSIONSHuman coronavirus strain", "TEST", 240, 275], ["HuCoV", "TEST", 282, 287], ["coronavirus", "OBSERVATION", 163, 174], ["infectious", "OBSERVATION", 305, 315]]], ["At 21 \u00b0C and RH of 30-40%, inoculums of 103 plaque-forming units (PFU) of HuCoV-229E persisted on polyfluorotetraethylene (Teflon), polyvinyl chloride (PVC), ceramic tiles, glass, and stainless steel for at least 5 d, as well as on silicon rubber for 3 d.Survival of coronavirus on inanimate surfaces in households or hospitals ::: RESULTS AND DISCUSSIONSInfectivity of HuCoV- 229E was undetectable after drying on aluminum, sterile latex surgical gloves, and sterile cotton gauze sponges at RT for 3 h; HuCoV OC43 survived 1 h or less[34].", [["plaque", "ANATOMY", 44, 50], ["HuCoV-229E", "CHEMICAL", 74, 84], ["polyfluorotetraethylene", "CHEMICAL", 98, 121], ["polyvinyl chloride", "CHEMICAL", 132, 150], ["HuCoV- 229E", "CHEMICAL", 370, 381], ["aluminum", "CHEMICAL", 415, 423], ["HuCoV-229E", "CHEMICAL", 74, 84], ["polyfluorotetraethylene", "CHEMICAL", 98, 121], ["Teflon", "CHEMICAL", 123, 129], ["polyvinyl chloride", "CHEMICAL", 132, 150], ["PVC", "CHEMICAL", 152, 155], ["silicon", "CHEMICAL", 232, 239], ["HuCoV- 229E", "CHEMICAL", 370, 381], ["aluminum", "CHEMICAL", 415, 423], ["HuCoV-229E", "SIMPLE_CHEMICAL", 74, 84], ["polyfluorotetraethylene", "SIMPLE_CHEMICAL", 98, 121], ["Teflon", "SIMPLE_CHEMICAL", 123, 129], ["polyvinyl chloride", "SIMPLE_CHEMICAL", 132, 150], ["coronavirus", "ORGANISM", 267, 278], ["HuCoV- 229E", "CELL", 370, 381], ["aluminum", "SIMPLE_CHEMICAL", 415, 423], ["HuCoV-229E", "SPECIES", 74, 84], ["HuCoV- 229E", "SPECIES", 370, 381], ["cotton", "SPECIES", 468, 474], ["RH", "TEST", 13, 15], ["inoculums", "TEST", 27, 36], ["plaque", "TEST", 44, 50], ["HuCoV", "TEST", 74, 79], ["polyfluorotetraethylene (Teflon", "TREATMENT", 98, 129], ["polyvinyl chloride (PVC", "TREATMENT", 132, 155], ["ceramic tiles, glass, and stainless steel", "TREATMENT", 158, 199], ["silicon rubber", "TREATMENT", 232, 246], ["coronavirus", "PROBLEM", 267, 278], ["HuCoV", "TEST", 370, 375], ["aluminum", "TREATMENT", 415, 423], ["sterile latex surgical gloves", "TREATMENT", 425, 454], ["sterile cotton gauze sponges", "TREATMENT", 460, 488], ["stainless steel", "OBSERVATION_MODIFIER", 184, 199]]], ["Contaminated droplets will be absorbed faster on cotton materials than on fluid-repellent materials, and cotton gowns offer protection against droplets bearing viruses.", [["cotton", "SPECIES", 105, 111], ["Contaminated droplets", "PROBLEM", 0, 21], ["cotton materials", "TREATMENT", 49, 65], ["fluid-repellent materials", "TREATMENT", 74, 99], ["cotton gowns", "TREATMENT", 105, 117]]], ["Droplets or fomites that persiston a nonabsorbent disposable gown or gloves may be a risk to contaminate the environment.Survival of coronavirus on inanimate surfaces in households or hospitals ::: RESULTS AND DISCUSSIONSSARS-CoV strain GVU6109 was isolated from a lung tissue specimen of a SARS patient during the SARS outbreak in 2003[35]; its infectivity at 104 tissue culture infection doses (TCID50)/mL vanished within 5 min after drying on paper or a cotton gown at RT[35], showing that the viral infectivity perished faster on the cotton gown than on an impervious surface (e.g., the disposable gown) (5 min vs 60 min at 104 TCID50/mL, 1 h vs 24 h at 105 TCID50/mL )[35].Survival of coronavirus on inanimate surfaces in households or hospitals ::: RESULTS AND DISCUSSIONSA piece of sterilized paper was experimentally contaminated with a higher titer virus 105 TCID50/mL, equivalent to that of fecal excreta.", [["lung tissue specimen", "ANATOMY", 265, 285], ["tissue culture", "ANATOMY", 365, 379], ["surface", "ANATOMY", 572, 579], ["fecal excreta", "ANATOMY", 901, 914], ["SARS", "DISEASE", 291, 295], ["SARS", "DISEASE", 315, 319], ["infection", "DISEASE", 380, 389], ["coronavirus", "ORGANISM", 133, 144], ["-CoV strain", "ORGANISM", 225, 236], ["GVU6109", "ORGANISM", 237, 244], ["lung tissue specimen", "TISSUE", 265, 285], ["patient", "ORGANISM", 296, 303], ["coronavirus", "ORGANISM", 690, 701], ["fecal excreta", "ORGANISM_SUBSTANCE", 901, 914], ["patient", "SPECIES", 296, 303], ["cotton", "SPECIES", 457, 463], ["cotton", "SPECIES", 538, 544], ["a nonabsorbent disposable gown", "TREATMENT", 35, 65], ["gloves", "TREATMENT", 69, 75], ["coronavirus", "PROBLEM", 133, 144], ["CoV strain GVU6109", "PROBLEM", 226, 244], ["a lung tissue specimen", "PROBLEM", 263, 285], ["a SARS", "PROBLEM", 289, 295], ["its infectivity", "PROBLEM", 342, 357], ["a cotton gown", "TREATMENT", 455, 468], ["the viral infectivity", "PROBLEM", 493, 514], ["the cotton gown", "TREATMENT", 534, 549], ["the disposable gown", "TREATMENT", 587, 606], ["coronavirus", "PROBLEM", 690, 701], ["DISCUSSIONSA piece of sterilized paper", "TREATMENT", 767, 805], ["a higher titer virus", "TREATMENT", 843, 863], ["coronavirus", "OBSERVATION", 133, 144], ["lung", "ANATOMY", 265, 269], ["viral infectivity", "OBSERVATION", 497, 514], ["coronavirus", "OBSERVATION", 690, 701], ["fecal", "ANATOMY", 901, 906], ["excreta", "OBSERVATION", 907, 914]]], ["The sample was allowed to be absorbed at RT for 3 h, then placed into a VeroE6 cell culture tube, and no viral infectivity was detected.", [["sample", "ANATOMY", 4, 10], ["cell culture tube", "ANATOMY", 79, 96], ["VeroE6 cell", "CELL", 72, 83], ["tube", "TISSUE", 92, 96], ["VeroE6 cell culture tube", "CELL_LINE", 72, 96], ["a VeroE6 cell culture tube", "TREATMENT", 70, 96], ["viral infectivity", "PROBLEM", 105, 122], ["culture tube", "OBSERVATION", 84, 96], ["no", "UNCERTAINTY", 102, 104], ["viral infectivity", "OBSERVATION", 105, 122]]], ["With 106 TCID50/mL, no viral infectivity was shown after 24 h.", [["viral infectivity", "PROBLEM", 23, 40], ["no", "UNCERTAINTY", 20, 22], ["viral infectivity", "OBSERVATION", 23, 40]]], ["A higher concentration of 104 virus that was dropped on paper and allowed to dry at RT showed no viral infectivity within 5 min.", [["A higher concentration of 104 virus", "PROBLEM", 0, 35], ["viral infectivity", "PROBLEM", 97, 114], ["higher", "OBSERVATION_MODIFIER", 2, 8], ["concentration", "OBSERVATION_MODIFIER", 9, 22], ["104 virus", "OBSERVATION_MODIFIER", 26, 35], ["no", "UNCERTAINTY", 94, 96], ["viral infectivity", "OBSERVATION", 97, 114]]], ["Usually the viral titer in nasopharyngeal aspirate specimens is 102.2 TCID50/mL[35].", [["nasopharyngeal aspirate specimens", "ANATOMY", 27, 60], ["nasopharyngeal aspirate specimens", "CANCER", 27, 60], ["the viral titer", "TEST", 8, 23], ["nasopharyngeal aspirate specimens", "TEST", 27, 60], ["viral titer", "OBSERVATION", 12, 23], ["nasopharyngeal", "ANATOMY", 27, 41]]], ["Therefore, the risk of infection by contact with a droplet contaminated paper is small.", [["infection", "DISEASE", 23, 32], ["infection", "PROBLEM", 23, 32], ["a droplet contaminated", "TREATMENT", 49, 71], ["infection", "OBSERVATION", 23, 32], ["small", "OBSERVATION_MODIFIER", 81, 86]]], ["Hand washing after touching potential materials is effective against SARS-CoV-2 transmission.Survival of SARS-CoV in liquid: water, urine, and sewage ::: RESULTS AND DISCUSSIONSThe survival time of SARS-CoV is impacted by viral stains, the types of solutions it stayed in, temperature, and viral titers.", [["urine", "ANATOMY", 132, 137], ["SARS", "DISEASE", 69, 73], ["SARS", "DISEASE", 105, 109], ["SARS", "DISEASE", 198, 202], ["SARS-CoV-2", "ORGANISM", 69, 79], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 105, 113], ["urine", "ORGANISM_SUBSTANCE", 132, 137], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 198, 206], ["SARS-CoV", "SPECIES", 69, 77], ["SARS-CoV", "SPECIES", 105, 113], ["SARS-CoV", "SPECIES", 198, 206], ["Hand washing", "TREATMENT", 0, 12], ["touching potential materials", "TREATMENT", 19, 47], ["SARS", "PROBLEM", 69, 73], ["SARS", "PROBLEM", 105, 109], ["SARS", "PROBLEM", 198, 202], ["viral stains", "TEST", 222, 234], ["temperature", "TEST", 273, 284], ["viral titers", "PROBLEM", 290, 302], ["washing", "OBSERVATION", 5, 12], ["SARS", "OBSERVATION", 105, 109], ["viral titers", "OBSERVATION", 290, 302]]], ["It could survive for 14 d at 4 \u00b0C, 2 d at 20 \u00b0C in dechlorinated tap water or domestic sewage, and 14 d at 20 \u00b0C in BPS.", [["dechlorinated tap water", "TREATMENT", 51, 74], ["domestic sewage", "TREATMENT", 78, 93], ["BPS", "TEST", 116, 119]]], ["The SARS-CoV strain P9 was isolated from a pharyngeal swab of SARS patients[26].", [["pharyngeal swab", "ANATOMY", 43, 58], ["SARS", "DISEASE", 62, 66], ["SARS-CoV strain P9", "ORGANISM", 4, 22], ["pharyngeal swab", "MULTI-TISSUE_STRUCTURE", 43, 58], ["patients", "ORGANISM", 67, 75], ["patients", "SPECIES", 67, 75], ["SARS-CoV", "SPECIES", 4, 12], ["The SARS-CoV strain P9", "PROBLEM", 0, 22], ["a pharyngeal swab", "TEST", 41, 58], ["pharyngeal", "ANATOMY", 43, 53]]], ["In testing conditions, it could survive in serum, 1:20 diluted sputum, and feces for at least 4 d (96 h), and in urine for at least 3 d (72 h) with a low level of infectivity[26].", [["serum", "ANATOMY", 43, 48], ["sputum", "ANATOMY", 63, 69], ["feces", "ANATOMY", 75, 80], ["urine", "ANATOMY", 113, 118], ["serum", "ORGANISM_SUBSTANCE", 43, 48], ["sputum", "ORGANISM_SUBSTANCE", 63, 69], ["feces", "ORGANISM_SUBSTANCE", 75, 80], ["urine", "ORGANISM_SUBSTANCE", 113, 118], ["serum", "TEST", 43, 48], ["diluted sputum", "TEST", 55, 69], ["feces", "TEST", 75, 80], ["urine", "TEST", 113, 118], ["a low level of infectivity", "PROBLEM", 148, 174]]], ["SARS-CoV P9 infectivity at RT persisted for 60 h after exposure, started to drop after 72 h, and was almost detectable after 120 h[26].", [["SARS", "DISEASE", 0, 4], ["SARS-CoV P9", "ORGANISM", 0, 11], ["SARS-CoV", "SPECIES", 0, 8], ["SARS", "PROBLEM", 0, 4], ["CoV P9 infectivity", "PROBLEM", 5, 23], ["CoV P9", "OBSERVATION_MODIFIER", 5, 11]]], ["It stayed stable at 4 \u00b0C, 20 \u00b0C and at 37 \u00b0C for at least 2 h with infectivity in cells.", [["cells", "ANATOMY", 82, 87], ["cells", "CELL", 82, 87], ["infectivity in cells", "PROBLEM", 67, 87], ["stable", "OBSERVATION_MODIFIER", 10, 16], ["infectivity", "OBSERVATION", 67, 78]]], ["A short time exposure can inactivate complement at 56 \u00b0C, and antibody at 67 \u00b0C, which is not enough to eliminate SARS-CoV infectivity; the conditions for SARS-CoV to become non-infectious should be at 56 \u00b0C for 90 min, 67 \u00b0C for 60 min, and 75 \u00b0C for 30 min, respectively[26].", [["SARS", "DISEASE", 114, 118], ["SARS", "DISEASE", 155, 159], ["SARS-CoV", "ORGANISM", 114, 122], ["SARS-CoV", "ORGANISM", 155, 163], ["SARS-CoV", "SPECIES", 114, 122], ["SARS-CoV", "SPECIES", 155, 163], ["antibody", "TEST", 62, 70], ["SARS", "PROBLEM", 114, 118], ["CoV infectivity", "PROBLEM", 119, 134], ["SARS", "PROBLEM", 155, 159], ["CoV", "PROBLEM", 160, 163], ["non-infectious", "PROBLEM", 174, 188], ["non-infectious", "OBSERVATION", 174, 188]]], ["Another study shows that coronaviruses remain infective at 4 \u00b0C for several months, and at -60 \u00b0C for many years[36], but are inactivated at 56 \u00b0C within 10-15 min, and at 37 \u00b0C after several days[36].Survival of SARS-CoV in liquid: water, urine, and sewage ::: RESULTS AND DISCUSSIONSSARS-CoV GVU6109 (106 TCID50/mL) can remain infectious in respiratory specimens for >7 d at RT, for > 20 d at 4 \u00b0C[35], and for 4 d in diarrheal stool samples at pH 9 at RT[35].Survival of SARS-CoV in liquid: water, urine, and sewage ::: RESULTS AND DISCUSSIONSSARS-CoV HKU 39849 is relatively more stable than HuCoV 229E or OC43 and some other viral respiratory pathogens such as RSV.", [["urine", "ANATOMY", 240, 245], ["respiratory specimens", "ANATOMY", 343, 364], ["samples", "ANATOMY", 436, 443], ["urine", "ANATOMY", 501, 506], ["SARS", "DISEASE", 213, 217], ["diarrheal", "DISEASE", 420, 429], ["SARS", "DISEASE", 474, 478], ["HKU 39849", "CHEMICAL", 555, 564], ["coronaviruses", "ORGANISM", 25, 38], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 213, 221], ["urine", "ORGANISM_SUBSTANCE", 240, 245], ["-CoV GVU6109", "ORGANISM", 289, 301], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 474, 482], ["urine", "ORGANISM_SUBSTANCE", 501, 506], ["-CoV HKU 39849", "ORGANISM", 550, 564], ["RSV", "ORGANISM", 666, 669], ["SARS-CoV", "SPECIES", 213, 221], ["SARS-CoV", "SPECIES", 474, 482], ["HuCoV 229E", "SPECIES", 596, 606], ["RSV", "SPECIES", 666, 669], ["Another study", "TEST", 0, 13], ["coronaviruses", "PROBLEM", 25, 38], ["infective", "PROBLEM", 46, 55], ["SARS", "PROBLEM", 213, 217], ["respiratory specimens", "TEST", 343, 364], ["diarrheal stool samples", "TEST", 420, 443], ["pH", "TEST", 447, 449], ["SARS", "PROBLEM", 474, 478], ["CoV HKU", "TEST", 551, 558], ["OC43", "PROBLEM", 610, 614], ["some other viral respiratory pathogens", "PROBLEM", 619, 657], ["RSV", "PROBLEM", 666, 669], ["coronaviruses", "OBSERVATION", 25, 38], ["infective", "OBSERVATION", 46, 55], ["SARS", "OBSERVATION", 213, 217], ["infectious", "OBSERVATION", 329, 339], ["SARS", "OBSERVATION", 474, 478], ["viral", "OBSERVATION_MODIFIER", 630, 635], ["respiratory pathogens", "OBSERVATION", 636, 657]]], ["It is stable for 3 wk at RT in a liquid environment and after being dried on plastic, and its viability can be retained from 5 d to 2 wk at 22-25 \u00b0C at a relative humidity (RH) of 40-50%[37], which is like air conditioned indoor environments.", [["stable", "OBSERVATION_MODIFIER", 6, 12]]], ["High RH of > 95% and at 28 \u00b0C or 33 \u00b0C did not significantly affect the infectivity of SARS-CoV HKU 39849.", [["SARS-CoV HKU 39849", "CHEMICAL", 87, 105], ["SARS-CoV HKU 39849", "SPECIES", 87, 105], ["High RH", "TEST", 0, 7], ["CoV HKU", "TEST", 92, 99]]], ["Increasing the temperature to 38 \u00b0C can suppress the virus.", [["the temperature", "TEST", 11, 26], ["the virus", "PROBLEM", 49, 58]]], ["The viral viability was rapidly lost (3 log10) at 38 \u00b0C and a RH of > 95%.Survival of SARS-CoV in liquid: water, urine, and sewage ::: RESULTS AND DISCUSSIONSAt 25 \u00b0C, the time required for a 99% reduction in reagent-grade water was 22 d for transmissible gastroenteritis virus (TGEV) and 17 d for mouse hepatitis virus (MHV).", [["urine", "ANATOMY", 113, 118], ["SARS", "DISEASE", 86, 90], ["transmissible gastroenteritis", "DISEASE", 242, 271], ["mouse hepatitis virus", "DISEASE", 298, 319], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 86, 94], ["urine", "ORGANISM_SUBSTANCE", 113, 118], ["TGEV", "ORGANISM", 279, 283], ["mouse hepatitis virus", "ORGANISM", 298, 319], ["MHV", "ORGANISM", 321, 324], ["transmissible gastroenteritis virus", "SPECIES", 242, 277], ["mouse", "SPECIES", 298, 303], ["hepatitis virus", "SPECIES", 304, 319], ["SARS-CoV", "SPECIES", 86, 94], ["transmissible gastroenteritis virus", "SPECIES", 242, 277], ["TGEV", "SPECIES", 279, 283], ["mouse hepatitis virus", "SPECIES", 298, 319], ["MHV", "SPECIES", 321, 324], ["The viral viability", "TEST", 0, 19], ["a RH", "TEST", 60, 64], ["SARS", "PROBLEM", 86, 90], ["a 99% reduction", "TREATMENT", 190, 205], ["reagent-grade water", "TREATMENT", 209, 228], ["transmissible gastroenteritis virus", "PROBLEM", 242, 277], ["mouse hepatitis virus", "PROBLEM", 298, 319], ["viral viability", "OBSERVATION", 4, 19], ["SARS", "OBSERVATION", 86, 90]]], ["In pasteurized settled sewage, a shorter time (9 d for TGEV and 7 d for MHV) was needed for a 99% reduction.These data suggest that contaminated water is a potential vehicle for human exposure[36].Survival of SARS-CoV in vegetables under household refrigeration conditions ::: RESULTS AND DISCUSSIONSBovine coronavirus is a pneumo-enteric virus that infects the respiratory tract and intestines of cattle and wild ruminants.", [["vegetables", "ANATOMY", 221, 231], ["respiratory tract", "ANATOMY", 362, 379], ["intestines", "ANATOMY", 384, 394], ["SARS", "DISEASE", 209, 213], ["human", "ORGANISM", 178, 183], ["SARS-CoV", "ORGANISM", 209, 217], ["vegetables", "ORGANISM_SUBDIVISION", 221, 231], ["DISCUSSIONSBovine coronavirus", "ORGANISM", 289, 318], ["respiratory tract", "ORGANISM_SUBDIVISION", 362, 379], ["intestines", "ORGAN", 384, 394], ["cattle", "ORGANISM", 398, 404], ["human", "SPECIES", 178, 183], ["cattle", "SPECIES", 398, 404], ["TGEV", "SPECIES", 55, 59], ["MHV", "SPECIES", 72, 75], ["human", "SPECIES", 178, 183], ["SARS-CoV", "SPECIES", 209, 217], ["cattle", "SPECIES", 398, 404], ["TGEV", "TREATMENT", 55, 59], ["MHV)", "TREATMENT", 72, 76], ["a 99% reduction", "TREATMENT", 92, 107], ["SARS", "PROBLEM", 209, 213], ["DISCUSSIONSBovine coronavirus", "PROBLEM", 289, 318], ["a pneumo-enteric virus", "PROBLEM", 322, 344], ["SARS", "OBSERVATION", 209, 213], ["respiratory tract", "ANATOMY", 362, 379], ["intestines", "ANATOMY", 384, 394]]], ["Infectivity of bovine coronaviruses strain 88 (BCoV-88) on the surface of romaine lettuce under household refrigeration conditions could sustainfor at least 14 d[38].Survival of SARS-CoV in vegetables under household refrigeration conditions ::: RESULTS AND DISCUSSIONSThe BCoV-88 infectivity in 10% bovine fecal suspension decreased faster than in a minimum essential medium of 2% FBS suspension, yet the reason is unclear.", [["surface", "ANATOMY", 63, 70], ["vegetables", "ANATOMY", 190, 200], ["fecal", "ANATOMY", 307, 312], ["FBS", "ANATOMY", 382, 385], ["BCoV-88", "CHEMICAL", 47, 54], ["SARS", "DISEASE", 178, 182], ["bovine coronaviruses strain 88", "ORGANISM", 15, 45], ["BCoV-88", "ORGANISM", 47, 54], ["surface", "CELLULAR_COMPONENT", 63, 70], ["romaine lettuce", "ORGANISM", 74, 89], ["SARS-CoV", "ORGANISM", 178, 186], ["vegetables", "ORGANISM_SUBDIVISION", 190, 200], ["BCoV-88", "CELL", 273, 280], ["bovine", "ORGANISM", 300, 306], ["fecal", "ORGANISM_SUBSTANCE", 307, 312], ["FBS", "ORGANISM_SUBSTANCE", 382, 385], ["bovine", "SPECIES", 15, 21], ["bovine", "SPECIES", 300, 306], ["bovine coronaviruses strain 88 (BCoV-88", "SPECIES", 15, 54], ["lettuce", "SPECIES", 82, 89], ["SARS-CoV", "SPECIES", 178, 186], ["bovine", "SPECIES", 300, 306], ["bovine coronaviruses strain", "TEST", 15, 42], ["BCoV", "TEST", 47, 51], ["SARS", "PROBLEM", 178, 182], ["BCoV", "TEST", 273, 277], ["infectivity", "TEST", 281, 292], ["bovine fecal suspension", "TEST", 300, 323], ["2% FBS suspension", "TREATMENT", 379, 396], ["bovine coronaviruses", "OBSERVATION", 15, 35], ["SARS", "OBSERVATION", 178, 182]]], ["In bovine, there are abundant proteolytic or lipolytic enzymes like proteases or lipases in bovine intestines and bovine fecal suspensions, the virion surface spike glycoproteins are sensitive to protease cleavage, and the envelope is sensitive to lipase.", [["intestines", "ANATOMY", 99, 109], ["fecal suspensions", "ANATOMY", 121, 138], ["surface", "ANATOMY", 151, 158], ["bovine", "ORGANISM", 3, 9], ["bovine", "ORGANISM", 92, 98], ["intestines", "ORGAN", 99, 109], ["bovine", "ORGANISM", 114, 120], ["fecal", "ORGANISM_SUBSTANCE", 121, 126], ["lipase", "GENE_OR_GENE_PRODUCT", 248, 254], ["lipolytic enzymes", "PROTEIN", 45, 62], ["proteases", "PROTEIN", 68, 77], ["lipases", "PROTEIN", 81, 88], ["virion surface spike glycoproteins", "PROTEIN", 144, 178], ["protease", "PROTEIN", 196, 204], ["lipase", "PROTEIN", 248, 254], ["bovine", "SPECIES", 3, 9], ["bovine", "SPECIES", 92, 98], ["bovine", "SPECIES", 114, 120], ["bovine", "SPECIES", 3, 9], ["bovine", "SPECIES", 92, 98], ["bovine", "SPECIES", 114, 120], ["abundant proteolytic or lipolytic enzymes", "PROBLEM", 21, 62], ["lipases in bovine intestines", "PROBLEM", 81, 109], ["bovine fecal suspensions", "TREATMENT", 114, 138], ["the virion surface spike glycoproteins", "PROBLEM", 140, 178], ["protease cleavage", "TREATMENT", 196, 213], ["lipase", "TEST", 248, 254], ["abundant", "OBSERVATION_MODIFIER", 21, 29], ["proteolytic", "OBSERVATION", 30, 41], ["intestines", "ANATOMY", 99, 109], ["bovine fecal suspensions", "OBSERVATION", 114, 138]]], ["Loss of a functional spike glycoprotein on the virion surface or loss of the virus envelope can confer BCoV-88 infectivity.Survival of SARS-CoV in vegetables under household refrigeration conditions ::: RESULTS AND DISCUSSIONSHuCoV strains 229E and OC43 cause one-third of common colds and hospital-acquired upper respiratory tract HuCoV infections, and survive in saline solution for 6 d[27].", [["virion surface", "ANATOMY", 47, 61], ["vegetables", "ANATOMY", 147, 157], ["SARS", "DISEASE", 135, 139], ["colds", "DISEASE", 280, 285], ["infections", "DISEASE", 338, 348], ["virion surface", "CELLULAR_COMPONENT", 47, 61], ["BCoV-88", "GENE_OR_GENE_PRODUCT", 103, 110], ["SARS-CoV", "ORGANISM", 135, 143], ["vegetables", "ORGANISM_SUBDIVISION", 147, 157], ["DISCUSSIONSHuCoV strains 229E", "CELL", 215, 244], ["upper", "ORGANISM_SUBDIVISION", 308, 313], ["respiratory tract", "ORGANISM_SUBDIVISION", 314, 331], ["functional spike glycoprotein", "PROTEIN", 10, 39], ["BCoV-88", "SPECIES", 103, 110], ["SARS-CoV", "SPECIES", 135, 143], ["a functional spike glycoprotein", "PROBLEM", 8, 39], ["the virion surface", "TREATMENT", 43, 61], ["loss of the virus envelope", "PROBLEM", 65, 91], ["BCoV", "TEST", 103, 107], ["SARS", "PROBLEM", 135, 139], ["common colds", "PROBLEM", 273, 285], ["acquired upper respiratory tract HuCoV infections", "PROBLEM", 299, 348], ["survive in saline solution", "TREATMENT", 354, 380], ["functional spike", "OBSERVATION", 10, 26], ["SARS", "OBSERVATION", 135, 139], ["upper", "ANATOMY_MODIFIER", 308, 313], ["respiratory tract", "ANATOMY", 314, 331]]], ["It is reported that there was an < 1 log10 infectivity decrease for both TGEV and MHV at 4 \u00b0C after 4 wk[36].", [["TGEV", "ORGANISM", 73, 77], ["TGEV", "SPECIES", 73, 77], ["MHV", "SPECIES", 82, 85], ["MHV", "TREATMENT", 82, 85]]], ["At 4 \u00b0C, the time required to achieve a 4 log10 reduction in infectivity titer in pasteurized settled sewage was 98 d for TGEV vs 139 d for MHV, and the predicted time for an 4 log10 infectivity reduction of both TGEV and MHV in reagent-grade water was approximately one year[36].Temperature and humidity impact the persistence time of viruses ::: RESULTS AND DISCUSSIONSPersistence of most bacteria, fungi, and viruses (e.g., SARS-CoV) on surfaces depends on environmental conditions[37], such as air temperature and RH[39], inoculums, and the materials that they stayed on.", [["TGEV", "ORGANISM", 122, 126], ["MHV", "ORGANISM", 140, 143], ["TGEV", "ORGANISM", 213, 217], ["MHV", "ORGANISM", 222, 225], ["TGEV", "SPECIES", 213, 217], ["TGEV", "SPECIES", 122, 126], ["MHV", "SPECIES", 140, 143], ["TGEV", "SPECIES", 213, 217], ["MHV", "SPECIES", 222, 225], ["SARS-CoV", "SPECIES", 427, 435], ["a 4 log10 reduction", "TREATMENT", 38, 57], ["infectivity titer", "TREATMENT", 61, 78], ["TGEV", "PROBLEM", 122, 126], ["MHV", "PROBLEM", 140, 143], ["an 4 log10 infectivity reduction", "TREATMENT", 172, 204], ["both TGEV", "TREATMENT", 208, 217], ["MHV in reagent-grade water", "TREATMENT", 222, 248], ["Temperature", "TEST", 280, 291], ["most bacteria", "PROBLEM", 386, 399], ["fungi", "PROBLEM", 401, 406], ["viruses", "PROBLEM", 412, 419], ["SARS", "PROBLEM", 427, 431], ["air temperature", "TEST", 498, 513], ["viruses", "OBSERVATION", 412, 419]]], ["Low temperature, high inoculums, and proper RH are associated with longer persistence time for most viruses.", [["Low temperature", "PROBLEM", 0, 15], ["high inoculums", "PROBLEM", 17, 31], ["proper RH", "PROBLEM", 37, 46], ["most viruses", "PROBLEM", 95, 107], ["high inoculums", "OBSERVATION_MODIFIER", 17, 31]]], ["The role of the environment on the survival of viruses in the air may be more complex and significant[40].", [["air", "ANATOMY", 62, 65], ["may be", "UNCERTAINTY", 66, 72], ["more complex", "OBSERVATION_MODIFIER", 73, 85]]], ["RH impacts the survival time of viruses, and the relationship between the inactivation of RH and temperature was not monotony.", [["viruses", "PROBLEM", 32, 39], ["viruses", "OBSERVATION", 32, 39]]], ["The temperature impacts the survival of the virus more significantly than that of RH.", [["the virus", "PROBLEM", 40, 49]]], ["In all water types tested (reagent-grade water, lake water and settled sewage), the titer of infectious virus declined more rapidly at 25 \u00b0C than at 4 \u00b0C[36].Temperature and humidity impact the persistence time of viruses ::: RESULTS AND DISCUSSIONSA high RH of > 95% and temperature of 28 \u00b0C or 33 \u00b0C did not significantly affect the infectivity of SARS-CoV HKU 39849.", [["SARS-CoV HKU 39849", "CHEMICAL", 350, 368], ["SARS-CoV HKU 39849", "SPECIES", 350, 368], ["infectious virus", "PROBLEM", 93, 109], ["Temperature", "TEST", 158, 169], ["temperature", "TEST", 272, 283], ["CoV HKU", "TEST", 355, 362], ["infectious", "OBSERVATION", 93, 103]]], ["Increasing the temperature to 38 \u00b0C disfavors the virus, with the virus rapidly losing viability (3 log10) at 38 \u00b0C and RH of > 95% (Table 1)[37].", [["the temperature", "TEST", 11, 26], ["the virus", "PROBLEM", 46, 55], ["the virus", "PROBLEM", 62, 71], ["RH", "TEST", 120, 122]]], ["A high temperature (e.g., 30 \u00b0C or 40 \u00b0C) reduced the persistence duration of highly pathogenic MERS-CoV, TGEV, and MHV.", [["MERS-CoV", "ORGANISM", 96, 104], ["TGEV", "ORGANISM", 106, 110], ["MHV", "ORGANISM", 116, 119], ["MERS-CoV", "SPECIES", 96, 104], ["TGEV", "SPECIES", 106, 110], ["MHV", "SPECIES", 116, 119], ["A high temperature", "PROBLEM", 0, 18], ["TGEV", "PROBLEM", 106, 110], ["high temperature", "OBSERVATION_MODIFIER", 2, 18], ["MHV", "ANATOMY", 116, 119]]], ["The persistence of SARS-CoV was longer with higher inocula.", [["SARS", "DISEASE", 19, 23], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 19, 27], ["SARS-CoV", "SPECIES", 19, 27], ["SARS-CoV", "PROBLEM", 19, 27], ["higher inocula", "PROBLEM", 44, 58], ["persistence", "OBSERVATION_MODIFIER", 4, 15], ["SARS", "OBSERVATION", 19, 23]]], ["HCoV-229E at RT persists longer at RH 50% than at RH 30%.Temperature and humidity impact the persistence time of viruses ::: RESULTS AND DISCUSSIONSThe survival of airborne HuCoV 229E was investigated under different conditions of temperature and RH.", [["HCoV-229E", "CHEMICAL", 0, 9], ["HuCoV 229E", "CHEMICAL", 173, 183], ["HuCoV 229E", "CHEMICAL", 173, 183], ["HCoV", "TEST", 0, 4], ["Temperature", "TEST", 57, 68], ["airborne HuCoV 229E", "TEST", 164, 183]]], ["At 20 \u00b0C, at 50% RH, aerosolized HuCoV-229E was found to survive best with a half-life of 67.33 \u00b1 8.24 h, with nearly 20% infectious virus detectable at 6 d; while at 30% RH the virus half-life was 26.76 \u00b1 6.21 h.", [["HuCoV-229E", "CHEMICAL", 33, 43], ["HuCoV-229E", "CHEMICAL", 33, 43], ["HuCoV-229E", "SIMPLE_CHEMICAL", 33, 43], ["HuCoV-229E", "SPECIES", 33, 43], ["aerosolized HuCoV", "TEST", 21, 38], ["nearly 20% infectious virus", "PROBLEM", 111, 138]]], ["At high 80% RH, the half-life was only about 3 h, and no virus in aerosols could be detected after 24 h.", [["virus in aerosols", "PROBLEM", 57, 74], ["no", "UNCERTAINTY", 54, 56], ["virus", "OBSERVATION", 57, 62]]], ["At 6 \u00b0C, in either 50% or 30% RH conditions, the survival of HuCoV-229E was significantly enhanced, with the decay pattern essentially similar to that seen at 20 \u00b1 1 \u00b0C. At 6 \u00b0C in 80% RH, however, the HuCoV-229E half-life increased to 86.01 \u00b1 5.28 h, nearly 30 times that found at 20 \u00b0C and 80% RH[40].Human coronaviruses on metal-containing copper surfaces areeffectively inactivated ::: RESULTS AND DISCUSSIONSTGEV and MHV were used as conservative surrogates for modeling exposure to determine the effects of AT and RH on the survival of coronaviruses on stainless steel[39].", [["HuCoV-229E", "CHEMICAL", 61, 71], ["metal", "CHEMICAL", 326, 331], ["copper", "CHEMICAL", 343, 349], ["HuCoV-229E", "CHEMICAL", 61, 71], ["copper", "CHEMICAL", 343, 349], ["stainless steel", "CHEMICAL", 559, 574], ["HuCoV-229E", "SIMPLE_CHEMICAL", 61, 71], ["Human", "ORGANISM", 303, 308], ["copper surfaces", "SIMPLE_CHEMICAL", 343, 358], ["MHV", "ORGANISM", 422, 425], ["coronaviruses", "ORGANISM", 542, 555], ["HuCoV", "PROTEIN", 202, 207], ["Human", "SPECIES", 303, 308], ["HuCoV-229E", "SPECIES", 61, 71], ["Human coronaviruses", "SPECIES", 303, 322], ["MHV", "SPECIES", 422, 425], ["HuCoV", "TEST", 61, 66], ["the HuCoV", "TEST", 198, 207], ["Human coronaviruses", "PROBLEM", 303, 322], ["MHV", "TREATMENT", 422, 425], ["conservative surrogates", "TREATMENT", 439, 462], ["modeling exposure", "PROBLEM", 467, 484], ["coronaviruses on stainless steel", "TREATMENT", 542, 574]]], ["At 4 \u00b0C, the infectious virus persisted for 28 d, and the lowest level of inactivation occurred at low RH (e.g., 20%).", [["the infectious virus", "PROBLEM", 9, 29], ["inactivation", "PROBLEM", 74, 86], ["infectious", "OBSERVATION", 13, 23]]], ["The results show that high numbers of TGEV and MHV may survive for days on surfaces at ATs and RHs typical of indoor environments.", [["TGEV", "ORGANISM", 38, 42], ["MHV", "ORGANISM", 47, 50], ["TGEV", "SPECIES", 38, 42], ["MHV", "SPECIES", 47, 50], ["high numbers of TGEV", "PROBLEM", 22, 42], ["high", "OBSERVATION_MODIFIER", 22, 26]]], ["Both viruses were inactivated more rapidly at 40 \u00b0C than at 20 \u00b0C.Human coronaviruses on metal-containing copper surfaces areeffectively inactivated ::: RESULTS AND DISCUSSIONSMetal containing copper may demonstrate antiviral activity.", [["metal", "CHEMICAL", 89, 94], ["copper", "CHEMICAL", 106, 112], ["copper", "CHEMICAL", 193, 199], ["copper", "CHEMICAL", 106, 112], ["copper", "CHEMICAL", 193, 199], ["Human", "ORGANISM", 66, 71], ["copper surfaces", "SIMPLE_CHEMICAL", 106, 121], ["copper", "SIMPLE_CHEMICAL", 193, 199], ["Human", "SPECIES", 66, 71], ["Human coronaviruses", "SPECIES", 66, 85], ["Human coronaviruses", "PROBLEM", 66, 85], ["viruses", "OBSERVATION", 5, 12], ["antiviral activity", "OBSERVATION", 216, 234]]], ["Two metal catalysts, Ag/Al2O3 and Cu/Al2O3, can inhibit the transmission of SARS and other respiratory infectious diseases[3].", [["Ag", "CHEMICAL", 21, 23], ["Al2O3", "CHEMICAL", 24, 29], ["Cu", "CHEMICAL", 34, 36], ["Al2O3", "CHEMICAL", 37, 42], ["SARS", "DISEASE", 76, 80], ["respiratory infectious diseases", "DISEASE", 91, 122], ["Ag", "CHEMICAL", 21, 23], ["Al2O3", "CHEMICAL", 24, 29], ["Cu", "CHEMICAL", 34, 36], ["Al2O3", "CHEMICAL", 37, 42], ["Ag/Al2O3", "SIMPLE_CHEMICAL", 21, 29], ["Cu/Al2O3", "SIMPLE_CHEMICAL", 34, 42], ["Two metal catalysts", "TREATMENT", 0, 19], ["Ag/Al2O3 and Cu/Al2O3", "TREATMENT", 21, 42], ["SARS", "PROBLEM", 76, 80], ["other respiratory infectious diseases", "PROBLEM", 85, 122], ["metal catalysts", "OBSERVATION", 4, 19], ["respiratory", "ANATOMY", 91, 102], ["infectious", "OBSERVATION", 103, 113]]], ["Two metal catalysts, Ag/Al2O3 and Cu/Al2O3, were pressed into wafers.", [["Ag", "CHEMICAL", 21, 23], ["Al2O3", "CHEMICAL", 24, 29], ["Cu", "CHEMICAL", 34, 36], ["Al2O3", "CHEMICAL", 37, 42], ["Ag", "CHEMICAL", 21, 23], ["Al2O3", "CHEMICAL", 24, 29], ["Cu", "CHEMICAL", 34, 36], ["Al2O3", "CHEMICAL", 37, 42], ["Ag/Al2O3", "SIMPLE_CHEMICAL", 21, 29], ["Cu/Al2O3", "SIMPLE_CHEMICAL", 34, 42], ["Ag", "PROTEIN", 21, 23], ["Two metal catalysts", "TREATMENT", 0, 19], ["Ag/Al2O3 and Cu/Al2O3", "TREATMENT", 21, 42], ["metal catalysts", "OBSERVATION", 4, 19]]], ["One hundred \u03bcL 106 TCID50/mL SARS-CoV, 100\u03bcL 106 PFU/mL recombinant baculovirus expressing hamster's prion protein, and roughly 106E. coli were slowly dropped onto the surfaces of the catalyst wafers and exposed for 5 min and 20 min, respectively.", [["SARS", "DISEASE", 29, 33], ["baculovirus", "ORGANISM", 68, 79], ["hamster", "ORGANISM", 91, 98], ["coli", "ORGANISM", 134, 138], ["recombinant baculovirus expressing hamster's prion protein", "PROTEIN", 56, 114], ["106E", "PROTEIN", 128, 132], ["hamster", "SPECIES", 91, 98], ["coli", "SPECIES", 134, 138], ["SARS-CoV", "SPECIES", 29, 37], ["baculovirus", "SPECIES", 68, 79], ["hamster", "SPECIES", 91, 98], ["coli", "SPECIES", 134, 138], ["SARS", "TEST", 29, 33], ["CoV", "TEST", 34, 37], ["PFU/mL recombinant baculovirus", "TREATMENT", 49, 79], ["prion protein", "TEST", 101, 114], ["coli", "PROBLEM", 134, 138], ["the catalyst wafers", "TREATMENT", 180, 199], ["slowly", "OBSERVATION_MODIFIER", 144, 150], ["dropped", "OBSERVATION_MODIFIER", 151, 158], ["surfaces", "OBSERVATION_MODIFIER", 168, 176]]], ["The infectivity of SARS-CoV in Vero cells and baculovirus in Sf9 cells dropped down to a very low and undetectable level, with no colony detected using a bacterial culture method.", [["Vero cells", "ANATOMY", 31, 41], ["Sf9 cells", "ANATOMY", 61, 70], ["colony", "ANATOMY", 130, 136], ["SARS", "DISEASE", 19, 23], ["SARS-CoV", "ORGANISM", 19, 27], ["Vero cells", "CELL", 31, 41], ["baculovirus", "ORGANISM", 46, 57], ["Sf9 cells", "CELL", 61, 70], ["Vero cells", "CELL_LINE", 31, 41], ["Sf9 cells", "CELL_LINE", 61, 70], ["SARS-CoV", "SPECIES", 19, 27], ["baculovirus", "SPECIES", 46, 57], ["Sf9", "SPECIES", 61, 64], ["SARS", "PROBLEM", 19, 23], ["CoV in Vero cells", "PROBLEM", 24, 41], ["baculovirus in Sf9 cells", "TEST", 46, 70], ["colony", "PROBLEM", 130, 136], ["a bacterial culture method", "TEST", 152, 178], ["infectivity", "OBSERVATION_MODIFIER", 4, 15], ["SARS", "OBSERVATION", 19, 23], ["Vero cells", "ANATOMY", 31, 41], ["no", "UNCERTAINTY", 127, 129], ["colony", "OBSERVATION", 130, 136]]], ["The expression of hamster's prion protein reduced to 21.8% in the preparation of Sf9 cells infected with recombinant baculovirus after exposing for 5 min, and was undetectable after exposing for 20 min.", [["Sf9 cells", "ANATOMY", 81, 90], ["hamster", "ORGANISM", 18, 25], ["Sf9 cells", "CELL", 81, 90], ["baculovirus", "ORGANISM", 117, 128], ["hamster's prion protein", "PROTEIN", 18, 41], ["Sf9 cells", "CELL_LINE", 81, 90], ["hamster", "SPECIES", 18, 25], ["hamster", "SPECIES", 18, 25], ["Sf9", "SPECIES", 81, 84], ["baculovirus", "SPECIES", 117, 128], ["hamster's prion protein", "TEST", 18, 41], ["Sf9 cells", "TREATMENT", 81, 90], ["recombinant baculovirus", "TREATMENT", 105, 128]]], ["Bacterial membranes seemed to be cracked and the cytoplasm seemed to be effluent from cell bodies.", [["Bacterial membranes", "ANATOMY", 0, 19], ["cytoplasm", "ANATOMY", 49, 58], ["cell bodies", "ANATOMY", 86, 97], ["Bacterial membranes", "CELLULAR_COMPONENT", 0, 19], ["cytoplasm", "ORGANISM_SUBSTANCE", 49, 58], ["cell bodies", "CELLULAR_COMPONENT", 86, 97], ["Bacterial membranes", "PROBLEM", 0, 19], ["the cytoplasm", "PROBLEM", 45, 58], ["membranes", "OBSERVATION", 10, 19], ["cracked", "OBSERVATION", 33, 40], ["seemed to be", "UNCERTAINTY", 59, 71], ["effluent", "OBSERVATION", 72, 80], ["cell bodies", "OBSERVATION", 86, 97]]], ["Exposures to the surfaces of Ag/Al2O3 and Cu/Al2O3 for 5-20 min can destroy the replication and propagation abilities of SARS-CoV, baculovirus, and E. coli.Human coronaviruses on metal-containing copper surfaces areeffectively inactivated ::: RESULTS AND DISCUSSIONSHuCoV-229E on copper and copper alloy surfaces was inactivated by released copper ion and reactive oxygen species, resulting in irreversible fragmentation of the viral genome, which was visibly confirmed by morphological changes under transmission electron microscopy.", [["Ag", "CHEMICAL", 29, 31], ["Al2O3", "CHEMICAL", 32, 37], ["Cu", "CHEMICAL", 42, 44], ["Al2O3", "CHEMICAL", 45, 50], ["SARS", "DISEASE", 121, 125], ["metal", "CHEMICAL", 179, 184], ["copper", "CHEMICAL", 196, 202], ["DISCUSSIONSHuCoV-229E", "CHEMICAL", 255, 276], ["copper", "CHEMICAL", 280, 286], ["copper", "CHEMICAL", 291, 297], ["copper", "CHEMICAL", 341, 347], ["oxygen", "CHEMICAL", 365, 371], ["Ag", "CHEMICAL", 29, 31], ["Al2O3", "CHEMICAL", 32, 37], ["Cu", "CHEMICAL", 42, 44], ["Al2O3", "CHEMICAL", 45, 50], ["copper", "CHEMICAL", 196, 202], ["copper", "CHEMICAL", 280, 286], ["copper", "CHEMICAL", 291, 297], ["copper", "CHEMICAL", 341, 347], ["oxygen", "CHEMICAL", 365, 371], ["Ag/Al2O3", "SIMPLE_CHEMICAL", 29, 37], ["Cu/Al2O3", "SIMPLE_CHEMICAL", 42, 50], ["SARS-CoV", "ORGANISM", 121, 129], ["baculovirus", "ORGANISM", 131, 142], ["E. coli", "ORGANISM", 148, 155], ["Human", "ORGANISM", 156, 161], ["copper surfaces", "SIMPLE_CHEMICAL", 196, 211], ["DISCUSSIONSHuCoV-229E", "CELL", 255, 276], ["copper", "SIMPLE_CHEMICAL", 280, 286], ["copper", "SIMPLE_CHEMICAL", 291, 297], ["copper ion", "SIMPLE_CHEMICAL", 341, 351], ["reactive oxygen species", "SIMPLE_CHEMICAL", 356, 379], ["Ag", "PROTEIN", 29, 31], ["viral genome", "DNA", 428, 440], ["E. coli", "SPECIES", 148, 155], ["Human", "SPECIES", 156, 161], ["SARS-CoV", "SPECIES", 121, 129], ["baculovirus", "SPECIES", 131, 142], ["E. coli", "SPECIES", 148, 155], ["Human coronaviruses", "SPECIES", 156, 175], ["Ag/Al2O3 and Cu/Al2O3", "TREATMENT", 29, 50], ["the replication", "PROBLEM", 76, 91], ["SARS", "PROBLEM", 121, 125], ["CoV", "PROBLEM", 126, 129], ["baculovirus", "PROBLEM", 131, 142], ["E. coli", "PROBLEM", 148, 155], ["Human coronaviruses", "PROBLEM", 156, 175], ["copper and copper alloy surfaces", "TREATMENT", 280, 312], ["reactive oxygen species", "PROBLEM", 356, 379], ["irreversible fragmentation of the viral genome", "PROBLEM", 394, 440], ["electron microscopy", "TEST", 514, 533], ["E. coli", "OBSERVATION", 148, 155], ["reactive", "OBSERVATION_MODIFIER", 356, 364], ["oxygen species", "OBSERVATION", 365, 379], ["irreversible", "OBSERVATION_MODIFIER", 394, 406], ["fragmentation", "OBSERVATION", 407, 420], ["viral genome", "OBSERVATION", 428, 440]]], ["The rate of inactivation was directly proportional to the percentage of copper.", [["copper", "CHEMICAL", 72, 78], ["copper", "CHEMICAL", 72, 78], ["copper", "SIMPLE_CHEMICAL", 72, 78]]], ["Coronavirus was inactivated in 40 min on brass and 120 min on copper nickels containing less than 70% copper.", [["Coronavirus", "CHEMICAL", 0, 11], ["copper", "CHEMICAL", 62, 68], ["copper", "CHEMICAL", 102, 108], ["copper nickels", "CHEMICAL", 62, 76], ["copper", "CHEMICAL", 102, 108], ["copper", "SIMPLE_CHEMICAL", 62, 68], ["nickels", "SIMPLE_CHEMICAL", 69, 76], ["copper", "SIMPLE_CHEMICAL", 102, 108], ["Coronavirus", "PROBLEM", 0, 11]]], ["Brass containing at least 70% (e.g.,90%, 95%, and 100%) copper effectively inactivated 103 PFU HuCoV-229E within 20 min.", [["copper", "CHEMICAL", 56, 62], ["HuCoV-229E", "CHEMICAL", 95, 105], ["copper", "CHEMICAL", 56, 62], ["HuCoV-229E", "CHEMICAL", 95, 105], ["copper", "SIMPLE_CHEMICAL", 56, 62], ["Brass", "TEST", 0, 5], ["e.g.", "TEST", 31, 35], ["PFU HuCoV", "TEST", 91, 100]]], ["HuCoV-229E on brass and copper nickel surfaces at RT (21 \u00b0C) can be inactivated; 103 PFU inoculum was applied as 1\u03bcL/cm2 copper and cartridge brass, respectively, and was dried immediately, and the viruses were inactivated within 5 min, which simulates fingertip touch contamination.", [["HuCoV-229E", "CHEMICAL", 0, 10], ["copper", "CHEMICAL", 24, 30], ["copper", "CHEMICAL", 121, 127], ["HuCoV-229E", "CHEMICAL", 0, 10], ["copper nickel", "CHEMICAL", 24, 37], ["copper", "CHEMICAL", 121, 127], ["HuCoV-229E", "SIMPLE_CHEMICAL", 0, 10], ["copper nickel", "SIMPLE_CHEMICAL", 24, 37], ["copper", "SIMPLE_CHEMICAL", 121, 127], ["HuCoV", "TEST", 0, 5], ["brass and copper nickel surfaces", "TREATMENT", 14, 46], ["PFU inoculum", "TREATMENT", 85, 97], ["copper and cartridge brass", "TREATMENT", 121, 147], ["the viruses", "PROBLEM", 194, 205], ["fingertip touch", "OBSERVATION", 253, 268]]], ["Approximately 103 PFU in simulated wet-droplet contamination was inactivated in less than 60 min.", [["droplet contamination", "PROBLEM", 39, 60], ["droplet contamination", "OBSERVATION", 39, 60]]], ["The SARS-CoV strain P9 in culture medium lost viral infectivity at an undetectable level after UV irradiation for 60 min[26].CONCLUSIONThe most common nosocomial coronaviruses may well survive or persist on inanimate surfaces for up to a month.", [["UV", "CHEMICAL", 95, 97], ["SARS-CoV", "ORGANISM", 4, 12], ["coronaviruses", "ORGANISM", 162, 175], ["SARS-CoV", "SPECIES", 4, 12], ["The SARS", "PROBLEM", 0, 8], ["CoV strain P9", "PROBLEM", 9, 22], ["culture medium", "TEST", 26, 40], ["viral infectivity", "PROBLEM", 46, 63], ["UV irradiation", "TREATMENT", 95, 109], ["The most common nosocomial coronaviruses", "PROBLEM", 135, 175]]], ["The risk of transmission via touching contaminated paper is low, while respiratory and fecal specimens can maintain infectivity for quite a long time at room temperature.", [["respiratory", "ANATOMY", 71, 82], ["fecal specimens", "ANATOMY", 87, 102], ["fecal specimens", "ORGANISM_SUBSTANCE", 87, 102], ["respiratory and fecal specimens", "PROBLEM", 71, 102]]], ["SARS-CoV-2 could exist in the air in poorly ventilated buses for at least 30 min.", [["SARS", "DISEASE", 0, 4], ["air", "OBSERVATION", 30, 33]]], ["Absorbent materials like cotton are safer than nonabsorptive materials for protection from viral infection.", [["viral infection", "DISEASE", 91, 106], ["cotton", "SPECIES", 25, 31], ["Absorbent materials", "TREATMENT", 0, 19], ["cotton", "PROBLEM", 25, 31], ["nonabsorptive materials", "TREATMENT", 47, 70], ["viral infection", "PROBLEM", 91, 106], ["viral", "OBSERVATION_MODIFIER", 91, 96], ["infection", "OBSERVATION", 97, 106]]], ["Proper preventive strategies such as washing hands and wearing masks are critical for containing COVID-19.", [["COVID-19", "CHEMICAL", 97, 105], ["Proper preventive strategies", "TREATMENT", 0, 28], ["washing hands", "TREATMENT", 37, 50], ["wearing masks", "TREATMENT", 55, 68], ["COVID", "TEST", 97, 102]]]], "07224bbf85be6014f41c08ef9d41394777284f60": [["IntroductionChagas disease is an anthropozoonosis from the Central and South American continent, caused by the protozoan flagellate Trypanosoma cruzi (T. cruzi) and considered a neglected parasitic illness which has spread from its original boundaries to historically non-endemic areas due to widespread migration 1,2 .", [["Chagas disease", "DISEASE", 12, 26], ["Trypanosoma cruzi", "DISEASE", 132, 149], ["T. cruzi", "DISEASE", 151, 159], ["parasitic illness", "DISEASE", 188, 205], ["protozoan", "ORGANISM", 111, 120], ["flagellate", "ORGANISM", 121, 131], ["Trypanosoma cruzi", "ORGANISM", 132, 149], ["T. cruzi", "ORGANISM", 151, 159], ["Trypanosoma cruzi", "SPECIES", 132, 149], ["T. cruzi", "SPECIES", 151, 159], ["Trypanosoma cruzi", "SPECIES", 132, 149], ["T. cruzi", "SPECIES", 151, 159], ["IntroductionChagas disease", "PROBLEM", 0, 26], ["the protozoan flagellate Trypanosoma cruzi (T. cruzi", "PROBLEM", 107, 159], ["a neglected parasitic illness", "PROBLEM", 176, 205], ["historically non-endemic areas", "PROBLEM", 255, 285], ["widespread migration", "PROBLEM", 293, 313], ["Chagas disease", "OBSERVATION", 12, 26], ["Central", "ANATOMY_MODIFIER", 59, 66], ["neglected", "OBSERVATION_MODIFIER", 178, 187], ["parasitic", "OBSERVATION_MODIFIER", 188, 197], ["illness", "OBSERVATION", 198, 205], ["widespread", "OBSERVATION_MODIFIER", 293, 303], ["migration", "OBSERVATION", 304, 313]]], ["Around 6-7 million subjects are infected with T. cruzi worldwide.", [["T. cruzi", "DISEASE", 46, 54], ["subjects", "ORGANISM", 19, 27], ["T. cruzi", "ORGANISM", 46, 54], ["T. cruzi", "SPECIES", 46, 54], ["T. cruzi", "SPECIES", 46, 54], ["infected", "OBSERVATION", 32, 40], ["cruzi worldwide", "OBSERVATION", 49, 64]]], ["According to the Bulletin of the World Health Organization the increased frequency of T. cruzi infected people in the United States, Europe and the Western Pacific Region is evidenced 2 .", [["T. cruzi infected", "DISEASE", 86, 103], ["T. cruzi", "ORGANISM", 86, 94], ["people", "ORGANISM", 104, 110], ["T. cruzi", "SPECIES", 86, 94], ["people", "SPECIES", 104, 110], ["T. cruzi", "SPECIES", 86, 94], ["increased", "OBSERVATION_MODIFIER", 63, 72]]], ["Chagas disease has become an important threat being considered an extremely debilitating illness, normally linked to poverty, affecting populations with low visibility and exerts a considerable impact on morbidity and mortality with more than 10 000 deaths annually in Latin America 3 Chagas disease has increased incidence in immunocompromised people and elderly population 4 .IntroductionIt is well established that immune cells share receptors for hormones and cytokines through the action of systemic and local regulatory mechanisms.", [["immune cells", "ANATOMY", 418, 430], ["Chagas disease", "DISEASE", 0, 14], ["poverty", "DISEASE", 117, 124], ["deaths", "DISEASE", 250, 256], ["Chagas disease", "DISEASE", 285, 299], ["people", "ORGANISM", 345, 351], ["immune cells", "CELL", 418, 430], ["immune cells", "CELL_TYPE", 418, 430], ["cytokines", "PROTEIN", 464, 473], ["people", "SPECIES", 345, 351], ["Chagas disease", "PROBLEM", 0, 14], ["an extremely debilitating illness", "PROBLEM", 63, 96], ["low visibility", "PROBLEM", 153, 167], ["Chagas disease", "PROBLEM", 285, 299], ["hormones", "TREATMENT", 451, 459], ["cytokines", "TREATMENT", 464, 473], ["systemic and local regulatory mechanisms", "TREATMENT", 496, 536], ["debilitating", "OBSERVATION_MODIFIER", 76, 88], ["illness", "OBSERVATION", 89, 96], ["low visibility", "OBSERVATION_MODIFIER", 153, 167], ["increased", "OBSERVATION_MODIFIER", 304, 313], ["incidence", "OBSERVATION_MODIFIER", 314, 323], ["immunocompromised", "OBSERVATION", 327, 344]]], ["When one of these systems is disturbed by pathogen invasion, the physiological profile of these interactions changes, triggering the release of proinflammatory cytokines and hormones.", [["proinflammatory cytokines", "PROTEIN", 144, 169], ["pathogen invasion", "PROBLEM", 42, 59], ["these interactions changes", "PROBLEM", 90, 116], ["pathogen", "OBSERVATION_MODIFIER", 42, 50], ["invasion", "OBSERVATION", 51, 59], ["proinflammatory cytokines", "OBSERVATION", 144, 169]]], ["The immuno-endocrine balance can deeply influence the experimental T. cruzi progression inside the host's body 5 .IntroductionSome available data also reveal that a deregulation of the hypothalamicpituitary-adrenal (HPA) axis during the acute T. cruzi infection induces an immunosuppression that is related to endocrine changes involving a circuit with regulatory properties in which cytokines and hormones produced by the HPA axis play essential role 6 .", [["body", "ANATOMY", 106, 110], ["endocrine", "ANATOMY", 310, 319], ["T. cruzi infection", "DISEASE", 243, 261], ["T. cruzi", "ORGANISM", 67, 75], ["body", "ORGANISM_SUBDIVISION", 106, 110], ["hypothalamicpituitary-", "GENE_OR_GENE_PRODUCT", 185, 207], ["adrenal", "ORGAN", 207, 214], ["HPA", "GENE_OR_GENE_PRODUCT", 216, 219], ["T. cruzi", "ORGANISM", 243, 251], ["endocrine", "ANATOMICAL_SYSTEM", 310, 319], ["cytokines", "PROTEIN", 384, 393], ["T. cruzi", "SPECIES", 67, 75], ["T. cruzi", "SPECIES", 243, 251], ["T. cruzi", "SPECIES", 67, 75], ["T. cruzi", "SPECIES", 243, 251], ["The immuno-endocrine balance", "TEST", 0, 28], ["the hypothalamicpituitary-adrenal (HPA) axis", "PROBLEM", 181, 225], ["the acute T. cruzi infection", "PROBLEM", 233, 261], ["an immunosuppression", "TREATMENT", 270, 290], ["endocrine changes", "PROBLEM", 310, 327], ["a circuit", "TREATMENT", 338, 347], ["cytokines and hormones", "TREATMENT", 384, 406], ["cruzi progression", "OBSERVATION", 70, 87], ["adrenal", "ANATOMY", 207, 214], ["acute", "OBSERVATION_MODIFIER", 237, 242], ["cruzi infection", "OBSERVATION", 246, 261], ["immunosuppression", "OBSERVATION", 273, 290]]], ["This immuno-endocrine cross-talk begins when HPA axis stimulation promotes the secretion of pituitary adrenocorticotropic hormone (ACTH) andIntroductionadrenocortical glucocorticoids (GCs), triggered by the release pro-inflammatory cytokines like IL-6 or IL-1\u03b2 into the circulation 7, 8 .", [["pituitary adrenocorticotropic hormone", "GENE_OR_GENE_PRODUCT", 92, 129], ["ACTH", "GENE_OR_GENE_PRODUCT", 131, 135], ["Introductionadrenocortical glucocorticoids", "SIMPLE_CHEMICAL", 140, 182], ["GCs", "SIMPLE_CHEMICAL", 184, 187], ["IL-6", "GENE_OR_GENE_PRODUCT", 247, 251], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 255, 260], ["pro-inflammatory cytokines", "PROTEIN", 215, 241], ["IL-6", "PROTEIN", 247, 251], ["IL-1\u03b2", "PROTEIN", 255, 260], ["HPA axis stimulation", "TREATMENT", 45, 65], ["pituitary adrenocorticotropic hormone", "TEST", 92, 129], ["Introductionadrenocortical glucocorticoids", "TREATMENT", 140, 182], ["the release pro-inflammatory cytokines", "TEST", 203, 241], ["IL", "TEST", 247, 249], ["IL", "TEST", 255, 257], ["circulation", "ANATOMY", 270, 281]]], ["Others data show that glucocorticoids J o u r n a l P r e -p r o o f drive changes in the mitochondrial biogenesis 9 interfering with the stress response.IntroductionAlthough active glucocorticoids in the circulation are primarily derived from the adrenal gland as part of the HPA axis, they can also be produced from their inactive substrate 11-dehydrocorticosterone (11-DHC) by the enzyme 11\u03b2-HSD1 10 as well in other sites such as thymus, brain and intestinal tract 11 .", [["mitochondrial", "ANATOMY", 90, 103], ["adrenal gland", "ANATOMY", 248, 261], ["sites", "ANATOMY", 420, 425], ["thymus", "ANATOMY", 434, 440], ["brain", "ANATOMY", 442, 447], ["intestinal tract", "ANATOMY", 452, 468], ["glucocorticoids", "CHEMICAL", 182, 197], ["11-dehydrocorticosterone", "CHEMICAL", 343, 367], ["11-DHC", "CHEMICAL", 369, 375], ["11-dehydrocorticosterone", "CHEMICAL", 343, 367], ["11-DHC", "CHEMICAL", 369, 375], ["mitochondrial", "CELLULAR_COMPONENT", 90, 103], ["glucocorticoids", "SIMPLE_CHEMICAL", 182, 197], ["adrenal gland", "ORGAN", 248, 261], ["11-dehydrocorticosterone", "SIMPLE_CHEMICAL", 343, 367], ["11-DHC", "SIMPLE_CHEMICAL", 369, 375], ["\u03b2-HSD1 10", "GENE_OR_GENE_PRODUCT", 393, 402], ["thymus", "ORGAN", 434, 440], ["brain", "ORGAN", 442, 447], ["intestinal tract", "ORGAN", 452, 468], ["\u03b2", "PROTEIN", 393, 394], ["HSD1 10", "PROTEIN", 395, 402], ["Others data", "TEST", 0, 11], ["glucocorticoids", "TEST", 22, 37], ["drive changes", "PROBLEM", 69, 82], ["the mitochondrial biogenesis", "TREATMENT", 86, 114], ["active glucocorticoids in the circulation", "PROBLEM", 175, 216], ["the enzyme", "TEST", 380, 390], ["thymus, brain and intestinal tract", "PROBLEM", 434, 468], ["mitochondrial biogenesis", "OBSERVATION", 90, 114], ["active", "OBSERVATION_MODIFIER", 175, 181], ["glucocorticoids", "OBSERVATION", 182, 197], ["circulation", "ANATOMY", 205, 216], ["adrenal gland", "ANATOMY", 248, 261], ["thymus", "ANATOMY", 434, 440], ["brain", "ANATOMY", 442, 447], ["intestinal tract", "ANATOMY", 452, 468]]], ["Additionally, elevated corticosterone levels contributes to the aging process and age-related diseases 12 .IntroductionMelatonin (N-acetyl-5-methoxytryptamine) is a pleiotropic 13 signaling substance with vital role in adjusting the circadian rhythmicity 14, 15 and mitochondrial homeostasis 16 .", [["mitochondrial", "ANATOMY", 266, 279], ["corticosterone", "CHEMICAL", 23, 37], ["Melatonin", "CHEMICAL", 119, 128], ["N-acetyl-5-methoxytryptamine", "CHEMICAL", 130, 158], ["corticosterone", "CHEMICAL", 23, 37], ["Melatonin", "CHEMICAL", 119, 128], ["N-acetyl-5-methoxytryptamine", "CHEMICAL", 130, 158], ["corticosterone", "SIMPLE_CHEMICAL", 23, 37], ["Melatonin", "SIMPLE_CHEMICAL", 119, 128], ["N-acetyl-5-methoxytryptamine", "SIMPLE_CHEMICAL", 130, 158], ["mitochondrial", "CELLULAR_COMPONENT", 266, 279], ["elevated corticosterone levels", "PROBLEM", 14, 44], ["the aging process", "PROBLEM", 60, 77], ["related diseases", "PROBLEM", 86, 102], ["IntroductionMelatonin (N-acetyl", "TREATMENT", 107, 138], ["methoxytryptamine", "TREATMENT", 141, 158], ["the circadian rhythmicity", "TEST", 229, 254], ["elevated", "OBSERVATION_MODIFIER", 14, 22], ["corticosterone levels", "OBSERVATION", 23, 44]]], ["The finding of melatonin synthesis in mitochondria 16 where it likely functions as an effective antioxidant 13, 16, 17 , anti-apoptotic 18 , anti-aging 19 , oncostatic 20 , immunomodulatory [21] [22] [23] , free radical scavenger 24 and progesterone) at tissue and systemic level by using a high-resolution multiple reaction monitoring (MRM HR ) -based mass spectrometry approach.", [["mitochondria", "ANATOMY", 38, 50], ["tissue", "ANATOMY", 254, 260], ["melatonin", "CHEMICAL", 15, 24], ["[21] [22] [23]", "CHEMICAL", 190, 204], ["progesterone", "CHEMICAL", 237, 249], ["melatonin", "CHEMICAL", 15, 24], ["progesterone", "CHEMICAL", 237, 249], ["melatonin", "SIMPLE_CHEMICAL", 15, 24], ["mitochondria", "CELLULAR_COMPONENT", 38, 50], ["oncostatic 20", "SIMPLE_CHEMICAL", 157, 170], ["immunomodulatory [21] [22] [23] , free radical scavenger 24", "SIMPLE_CHEMICAL", 173, 232], ["progesterone", "SIMPLE_CHEMICAL", 237, 249], ["tissue", "TISSUE", 254, 260], ["melatonin synthesis in mitochondria", "PROBLEM", 15, 50], ["an effective antioxidant", "TEST", 83, 107], ["anti-apoptotic", "TEST", 121, 135], ["free radical scavenger", "TREATMENT", 207, 229], ["progesterone", "TREATMENT", 237, 249], ["a high-resolution multiple reaction monitoring", "TREATMENT", 289, 335], ["based mass spectrometry approach", "PROBLEM", 347, 379], ["mass", "OBSERVATION", 353, 357]]], ["The cytokine repertoire, including IL-1\u03b1 and IL-1\u03b2, IL-6 and TGF-\u03b2 were also evaluated during the development of acute T. cruzi infection.ReagentsThe molecular standards cortisol, cortisone, corticosterone, progesterone, aldosterone, cortisone-d8, corticosterone-d4 and formic acid were purchased fromExperimental infection, treatment and euthanasiaMale Wistar rats were infected with the Y strain of T. cruzi (1 x 10 5 blood trypomastigotes/animal, intraperitoneally).", [["blood", "ANATOMY", 420, 425], ["intraperitoneally", "ANATOMY", 450, 467], ["T. cruzi infection", "DISEASE", 119, 137], ["cortisol", "CHEMICAL", 170, 178], ["cortisone", "CHEMICAL", 180, 189], ["corticosterone", "CHEMICAL", 191, 205], ["progesterone", "CHEMICAL", 207, 219], ["aldosterone", "CHEMICAL", 221, 232], ["cortisone-d8, corticosterone-d4 and formic acid", "CHEMICAL", 234, 281], ["fromExperimental infection", "DISEASE", 297, 323], ["T. cruzi", "DISEASE", 401, 409], ["cortisol", "CHEMICAL", 170, 178], ["cortisone", "CHEMICAL", 180, 189], ["corticosterone", "CHEMICAL", 191, 205], ["progesterone", "CHEMICAL", 207, 219], ["aldosterone", "CHEMICAL", 221, 232], ["cortisone-d8", "CHEMICAL", 234, 246], ["corticosterone-d4", "CHEMICAL", 248, 265], ["formic acid", "CHEMICAL", 270, 281], ["IL-1\u03b1", "GENE_OR_GENE_PRODUCT", 35, 40], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 45, 50], ["IL-6", "GENE_OR_GENE_PRODUCT", 52, 56], ["TGF-\u03b2", "GENE_OR_GENE_PRODUCT", 61, 66], ["T. cruzi", "ORGANISM", 119, 127], ["cortisol", "SIMPLE_CHEMICAL", 170, 178], ["cortisone", "SIMPLE_CHEMICAL", 180, 189], ["corticosterone", "SIMPLE_CHEMICAL", 191, 205], ["progesterone", "SIMPLE_CHEMICAL", 207, 219], ["aldosterone", "SIMPLE_CHEMICAL", 221, 232], ["cortisone-d8", "SIMPLE_CHEMICAL", 234, 246], ["corticosterone-d4", "SIMPLE_CHEMICAL", 248, 265], ["formic acid", "SIMPLE_CHEMICAL", 270, 281], ["euthanasiaMale", "ORGANISM", 339, 353], ["Wistar rats", "ORGANISM", 354, 365], ["Y strain", "ORGANISM", 389, 397], ["T. cruzi", "ORGANISM", 401, 409], ["blood", "ORGANISM_SUBSTANCE", 420, 425], ["cytokine repertoire", "PROTEIN", 4, 23], ["IL-6", "PROTEIN", 52, 56], ["TGF-\u03b2", "PROTEIN", 61, 66], ["T. cruzi", "SPECIES", 119, 127], ["rats", "SPECIES", 361, 365], ["T. cruzi", "SPECIES", 401, 409], ["T. cruzi", "SPECIES", 119, 127], ["T. cruzi", "SPECIES", 401, 409], ["The cytokine repertoire", "TEST", 0, 23], ["IL", "TEST", 35, 37], ["IL", "TEST", 45, 47], ["IL", "TEST", 52, 54], ["TGF", "TEST", 61, 64], ["acute T. cruzi infection", "PROBLEM", 113, 137], ["cortisol", "TEST", 170, 178], ["cortisone", "TREATMENT", 180, 189], ["corticosterone", "TREATMENT", 191, 205], ["progesterone", "TREATMENT", 207, 219], ["aldosterone", "TREATMENT", 221, 232], ["cortisone", "TREATMENT", 234, 243], ["corticosterone", "TREATMENT", 248, 262], ["formic acid", "TREATMENT", 270, 281], ["fromExperimental infection", "PROBLEM", 297, 323], ["treatment", "TREATMENT", 325, 334], ["euthanasiaMale Wistar rats", "TREATMENT", 339, 365], ["T. cruzi", "PROBLEM", 401, 409], ["blood trypomastigotes", "TEST", 420, 441], ["acute", "OBSERVATION_MODIFIER", 113, 118], ["cruzi infection", "OBSERVATION", 122, 137], ["infection", "OBSERVATION", 314, 323]]], ["Melatonin treatment (5 mg/kg/day; orally; cruzi infected melatonin treated (MMI).", [["Melatonin", "CHEMICAL", 0, 9], ["melatonin", "CHEMICAL", 57, 66], ["Melatonin", "CHEMICAL", 0, 9], ["melatonin", "CHEMICAL", 57, 66], ["Melatonin", "SIMPLE_CHEMICAL", 0, 9], ["melatonin", "SIMPLE_CHEMICAL", 57, 66], ["Melatonin treatment", "TREATMENT", 0, 19], ["cruzi infected melatonin", "TREATMENT", 42, 66]]], ["After a short time animals were humanely anaesthetized with tribromoethanol 2.5% by administration of 0.1mL/ 10 g of body weight and decapitated (at 9 th dpi) for blood, serum and tissue collection for the performance of experimental protocols.Tandem mass spectrometry (LC-MS/MS)Corticosterone and 11DHC from plasma and adrenal were quantified by mass Kyoto, Japan).", [["body", "ANATOMY", 117, 121], ["blood", "ANATOMY", 163, 168], ["serum", "ANATOMY", 170, 175], ["tissue", "ANATOMY", 180, 186], ["plasma", "ANATOMY", 309, 315], ["adrenal", "ANATOMY", 320, 327], ["tribromoethanol", "CHEMICAL", 60, 75], ["Corticosterone", "CHEMICAL", 279, 293], ["11DHC", "CHEMICAL", 298, 303], ["tribromoethanol", "CHEMICAL", 60, 75], ["Corticosterone", "CHEMICAL", 279, 293], ["tribromoethanol", "SIMPLE_CHEMICAL", 60, 75], ["body", "ORGANISM_SUBDIVISION", 117, 121], ["blood", "ORGANISM_SUBSTANCE", 163, 168], ["serum", "ORGANISM_SUBSTANCE", 170, 175], ["tissue", "TISSUE", 180, 186], ["Corticosterone", "SIMPLE_CHEMICAL", 279, 293], ["11DHC", "SIMPLE_CHEMICAL", 298, 303], ["plasma", "ORGANISM_SUBSTANCE", 309, 315], ["adrenal", "ORGAN", 320, 327], ["tribromoethanol", "TREATMENT", 60, 75], ["blood, serum and tissue collection", "TEST", 163, 197], ["experimental protocols", "TREATMENT", 221, 243], ["Tandem mass spectrometry", "TEST", 244, 268], ["LC", "TEST", 270, 272], ["MS", "TEST", 273, 275], ["MS", "TEST", 276, 278], ["Corticosterone", "TEST", 279, 293], ["tissue", "ANATOMY", 180, 186], ["adrenal", "ANATOMY", 320, 327], ["mass", "OBSERVATION", 347, 351]]], ["Data were processed using PeakView and MultiQuant software.Cytokine assays and melatonin levelsSerum samples were used for the detection IL-1\u03b2, IL-6, TGF-\u03b2 and melatonin levels using two-site sandwich ELISA with monoclonal antibody.", [["Serum samples", "ANATOMY", 95, 108], ["melatonin", "CHEMICAL", 79, 88], ["melatonin", "CHEMICAL", 160, 169], ["melatonin", "CHEMICAL", 79, 88], ["melatonin", "CHEMICAL", 160, 169], ["melatonin", "SIMPLE_CHEMICAL", 79, 88], ["Serum samples", "ORGANISM_SUBSTANCE", 95, 108], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 137, 142], ["IL-6", "GENE_OR_GENE_PRODUCT", 144, 148], ["TGF-\u03b2", "GENE_OR_GENE_PRODUCT", 150, 155], ["melatonin", "SIMPLE_CHEMICAL", 160, 169], ["Cytokine", "PROTEIN", 59, 67], ["monoclonal antibody", "PROTEIN", 212, 231], ["Cytokine assays", "TEST", 59, 74], ["melatonin levels", "TEST", 79, 95], ["Serum samples", "TEST", 95, 108], ["the detection IL", "TEST", 123, 139], ["IL", "TEST", 144, 146], ["TGF", "TEST", 150, 153], ["melatonin levels", "TEST", 160, 176], ["monoclonal antibody", "TEST", 212, 231], ["monoclonal antibody", "OBSERVATION", 212, 231]]], ["Standard curves were used for evaluating cytokine concentrations (pg/mL) read at 450nm and quantified by using an automated microplate ELISA reader (BIOTEK SYNERGY H1M).", [["cytokine", "PROTEIN", 41, 49], ["cytokine concentrations", "TREATMENT", 41, 64], ["an automated microplate ELISA", "TREATMENT", 111, 140]]], ["MILLIPLEX assay kit (Cat. # RECYTMAG-65K Millipore) and MAGPIX Multiplexing System (MilliporeSigma) was used for the detection of IL-1\u03b1.Statistical analysisGraph Pad Prism version 5.0 was used to analyze all data (GraphPad Software, Inc., San Diego, CA, USA; one-way ANOVA with Bonferroni's post test) based on variance difference significance among groups.", [["IL-1\u03b1", "GENE_OR_GENE_PRODUCT", 130, 135], ["IL-1\u03b1", "PROTEIN", 130, 135], ["RECYTMAG", "TEST", 28, 36], ["MAGPIX Multiplexing System (MilliporeSigma)", "TREATMENT", 56, 99], ["Statistical analysisGraph Pad Prism version", "TREATMENT", 136, 179], ["Bonferroni's post test", "TEST", 278, 300]]], ["Significance was assured for p < 0.05 (mean \u00b1 standard error of the mean (SEM).ResultsStudies in rats have demonstrated that during T. cruzi infection proinflammatory mediators such as IL-1\u03b1 and IL-6 trigger the stimulation of the HPA axis 6 The next step, the pro-inflammatory cytokines involved in the HPA regulation:ResultsIL-1\u03b1, IL-1\u03b2, IL-6 and TGF-\u03b2 were evaluated.", [["infection", "DISEASE", 141, 150], ["rats", "ORGANISM", 97, 101], ["T. cruzi", "ORGANISM", 132, 140], ["IL-1\u03b1", "GENE_OR_GENE_PRODUCT", 185, 190], ["IL-6", "GENE_OR_GENE_PRODUCT", 195, 199], ["ResultsIL-1\u03b1", "GENE_OR_GENE_PRODUCT", 319, 331], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 333, 338], ["IL-6", "GENE_OR_GENE_PRODUCT", 340, 344], ["TGF-\u03b2", "GENE_OR_GENE_PRODUCT", 349, 354], ["proinflammatory mediators", "PROTEIN", 151, 176], ["IL-1\u03b1 and IL-6", "PROTEIN", 185, 199], ["pro-inflammatory cytokines", "PROTEIN", 261, 287], ["IL-6", "PROTEIN", 340, 344], ["TGF-\u03b2", "PROTEIN", 349, 354], ["rats", "SPECIES", 97, 101], ["T. cruzi", "SPECIES", 132, 140], ["T. cruzi", "SPECIES", 132, 140], ["p", "TEST", 29, 30], ["T. cruzi infection proinflammatory mediators", "PROBLEM", 132, 176], ["IL", "TEST", 185, 187], ["IL", "TREATMENT", 195, 197], ["the pro-inflammatory cytokines", "TEST", 257, 287], ["the HPA regulation", "TEST", 300, 318], ["ResultsIL", "TEST", 319, 328], ["IL", "TEST", 333, 335], ["IL", "TEST", 340, 342], ["TGF", "TEST", 349, 352]]], ["A significant increase in IL-1\u03b1 ( Fig. 7A and B) concentrations was observed for infected middle-aged and young rats, when compared with the control ones.", [["IL-1\u03b1", "GENE_OR_GENE_PRODUCT", 26, 31], ["Fig. 7A", "GENE_OR_GENE_PRODUCT", 34, 41], ["B", "GENE_OR_GENE_PRODUCT", 46, 47], ["rats", "ORGANISM", 112, 116], ["IL-1\u03b1", "PROTEIN", 26, 31], ["rats", "SPECIES", 112, 116], ["A significant increase in IL", "TREATMENT", 0, 28], ["significant", "OBSERVATION_MODIFIER", 2, 13], ["increase", "OBSERVATION_MODIFIER", 14, 22]]], ["As expected, the immunosenescence process was linked to elevated levels of IL-1 \u03b2 ( Fig. 7C and D) and IL-6 ( Fig. 8A and B) as found for all middle-aged rats as compared to juvenile ones.", [["IL-1 \u03b2", "GENE_OR_GENE_PRODUCT", 75, 81], ["Fig. 7C", "GENE_OR_GENE_PRODUCT", 84, 91], ["D", "GENE_OR_GENE_PRODUCT", 96, 97], ["IL-6", "GENE_OR_GENE_PRODUCT", 103, 107], ["Fig. 8A", "GENE_OR_GENE_PRODUCT", 110, 117], ["B", "GENE_OR_GENE_PRODUCT", 122, 123], ["rats", "ORGANISM", 154, 158], ["IL-1 \u03b2", "PROTEIN", 75, 81], ["Fig. 7C and D", "PROTEIN", 84, 97], ["IL-6", "PROTEIN", 103, 107], ["rats", "SPECIES", 154, 158], ["the immunosenescence process", "PROBLEM", 13, 41], ["elevated levels", "PROBLEM", 56, 71], ["IL", "TEST", 75, 77], ["IL", "TEST", 103, 105]]], ["We further examine if melatonin's actions were related with alterations in the kinetics of cytokine output during the early T. cruzi infection.", [["melatonin", "CHEMICAL", 22, 31], ["T. cruzi infection", "DISEASE", 124, 142], ["melatonin", "CHEMICAL", 22, 31], ["melatonin", "SIMPLE_CHEMICAL", 22, 31], ["T. cruzi", "ORGANISM", 124, 132], ["cytokine", "PROTEIN", 91, 99], ["T. cruzi", "SPECIES", 124, 132], ["T. cruzi", "SPECIES", 124, 132], ["melatonin's actions", "PROBLEM", 22, 41], ["cytokine output", "PROBLEM", 91, 106], ["the early T. cruzi infection", "PROBLEM", 114, 142], ["cytokine output", "OBSERVATION", 91, 106], ["cruzi infection", "OBSERVATION", 127, 142]]], ["Our results demonstrated reduced IL-1\u03b1 and IL-1\u03b2 production, a key cytokine that has been entangled with chagasic cardiac hypertrophy, for middle-aged J o u r n a l P r e -p r o o f infected melatonin supplemented rats ( Fig. 7B and D) .", [["cardiac", "ANATOMY", 114, 121], ["chagasic cardiac hypertrophy", "DISEASE", 105, 133], ["melatonin", "CHEMICAL", 191, 200], ["melatonin", "CHEMICAL", 191, 200], ["IL-1\u03b1", "GENE_OR_GENE_PRODUCT", 33, 38], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 43, 48], ["cardiac", "ORGAN", 114, 121], ["melatonin", "SIMPLE_CHEMICAL", 191, 200], ["rats", "ORGANISM", 214, 218], ["IL", "PROTEIN", 33, 35], ["cytokine", "PROTEIN", 67, 75], ["rats", "SPECIES", 214, 218], ["reduced IL", "TREATMENT", 25, 35], ["chagasic cardiac hypertrophy", "PROBLEM", 105, 133], ["infected melatonin", "TREATMENT", 182, 200], ["reduced", "OBSERVATION_MODIFIER", 25, 32], ["cardiac", "ANATOMY", 114, 121], ["hypertrophy", "OBSERVATION", 122, 133]]], ["Melatonin treated middle-aged rats displayed lower levels of IL-6, excepting the young ones ( Fig. 8A and B) .", [["Melatonin", "CHEMICAL", 0, 9], ["Melatonin", "CHEMICAL", 0, 9], ["Melatonin", "SIMPLE_CHEMICAL", 0, 9], ["rats", "ORGANISM", 30, 34], ["IL-6", "GENE_OR_GENE_PRODUCT", 61, 65], ["B", "GENE_OR_GENE_PRODUCT", 106, 107], ["IL-6", "PROTEIN", 61, 65], ["rats", "SPECIES", 30, 34], ["Melatonin", "TREATMENT", 0, 9]]], ["Reduced concentrations of TGF-\u03b2 were triggered for young infected rats when compared to the untreated ones (Fig. 8D ).", [["TGF-\u03b2", "GENE_OR_GENE_PRODUCT", 26, 31], ["rats", "ORGANISM", 66, 70], ["TGF-\u03b2", "PROTEIN", 26, 31], ["rats", "SPECIES", 66, 70], ["Reduced concentrations of TGF", "PROBLEM", 0, 29], ["young infected rats", "PROBLEM", 51, 70], ["concentrations", "OBSERVATION_MODIFIER", 8, 22], ["TGF", "OBSERVATION", 26, 29]]], ["Melatonin treated middle-aged control groups displayed reduced concentrations of TGF-\u03b2 (Fig. 8C) .ResultsSince, an important decay in endogenous melatonin synthesis occurs with aging, systemic levels of this hormone were quantified in young and middle-aged groups.", [["Melatonin", "CHEMICAL", 0, 9], ["melatonin", "CHEMICAL", 145, 154], ["Melatonin", "CHEMICAL", 0, 9], ["melatonin", "CHEMICAL", 145, 154], ["Melatonin", "SIMPLE_CHEMICAL", 0, 9], ["TGF-\u03b2", "GENE_OR_GENE_PRODUCT", 81, 86], ["melatonin", "SIMPLE_CHEMICAL", 145, 154], ["TGF-\u03b2", "PROTEIN", 81, 86], ["Melatonin", "TREATMENT", 0, 9], ["reduced concentrations of TGF", "PROBLEM", 55, 84], ["endogenous melatonin synthesis", "TREATMENT", 134, 164], ["systemic levels", "TEST", 184, 199], ["this hormone", "TREATMENT", 203, 215], ["middle", "ANATOMY_MODIFIER", 245, 251]]], ["Serum melatonin levels were reduced with age and predominantly higher in young and middle-aged infected rats compared to control animals (Fig 9) .", [["Serum", "ANATOMY", 0, 5], ["melatonin", "CHEMICAL", 6, 15], ["melatonin", "CHEMICAL", 6, 15], ["Serum", "ORGANISM_SUBSTANCE", 0, 5], ["melatonin", "SIMPLE_CHEMICAL", 6, 15], ["rats", "ORGANISM", 104, 108], ["rats", "SPECIES", 104, 108], ["Serum melatonin levels", "TEST", 0, 22], ["predominantly", "OBSERVATION_MODIFIER", 49, 62], ["higher", "OBSERVATION_MODIFIER", 63, 69], ["middle", "OBSERVATION_MODIFIER", 83, 89]]], ["Melatonin levels were significantly higher in all middle-aged rats (control or infected)Resultssupplemented with melatonin, as compared to untreated ones.ResultsThe anti-apoptotic abilities of melatonin were evidenced in our study.", [["Melatonin", "CHEMICAL", 0, 9], ["melatonin", "CHEMICAL", 113, 122], ["melatonin", "CHEMICAL", 193, 202], ["Melatonin", "CHEMICAL", 0, 9], ["melatonin", "CHEMICAL", 113, 122], ["melatonin", "CHEMICAL", 193, 202], ["Melatonin", "SIMPLE_CHEMICAL", 0, 9], ["rats", "ORGANISM", 62, 66], ["melatonin", "SIMPLE_CHEMICAL", 113, 122], ["melatonin", "SIMPLE_CHEMICAL", 193, 202], ["rats", "SPECIES", 62, 66], ["Melatonin levels", "TEST", 0, 16], ["melatonin", "TREATMENT", 113, 122], ["melatonin", "TREATMENT", 193, 202], ["our study", "TEST", 221, 230], ["significantly", "OBSERVATION_MODIFIER", 22, 35], ["higher", "OBSERVATION_MODIFIER", 36, 42]]], ["Early and late thymocyte apoptosis from all middle-aged melatonin-treated animals were statistically reduced as compared to non-supplemented ones respectively (Fig 10A and B) .", [["thymocyte", "ANATOMY", 15, 24], ["melatonin", "CHEMICAL", 56, 65], ["melatonin", "CHEMICAL", 56, 65], ["thymocyte", "CELL", 15, 24], ["melatonin", "SIMPLE_CHEMICAL", 56, 65], ["animals", "ORGANISM", 74, 81], ["Early and late thymocyte apoptosis", "PROBLEM", 0, 34], ["all middle-aged melatonin", "TREATMENT", 40, 65], ["late thymocyte apoptosis", "OBSERVATION", 10, 34], ["middle", "ANATOMY_MODIFIER", 44, 50]]], ["However, as shown in Fig. 10 , the percentages of early (A) and late thymocyte apoptosis (B) did not significantly decline among all young melatonin-treated animals.ResultsSignificantly higher proportions of both early (A) and late apoptotic thymocytes (B) were displayed for all middle-aged animals, as compared to young counterparts ( Fig. 9) triggered by the ageing process.ResultsThe percentage of viable thymocytes in all young and middle-aged melatonin treated infected rats, was statistically enhanced when compared to untreated counterparts (Fig.10C ).", [["thymocyte", "ANATOMY", 69, 78], ["thymocytes", "ANATOMY", 242, 252], ["thymocytes", "ANATOMY", 409, 419], ["melatonin", "CHEMICAL", 139, 148], ["melatonin", "CHEMICAL", 449, 458], ["melatonin", "CHEMICAL", 139, 148], ["melatonin", "CHEMICAL", 449, 458], ["thymocyte", "CELL", 69, 78], ["melatonin", "SIMPLE_CHEMICAL", 139, 148], ["thymocytes", "CELL", 242, 252], ["B", "CELL", 254, 255], ["thymocytes", "CELL", 409, 419], ["melatonin", "SIMPLE_CHEMICAL", 449, 458], ["rats", "ORGANISM", 476, 480], ["apoptotic thymocytes", "CELL_TYPE", 232, 252], ["thymocytes", "CELL_TYPE", 409, 419], ["rats", "SPECIES", 476, 480], ["early (A) and late thymocyte apoptosis", "PROBLEM", 50, 88], ["late apoptotic thymocytes", "PROBLEM", 227, 252], ["viable thymocytes", "PROBLEM", 402, 419], ["melatonin", "TREATMENT", 449, 458], ["thymocyte apoptosis", "OBSERVATION", 69, 88], ["apoptotic thymocytes", "OBSERVATION", 232, 252], ["viable thymocytes", "OBSERVATION", 402, 419], ["middle", "ANATOMY_MODIFIER", 437, 443]]], ["Oppositely, a significant drop in the proportion of viable thymocytes in middle-aged control animals was observed as compared to young groups (Fig. 10 ).DiscussionA bulk of evidence has shown that altered steroidal hormone production might be related to a number of stress-induced disorders such as major depression, Currently is also known that a prolonged aldosterone treatment (between 4 and 5 weeks) triggers enhanced oxidative stress production and accounts for a proinflammatory phenotype.", [["thymocytes", "ANATOMY", 59, 69], ["major depression", "DISEASE", 299, 315], ["aldosterone", "CHEMICAL", 358, 369], ["aldosterone", "CHEMICAL", 358, 369], ["thymocytes", "CELL", 59, 69], ["aldosterone", "SIMPLE_CHEMICAL", 358, 369], ["thymocytes", "CELL_TYPE", 59, 69], ["a significant drop", "PROBLEM", 12, 30], ["viable thymocytes", "PROBLEM", 52, 69], ["altered steroidal hormone production", "PROBLEM", 197, 233], ["stress-induced disorders", "PROBLEM", 266, 290], ["major depression", "PROBLEM", 299, 315], ["a prolonged aldosterone treatment", "TREATMENT", 346, 379], ["enhanced oxidative stress production", "PROBLEM", 413, 449], ["a proinflammatory phenotype", "PROBLEM", 467, 494], ["significant", "OBSERVATION_MODIFIER", 14, 25], ["drop", "OBSERVATION_MODIFIER", 26, 30], ["proportion", "OBSERVATION_MODIFIER", 38, 48], ["viable", "OBSERVATION_MODIFIER", 52, 58], ["thymocytes", "OBSERVATION", 59, 69], ["middle", "OBSERVATION_MODIFIER", 73, 79], ["steroidal hormone", "OBSERVATION", 205, 222], ["oxidative stress production", "OBSERVATION", 422, 449], ["proinflammatory phenotype", "OBSERVATION", 469, 494]]], ["Although the exact role of melatonin on aldosterone production has remained controversial, we found that melatonin treatment decreased (2017) demonstrated that in lung tissue exposed to lipopolysaccharide, melatonin treatment downregulated the expression of TGF-\u03b21 81 .", [["lung tissue", "ANATOMY", 163, 174], ["melatonin", "CHEMICAL", 27, 36], ["aldosterone", "CHEMICAL", 40, 51], ["melatonin", "CHEMICAL", 105, 114], ["lipopolysaccharide", "CHEMICAL", 186, 204], ["melatonin", "CHEMICAL", 206, 215], ["melatonin", "CHEMICAL", 27, 36], ["aldosterone", "CHEMICAL", 40, 51], ["melatonin", "CHEMICAL", 105, 114], ["melatonin", "CHEMICAL", 206, 215], ["melatonin", "SIMPLE_CHEMICAL", 27, 36], ["aldosterone", "SIMPLE_CHEMICAL", 40, 51], ["melatonin", "SIMPLE_CHEMICAL", 105, 114], ["lung tissue", "TISSUE", 163, 174], ["lipopolysaccharide", "SIMPLE_CHEMICAL", 186, 204], ["melatonin", "SIMPLE_CHEMICAL", 206, 215], ["TGF-\u03b21 81", "GENE_OR_GENE_PRODUCT", 258, 267], ["TGF-\u03b21 81", "PROTEIN", 258, 267], ["melatonin on aldosterone production", "PROBLEM", 27, 62], ["melatonin treatment", "TREATMENT", 105, 124], ["lung tissue", "PROBLEM", 163, 174], ["lipopolysaccharide", "TREATMENT", 186, 204], ["melatonin treatment", "TREATMENT", 206, 225], ["TGF", "TEST", 258, 261], ["lung tissue", "ANATOMY", 163, 174]]], ["Our findings constitute the first report of reduced serum IL-1\u03b2 and IL-6 levels in middle-aged T. cruzi infected rats under melatonin therapy.", [["serum", "ANATOMY", 52, 57], ["T. cruzi infected", "DISEASE", 95, 112], ["melatonin", "CHEMICAL", 124, 133], ["melatonin", "CHEMICAL", 124, 133], ["serum", "ORGANISM_SUBSTANCE", 52, 57], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 58, 63], ["IL-6", "GENE_OR_GENE_PRODUCT", 68, 72], ["T. cruzi", "ORGANISM", 95, 103], ["rats", "ORGANISM", 113, 117], ["melatonin", "SIMPLE_CHEMICAL", 124, 133], ["serum IL-1\u03b2", "PROTEIN", 52, 63], ["T. cruzi", "SPECIES", 95, 103], ["rats", "SPECIES", 113, 117], ["T. cruzi", "SPECIES", 95, 103], ["reduced serum IL", "TEST", 44, 60], ["IL", "TEST", 68, 70], ["melatonin therapy", "TREATMENT", 124, 141], ["middle", "ANATOMY_MODIFIER", 83, 89]]], ["Melatonin also exerts a negative influence on TGF-\u03b2 production, with reduced levels for young infected and middle-aged control rats.DiscussionIn summary, for the first time our compelling data clearly showed the agerelated changes in adrenal and plasma steroidal hormones profiling as well cytokine production in Wistar rats confirming the efficiency of melatonin intervention in the regulation and signaling hormonal pathways and inflammatory mediators. and middle-aged melatonin infected (MMI).", [["adrenal", "ANATOMY", 234, 241], ["plasma", "ANATOMY", 246, 252], ["Melatonin", "CHEMICAL", 0, 9], ["melatonin", "CHEMICAL", 354, 363], ["melatonin", "CHEMICAL", 471, 480], ["Melatonin", "CHEMICAL", 0, 9], ["steroidal hormones", "CHEMICAL", 253, 271], ["melatonin", "CHEMICAL", 354, 363], ["melatonin", "CHEMICAL", 471, 480], ["Melatonin", "SIMPLE_CHEMICAL", 0, 9], ["TGF-\u03b2", "GENE_OR_GENE_PRODUCT", 46, 51], ["rats", "ORGANISM", 127, 131], ["adrenal", "ORGAN", 234, 241], ["plasma", "ORGANISM_SUBSTANCE", 246, 252], ["Wistar rats", "ORGANISM", 313, 324], ["melatonin", "SIMPLE_CHEMICAL", 354, 363], ["melatonin", "SIMPLE_CHEMICAL", 471, 480], ["TGF-\u03b2", "PROTEIN", 46, 51], ["cytokine", "PROTEIN", 290, 298], ["inflammatory mediators", "PROTEIN", 431, 453], ["rats", "SPECIES", 127, 131], ["rats", "SPECIES", 320, 324], ["Melatonin", "TREATMENT", 0, 9], ["TGF", "TEST", 46, 49], ["reduced levels", "PROBLEM", 69, 83], ["young infected", "PROBLEM", 88, 102], ["the agerelated changes in adrenal and plasma steroidal hormones profiling", "PROBLEM", 208, 281], ["melatonin intervention", "TREATMENT", 354, 376], ["inflammatory mediators", "PROBLEM", 431, 453], ["negative", "OBSERVATION", 24, 32], ["infected", "OBSERVATION", 94, 102], ["middle", "ANATOMY_MODIFIER", 107, 113], ["adrenal", "ANATOMY", 234, 241], ["inflammatory", "OBSERVATION_MODIFIER", 431, 443], ["middle", "ANATOMY_MODIFIER", 459, 465]]], ["Results are shown as the means \u00b1 SEM of n= 5 to 6 rats.", [["rats", "ORGANISM", 50, 54], ["rats", "SPECIES", 50, 54]]], ["One-way ANOVA followed by Bonferroni's multiple comparison test was used to compare groups (*P < 0.05).", [["Bonferroni's multiple comparison test", "TEST", 26, 63]]]], "PMC7229517": [["IntroductionMexico is not a place of religious monoculture.", [["IntroductionMexico", "TREATMENT", 0, 18]]], ["In Mexico, there is true religious pluralism.", [["religious pluralism", "OBSERVATION", 25, 44]]], ["Although a majority of Mexicans declares to profess the Catholic religion, the presence of other religions is extensive.", [["extensive", "OBSERVATION_MODIFIER", 110, 119]]]], "PMC7241386": [["IntroductionFirstly, identified in an outbreak in Wuhan city of China, the novel coronavirus disease 2019 (COVID-19) has caused a global pandemic in early 2020.", [["coronavirus disease", "DISEASE", 81, 100], ["COVID-19", "CHEMICAL", 107, 115], ["coronavirus", "ORGANISM", 81, 92], ["COVID-19", "ORGANISM", 107, 115], ["coronavirus", "SPECIES", 81, 92], ["coronavirus disease 2019 (COVID-19", "SPECIES", 81, 115], ["the novel coronavirus disease", "PROBLEM", 71, 100], ["COVID", "TEST", 107, 112], ["a global pandemic", "PROBLEM", 128, 145], ["coronavirus disease", "OBSERVATION", 81, 100], ["global", "OBSERVATION_MODIFIER", 130, 136], ["pandemic", "OBSERVATION", 137, 145]]], ["Alternatively named as the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus has been shown to induce various clinical manifestation in hosts ranging from asymptomatic conditions to severe symptoms including respiratory failure, shock, or multiorgan system dysfunction [1].", [["respiratory", "ANATOMY", 230, 241], ["multiorgan system", "ANATOMY", 261, 278], ["acute respiratory syndrome coronavirus", "DISEASE", 34, 72], ["respiratory failure", "DISEASE", 230, 249], ["shock", "DISEASE", 251, 256], ["multiorgan system dysfunction", "DISEASE", 261, 290], ["severe acute respiratory syndrome coronavirus 2", "ORGANISM", 27, 74], ["SARS-CoV-2", "ORGANISM", 76, 86], ["severe acute respiratory syndrome coronavirus", "SPECIES", 27, 72], ["SARS-CoV-2", "SPECIES", 76, 86], ["the severe acute respiratory syndrome coronavirus", "PROBLEM", 23, 72], ["SARS", "TEST", 76, 80], ["CoV", "TEST", 81, 84], ["the virus", "PROBLEM", 89, 98], ["asymptomatic conditions", "PROBLEM", 177, 200], ["severe symptoms", "PROBLEM", 204, 219], ["respiratory failure", "PROBLEM", 230, 249], ["shock", "PROBLEM", 251, 256], ["multiorgan system dysfunction", "PROBLEM", 261, 290], ["severe", "OBSERVATION_MODIFIER", 27, 33], ["acute", "OBSERVATION_MODIFIER", 34, 39], ["respiratory syndrome", "OBSERVATION", 40, 60], ["severe", "OBSERVATION_MODIFIER", 204, 210], ["respiratory failure", "OBSERVATION", 230, 249], ["shock", "OBSERVATION", 251, 256], ["multiorgan system dysfunction", "OBSERVATION", 261, 290]]], ["Identification of IgM and IgG antibodies in the affected persons implies the development of immunity against SARS-CoV-2 [2], [3], [4].", [["SARS", "DISEASE", 109, 113], ["IgM", "GENE_OR_GENE_PRODUCT", 18, 21], ["IgG antibodies", "GENE_OR_GENE_PRODUCT", 26, 40], ["persons", "ORGANISM", 57, 64], ["SARS-CoV-2", "ORGANISM", 109, 119], ["[3]", "SIMPLE_CHEMICAL", 125, 128], ["IgM", "PROTEIN", 18, 21], ["IgG antibodies", "PROTEIN", 26, 40], ["persons", "SPECIES", 57, 64], ["SARS-CoV", "SPECIES", 109, 117], ["IgM", "TEST", 18, 21], ["IgG antibodies in the affected persons", "PROBLEM", 26, 64], ["SARS", "TEST", 109, 113], ["CoV", "TEST", 114, 117], ["IgM", "OBSERVATION_MODIFIER", 18, 21]]], ["However, the virus might also induce dysregulation of immune responses in susceptible individuals as demonstrated by the decreased lymphocytes counts especially T cells, increased leukocytes counts and neutrophil-lymphocyte-ratio and other imbalances in the population of immune cells.", [["lymphocytes", "ANATOMY", 131, 142], ["T cells", "ANATOMY", 161, 168], ["leukocytes", "ANATOMY", 180, 190], ["neutrophil", "ANATOMY", 202, 212], ["lymphocyte", "ANATOMY", 213, 223], ["immune cells", "ANATOMY", 272, 284], ["lymphocytes", "CELL", 131, 142], ["T cells", "CELL", 161, 168], ["leukocytes", "CELL", 180, 190], ["neutrophil", "CELL", 202, 212], ["lymphocyte", "CELL", 213, 223], ["immune cells", "CELL", 272, 284], ["lymphocytes", "CELL_TYPE", 131, 142], ["T cells", "CELL_TYPE", 161, 168], ["leukocytes", "CELL_TYPE", 180, 190], ["neutrophil", "CELL_TYPE", 202, 212], ["immune cells", "CELL_TYPE", 272, 284], ["the virus", "PROBLEM", 9, 18], ["immune responses in susceptible individuals", "PROBLEM", 54, 97], ["the decreased lymphocytes counts", "PROBLEM", 117, 149], ["T cells", "PROBLEM", 161, 168], ["increased leukocytes counts", "PROBLEM", 170, 197], ["neutrophil", "TEST", 202, 212], ["lymphocyte", "TEST", 213, 223], ["other imbalances", "PROBLEM", 234, 250], ["immune cells", "PROBLEM", 272, 284], ["virus", "OBSERVATION", 13, 18], ["decreased", "OBSERVATION_MODIFIER", 121, 130], ["lymphocytes counts", "OBSERVATION", 131, 149], ["increased", "OBSERVATION_MODIFIER", 170, 179], ["leukocytes", "OBSERVATION_MODIFIER", 180, 190], ["counts", "OBSERVATION_MODIFIER", 191, 197], ["lymphocyte", "OBSERVATION", 213, 223], ["immune cells", "OBSERVATION", 272, 284]]], ["Moreover, severely affected patients have shown raised concentrations of infection-related markers and over-secretion of inflammatory cytokines.", [["infection", "DISEASE", 73, 82], ["patients", "ORGANISM", 28, 36], ["inflammatory cytokines", "PROTEIN", 121, 143], ["patients", "SPECIES", 28, 36], ["infection", "PROBLEM", 73, 82], ["related markers", "PROBLEM", 83, 98], ["inflammatory cytokines", "PROBLEM", 121, 143], ["severely", "OBSERVATION_MODIFIER", 10, 18], ["infection", "OBSERVATION", 73, 82], ["inflammatory cytokines", "OBSERVATION", 121, 143]]], ["Notably, this condition has been accompanied by a significant increase in the proportion of na\u00efve helper T cells while reduction in memory helper T cells and regulatory T cells [5].", [["na\u00efve helper T cells", "ANATOMY", 92, 112], ["memory helper T cells", "ANATOMY", 132, 153], ["regulatory T cells", "ANATOMY", 158, 176], ["helper T cells", "CELL", 98, 112], ["memory helper T cells", "CELL", 132, 153], ["regulatory T cells", "CELL", 158, 176], ["na\u00efve helper T cells", "CELL_TYPE", 92, 112], ["memory helper T cells", "CELL_TYPE", 132, 153], ["regulatory T cells", "CELL_TYPE", 158, 176], ["a significant increase", "PROBLEM", 48, 70], ["na\u00efve helper T cells", "PROBLEM", 92, 112], ["significant", "OBSERVATION_MODIFIER", 50, 61], ["increase", "OBSERVATION_MODIFIER", 62, 70]]], ["Based on the importance of immune responses in the determination of course of infection and the related complications, we performed a literature search to find the reported dysregulations in the levels of cytokines and immune cells in patients infected with SARS-CoV-19 and related viruses.SARS-CoV-2A recent study in Chinese patients affected with SARS-CoV-2 has shown elevated plasma concentrations of IL-1B, IL-1RA, IL-7, IL-8, IL-9, IL-10, basic FGF, GCSF, GMCSF, IFN-\u03b3, IFN-\u03b3-induced protein (IP)-10, monocyte chemotactic protein 1 (MCP1), MIP1A, MIP1B and TNF-\u03b1 in both patients needed ICU admission and non-ICU patients compared with healthy controls at initial assessment.", [["immune cells", "ANATOMY", 219, 231], ["plasma", "ANATOMY", 379, 385], ["infection", "DISEASE", 78, 87], ["SARS-CoV-19", "CHEMICAL", 258, 269], ["SARS", "DISEASE", 290, 294], ["SARS", "DISEASE", 349, 353], ["immune cells", "CELL", 219, 231], ["patients", "ORGANISM", 235, 243], ["SARS-CoV-19", "ORGANISM", 258, 269], ["SARS-CoV-2A", "ORGANISM", 290, 301], ["patients", "ORGANISM", 326, 334], ["SARS-CoV-2", "ORGANISM", 349, 359], ["plasma", "ORGANISM_SUBSTANCE", 379, 385], ["IL-1B", "GENE_OR_GENE_PRODUCT", 404, 409], ["IL-1RA", "GENE_OR_GENE_PRODUCT", 411, 417], ["IL-7", "GENE_OR_GENE_PRODUCT", 419, 423], ["IL-8", "GENE_OR_GENE_PRODUCT", 425, 429], ["IL-9", "GENE_OR_GENE_PRODUCT", 431, 435], ["IL-10", "GENE_OR_GENE_PRODUCT", 437, 442], ["basic", "GENE_OR_GENE_PRODUCT", 444, 449], ["FGF", "GENE_OR_GENE_PRODUCT", 450, 453], ["GCSF", "GENE_OR_GENE_PRODUCT", 455, 459], ["GMCSF", "GENE_OR_GENE_PRODUCT", 461, 466], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 468, 473], ["IFN-\u03b3-induced protein (IP)-10", "GENE_OR_GENE_PRODUCT", 475, 504], ["monocyte chemotactic protein 1", "GENE_OR_GENE_PRODUCT", 506, 536], ["MCP1", "GENE_OR_GENE_PRODUCT", 538, 542], ["MIP1A", "GENE_OR_GENE_PRODUCT", 545, 550], ["MIP1B", "GENE_OR_GENE_PRODUCT", 552, 557], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 562, 567], ["patients", "ORGANISM", 576, 584], ["patients", "ORGANISM", 618, 626], ["cytokines", "PROTEIN", 205, 214], ["immune cells", "CELL_TYPE", 219, 231], ["IL", "PROTEIN", 404, 406], ["IL-10", "PROTEIN", 437, 442], ["basic FGF", "PROTEIN", 444, 453], ["GCSF", "PROTEIN", 455, 459], ["GMCSF", "PROTEIN", 461, 466], ["IFN", "PROTEIN", 468, 471], ["IFN-\u03b3-induced protein (IP)-10", "PROTEIN", 475, 504], ["monocyte chemotactic protein 1", "PROTEIN", 506, 536], ["MCP1", "PROTEIN", 538, 542], ["MIP1A", "PROTEIN", 545, 550], ["MIP1B", "PROTEIN", 552, 557], ["TNF-\u03b1", "PROTEIN", 562, 567], ["patients", "SPECIES", 235, 243], ["patients", "SPECIES", 326, 334], ["patients", "SPECIES", 576, 584], ["patients", "SPECIES", 618, 626], ["SARS-CoV-19", "SPECIES", 258, 269], ["SARS-CoV", "SPECIES", 349, 357], ["infection", "PROBLEM", 78, 87], ["the related complications", "PROBLEM", 92, 117], ["the reported dysregulations", "PROBLEM", 160, 187], ["cytokines", "TREATMENT", 205, 214], ["immune cells", "PROBLEM", 219, 231], ["SARS", "PROBLEM", 258, 262], ["CoV", "TEST", 263, 266], ["related viruses", "PROBLEM", 274, 289], ["recent study", "TEST", 302, 314], ["SARS", "PROBLEM", 349, 353], ["CoV", "TEST", 354, 357], ["elevated plasma concentrations", "PROBLEM", 370, 400], ["IL", "TEST", 404, 406], ["IL", "TEST", 411, 413], ["IL", "TEST", 419, 421], ["IL", "TEST", 425, 427], ["IL", "TEST", 431, 433], ["IL", "TEST", 437, 439], ["basic FGF", "TEST", 444, 453], ["GCSF", "TEST", 455, 459], ["GMCSF", "TEST", 461, 466], ["IFN", "TEST", 468, 471], ["IFN", "TEST", 475, 478], ["IP", "TEST", 498, 500], ["monocyte chemotactic protein", "TEST", 506, 534], ["MCP1", "TEST", 538, 542], ["MIP1A", "TEST", 545, 550], ["MIP1B", "TEST", 552, 557], ["TNF", "TEST", 562, 565], ["initial assessment", "TEST", 661, 679], ["infection", "OBSERVATION", 78, 87], ["immune cells", "OBSERVATION", 219, 231], ["viruses", "OBSERVATION", 282, 289]]], ["Notably, author reported significant over-production of IL-2, IL-7, IL-10, GCSF, IP-10, MCP1, MIP1A, and TNF-\u03b1 in ICU patients compared with other group of SARS-CoV-2 infected persons [6].", [["SARS-CoV-2 infected", "DISEASE", 156, 175], ["IL-2", "GENE_OR_GENE_PRODUCT", 56, 60], ["IL-7", "GENE_OR_GENE_PRODUCT", 62, 66], ["IL-10", "GENE_OR_GENE_PRODUCT", 68, 73], ["GCSF", "GENE_OR_GENE_PRODUCT", 75, 79], ["IP-10", "GENE_OR_GENE_PRODUCT", 81, 86], ["MCP1", "GENE_OR_GENE_PRODUCT", 88, 92], ["MIP1A", "GENE_OR_GENE_PRODUCT", 94, 99], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 105, 110], ["patients", "ORGANISM", 118, 126], ["SARS-CoV-2", "ORGANISM", 156, 166], ["persons", "ORGANISM", 176, 183], ["IL", "PROTEIN", 56, 58], ["GCSF", "PROTEIN", 75, 79], ["MCP1", "PROTEIN", 88, 92], ["MIP1A", "PROTEIN", 94, 99], ["TNF-\u03b1", "PROTEIN", 105, 110], ["patients", "SPECIES", 118, 126], ["persons", "SPECIES", 176, 183], ["SARS-CoV", "SPECIES", 156, 164], ["IL", "TEST", 56, 58], ["IL", "TEST", 62, 64], ["IL", "TEST", 68, 70], ["GCSF", "TEST", 75, 79], ["IP", "TEST", 81, 83], ["MCP1", "TEST", 88, 92], ["MIP1A", "TEST", 94, 99], ["TNF", "TEST", 105, 108], ["SARS", "PROBLEM", 156, 160], ["significant", "OBSERVATION_MODIFIER", 25, 36]]], ["Another study has demonstrated associations between severity of SARS-CoV-2 infection and levels of IL-2R, IL-6, IL-8, IL-10 and TNF-\u03b1.", [["SARS", "DISEASE", 64, 68], ["infection", "DISEASE", 75, 84], ["CoV-2", "ORGANISM", 69, 74], ["IL-2R", "GENE_OR_GENE_PRODUCT", 99, 104], ["IL-6", "GENE_OR_GENE_PRODUCT", 106, 110], ["IL-8", "GENE_OR_GENE_PRODUCT", 112, 116], ["IL-10", "GENE_OR_GENE_PRODUCT", 118, 123], ["TNF-\u03b1.", "GENE_OR_GENE_PRODUCT", 128, 134], ["TNF", "PROTEIN", 128, 131], ["SARS-CoV", "SPECIES", 64, 72], ["Another study", "TEST", 0, 13], ["SARS", "PROBLEM", 64, 68], ["CoV", "TEST", 69, 72], ["2 infection", "PROBLEM", 73, 84], ["levels", "TEST", 89, 95], ["IL", "TEST", 99, 101], ["IL", "TEST", 106, 108], ["IL", "TEST", 112, 114], ["IL", "TEST", 118, 120], ["TNF", "TEST", 128, 131], ["SARS", "OBSERVATION", 64, 68], ["infection", "OBSERVATION", 75, 84]]], ["Moreover, disease severity was associated with both WBC and lymphocyte counts as well as quantities of neutrophils and eosinophils.", [["WBC", "ANATOMY", 52, 55], ["lymphocyte", "ANATOMY", 60, 70], ["neutrophils", "ANATOMY", 103, 114], ["eosinophils", "ANATOMY", 119, 130], ["WBC", "CELL", 52, 55], ["lymphocyte", "CELL", 60, 70], ["neutrophils", "CELL", 103, 114], ["eosinophils", "CELL", 119, 130], ["neutrophils", "CELL_TYPE", 103, 114], ["eosinophils", "CELL_TYPE", 119, 130], ["disease severity", "PROBLEM", 10, 26], ["both WBC", "TEST", 47, 55], ["lymphocyte counts", "TEST", 60, 77], ["neutrophils", "TEST", 103, 114], ["eosinophils", "TEST", 119, 130], ["disease", "OBSERVATION", 10, 17], ["lymphocyte counts", "OBSERVATION", 60, 77], ["neutrophils", "OBSERVATION", 103, 114], ["eosinophils", "OBSERVATION", 119, 130]]], ["Authors have suggested the IL-2R level >793.5U/mL, WBC>9.510^9/L among parameters that indicate progression of SARS-CoV-19 infection to critical conditions.", [["SARS", "DISEASE", 111, 115], ["infection", "DISEASE", 123, 132], ["IL-2R", "GENE_OR_GENE_PRODUCT", 27, 32], ["SARS-CoV-19", "ORGANISM", 111, 122], ["IL", "PROTEIN", 27, 29], ["SARS-CoV-19", "SPECIES", 111, 122], ["the IL", "TEST", 23, 29], ["WBC", "TEST", 51, 54], ["SARS", "PROBLEM", 111, 115], ["CoV", "PROBLEM", 116, 119], ["19 infection to critical conditions", "PROBLEM", 120, 155], ["progression", "OBSERVATION_MODIFIER", 96, 107], ["SARS", "OBSERVATION", 111, 115]]], ["Thus, inflammatory responses were shown to be correlated with the severity of SARS-CoV-19.", [["SARS", "DISEASE", 78, 82], ["SARS-CoV-19", "SPECIES", 78, 89], ["SARS", "TEST", 78, 82], ["CoV", "TEST", 83, 86], ["inflammatory", "OBSERVATION", 6, 18]]], ["Besides, IL-6, TNF-\u03b1 and IL-8 have been suggested as therapeutic targets [7].", [["IL-6", "GENE_OR_GENE_PRODUCT", 9, 13], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 15, 20], ["IL-8", "GENE_OR_GENE_PRODUCT", 25, 29], ["IL-6", "PROTEIN", 9, 13], ["TNF", "PROTEIN", 15, 18], ["IL-8", "PROTEIN", 25, 29], ["IL", "TEST", 9, 11], ["TNF", "TEST", 15, 18], ["IL", "TEST", 25, 27]]], ["A longitudinal study of cytokine levels and lymphocyte count in affected patients has revealed remarkable and continuous decreases in lymphocyte counts but elevations in neutrophil counts in severely infected cases compared with mild cases.", [["lymphocyte", "ANATOMY", 44, 54], ["lymphocyte", "ANATOMY", 134, 144], ["neutrophil", "ANATOMY", 170, 180], ["lymphocyte", "CELL", 44, 54], ["patients", "ORGANISM", 73, 81], ["lymphocyte", "CELL", 134, 144], ["neutrophil", "CELL", 170, 180], ["cytokine", "PROTEIN", 24, 32], ["patients", "SPECIES", 73, 81], ["A longitudinal study of cytokine levels", "TEST", 0, 39], ["lymphocyte count", "TEST", 44, 60], ["continuous decreases in lymphocyte counts", "PROBLEM", 110, 151], ["elevations", "PROBLEM", 156, 166], ["neutrophil counts", "TEST", 170, 187], ["severely infected cases", "PROBLEM", 191, 214], ["mild cases", "PROBLEM", 229, 239], ["remarkable", "OBSERVATION_MODIFIER", 95, 105], ["continuous", "OBSERVATION_MODIFIER", 110, 120], ["decreases", "OBSERVATION_MODIFIER", 121, 130], ["lymphocyte counts", "OBSERVATION", 134, 151], ["elevations", "OBSERVATION_MODIFIER", 156, 166], ["neutrophil counts", "OBSERVATION", 170, 187], ["severely", "OBSERVATION_MODIFIER", 191, 199], ["infected", "OBSERVATION", 200, 208], ["mild", "OBSERVATION_MODIFIER", 229, 233]]], ["Additionally, severely affected individuals had substantial reductions in T cells population, particularly CD8 + T cells, and upsurge in IL-6, IL-10, IL-2 and IFN-\u03b3 levels.", [["T cells", "ANATOMY", 74, 81], ["CD8 + T cells", "ANATOMY", 107, 120], ["individuals", "ORGANISM", 32, 43], ["T cells", "CELL", 74, 81], ["CD8", "GENE_OR_GENE_PRODUCT", 107, 110], ["IL-6", "GENE_OR_GENE_PRODUCT", 137, 141], ["IL-10", "GENE_OR_GENE_PRODUCT", 143, 148], ["IL-2", "GENE_OR_GENE_PRODUCT", 150, 154], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 159, 164], ["T cells population", "CELL_TYPE", 74, 92], ["CD8 + T cells", "CELL_TYPE", 107, 120], ["IFN", "PROTEIN", 159, 162], ["severely affected individuals", "PROBLEM", 14, 43], ["substantial reductions in T cells population", "PROBLEM", 48, 92], ["CD8 + T cells", "PROBLEM", 107, 120], ["IL", "TEST", 137, 139], ["IL", "TEST", 143, 145], ["IL", "TEST", 150, 152], ["IFN", "TEST", 159, 162], ["severely", "OBSERVATION_MODIFIER", 14, 22], ["affected", "OBSERVATION_MODIFIER", 23, 31], ["substantial", "OBSERVATION_MODIFIER", 48, 59], ["reductions", "OBSERVATION_MODIFIER", 60, 70]]], ["Notably, T cell counts and cytokine concentrations in severe SARS-CoV-2 infected patients who stayed alive gradually returned to their levels in the mild cases.", [["T cell", "ANATOMY", 9, 15], ["SARS-CoV-2 infected", "DISEASE", 61, 80], ["T cell", "CELL", 9, 15], ["SARS-CoV-2", "ORGANISM", 61, 71], ["patients", "ORGANISM", 81, 89], ["cytokine", "PROTEIN", 27, 35], ["CoV-2", "SPECIES", 66, 71], ["patients", "SPECIES", 81, 89], ["SARS-CoV", "SPECIES", 61, 69], ["T cell counts", "TEST", 9, 22], ["cytokine concentrations", "TEST", 27, 50], ["severe SARS", "PROBLEM", 54, 65], ["severe", "OBSERVATION_MODIFIER", 54, 60], ["mild", "OBSERVATION_MODIFIER", 149, 153]]], ["The most significant prognostic marker to show the course of infection has been the neutrophil-to-CD8+ T cell ratio [8].", [["neutrophil", "ANATOMY", 84, 94], ["CD8+ T cell", "ANATOMY", 98, 109], ["infection", "DISEASE", 61, 70], ["neutrophil", "CELL", 84, 94], ["CD8", "GENE_OR_GENE_PRODUCT", 98, 101], ["CD8", "PROTEIN", 98, 101], ["infection", "PROBLEM", 61, 70], ["the neutrophil", "TEST", 80, 94], ["infection", "OBSERVATION", 61, 70]]], ["IL-6 has also been among the up-regulated infection-related markers in the serum of patients with SARS-CoV-2 pneumonia [9].", [["serum", "ANATOMY", 75, 80], ["infection", "DISEASE", 42, 51], ["SARS-CoV-2 pneumonia", "DISEASE", 98, 118], ["IL-6", "GENE_OR_GENE_PRODUCT", 0, 4], ["serum", "ORGANISM_SUBSTANCE", 75, 80], ["patients", "ORGANISM", 84, 92], ["SARS-CoV-2", "ORGANISM", 98, 108], ["IL-6", "PROTEIN", 0, 4], ["patients", "SPECIES", 84, 92], ["CoV-2 pneumonia", "SPECIES", 103, 118], ["SARS", "PROBLEM", 98, 102], ["CoV-2 pneumonia", "PROBLEM", 103, 118], ["infection", "OBSERVATION", 42, 51], ["pneumonia", "OBSERVATION", 109, 118]]], ["Another study has demonstrated significant decrease in lymphocyte subsets both in severe and mild groups of patients with SARS-CoV-2 infection.", [["lymphocyte", "ANATOMY", 55, 65], ["SARS-CoV-2 infection", "DISEASE", 122, 142], ["lymphocyte", "CELL", 55, 65], ["patients", "ORGANISM", 108, 116], ["SARS-CoV-2", "ORGANISM", 122, 132], ["lymphocyte subsets", "CELL_TYPE", 55, 73], ["patients", "SPECIES", 108, 116], ["SARS-CoV-2", "SPECIES", 122, 132], ["Another study", "TEST", 0, 13], ["significant decrease in lymphocyte subsets", "PROBLEM", 31, 73], ["SARS", "PROBLEM", 122, 126], ["CoV-2 infection", "PROBLEM", 127, 142], ["significant", "OBSERVATION_MODIFIER", 31, 42], ["decrease", "OBSERVATION_MODIFIER", 43, 51], ["lymphocyte subsets", "OBSERVATION", 55, 73], ["both", "OBSERVATION_MODIFIER", 74, 78], ["severe", "OBSERVATION_MODIFIER", 82, 88], ["mild", "OBSERVATION_MODIFIER", 93, 97], ["groups", "OBSERVATION_MODIFIER", 98, 104], ["SARS", "OBSERVATION", 122, 126], ["CoV", "OBSERVATION_MODIFIER", 127, 130], ["infection", "OBSERVATION", 133, 142]]], ["Reduction in CD8 + T cells and increase in IL-6 levels were more prominent in the severely affected patients.", [["CD8 + T cells", "ANATOMY", 13, 26], ["CD8", "GENE_OR_GENE_PRODUCT", 13, 16], ["IL-6", "GENE_OR_GENE_PRODUCT", 43, 47], ["patients", "ORGANISM", 100, 108], ["CD8 + T cells", "CELL_TYPE", 13, 26], ["IL-6", "PROTEIN", 43, 47], ["patients", "SPECIES", 100, 108], ["Reduction", "TEST", 0, 9], ["CD8 + T cells", "PROBLEM", 13, 26], ["increase in IL-6 levels", "TEST", 31, 54], ["CD8 + T cells", "OBSERVATION", 13, 26], ["increase", "OBSERVATION_MODIFIER", 31, 39], ["IL", "OBSERVATION_MODIFIER", 43, 45], ["more prominent", "OBSERVATION_MODIFIER", 60, 74], ["severely", "OBSERVATION_MODIFIER", 82, 90], ["affected", "OBSERVATION_MODIFIER", 91, 99]]], ["Moreover, significant differences were detected between the severe and mild groups in CD4 + T, CD8 + T, IL-6 and IL-10 [7].SARS-CoVCellular immune responses to SARS-CoV infection have been previously assessed in an animal study.", [["CD4 + T", "ANATOMY", 86, 93], ["CD8 + T", "ANATOMY", 95, 102], ["SARS", "DISEASE", 123, 127], ["SARS-CoV infection", "DISEASE", 160, 178], ["CD4", "GENE_OR_GENE_PRODUCT", 86, 89], ["CD8 + T", "GENE_OR_GENE_PRODUCT", 95, 102], ["IL-6", "GENE_OR_GENE_PRODUCT", 104, 108], ["IL-10", "GENE_OR_GENE_PRODUCT", 113, 118], ["SARS-CoV", "ORGANISM", 160, 168], ["CD4", "PROTEIN", 86, 89], ["CD8", "PROTEIN", 95, 98], ["SARS-CoV", "SPECIES", 160, 168], ["the severe and mild groups", "PROBLEM", 56, 82], ["CD4", "TEST", 86, 89], ["CD8", "TEST", 95, 98], ["IL", "TEST", 104, 106], ["IL", "TEST", 113, 115], ["SARS", "PROBLEM", 123, 127], ["SARS", "PROBLEM", 160, 164], ["CoV infection", "PROBLEM", 165, 178], ["an animal study", "TEST", 212, 227], ["significant", "OBSERVATION_MODIFIER", 10, 21], ["severe", "OBSERVATION_MODIFIER", 60, 66], ["mild", "OBSERVATION_MODIFIER", 71, 75], ["infection", "OBSERVATION", 169, 178]]], ["Animals were exposed to the virus through an intranasal route.", [["Animals", "ORGANISM", 0, 7], ["the virus", "PROBLEM", 24, 33], ["an intranasal route", "TREATMENT", 42, 61]]], ["Such viral administration resulted in induction of pneumonia which was accompanied by over-production of TNF-\u03b1, IL-6, CXCL10, CCL2, CCL3, and CCL5.", [["pneumonia", "DISEASE", 51, 60], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 105, 110], ["IL-6", "GENE_OR_GENE_PRODUCT", 112, 116], ["CXCL10", "GENE_OR_GENE_PRODUCT", 118, 124], ["CCL2", "GENE_OR_GENE_PRODUCT", 126, 130], ["CCL3", "GENE_OR_GENE_PRODUCT", 132, 136], ["CCL5", "GENE_OR_GENE_PRODUCT", 142, 146], ["TNF", "PROTEIN", 105, 108], ["IL-6", "PROTEIN", 112, 116], ["CXCL10", "PROTEIN", 118, 124], ["CCL2", "PROTEIN", 126, 130], ["CCL3", "PROTEIN", 132, 136], ["CCL5", "PROTEIN", 142, 146], ["Such viral administration", "TREATMENT", 0, 25], ["pneumonia", "PROBLEM", 51, 60], ["TNF", "TEST", 105, 108], ["IL", "TEST", 112, 114], ["CXCL10", "TEST", 118, 124], ["CCL2", "TEST", 126, 130], ["CCL3", "TEST", 132, 136], ["CCL5", "PROBLEM", 142, 146], ["pneumonia", "OBSERVATION", 51, 60], ["CCL5", "ANATOMY", 142, 146]]], ["Notably, increased cytokine and chemokine levels were associated with relocation of NK cells, macrophages, and plasmacytoid dendritic cells (pDC) into the lungs.", [["NK cells", "ANATOMY", 84, 92], ["macrophages", "ANATOMY", 94, 105], ["plasmacytoid dendritic cells", "ANATOMY", 111, 139], ["pDC", "ANATOMY", 141, 144], ["lungs", "ANATOMY", 155, 160], ["NK cells", "CELL", 84, 92], ["macrophages", "CELL", 94, 105], ["plasmacytoid dendritic cells", "CELL", 111, 139], ["pDC", "CELL", 141, 144], ["lungs", "ORGAN", 155, 160], ["cytokine", "PROTEIN", 19, 27], ["chemokine", "PROTEIN", 32, 41], ["NK cells", "CELL_TYPE", 84, 92], ["macrophages", "CELL_TYPE", 94, 105], ["plasmacytoid dendritic cells", "CELL_TYPE", 111, 139], ["pDC", "CELL_TYPE", 141, 144], ["increased cytokine", "PROBLEM", 9, 27], ["chemokine levels", "TEST", 32, 48], ["NK cells", "PROBLEM", 84, 92], ["macrophages", "PROBLEM", 94, 105], ["plasmacytoid dendritic cells", "PROBLEM", 111, 139], ["increased", "OBSERVATION_MODIFIER", 9, 18], ["cytokine", "OBSERVATION_MODIFIER", 19, 27], ["NK cells", "OBSERVATION", 84, 92], ["plasmacytoid dendritic cells", "OBSERVATION", 111, 139], ["lungs", "ANATOMY", 155, 160]]], ["The viral clearance was accompanied by another round of cytokine and chemokine release and an inflow of T lymphocytes occurred.", [["T lymphocytes", "ANATOMY", 104, 117], ["T lymphocytes", "CELL", 104, 117], ["cytokine", "PROTEIN", 56, 64], ["chemokine", "PROTEIN", 69, 78], ["T lymphocytes", "CELL_TYPE", 104, 117], ["The viral clearance", "TEST", 0, 19], ["cytokine and chemokine release", "TREATMENT", 56, 86], ["an inflow of T lymphocytes", "PROBLEM", 91, 117], ["viral clearance", "OBSERVATION", 4, 19], ["inflow", "OBSERVATION", 94, 100], ["T lymphocytes", "OBSERVATION", 104, 117]]], ["Depletion studies showed the essential role of CD4+ but not CD8+ T cells in reduction of immune-mediated interstitial pneumonitis and enhancement of elimination of SARS-CoV from the lungs [10].", [["CD8+", "ANATOMY", 60, 64], ["T cells", "ANATOMY", 65, 72], ["interstitial", "ANATOMY", 105, 117], ["lungs", "ANATOMY", 182, 187], ["pneumonitis", "DISEASE", 118, 129], ["SARS", "DISEASE", 164, 168], ["CD4", "GENE_OR_GENE_PRODUCT", 47, 50], ["CD8", "GENE_OR_GENE_PRODUCT", 60, 63], ["T cells", "CELL", 65, 72], ["interstitial pneumonitis", "PATHOLOGICAL_FORMATION", 105, 129], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 164, 172], ["lungs", "ORGAN", 182, 187], ["CD4", "PROTEIN", 47, 50], ["CD8", "PROTEIN", 60, 63], ["T cells", "CELL_TYPE", 65, 72], ["SARS-CoV", "SPECIES", 164, 172], ["Depletion studies", "TEST", 0, 17], ["CD4", "TEST", 47, 50], ["T cells", "PROBLEM", 65, 72], ["immune-mediated interstitial pneumonitis", "PROBLEM", 89, 129], ["SARS", "PROBLEM", 164, 168], ["CD4", "OBSERVATION", 47, 50], ["not", "UNCERTAINTY", 56, 59], ["CD8", "OBSERVATION", 60, 63], ["reduction", "OBSERVATION_MODIFIER", 76, 85], ["interstitial", "ANATOMY_MODIFIER", 105, 117], ["pneumonitis", "OBSERVATION", 118, 129], ["enhancement", "OBSERVATION_MODIFIER", 134, 145], ["SARS", "OBSERVATION", 164, 168], ["lungs", "ANATOMY", 182, 187]]], ["An in vitro study has shown insignificant induction of IFN-\u03b2 expression in SARS-CoV infected macrophages, while up-regulation of CXCL10/IFN-\u03b3-inducible protein 10 and CCL2/monocyte chemotactic protein 1 [11].", [["macrophages", "ANATOMY", 93, 104], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 55, 60], ["SARS-CoV", "ORGANISM", 75, 83], ["macrophages", "CELL", 93, 104], ["CXCL10", "GENE_OR_GENE_PRODUCT", 129, 135], ["IFN-\u03b3-inducible protein 10", "GENE_OR_GENE_PRODUCT", 136, 162], ["CCL2", "GENE_OR_GENE_PRODUCT", 167, 171], ["monocyte chemotactic protein 1", "GENE_OR_GENE_PRODUCT", 172, 202], ["IFN", "PROTEIN", 55, 58], ["\u03b2", "PROTEIN", 59, 60], ["SARS-CoV infected macrophages", "CELL_TYPE", 75, 104], ["CXCL10", "PROTEIN", 129, 135], ["IFN", "PROTEIN", 136, 139], ["\u03b3-inducible protein 10", "PROTEIN", 140, 162], ["CCL2", "PROTEIN", 167, 171], ["monocyte chemotactic protein 1", "PROTEIN", 172, 202], ["SARS-CoV", "SPECIES", 75, 83], ["An in vitro study", "TEST", 0, 17], ["IFN", "TEST", 55, 58], ["SARS", "PROBLEM", 75, 79], ["CoV infected macrophages", "PROBLEM", 80, 104], ["CXCL10", "TEST", 129, 135], ["IFN", "TEST", 136, 139], ["inducible protein", "TEST", 142, 159], ["CCL2", "TEST", 167, 171], ["monocyte chemotactic protein", "TEST", 172, 200], ["insignificant", "OBSERVATION_MODIFIER", 28, 41], ["infected macrophages", "OBSERVATION", 84, 104]]], ["Wong et al. have assessed a number of cytokines and chemokines in patients affected with SARS.", [["SARS", "DISEASE", 89, 93], ["patients", "ORGANISM", 66, 74], ["cytokines", "PROTEIN", 38, 47], ["chemokines", "PROTEIN", 52, 62], ["patients", "SPECIES", 66, 74], ["cytokines and chemokines", "TREATMENT", 38, 62], ["SARS", "PROBLEM", 89, 93]]], ["They detected significant increase in Th1 cytokine IFN-\u03b3, inflammatory cytokines IL-1, IL-6 and IL-12, and some chemokines such as IL-8, MCP-1 and IP-10.", [["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 51, 56], ["IL-1", "GENE_OR_GENE_PRODUCT", 81, 85], ["IL-6", "GENE_OR_GENE_PRODUCT", 87, 91], ["IL-12", "GENE_OR_GENE_PRODUCT", 96, 101], ["IL-8", "GENE_OR_GENE_PRODUCT", 131, 135], ["MCP-1", "GENE_OR_GENE_PRODUCT", 137, 142], ["IP-10", "GENE_OR_GENE_PRODUCT", 147, 152], ["Th1 cytokine", "PROTEIN", 38, 50], ["IFN", "PROTEIN", 51, 54], ["inflammatory cytokines", "PROTEIN", 58, 80], ["IL-12", "PROTEIN", 96, 101], ["chemokines", "PROTEIN", 112, 122], ["IL-8", "PROTEIN", 131, 135], ["MCP", "PROTEIN", 137, 140], ["significant increase", "PROBLEM", 14, 34], ["Th1 cytokine IFN", "TEST", 38, 54], ["inflammatory cytokines IL", "TEST", 58, 83], ["IL", "TEST", 87, 89], ["IL", "TEST", 96, 98], ["IL", "TEST", 131, 133], ["MCP", "TEST", 137, 140], ["IP", "TEST", 147, 149], ["significant", "OBSERVATION_MODIFIER", 14, 25], ["increase", "OBSERVATION_MODIFIER", 26, 34], ["Th1 cytokine IFN", "OBSERVATION", 38, 54], ["inflammatory", "OBSERVATION_MODIFIER", 58, 70]]], ["Levels of chemokines were significantly decreased after corticosteroid therapy.", [["corticosteroid", "SIMPLE_CHEMICAL", 56, 70], ["chemokines", "PROTEIN", 10, 20], ["Levels of chemokines", "TEST", 0, 20], ["corticosteroid therapy", "TREATMENT", 56, 78], ["significantly", "OBSERVATION_MODIFIER", 26, 39], ["decreased", "OBSERVATION_MODIFIER", 40, 49], ["corticosteroid therapy", "OBSERVATION", 56, 78]]], ["They concluded induction of Th1 cell-mediated immune response in patients.", [["Th1 cell", "ANATOMY", 28, 36], ["Th1 cell", "CELL", 28, 36], ["patients", "ORGANISM", 65, 73], ["patients", "SPECIES", 65, 73]]], ["This observation was associated with induction of monocytes/macrophages and neutrophils [12].", [["monocytes", "ANATOMY", 50, 59], ["macrophages", "ANATOMY", 60, 71], ["neutrophils", "ANATOMY", 76, 87], ["monocytes", "CELL", 50, 59], ["macrophages", "CELL", 60, 71], ["neutrophils", "CELL", 76, 87], ["monocytes", "CELL_TYPE", 50, 59], ["macrophages", "CELL_TYPE", 60, 71], ["neutrophils", "CELL_TYPE", 76, 87], ["monocytes", "TEST", 50, 59], ["macrophages", "PROBLEM", 60, 71], ["neutrophils", "TEST", 76, 87]]], ["In another study in the pediatric setting, Ng et al. have demonstrated significant increase in circulating IL-1\u03b2 concentrations.", [["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 107, 112], ["IL-1\u03b2", "PROTEIN", 107, 112], ["another study", "TEST", 3, 16], ["Ng et al", "TREATMENT", 43, 51], ["circulating IL", "TREATMENT", 95, 109], ["significant", "OBSERVATION_MODIFIER", 71, 82], ["increase", "OBSERVATION_MODIFIER", 83, 91], ["circulating IL", "OBSERVATION", 95, 109]]], ["Yet, IL-6 and TNF-\u03b1 cytokines were slightly increased at the primary phase of the disease [13].", [["IL-6", "GENE_OR_GENE_PRODUCT", 5, 9], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 14, 19], ["IL-6", "PROTEIN", 5, 9], ["TNF-\u03b1 cytokines", "PROTEIN", 14, 29], ["IL", "TEST", 5, 7], ["TNF", "TEST", 14, 17], ["cytokines", "TEST", 20, 29], ["slightly", "OBSERVATION_MODIFIER", 35, 43], ["increased", "OBSERVATION_MODIFIER", 44, 53], ["primary phase", "OBSERVATION_MODIFIER", 61, 74]]], ["Zhang et al. did not detect any significant difference IL-1 and TNF-\u03b1 levels between normal controls, patients with SARS, severe SARS or those with SARS in convalescence.", [["SARS", "DISEASE", 116, 120], ["SARS", "DISEASE", 129, 133], ["SARS", "DISEASE", 148, 152], ["IL-1", "GENE_OR_GENE_PRODUCT", 55, 59], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 64, 69], ["patients", "ORGANISM", 102, 110], ["IL", "PROTEIN", 55, 57], ["TNF", "PROTEIN", 64, 67], ["patients", "SPECIES", 102, 110], ["IL", "TEST", 55, 57], ["TNF", "TEST", 64, 67], ["SARS", "PROBLEM", 116, 120], ["severe SARS", "PROBLEM", 122, 133], ["SARS", "PROBLEM", 148, 152]]], ["IL-6 levels were higher in SARS particularly those with severe SARS course.", [["SARS", "DISEASE", 27, 31], ["SARS", "DISEASE", 63, 67], ["IL-6", "GENE_OR_GENE_PRODUCT", 0, 4], ["IL-6", "PROTEIN", 0, 4], ["IL", "TEST", 0, 2], ["SARS", "PROBLEM", 27, 31], ["severe SARS course", "PROBLEM", 56, 74], ["severe", "OBSERVATION_MODIFIER", 56, 62], ["SARS", "OBSERVATION", 63, 67]]], ["Yet, IL-6 levels were not different between convalescent patients and healthy control, indicating the presence of a positive correlation between the serum IL-6 levels and severity of the disorder.", [["serum", "ANATOMY", 149, 154], ["IL-6", "GENE_OR_GENE_PRODUCT", 5, 9], ["patients", "ORGANISM", 57, 65], ["serum", "ORGANISM_SUBSTANCE", 149, 154], ["IL-6", "GENE_OR_GENE_PRODUCT", 155, 159], ["IL-6", "PROTEIN", 5, 9], ["serum IL-6", "PROTEIN", 149, 159], ["patients", "SPECIES", 57, 65], ["IL-6 levels", "TEST", 5, 16], ["the serum IL", "TEST", 145, 157], ["the disorder", "PROBLEM", 183, 195], ["disorder", "OBSERVATION", 187, 195]]], ["On the other hand, IL-8 and TGF-\u03b2 levels were negatively correlated with SARS severity.", [["SARS", "DISEASE", 73, 77], ["IL-8", "GENE_OR_GENE_PRODUCT", 19, 23], ["TGF-\u03b2", "GENE_OR_GENE_PRODUCT", 28, 33], ["IL-8", "PROTEIN", 19, 23], ["TGF-\u03b2", "PROTEIN", 28, 33], ["IL", "TEST", 19, 21], ["TGF-\u03b2 levels", "TEST", 28, 40], ["SARS severity", "PROBLEM", 73, 86]]], ["IFN-\u03b3 and IL-4 concentrations were reduced, whereas IL-10 concentrations were elevated in convalescent SARS patients.", [["SARS", "DISEASE", 103, 107], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 0, 5], ["IL-4", "GENE_OR_GENE_PRODUCT", 10, 14], ["IL-10", "GENE_OR_GENE_PRODUCT", 52, 57], ["patients", "ORGANISM", 108, 116], ["IFN", "PROTEIN", 0, 3], ["patients", "SPECIES", 108, 116], ["IFN", "TEST", 0, 3], ["IL", "TREATMENT", 10, 12], ["IL", "TEST", 52, 54]]], ["Taken together, various immunoregulatory conditions are present during and subsequent to SARS infection [14].Middle East respiratory syndrome coronavirus (MERS-CoV)Lau et al. have assessed transcript levels of TNF-\u03b1, IL-1\u03b2, IL-6, IL-8, IFN-\u03b2, MCP1, TGF-\u03b2 and IP-10 in cell lysates of polarized airway epithelial Calu-3 cells infected with MERS-CoV or SARS-CoV.", [["cell lysates", "ANATOMY", 268, 280], ["airway epithelial Calu-3 cells", "ANATOMY", 294, 324], ["SARS infection", "DISEASE", 89, 103], ["Middle East respiratory syndrome coronavirus", "DISEASE", 109, 153], ["Middle East respiratory syndrome coronavirus", "ORGANISM", 109, 153], ["MERS-CoV", "ORGANISM", 155, 163], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 210, 215], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 217, 222], ["IL-6", "GENE_OR_GENE_PRODUCT", 224, 228], ["IL-8", "GENE_OR_GENE_PRODUCT", 230, 234], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 236, 241], ["MCP1", "GENE_OR_GENE_PRODUCT", 243, 247], ["TGF-\u03b2", "GENE_OR_GENE_PRODUCT", 249, 254], ["IP-10", "GENE_OR_GENE_PRODUCT", 259, 264], ["cell lysates", "CELL", 268, 280], ["airway epithelial Calu-3 cells", "CELL", 294, 324], ["SARS-CoV", "ORGANISM", 351, 359], ["TNF", "PROTEIN", 210, 213], ["IL-8", "PROTEIN", 230, 234], ["IFN", "PROTEIN", 236, 239], ["MCP1", "PROTEIN", 243, 247], ["TGF-\u03b2", "PROTEIN", 249, 254], ["IP-10", "PROTEIN", 259, 264], ["polarized airway epithelial Calu-3 cells", "CELL_LINE", 284, 324], ["Middle East respiratory syndrome coronavirus", "SPECIES", 109, 153], ["MERS-CoV", "SPECIES", 155, 163], ["MERS-CoV", "SPECIES", 339, 347], ["SARS-CoV", "SPECIES", 351, 359], ["various immunoregulatory conditions", "PROBLEM", 16, 51], ["SARS infection", "PROBLEM", 89, 103], ["Middle East respiratory syndrome coronavirus", "PROBLEM", 109, 153], ["transcript levels", "TEST", 189, 206], ["TNF", "TEST", 210, 213], ["IL", "TEST", 217, 219], ["IL", "TEST", 224, 226], ["IL", "TEST", 230, 232], ["IFN", "TEST", 236, 239], ["MCP1", "TEST", 243, 247], ["TGF", "TEST", 249, 252], ["IP", "TEST", 259, 261], ["cell lysates", "TEST", 268, 280], ["polarized airway epithelial Calu", "TEST", 284, 316], ["MERS-CoV", "PROBLEM", 339, 347], ["SARS", "PROBLEM", 351, 355], ["CoV", "PROBLEM", 356, 359], ["immunoregulatory conditions", "OBSERVATION", 24, 51], ["respiratory syndrome", "OBSERVATION", 121, 141], ["MCP1", "ANATOMY", 243, 247], ["airway epithelial", "ANATOMY", 294, 311]]], ["MERS-CoV induced higher levels of IL-1\u03b2, IL-6 and IL-8, while lower levels of TNF-\u03b1, IFN-\u03b2 and IP-10 compared with SARS-CoV.", [["MERS-CoV", "GENE_OR_GENE_PRODUCT", 0, 8], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 34, 39], ["IL-6", "GENE_OR_GENE_PRODUCT", 41, 45], ["IL-8", "GENE_OR_GENE_PRODUCT", 50, 54], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 78, 83], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 85, 90], ["IP-10", "GENE_OR_GENE_PRODUCT", 95, 100], ["SARS-CoV", "ORGANISM", 115, 123], ["IL-8", "PROTEIN", 50, 54], ["TNF", "PROTEIN", 78, 81], ["IFN", "PROTEIN", 85, 88], ["MERS-CoV", "SPECIES", 0, 8], ["SARS-CoV", "SPECIES", 115, 123], ["IL", "TEST", 34, 36], ["IL", "TEST", 41, 43], ["IL", "TEST", 50, 52], ["TNF", "TEST", 78, 81], ["IFN", "TEST", 85, 88], ["IP", "TEST", 95, 97]]], ["Their experiments confirmed the diminished induction of innate immunity and postponed proinflammatory cytokine production by MERS-CoV [15].", [["MERS-CoV", "GENE_OR_GENE_PRODUCT", 125, 133], ["proinflammatory cytokine", "PROTEIN", 86, 110], ["MERS-CoV", "SPECIES", 125, 133], ["innate immunity", "TREATMENT", 56, 71], ["proinflammatory cytokine production", "TREATMENT", 86, 121], ["diminished", "OBSERVATION_MODIFIER", 32, 42]]], ["Kim et al. have reported higher neutrophil counts in severe MERS-CoV compared with mild cases.", [["neutrophil", "ANATOMY", 32, 42], ["MERS-CoV", "DISEASE", 60, 68], ["neutrophil", "CELL", 32, 42], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 60, 68], ["MERS-CoV", "SPECIES", 60, 68], ["higher neutrophil counts", "PROBLEM", 25, 49], ["severe MERS", "PROBLEM", 53, 64], ["mild cases", "PROBLEM", 83, 93], ["higher", "OBSERVATION_MODIFIER", 25, 31], ["neutrophil counts", "OBSERVATION", 32, 49], ["severe", "OBSERVATION_MODIFIER", 53, 59], ["MERS", "OBSERVATION", 60, 64]]], ["Moreover, IL-6 and CXCL-10 levels were higher in severe cases compared with mild cases.", [["IL-6", "GENE_OR_GENE_PRODUCT", 10, 14], ["CXCL-10", "GENE_OR_GENE_PRODUCT", 19, 26], ["IL", "PROTEIN", 10, 12], ["CXCL", "PROTEIN", 19, 23], ["Moreover", "TEST", 0, 8], ["IL", "TEST", 10, 12], ["CXCL", "TEST", 19, 23], ["mild cases", "PROBLEM", 76, 86], ["severe", "OBSERVATION_MODIFIER", 49, 55], ["mild", "OBSERVATION_MODIFIER", 76, 80]]], ["Besides, they could not detect IFN-\u03b1 response in mild cases [16].", [["IFN-\u03b1", "GENE_OR_GENE_PRODUCT", 31, 36], ["IFN", "PROTEIN", 31, 34], ["IFN", "TEST", 31, 34], ["mild cases", "PROBLEM", 49, 59], ["mild", "OBSERVATION_MODIFIER", 49, 53]]], ["Zhou et al. have shown ability of MERS-CoV but not SARS-CoV in replication in monocyte-derived macrophages.", [["monocyte", "ANATOMY", 78, 86], ["macrophages", "ANATOMY", 95, 106], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 34, 42], ["SARS-CoV", "ORGANISM", 51, 59], ["monocyte", "CELL", 78, 86], ["macrophages", "CELL", 95, 106], ["monocyte", "CELL_TYPE", 78, 86], ["macrophages", "CELL_TYPE", 95, 106], ["MERS-CoV", "SPECIES", 34, 42], ["SARS-CoV", "SPECIES", 51, 59], ["CoV", "PROBLEM", 39, 42], ["SARS", "PROBLEM", 51, 55], ["CoV", "PROBLEM", 56, 59], ["monocyte", "ANATOMY", 78, 86], ["macrophages", "ANATOMY", 95, 106]]], ["MERS-CoV induced remarkably elevated concentrations of IL-12, IFN-\u03b3, and chemokines compared with SARS-CoV [17].", [["MERS-CoV", "GENE_OR_GENE_PRODUCT", 0, 8], ["IL-12", "GENE_OR_GENE_PRODUCT", 55, 60], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 62, 67], ["SARS-CoV", "ORGANISM", 98, 106], ["IL-12", "PROTEIN", 55, 60], ["IFN", "PROTEIN", 62, 65], ["\u03b3", "PROTEIN", 66, 67], ["chemokines", "PROTEIN", 73, 83], ["MERS-CoV", "SPECIES", 0, 8], ["SARS-CoV", "SPECIES", 98, 106], ["elevated concentrations", "PROBLEM", 28, 51], ["IL", "TEST", 55, 57], ["IFN", "TEST", 62, 65]]], ["Mahallawi et al. have demonstrated a noticeable pro-inflammatory Th1 and Th17 response in patients affected with MERS-CoV.", [["Th17", "CELL", 73, 77], ["patients", "ORGANISM", 90, 98], ["MERS-CoV", "ORGANISM", 113, 121], ["patients", "SPECIES", 90, 98], ["MERS-CoV", "SPECIES", 113, 121], ["a noticeable pro-inflammatory Th1", "PROBLEM", 35, 68], ["noticeable", "OBSERVATION_MODIFIER", 37, 47], ["pro-inflammatory Th1", "OBSERVATION", 48, 68]]], ["These patients had elevated levels of IFN-\u03b3, TNF-\u03b1, IL-15 and IL-17 compared to controls.", [["patients", "ORGANISM", 6, 14], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 38, 43], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 45, 50], ["IL-15", "GENE_OR_GENE_PRODUCT", 52, 57], ["IL-17", "GENE_OR_GENE_PRODUCT", 62, 67], ["IFN", "PROTEIN", 38, 41], ["TNF", "PROTEIN", 45, 48], ["IL-17", "PROTEIN", 62, 67], ["patients", "SPECIES", 6, 14], ["elevated levels", "PROBLEM", 19, 34], ["IFN", "TEST", 38, 41], ["TNF", "TEST", 45, 48], ["IL", "TEST", 52, 54], ["IL", "TEST", 62, 64], ["elevated", "OBSERVATION", 19, 27]]], ["Totally, cytokines profiles indicated an obvious pro-inflammatory immune reactions in the acute course of MERS-CoV infection [18].InfluenzaPirhonen et al. have demonstrated induction of trivial amounts of IL-1\u03b2 or IL-18 in influenza virus-infected monocytes, while GM-CSF-differentiated macrophages secreted high amounts of these cytokines.", [["monocytes", "ANATOMY", 248, 257], ["macrophages", "ANATOMY", 287, 298], ["MERS-CoV infection", "DISEASE", 106, 124], ["GM", "CHEMICAL", 265, 267], ["MERS-CoV", "ORGANISM", 106, 114], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 205, 210], ["IL-18", "GENE_OR_GENE_PRODUCT", 214, 219], ["influenza virus", "ORGANISM", 223, 238], ["monocytes", "CELL", 248, 257], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 265, 271], ["macrophages", "CELL", 287, 298], ["cytokines", "PROTEIN", 9, 18], ["IL-1\u03b2", "PROTEIN", 205, 210], ["IL-18", "PROTEIN", 214, 219], ["infected monocytes", "CELL_TYPE", 239, 257], ["CSF", "PROTEIN", 268, 271], ["differentiated macrophages", "CELL_TYPE", 272, 298], ["cytokines", "PROTEIN", 330, 339], ["influenza virus", "SPECIES", 223, 238], ["MERS-CoV", "SPECIES", 106, 114], ["cytokines profiles", "TEST", 9, 27], ["an obvious pro-inflammatory immune reactions", "PROBLEM", 38, 82], ["MERS", "PROBLEM", 106, 110], ["CoV infection", "PROBLEM", 111, 124], ["IL", "TEST", 205, 207], ["IL", "TEST", 214, 216], ["influenza virus", "PROBLEM", 223, 238], ["infected monocytes", "PROBLEM", 239, 257], ["GM", "TEST", 265, 267], ["CSF", "TEST", 268, 271], ["these cytokines", "PROBLEM", 324, 339], ["obvious", "OBSERVATION_MODIFIER", 41, 48], ["pro-inflammatory immune", "OBSERVATION", 49, 72], ["acute", "OBSERVATION_MODIFIER", 90, 95], ["CoV", "OBSERVATION_MODIFIER", 111, 114], ["infection", "OBSERVATION", 115, 124], ["infected monocytes", "OBSERVATION", 239, 257], ["macrophages", "OBSERVATION", 287, 298], ["high amounts", "OBSERVATION_MODIFIER", 308, 320]]], ["In vitro experiments indicated that the role of cellular differentiation in the aptitude of monocytes/macrophages to secrete IL-1\u03b2 and IL-18 following exposure with virus infections [19].", [["cellular", "ANATOMY", 48, 56], ["monocytes", "ANATOMY", 92, 101], ["macrophages", "ANATOMY", 102, 113], ["infections", "DISEASE", 171, 181], ["cellular", "CELL", 48, 56], ["monocytes", "CELL", 92, 101], ["macrophages", "CELL", 102, 113], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 125, 130], ["IL-18", "GENE_OR_GENE_PRODUCT", 135, 140], ["monocytes", "CELL_TYPE", 92, 101], ["macrophages", "CELL_TYPE", 102, 113], ["IL-1\u03b2", "PROTEIN", 125, 130], ["IL-18", "PROTEIN", 135, 140], ["monocytes/macrophages", "TREATMENT", 92, 113], ["secrete IL", "TEST", 117, 127], ["IL", "TEST", 135, 137], ["virus infections", "PROBLEM", 165, 181]]], ["In addition, Ramos et al. have reported lower monocyte counts and a marginally lower median level of IL-6 in patients infected with influenza compared with the control group [20].Influenza", [["monocyte", "ANATOMY", 46, 54], ["influenza", "DISEASE", 132, 141], ["Influenza", "DISEASE", 179, 188], ["monocyte", "CELL", 46, 54], ["IL-6", "GENE_OR_GENE_PRODUCT", 101, 105], ["patients", "ORGANISM", 109, 117], ["Influenza", "ORGANISM", 179, 188], ["IL-6", "PROTEIN", 101, 105], ["patients", "SPECIES", 109, 117], ["Influenza", "SPECIES", 179, 188], ["Influenza", "SPECIES", 179, 188], ["lower monocyte counts", "PROBLEM", 40, 61], ["influenza", "PROBLEM", 132, 141], ["Influenza", "PROBLEM", 179, 188], ["lower monocyte", "OBSERVATION_MODIFIER", 40, 54]]]], "3cf1f808f49e43893ea0ab177f1fca607cc40dee": [["DEVELOPING TOBACCO MOSAIC VIRUS FOR DELIVERY OF VACCINE EPITOPESTobacco mosaic virus is a rod-shaped particle composed of =2,100 capsid molecules that are arranged in an elongated helix; intersubunit interactions are stabilized by the presence of single-stranded viral RNA in the core of the assembled coat protein (CP) molecules.'", [["EPITOPESTobacco mosaic virus", "ORGANISM", 56, 84], ["2,100 capsid molecules", "PROTEIN", 123, 145], ["single-stranded viral RNA", "RNA", 247, 272], ["assembled coat protein (CP) molecules", "PROTEIN", 292, 329], ["EPITOPESTobacco mosaic virus", "SPECIES", 56, 84], ["VACCINE EPITOPESTobacco mosaic virus", "TREATMENT", 48, 84], ["a rod-shaped particle", "PROBLEM", 88, 109], ["single-stranded viral RNA", "PROBLEM", 247, 272], ["TOBACCO MOSAIC VIRUS", "OBSERVATION", 11, 31], ["mosaic virus", "OBSERVATION", 72, 84], ["viral RNA", "OBSERVATION", 263, 272]]], ["Both amino-and carboxy-termini are exposed on the surface of the virion.DEVELOPING TOBACCO MOSAIC VIRUS FOR DELIVERY OF VACCINE EPITOPESSeveral different approaches have been taken to develop TMV as a vaccine, while attempting to ensure that the modified CP molecules retain the capacity to assemble and to produce virus particles while maintaining, if possible, the ability to cause a systemic infection in the host.", [["surface", "ANATOMY", 50, 57], ["virion", "ANATOMY", 65, 71], ["amino-and carboxy-termini", "CHEMICAL", 5, 30], ["infection", "DISEASE", 395, 404], ["amino", "CHEMICAL", 5, 10], ["carboxy", "CHEMICAL", 15, 22], ["amino", "AMINO_ACID", 5, 10], ["surface", "CELLULAR_COMPONENT", 50, 57], ["virion", "CELLULAR_COMPONENT", 65, 71], ["TMV", "ORGANISM", 192, 195], ["amino-and carboxy-termini", "PROTEIN", 5, 30], ["CP molecules", "PROTEIN", 255, 267], ["TMV", "SPECIES", 192, 195], ["Both amino", "TREATMENT", 0, 10], ["carboxy-termini", "TREATMENT", 15, 30], ["VACCINE EPITOPESSeveral different approaches", "TREATMENT", 120, 164], ["TMV", "TREATMENT", 192, 195], ["a vaccine", "TREATMENT", 199, 208], ["the modified CP molecules", "PROBLEM", 242, 267], ["the capacity", "PROBLEM", 275, 287], ["virus particles", "PROBLEM", 315, 330], ["a systemic infection in the host", "PROBLEM", 384, 416], ["virion", "ANATOMY", 65, 71], ["TOBACCO MOSAIC VIRUS", "OBSERVATION", 83, 103], ["systemic", "OBSERVATION_MODIFIER", 386, 394], ["infection", "OBSERVATION", 395, 404]]], ["In one such example, Clark et at.4 demonstrated that adding sequences from the CP of sunn hemp mosaic virus to the COOH-terminus of the TMV CP did not reduce virion assembly or the ability of the virus to cause a systemic infection.", [["systemic infection", "DISEASE", 213, 231], ["COOH", "CHEMICAL", 115, 119], ["sunn hemp mosaic virus", "ORGANISM", 85, 107], ["TMV CP", "ORGANISM", 136, 142], ["COOH-terminus", "PROTEIN", 115, 128], ["sunn hemp mosaic virus", "SPECIES", 85, 107], ["sunn hemp mosaic virus", "SPECIES", 85, 107], ["TMV", "SPECIES", 136, 139], ["the CP", "TEST", 75, 81], ["sunn hemp mosaic virus", "TREATMENT", 85, 107], ["the TMV CP", "PROBLEM", 132, 142], ["the virus", "PROBLEM", 192, 201], ["a systemic infection", "PROBLEM", 211, 231], ["mosaic virus", "OBSERVATION", 95, 107], ["systemic", "OBSERVATION_MODIFIER", 213, 221], ["infection", "OBSERVATION", 222, 231]]], ["In other cases, however, protein fusions limited systemic infection or caused local necrosis to which virus infection was limited.", [["infection", "DISEASE", 58, 67], ["necrosis", "DISEASE", 84, 92], ["infection", "DISEASE", 108, 117], ["protein fusions", "PROBLEM", 25, 40], ["systemic infection", "PROBLEM", 49, 67], ["local necrosis", "PROBLEM", 78, 92], ["virus infection", "PROBLEM", 102, 117], ["systemic", "OBSERVATION_MODIFIER", 49, 57], ["infection", "OBSERVATION", 58, 67], ["local", "OBSERVATION_MODIFIER", 78, 83], ["necrosis", "OBSERVATION", 84, 92]]], ["Because necrotic reactions and other limiting local or systemic infections reduced dramatically the amount of virus that is produced, several different approaches have been taken.DEVELOPING TOBACCO MOSAIC VIRUS FOR DELIVERY OF VACCINE EPITOPESOne approach was to use two mutant viruses, one of which encoded wild-type CP but did not produce movement protein and was dependent on infection by the second virus, which produced movement protein in addition to modified CP (J. H. Fitchen and R. N. Beachy, unpublished data) .", [["necrotic", "DISEASE", 8, 16], ["infections", "DISEASE", 64, 74], ["infection", "DISEASE", 379, 388], ["wild-type CP", "ORGANISM", 308, 320], ["movement protein", "PROTEIN", 341, 357], ["necrotic reactions", "PROBLEM", 8, 26], ["systemic infections", "PROBLEM", 55, 74], ["virus", "PROBLEM", 110, 115], ["VACCINE EPITOPESOne approach", "TREATMENT", 227, 255], ["two mutant viruses", "PROBLEM", 267, 285], ["type CP", "PROBLEM", 313, 320], ["movement protein", "PROBLEM", 341, 357], ["infection", "PROBLEM", 379, 388], ["the second virus", "PROBLEM", 392, 408], ["movement protein", "PROBLEM", 425, 441], ["modified CP", "PROBLEM", 457, 468], ["necrotic", "OBSERVATION_MODIFIER", 8, 16], ["systemic", "OBSERVATION_MODIFIER", 55, 63], ["infections", "OBSERVATION", 64, 74], ["amount", "OBSERVATION_MODIFIER", 100, 106], ["virus", "OBSERVATION", 110, 115], ["TOBACCO MOSAIC VIRUS", "OBSERVATION", 190, 210], ["infection", "OBSERVATION", 379, 388]]], ["Such an infection would produce virions comprised of both types of CP while limiting the infection by the virus that produces wild-type CP; furthermore, in those cases in which the epitope prevented efficient local and/or system infection, sufficient levels of wild-type CP accumulate to ensure spread of the infection (as demonstrated in FIG.", [["virions", "ANATOMY", 32, 39], ["infection", "DISEASE", 8, 17], ["CP", "CHEMICAL", 67, 69], ["infection", "DISEASE", 89, 98], ["infection", "DISEASE", 229, 238], ["infection", "DISEASE", 309, 318], ["wild-type CP", "ORGANISM", 126, 138], ["wild-type CP", "ORGANISM", 261, 273], ["an infection", "PROBLEM", 5, 17], ["virions", "PROBLEM", 32, 39], ["CP", "PROBLEM", 67, 69], ["the infection", "PROBLEM", 85, 98], ["the virus", "PROBLEM", 102, 111], ["type CP", "PROBLEM", 131, 138], ["system infection", "PROBLEM", 222, 238], ["type CP", "PROBLEM", 266, 273], ["the infection", "PROBLEM", 305, 318], ["infection", "OBSERVATION", 8, 17], ["both types", "OBSERVATION_MODIFIER", 53, 63], ["infection", "OBSERVATION", 89, 98], ["infection", "OBSERVATION", 229, 238], ["spread", "OBSERVATION_MODIFIER", 295, 301], ["infection", "OBSERVATION", 309, 318]]], ["A second approach was to construct the virus so that a \"leaky\" termination codon separates the C P from a COOH-terminal peptide; at a frequency determined by the infected cell some of the coat protein is wild type, while the remainder is modified by an extension at the COOH-terminu-~ This results in virus particles that contain both mutant and wild-type CP.DEVELOPING TOBACCO MOSAIC VIRUS FOR DELIVERY OF VACCINE EPITOPESWe have adopted a third strategy that involves inserting epitope sequences at a site in the coat protein that is less likely to interfere with virus assembly or systemic infection.", [["cell", "ANATOMY", 171, 175], ["systemic infection", "DISEASE", 584, 602], ["COOH", "CHEMICAL", 106, 110], ["COOH", "CHEMICAL", 270, 274], ["cell", "CELL", 171, 175], ["wild-type CP", "ORGANISM", 346, 358], ["C P", "DNA", 95, 98], ["COOH", "PROTEIN", 106, 110], ["coat protein", "PROTEIN", 188, 200], ["COOH", "PROTEIN", 270, 274], ["terminu", "PROTEIN", 275, 282], ["coat protein", "PROTEIN", 515, 527], ["A second approach", "TREATMENT", 0, 17], ["the virus", "PROBLEM", 35, 44], ["a \"leaky\" termination codon", "TREATMENT", 53, 80], ["a COOH-terminal peptide", "TREATMENT", 104, 127], ["the infected cell", "PROBLEM", 158, 175], ["virus particles", "PROBLEM", 301, 316], ["wild-type CP", "PROBLEM", 346, 358], ["VACCINE EPITOPESWe", "TREATMENT", 407, 425], ["a third strategy", "TREATMENT", 439, 455], ["inserting epitope sequences", "PROBLEM", 470, 497], ["virus assembly", "PROBLEM", 566, 580], ["systemic infection", "PROBLEM", 584, 602], ["virus", "OBSERVATION", 39, 44], ["infected cell", "OBSERVATION", 162, 175], ["coat protein", "OBSERVATION", 188, 200], ["wild type", "OBSERVATION", 204, 213], ["virus particles", "OBSERVATION", 301, 316], ["both", "OBSERVATION_MODIFIER", 330, 334], ["mutant", "OBSERVATION_MODIFIER", 335, 341], ["TOBACCO MOSAIC VIRUS", "OBSERVATION", 370, 390], ["less likely", "UNCERTAINTY", 536, 547], ["systemic", "OBSERVATION_MODIFIER", 584, 592], ["infection", "OBSERVATION", 593, 602]]], ["As shown in FIGURE I , the site of insertion was selected to be outside of the sequences that are required for intramolecular structure or intersubunit assembly3 ; epitopes are generally inserted between amino acids 154 and 155.", [["amino acids", "CHEMICAL", 204, 215], ["amino acids", "CHEMICAL", 204, 215], ["FIGURE I", "GENE_OR_GENE_PRODUCT", 12, 20], ["amino acids", "AMINO_ACID", 204, 215], ["FIGURE I", "PROTEIN", 12, 20], ["intersubunit assembly3", "PROTEIN", 139, 161], ["epitopes", "PROTEIN", 164, 172], ["amino acids 154 and 155", "PROTEIN", 204, 227], ["insertion", "TREATMENT", 35, 44], ["the sequences", "TEST", 75, 88], ["intramolecular structure or intersubunit assembly3", "PROBLEM", 111, 161], ["epitopes", "TREATMENT", 164, 172], ["amino acids", "TEST", 204, 215]]], ["In most cases, this leads to the accumulation solely of modified coat proteins in sufficiently large amounts for large scale purification.", [["modified coat proteins", "PROTEIN", 56, 78], ["modified coat proteins", "TREATMENT", 56, 78], ["large scale purification", "TREATMENT", 113, 137]]], ["TABLE 1 presents the results of some studies of sequences that were added as COOH-terminal extensions of the CP or between amino acids 154 and 155.", [["amino acids", "CHEMICAL", 123, 134], ["COOH", "CHEMICAL", 77, 81], ["amino acids", "CHEMICAL", 123, 134], ["amino acids", "AMINO_ACID", 123, 134], ["COOH", "PROTEIN", 77, 81], ["CP", "PROTEIN", 109, 111], ["amino acids 154 and 155", "PROTEIN", 123, 146], ["some studies of sequences", "TEST", 32, 57], ["the CP", "PROBLEM", 105, 111], ["amino acids", "TEST", 123, 134]]], ["As indicated in the right-hand column, the various sequences induced different types of symptoms in the host.", [["right-hand column", "ANATOMY", 20, 37], ["symptoms in the host", "PROBLEM", 88, 108], ["right", "ANATOMY_MODIFIER", 20, 25], ["hand", "ANATOMY", 26, 30], ["column", "ANATOMY_MODIFIER", 31, 37]]], ["At the current time, we are unable to predict if specific sequences will or will not induce chlorosis or necrosis in Nicotiana tabucum.DEVELOPING TOBACCO MOSAIC VIRUS FOR DELIVERY OF VACCINE EPITOPESPlants that are infected with TMV produce large amounts of CP, most or all of which is assembled with viral RNA to produce progeny virions.", [["virions", "ANATOMY", 330, 337], ["chlorosis", "DISEASE", 92, 101], ["necrosis", "DISEASE", 105, 113], ["Nicotiana tabucum", "ORGANISM", 117, 134], ["TMV", "ORGANISM", 229, 232], ["viral RNA", "RNA", 301, 310], ["Nicotiana tabucum", "SPECIES", 117, 134], ["Nicotiana tabucum", "SPECIES", 117, 134], ["TMV", "SPECIES", 229, 232], ["chlorosis", "PROBLEM", 92, 101], ["necrosis", "PROBLEM", 105, 113], ["VACCINE EPITOPESPlants", "TREATMENT", 183, 205], ["CP", "PROBLEM", 258, 260], ["viral RNA", "PROBLEM", 301, 310], ["necrosis", "OBSERVATION", 105, 113], ["TOBACCO MOSAIC VIRUS", "OBSERVATION", 146, 166], ["large", "OBSERVATION_MODIFIER", 241, 246], ["amounts", "OBSERVATION_MODIFIER", 247, 254], ["viral RNA", "OBSERVATION", 301, 310], ["progeny virions", "OBSERVATION", 322, 337]]], ["In chronically infected tobacco leaves, 10-40% of the leaf protein can be TMV CP.", [["leaves", "ANATOMY", 32, 38], ["leaf", "ANATOMY", 54, 58], ["tobacco", "ORGANISM", 24, 31], ["leaves", "DEVELOPING_ANATOMICAL_STRUCTURE", 32, 38], ["leaf", "ORGAN", 54, 58], ["TMV", "ORGANISM", 74, 77], ["leaf protein", "PROTEIN", 54, 66], ["tobacco", "SPECIES", 24, 31], ["tobacco", "SPECIES", 24, 31], ["the leaf protein", "PROBLEM", 50, 66], ["TMV CP", "PROBLEM", 74, 80], ["chronically", "OBSERVATION_MODIFIER", 3, 14], ["infected", "OBSERVATION", 15, 23]]], ["Likewise, plants infected with modified virus can produce large amounts of the modified CP.", [["modified virus", "PROBLEM", 31, 45], ["the modified CP", "PROBLEM", 75, 90], ["infected", "OBSERVATION", 17, 25], ["large", "OBSERVATION_MODIFIER", 58, 63], ["amounts", "OBSERVATION_MODIFIER", 64, 71]]], ["As shown in FIGURE 2 SDS-PAGE analysis of the proteins extracted from leaves infected with TMV in which the coat protein is modified by insertion of nucleotides that encode the 9 amino acid sequence derived from the hemagglutinin of influenza virus revealed a prominent protein band representing the modified coat protein (lanes 2 , 3, 4, and 5).", [["leaves", "ANATOMY", 70, 76], ["amino acid", "CHEMICAL", 179, 189], ["nucleotides", "CHEMICAL", 149, 160], ["amino acid", "CHEMICAL", 179, 189], ["leaves", "ORGANISM_SUBDIVISION", 70, 76], ["TMV", "ORGANISM", 91, 94], ["amino acid", "AMINO_ACID", 179, 189], ["influenza virus", "ORGANISM", 233, 248], ["coat protein", "PROTEIN", 108, 120], ["9 amino acid sequence", "PROTEIN", 177, 198], ["hemagglutinin", "PROTEIN", 216, 229], ["protein band", "PROTEIN", 270, 282], ["modified coat protein", "PROTEIN", 300, 321], ["lanes 2 , 3, 4, and 5", "PROTEIN", 323, 344], ["influenza virus", "SPECIES", 233, 248], ["TMV", "SPECIES", 91, 94], ["influenza virus", "SPECIES", 233, 248], ["the proteins", "PROBLEM", 42, 54], ["TMV", "TREATMENT", 91, 94], ["the coat protein", "TREATMENT", 104, 120], ["insertion of nucleotides", "TREATMENT", 136, 160], ["the 9 amino acid sequence", "TEST", 173, 198], ["influenza virus", "PROBLEM", 233, 248], ["a prominent protein band", "PROBLEM", 258, 282], ["prominent", "OBSERVATION_MODIFIER", 260, 269], ["protein band", "OBSERVATION", 270, 282]]], ["Furthermore, the virus was readily purified by PEG precipitation, effecting rapid and easy enrichment of the virions (FIG.", [["virions", "ANATOMY", 109, 116], ["PEG", "CHEMICAL", 47, 50], ["PEG", "CHEMICAL", 47, 50], ["PEG", "SIMPLE_CHEMICAL", 47, 50], ["the virus", "PROBLEM", 13, 22], ["PEG precipitation", "TREATMENT", 47, 64], ["virus", "OBSERVATION", 17, 22], ["PEG precipitation", "OBSERVATION", 47, 64], ["rapid", "OBSERVATION_MODIFIER", 76, 81], ["virions", "ANATOMY", 109, 116]]], ["To date, the sequences added to the coat protein were retained during virus replication, local and systemic spread, and purification.", [["coat protein", "PROTEIN", 36, 48], ["the coat protein", "TEST", 32, 48], ["virus replication", "TREATMENT", 70, 87]]], ["However, it is likely that not all sequences will be equally stable when added to the TMV coat protein.DEVELOPING TOBACCO MOSAIC VIRUS FOR DELIVERY OF VACCINE EPITOPESWe selected for further studies a sequence derived from the murine zona pellucida 3.", [["TMV", "ORGANISM", 86, 89], ["murine", "ORGANISM", 227, 233], ["zona pellucida 3", "ORGANISM", 234, 250], ["TMV coat protein", "PROTEIN", 86, 102], ["murine", "SPECIES", 227, 233], ["TMV", "SPECIES", 86, 89], ["the TMV coat protein", "TEST", 82, 102], ["VACCINE EPITOPESWe", "TREATMENT", 151, 169], ["further studies", "TEST", 183, 198], ["the murine zona pellucida", "TREATMENT", 223, 248], ["TOBACCO MOSAIC VIRUS", "OBSERVATION", 114, 134]]], ["ZP3 is one of the three glycoproteins that comprise the covering of unfertilized eggs and is the primary binding site for sperm during fertilization.* It was previously demonstrated that an epitope comprising amino acids 336-343,ANNALS NEW YORK ACADEMY OF SCIENCESa B-cell epitope, is responsible for inducing antibody-mediated contra DNA sequence encoding these amino acids was placed between codons 154 and 155 in the TMV CP gene on the infectious cloned cDNA, and plants were infected with the modified virus. '\"", [["eggs", "ANATOMY", 81, 85], ["sperm", "ANATOMY", 122, 127], ["amino acids 336-343", "CHEMICAL", 209, 228], ["amino acids", "CHEMICAL", 363, 374], ["amino acids", "CHEMICAL", 209, 220], ["amino acids", "CHEMICAL", 363, 374], ["ZP3", "GENE_OR_GENE_PRODUCT", 0, 3], ["eggs", "DEVELOPING_ANATOMICAL_STRUCTURE", 81, 85], ["sperm", "CELLULAR_COMPONENT", 122, 127], ["amino acids", "AMINO_ACID", 209, 220], ["336-343", "AMINO_ACID", 221, 228], ["DNA", "CELLULAR_COMPONENT", 335, 338], ["amino acids", "AMINO_ACID", 363, 374], ["TMV CP", "ORGANISM", 420, 426], ["ZP3", "PROTEIN", 0, 3], ["sperm", "CELL_TYPE", 122, 127], ["amino acids 336-343", "PROTEIN", 209, 228], ["ANNALS", "PROTEIN", 229, 235], ["SCIENCESa B-cell epitope", "PROTEIN", 256, 280], ["contra DNA sequence", "DNA", 328, 347], ["TMV CP gene", "DNA", 420, 431], ["infectious cloned cDNA", "DNA", 439, 461], ["ZP3", "TREATMENT", 0, 3], ["the three glycoproteins", "TREATMENT", 14, 37], ["unfertilized eggs", "PROBLEM", 68, 85], ["an epitope comprising amino acids", "TEST", 187, 220], ["SCIENCESa B-cell epitope", "TREATMENT", 256, 280], ["inducing antibody", "PROBLEM", 301, 318], ["contra DNA sequence", "TREATMENT", 328, 347], ["these amino acids", "TREATMENT", 357, 374], ["codons", "TEST", 394, 400], ["the infectious cloned cDNA", "PROBLEM", 435, 461], ["the modified virus", "PROBLEM", 493, 511], ["unfertilized eggs", "OBSERVATION", 68, 85], ["cell epitope", "OBSERVATION", 268, 280]]], ["Enriched preparations of virus particles isolated from these plants or unmodified virus were parenterally administered to mice: both wild-type and modified TMV induced antibodies against the coat protein of TMV, and the modified virus also induced antibodies that recognized ZP3 on ELISA.", [["mice", "ORGANISM", 122, 126], ["TMV", "ORGANISM", 156, 159], ["TMV", "ORGANISM", 207, 210], ["ZP3", "GENE_OR_GENE_PRODUCT", 275, 278], ["antibodies", "PROTEIN", 168, 178], ["coat protein", "PROTEIN", 191, 203], ["antibodies", "PROTEIN", 248, 258], ["ZP3", "PROTEIN", 275, 278], ["mice", "SPECIES", 122, 126], ["mice", "SPECIES", 122, 126], ["TMV", "SPECIES", 156, 159], ["TMV", "SPECIES", 207, 210], ["Enriched preparations of virus particles", "TREATMENT", 0, 40], ["unmodified virus", "TREATMENT", 71, 87], ["modified TMV induced antibodies", "TREATMENT", 147, 178], ["the coat protein", "TEST", 187, 203], ["TMV", "PROBLEM", 207, 210], ["the modified virus", "PROBLEM", 216, 234], ["virus particles", "OBSERVATION", 25, 40]]], ["Histologic and immunologic analyses of ovaries collected from immunized mice showed that after treatment with the modified virus, antibodies were recruited and bound to the zona pellucida.", [["ovaries", "ANATOMY", 39, 46], ["zona pellucida", "ANATOMY", 173, 187], ["ovaries", "ORGAN", 39, 46], ["mice", "ORGANISM", 72, 76], ["zona pellucida", "ORGANISM", 173, 187], ["antibodies", "PROTEIN", 130, 140], ["mice", "SPECIES", 72, 76], ["mice", "SPECIES", 72, 76], ["Histologic and immunologic analyses", "TEST", 0, 35], ["treatment", "TREATMENT", 95, 104], ["the modified virus", "PROBLEM", 110, 128], ["antibodies", "PROBLEM", 130, 140], ["ovaries", "ANATOMY", 39, 46]]], ["These studies demonstrated that the TMV-borne epitope can induce a B-cell-mediated response.", [["B-cell", "ANATOMY", 67, 73], ["TMV", "ORGANISM", 36, 39], ["B-cell", "CELL", 67, 73], ["TMV-borne epitope", "PROTEIN", 36, 53], ["These studies", "TEST", 0, 13], ["the TMV-borne epitope", "PROBLEM", 32, 53]]], ["Immunized and control mice were then used in fecundity assays to determine if immunization regimens had a positive or a negative impact on fertility of the mice.", [["mice", "ORGANISM", 22, 26], ["mice", "ORGANISM", 156, 160], ["mice", "SPECIES", 22, 26], ["mice", "SPECIES", 156, 160], ["mice", "SPECIES", 22, 26], ["mice", "SPECIES", 156, 160], ["fecundity assays", "TEST", 45, 61], ["immunization regimens", "TREATMENT", 78, 99]]], ["However, in these studies it was not possible to assess the fertility of the mice, and additional studies are needed.ANNALS NEW YORK ACADEMY OF SCIENCESOther studies are in progress to determine if TMV can be used effectively to carry an epitope derived from a mouse hepatitis virus, a coronavirus.", [["hepatitis virus", "DISEASE", 267, 282], ["coronavirus", "DISEASE", 286, 297], ["mice", "ORGANISM", 77, 81], ["TMV", "ORGANISM", 198, 201], ["mouse hepatitis virus", "ORGANISM", 261, 282], ["coronavirus", "ORGANISM", 286, 297], ["mice", "SPECIES", 77, 81], ["mouse", "SPECIES", 261, 266], ["hepatitis virus", "SPECIES", 267, 282], ["mice", "SPECIES", 77, 81], ["TMV", "SPECIES", 198, 201], ["mouse hepatitis virus", "SPECIES", 261, 282], ["these studies", "TEST", 12, 25], ["additional studies", "TEST", 87, 105], ["SCIENCESOther studies", "TEST", 144, 165], ["TMV", "PROBLEM", 198, 201], ["an epitope", "PROBLEM", 235, 245], ["a mouse hepatitis virus", "PROBLEM", 259, 282], ["a coronavirus", "PROBLEM", 284, 297]]], ["In the near future we will determine if TMV can be used to confer protective immunity against this virus (J. H. Fitchen, work in progress).DEVELOPING JMV POTYVIRUS FOR DELIVERY OF VACCINE EPITOPESPotyviruses, like TMV, are comprised of single-stranded (+) sense RNA, and they assemble to form elongated helical rod-shaped particles.", [["TMV", "ORGANISM", 40, 43], ["TMV", "ORGANISM", 214, 217], ["single-stranded (+) sense RNA", "RNA", 236, 265], ["elongated helical rod-shaped particles", "CELL_TYPE", 293, 331], ["TMV", "SPECIES", 40, 43], ["TMV", "PROBLEM", 40, 43], ["VACCINE EPITOPESPotyviruses", "TREATMENT", 180, 207], ["TMV", "PROBLEM", 214, 217], ["single-stranded (+) sense RNA", "PROBLEM", 236, 265], ["elongated helical rod-shaped particles", "PROBLEM", 293, 331], ["JMV POTYVIRUS", "OBSERVATION", 150, 163], ["elongated", "OBSERVATION_MODIFIER", 293, 302], ["helical rod-", "OBSERVATION_MODIFIER", 303, 315], ["shaped", "OBSERVATION_MODIFIER", 315, 321], ["particles", "OBSERVATION_MODIFIER", 322, 331]]], ["However, potyviruses are flexuous rather than rigid rods due to the nature of the capsid protein molecule.", [["potyviruses", "ANATOMY", 9, 20], ["capsid protein molecule", "PROTEIN", 82, 105], ["potyviruses", "PROBLEM", 9, 20], ["flexuous", "PROBLEM", 25, 33], ["rigid rods", "PROBLEM", 46, 56], ["the capsid protein molecule", "PROBLEM", 78, 105], ["potyviruses", "OBSERVATION", 9, 20], ["capsid", "OBSERVATION", 82, 88], ["protein molecule", "OBSERVATION", 89, 105]]], ["Like TMV, the NH,-and COOH-termini of the CP are exposed on the surface of the virus particle: the exposed amino terminal amino acid sequence can be greater than 30 amino acids.", [["surface", "ANATOMY", 64, 71], ["amino terminal amino acid", "CHEMICAL", 107, 132], ["amino acids", "CHEMICAL", 165, 176], ["NH", "CHEMICAL", 14, 16], ["COOH", "CHEMICAL", 22, 26], ["amino", "CHEMICAL", 107, 112], ["amino acid", "CHEMICAL", 122, 132], ["amino acids", "CHEMICAL", 165, 176], ["TMV", "ORGANISM", 5, 8], ["surface", "CELLULAR_COMPONENT", 64, 71], ["amino terminal", "CELLULAR_COMPONENT", 107, 121], ["amino acid", "AMINO_ACID", 122, 132], ["amino acids", "AMINO_ACID", 165, 176], ["NH,-and COOH-termini", "PROTEIN", 14, 34], ["CP", "PROTEIN", 42, 44], ["amino terminal amino acid sequence", "PROTEIN", 107, 141], ["the CP", "PROBLEM", 38, 44], ["the exposed amino terminal amino acid sequence", "TREATMENT", 95, 141], ["amino acids", "TEST", 165, 176], ["virus", "OBSERVATION", 79, 84]]], ["A single report describes the results of studies with sequences fused to coat proteins of johnsongrass mosaic potyvirus (JMV).2 Fusion proteins were made at the amino terminus of the CP of JMV with an octapeptide derived from Plasmodium jalciparum or the 10 amino acid luteinizing hormone releasing factor.", [["Plasmodium jalciparum", "DISEASE", 226, 247], ["amino acid", "CHEMICAL", 258, 268], ["amino", "CHEMICAL", 161, 166], ["amino acid", "CHEMICAL", 258, 268], ["johnsongrass mosaic potyvirus", "ORGANISM", 90, 119], ["JMV", "CANCER", 121, 124], ["Plasmodium jalciparum", "ORGANISM", 226, 247], ["luteinizing hormone releasing factor", "GENE_OR_GENE_PRODUCT", 269, 305], ["coat proteins", "PROTEIN", 73, 86], ["Fusion proteins", "PROTEIN", 128, 143], ["amino terminus", "PROTEIN", 161, 175], ["JMV", "PROTEIN", 189, 192], ["amino acid luteinizing hormone releasing factor", "PROTEIN", 258, 305], ["johnsongrass mosaic potyvirus", "SPECIES", 90, 119], ["Plasmodium jalciparum", "SPECIES", 226, 247], ["johnsongrass mosaic potyvirus", "SPECIES", 90, 119], ["JMV", "SPECIES", 121, 124], ["Plasmodium jalciparum", "SPECIES", 226, 247], ["studies", "TEST", 41, 48], ["johnsongrass mosaic potyvirus", "PROBLEM", 90, 119], ["2 Fusion proteins", "TREATMENT", 126, 143], ["the CP of JMV", "PROBLEM", 179, 192], ["an octapeptide", "TREATMENT", 198, 212], ["Plasmodium jalciparum", "TREATMENT", 226, 247], ["the 10 amino acid luteinizing hormone", "TREATMENT", 251, 288]]], ["In another construct, the 26-kD protein Sj-26-glutathione S-transferase from Shistosoma ,japonica replaced 62 amino acids at the NH,terminus of the CP.", [["Sj-26-glutathione", "CHEMICAL", 40, 57], ["amino acids", "CHEMICAL", 110, 121], ["Sj-26-glutathione", "CHEMICAL", 40, 57], ["amino acids", "CHEMICAL", 110, 121], ["NH", "CHEMICAL", 129, 131], ["Sj-26-glutathione S-transferase", "GENE_OR_GENE_PRODUCT", 40, 71], ["japonica", "ORGANISM", 89, 97], ["amino acids", "AMINO_ACID", 110, 121], ["26-kD protein", "PROTEIN", 26, 39], ["Sj", "PROTEIN", 40, 42], ["glutathione S-transferase", "PROTEIN", 46, 71], ["NH,terminus", "PROTEIN", 129, 140], ["kD protein Sj", "TEST", 29, 42], ["glutathione S-transferase", "TEST", 46, 71], ["Shistosoma", "PROBLEM", 77, 87], ["amino acids", "TREATMENT", 110, 121], ["the CP", "PROBLEM", 144, 150]]], ["Fusion proteins comprising the CP plus added sequences accumulated in E . coli and assembled to form virus-like particles.", [["coli", "ORGANISM", 74, 78], ["CP", "PROTEIN", 31, 33], ["coli", "SPECIES", 74, 78], ["coli", "SPECIES", 74, 78], ["Fusion proteins", "PROBLEM", 0, 15], ["the CP", "PROBLEM", 27, 33], ["coli", "PROBLEM", 74, 78], ["virus", "PROBLEM", 101, 106], ["virus", "OBSERVATION", 101, 106], ["particles", "OBSERVATION_MODIFIER", 112, 121]]], ["Injection of the Sj-26: CP fusion to mice elicited antibody response to Sj-26.", [["Sj-26", "CHEMICAL", 17, 22], ["Sj-26", "CHEMICAL", 72, 77], ["Sj-26", "CHEMICAL", 72, 77], ["Sj-26", "GENE_OR_GENE_PRODUCT", 17, 22], ["CP", "GENE_OR_GENE_PRODUCT", 24, 26], ["mice", "ORGANISM", 37, 41], ["mice", "SPECIES", 37, 41], ["mice", "SPECIES", 37, 41], ["CP fusion", "TREATMENT", 24, 33], ["antibody response", "TEST", 51, 68], ["Sj", "TEST", 72, 74]]], ["These studies demonstrate the capacity of modified potyvirus CP to assemble to form virus-like particles (VLP), including very large proteins.", [["potyvirus CP", "ORGANISM", 51, 63], ["VLP", "ORGANISM", 106, 109], ["potyvirus", "SPECIES", 51, 60], ["These studies", "TEST", 0, 13], ["modified potyvirus CP", "PROBLEM", 42, 63], ["virus", "PROBLEM", 84, 89], ["very large proteins", "PROBLEM", 122, 141], ["potyvirus", "OBSERVATION", 51, 60], ["large", "OBSERVATION_MODIFIER", 127, 132], ["proteins", "OBSERVATION", 133, 141]]], ["However, it is unknown if virions encapsidated by these mutant CP molecules can cause local and systemic infections in plants.DEVELOPING CPMV FOR DELIVERY OF VACCINE EPITOPESThe structure of CPMV, determined to the atomic level in the late 1980s (reviewed by Chen et al.\") , revealed that the virus surface includes several exposed loops.", [["surface", "ANATOMY", 299, 306], ["infections", "DISEASE", 105, 115], ["mutant CP molecules", "PROTEIN", 56, 75], ["CPMV", "PROTEIN", 191, 195], ["virions", "PROBLEM", 26, 33], ["these mutant CP molecules", "PROBLEM", 50, 75], ["local and systemic infections in plants", "PROBLEM", 86, 125], ["the virus surface", "PROBLEM", 289, 306], ["systemic", "OBSERVATION_MODIFIER", 96, 104], ["infections", "OBSERVATION", 105, 115], ["CPMV", "OBSERVATION", 137, 141], ["CPMV", "OBSERVATION", 191, 195], ["virus", "OBSERVATION", 293, 298], ["several", "OBSERVATION_MODIFIER", 316, 323], ["exposed loops", "OBSERVATION", 324, 337]]], ["Of particular interest for developing CPMV as a vaccine is a loop made of amino acids 20-27 of the S capsid subunit; the loop lies on the surface of the virus and is not directly involved in intersubunit interactions.", [["surface", "ANATOMY", 138, 145], ["CPMV", "CHEMICAL", 38, 42], ["amino acids 20-27", "CHEMICAL", 74, 91], ["amino acids", "CHEMICAL", 74, 85], ["CPMV", "CANCER", 38, 42], ["amino acids", "AMINO_ACID", 74, 85], ["surface", "CELLULAR_COMPONENT", 138, 145], ["CPMV", "PROTEIN", 38, 42], ["amino acids 20-27", "PROTEIN", 74, 91], ["S capsid subunit", "PROTEIN", 99, 115], ["CPMV", "SPECIES", 38, 42], ["developing CPMV", "TREATMENT", 27, 42], ["a vaccine", "TREATMENT", 46, 55], ["amino acids", "TEST", 74, 85], ["the S capsid subunit", "TREATMENT", 95, 115], ["virus", "OBSERVATION", 153, 158]]], ["Usha et ~1 . '~ inserted into the infectious cloned cDNA of CPMV DNA sequences to encode amino acids 136-160 from VP1 of foot and mouth disease virus for expression between amino acids 18 and 19 of the S-peptide.", [["amino acids 136-160", "CHEMICAL", 89, 108], ["foot and mouth disease", "DISEASE", 121, 143], ["amino acids", "CHEMICAL", 173, 184], ["amino acids", "CHEMICAL", 89, 100], ["amino acids", "CHEMICAL", 173, 184], ["S-peptide", "CHEMICAL", 202, 211], ["CPMV DNA", "CELLULAR_COMPONENT", 60, 68], ["amino acids", "AMINO_ACID", 89, 100], ["136-160", "AMINO_ACID", 101, 108], ["foot and mouth disease virus", "ORGANISM", 121, 149], ["amino acids", "AMINO_ACID", 173, 184], ["S-peptide", "GENE_OR_GENE_PRODUCT", 202, 211], ["Usha et ~1", "DNA", 0, 10], ["infectious cloned cDNA", "DNA", 34, 56], ["CPMV DNA sequences", "DNA", 60, 78], ["amino acids 136-160", "PROTEIN", 89, 108], ["amino acids 18 and 19", "PROTEIN", 173, 194], ["S-peptide", "PROTEIN", 202, 211], ["CPMV", "SPECIES", 60, 64], ["foot and mouth disease virus", "SPECIES", 121, 149], ["CPMV DNA sequences", "TEST", 60, 78], ["amino acids", "TEST", 89, 100], ["mouth disease virus", "PROBLEM", 130, 149], ["amino acids", "TEST", 173, 184], ["infectious", "OBSERVATION", 34, 44], ["foot", "ANATOMY", 121, 125], ["mouth", "ANATOMY", 130, 135]]], ["Transcripts derived from the modified clone were inoculated into protoplasts and whole plants.", [["protoplasts", "ANATOMY", 65, 76], ["clone", "CELL", 38, 43], ["protoplasts", "CELL", 65, 76], ["modified clone", "CELL_LINE", 29, 43], ["the modified clone", "TREATMENT", 25, 43]]], ["Chimeric virus particles accumulated in protoplasts and inoculated leaves but not in upper leaves; the added sequence is likely responsible for restricting systemic spread of the virus.", [["protoplasts", "ANATOMY", 40, 51], ["leaves", "ANATOMY", 67, 73], ["leaves", "ANATOMY", 91, 97], ["Chimeric virus particles", "ORGANISM", 0, 24], ["protoplasts", "CELL", 40, 51], ["leaves", "ORGANISM_SUBDIVISION", 67, 73], ["upper leaves", "ORGANISM_SUBDIVISION", 85, 97], ["Chimeric virus particles", "PROBLEM", 0, 24], ["the virus", "PROBLEM", 175, 184], ["virus", "OBSERVATION", 9, 14], ["inoculated leaves", "OBSERVATION", 56, 73], ["upper", "ANATOMY_MODIFIER", 85, 90], ["likely responsible for", "UNCERTAINTY", 121, 143], ["virus", "OBSERVATION", 179, 184]]], ["Virus particles that were recovered reacted with antibodies raised against FMDV, confirming that the FMDV sequence was retained in the virus capsid.DEVELOPING CPMV FOR DELIVERY OF VACCINE EPITOPESIt was subsequently found that the FMDV sequences inserted in CPMV were rapidly lost upon serial passaging of the virus, a result that led the investigators to redesign the chimeric protein in order to stabilize inserted sequences.", [["Virus", "ORGANISM", 0, 5], ["FMDV", "ORGANISM", 75, 79], ["FMDV", "ORGANISM", 101, 105], ["FMDV", "ORGANISM", 231, 235], ["CPMV", "GENE_OR_GENE_PRODUCT", 258, 262], ["antibodies", "PROTEIN", 49, 59], ["FMDV sequence", "DNA", 101, 114], ["FMDV sequences", "DNA", 231, 245], ["CPMV", "DNA", 258, 262], ["chimeric protein", "PROTEIN", 369, 385], ["FMDV", "SPECIES", 75, 79], ["FMDV", "SPECIES", 101, 105], ["FMDV", "SPECIES", 231, 235], ["FMDV", "SPECIES", 75, 79], ["FMDV", "SPECIES", 101, 105], ["FMDV", "SPECIES", 231, 235], ["CPMV", "SPECIES", 258, 262], ["Virus particles", "PROBLEM", 0, 15], ["antibodies", "PROBLEM", 49, 59], ["FMDV", "PROBLEM", 75, 79], ["the FMDV sequence", "TEST", 97, 114], ["the virus capsid", "PROBLEM", 131, 147], ["VACCINE EPITOPESIt", "TREATMENT", 180, 198], ["the FMDV sequences", "TREATMENT", 227, 245], ["the virus", "PROBLEM", 306, 315], ["the chimeric protein", "TEST", 365, 385], ["virus capsid", "OBSERVATION", 135, 147], ["CPMV", "OBSERVATION", 159, 163]]], ["Porta et ~1 . '~ subsequently carried out mutagenesis reactions that led to the insertion of foreign sequences between amino acids 22 and 23 of the S-protein.", [["amino acids", "CHEMICAL", 119, 130], ["amino acids", "CHEMICAL", 119, 130], ["amino acids", "AMINO_ACID", 119, 130], ["S-protein", "GENE_OR_GENE_PRODUCT", 148, 157], ["amino acids 22 and 23", "PROTEIN", 119, 140], ["S-protein", "PROTEIN", 148, 157], ["mutagenesis reactions", "PROBLEM", 42, 63], ["the insertion of foreign sequences", "TREATMENT", 76, 110], ["amino acids", "TEST", 119, 130]]], ["Sequences that were stable included amino acids 141-159 of VP1 of FDMV, amino acids 85-98 of human rhinovirus 14 , and amino acids 731-752 of gp41 from human immunodeficiency virus 111 (HIV-111).", [["amino acids 141-159 of VP1 of FDMV", "CHEMICAL", 36, 70], ["amino acids 85-98", "CHEMICAL", 72, 89], ["amino acids 731-752", "CHEMICAL", 119, 138], ["human immunodeficiency virus", "DISEASE", 152, 180], ["amino acids", "CHEMICAL", 36, 47], ["amino acids", "CHEMICAL", 72, 83], ["amino acids", "CHEMICAL", 119, 130], ["amino acids", "AMINO_ACID", 36, 47], ["141-159", "AMINO_ACID", 48, 55], ["FDMV", "GENE_OR_GENE_PRODUCT", 66, 70], ["amino acids", "AMINO_ACID", 72, 83], ["human rhinovirus 14", "ORGANISM", 93, 112], ["amino acids", "AMINO_ACID", 119, 130], ["731-752", "AMINO_ACID", 131, 138], ["human immunodeficiency virus 111", "ORGANISM", 152, 184], ["HIV-111", "ORGANISM", 186, 193], ["amino acids 141-159", "PROTEIN", 36, 55], ["VP1", "PROTEIN", 59, 62], ["FDMV", "PROTEIN", 66, 70], ["amino acids 85-98", "PROTEIN", 72, 89], ["gp41", "PROTEIN", 142, 146], ["human", "SPECIES", 93, 98], ["human", "SPECIES", 152, 157], ["immunodeficiency virus", "SPECIES", 158, 180], ["HIV", "SPECIES", 186, 189], ["human rhinovirus", "SPECIES", 93, 109], ["human immunodeficiency virus", "SPECIES", 152, 180], ["HIV-111", "SPECIES", 186, 193], ["Sequences", "TEST", 0, 9], ["amino acids", "TEST", 36, 47], ["VP1", "TEST", 59, 62], ["FDMV", "TEST", 66, 70], ["amino acids", "TEST", 72, 83], ["human rhinovirus", "TEST", 93, 109], ["amino acids", "TEST", 119, 130], ["gp41", "TEST", 142, 146], ["human immunodeficiency virus", "TEST", 152, 180], ["HIV", "TEST", 186, 189]]], ["These viruses were reactive with antibodies directed against the specific peptides, and in the case of the HRV-14 epitope, the virus was active as a vaccine in injected rabbits and induced antibodies directed against HRV-14.DEVELOPING CPMV FOR DELIVERY OF VACCINE EPITOPESModified CPMV that contained the sequences from gp41 of HIV-I11 was used to inject C57/BL6 mice.", [["HRV-14", "ORGANISM", 107, 113], ["rabbits", "ORGANISM", 169, 176], ["HRV-14", "ORGANISM", 217, 223], ["gp41", "GENE_OR_GENE_PRODUCT", 320, 324], ["HIV-I11", "ORGANISM", 328, 335], ["C57/BL6 mice", "ORGANISM", 355, 367], ["antibodies", "PROTEIN", 33, 43], ["HRV-14 epitope", "PROTEIN", 107, 121], ["CPMV", "PROTEIN", 281, 285], ["gp41", "PROTEIN", 320, 324], ["rabbits", "SPECIES", 169, 176], ["HIV", "SPECIES", 328, 331], ["mice", "SPECIES", 363, 367], ["rabbits", "SPECIES", 169, 176], ["HIV-I11", "SPECIES", 328, 335], ["mice", "SPECIES", 363, 367], ["These viruses", "PROBLEM", 0, 13], ["antibodies", "TREATMENT", 33, 43], ["the HRV", "TEST", 103, 110], ["the virus", "PROBLEM", 123, 132], ["a vaccine in injected rabbits", "TREATMENT", 147, 176], ["induced antibodies", "PROBLEM", 181, 199], ["HRV", "TEST", 217, 220], ["VACCINE EPITOPESModified CPMV", "TREATMENT", 256, 285], ["the sequences", "TEST", 301, 314], ["HIV-I11", "TREATMENT", 328, 335], ["viruses", "OBSERVATION", 6, 13], ["reactive", "OBSERVATION_MODIFIER", 19, 27], ["CPMV", "OBSERVATION", 235, 239]]], ["Antibodies recovered from injected mice reacted with purified peptide and in in vitro assays neutralized HIV-I strain IIIB as well as HIV-I strains R F and SF2I4 (McLain and Dimmock, 1994) .", [["mice", "ORGANISM", 35, 39], ["HIV-I strain IIIB", "ORGANISM", 105, 122], ["HIV-I", "ORGANISM", 134, 139], ["R F", "GENE_OR_GENE_PRODUCT", 148, 151], ["SF2I4", "ORGANISM", 156, 161], ["mice", "SPECIES", 35, 39], ["HIV", "SPECIES", 105, 108], ["HIV", "SPECIES", 134, 137], ["mice", "SPECIES", 35, 39], ["HIV-I", "SPECIES", 105, 110], ["HIV-I", "SPECIES", 134, 139], ["Antibodies", "TEST", 0, 10], ["purified peptide", "TREATMENT", 53, 69], ["I strain IIIB", "PROBLEM", 109, 122]]], ["Titers of neutralizing antibodies declined to undetectable levels several weeks after the second injection but were stimulated upon reinjection.", [["neutralizing antibodies", "PROTEIN", 10, 33], ["neutralizing antibodies", "TEST", 10, 33], ["the second injection", "TREATMENT", 86, 106], ["reinjection", "TREATMENT", 132, 143]]], ["The results of these studies demonstrated the use of CPMV as a carrier of vaccine epitopes and indicate that this virus may be especially well suited for presenting epitopes that are structured as a loop rather than as a linear array or random coil.CONCLUSIONSThe results of studies in structural biology, virology, and immunology completed during the recent 20 years have made it possible to contemplate the development of plant viruses as carriers of vaccine epitopes.", [["CPMV", "CHEMICAL", 53, 57], ["CPMV", "SIMPLE_CHEMICAL", 53, 57], ["epitopes", "PROTEIN", 165, 173], ["vaccine epitopes", "PROTEIN", 453, 469], ["these studies", "TEST", 15, 28], ["CPMV", "TREATMENT", 53, 57], ["a carrier of vaccine epitopes", "TREATMENT", 61, 90], ["this virus", "PROBLEM", 109, 119], ["a linear array or random coil", "TREATMENT", 219, 248], ["plant viruses", "PROBLEM", 424, 437], ["vaccine epitopes", "TREATMENT", 453, 469], ["plant viruses", "OBSERVATION", 424, 437]]], ["As described herein, wellcharacterized epitopes can be added to the capsid proteins of plant viruses, recovered in large quantities, and injected to induce immune responses in animals.", [["wellcharacterized epitopes", "PROTEIN", 21, 47], ["capsid proteins", "PROTEIN", 68, 83], ["wellcharacterized epitopes", "TREATMENT", 21, 47], ["plant viruses", "PROBLEM", 87, 100], ["plant viruses", "OBSERVATION", 87, 100], ["large", "OBSERVATION_MODIFIER", 115, 120]]], ["Whereas early studies have concentrated on confirming the stability of the modified viruses and their capacity to induce the predicted antibody response, ongoing studies will determine whether the induced antibodies provide protective immunity against disease agents.", [["induced antibodies", "PROTEIN", 197, 215], ["early studies", "TEST", 8, 21], ["the modified viruses", "PROBLEM", 71, 91], ["the predicted antibody response", "PROBLEM", 121, 152], ["ongoing studies", "TEST", 154, 169], ["the induced antibodies", "TREATMENT", 193, 215], ["disease agents", "TREATMENT", 252, 266], ["viruses", "OBSERVATION", 84, 91], ["antibody response", "OBSERVATION", 135, 152]]], ["Studies in this laboratory have used TMV to carry an epitope from mouse hepatitis coronavirus (J. H. Fitchen, M. Buchmeier, and R. N. Beachy, work in progress).", [["hepatitis coronavirus", "DISEASE", 72, 93], ["TMV", "ORGANISM", 37, 40], ["mouse", "ORGANISM", 66, 71], ["hepatitis coronavirus", "ORGANISM", 72, 93], ["mouse", "SPECIES", 66, 71], ["hepatitis coronavirus", "SPECIES", 72, 93], ["TMV", "SPECIES", 37, 40], ["mouse hepatitis coronavirus", "SPECIES", 66, 93], ["this laboratory", "TEST", 11, 26], ["TMV", "PROBLEM", 37, 40], ["an epitope from mouse hepatitis coronavirus", "PROBLEM", 50, 93]]], ["Future research goals include the development of a better understanding of how modified, nonreplicating viruses, such as those described here, induce B-cell and T-cell responses, and the induction and maintenance of protective immunity.", [["B-cell", "ANATOMY", 150, 156], ["T-cell", "ANATOMY", 161, 167], ["B-cell", "CELL", 150, 156], ["T-cell", "CELL", 161, 167], ["nonreplicating viruses", "PROBLEM", 89, 111], ["protective immunity", "TREATMENT", 216, 235], ["viruses", "OBSERVATION", 104, 111]]], ["Although an important future goal is to deliver plant virus-based vaccines as a component of food, considerable experimentation will be required before we can understand how such immunization can be accomplished and how oral tolerance can be avoided in the process.", [["oral", "ANATOMY", 220, 224], ["oral", "ORGANISM_SUBDIVISION", 220, 224], ["plant virus-based vaccines", "TREATMENT", 48, 74], ["such immunization", "TREATMENT", 174, 191]]]]}